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ABSTRACT
The primary aims of this project were to cany out a comprehensive investigation of telomere and 
telomerase biology in the dog and cat, and more specifically to investigate the potential of telomeres 
and telomerase as targets for novel cancer chemotherapeutics.
Telomeres are nucleoprotein structures that cap the ends of all eukaryotic chromosomes analysed to 
date. The mammalian telomere is composed of duplex, non-coding hexanucleotide DNA repeats of the 
sequence (TTAGGG)n, terminating in a 3' single-stranded DNA overhang of varying length. The 
protein components of the telomere are involved in the maintenance of normal structure of the 
telomere, and the proper functioning of that structure within the cell.
Not all of the functions of the telomere are fully understood, however of primary interest is the 
regulation and restriction of cellular replication via a proposed telomere based ‘mitotic clock.’ This 
counting mechanism is based on the generally irretrievable telomere loss that accompanies cell 
division, referred to as the ‘end replication problem.’ The telomere attrition caused by end replication 
problem eventually triggers a replicative arrest and a characteristic cellular phenotype, referred to as 
senescence. Senescence has been linked to organ dysfunction and organismal ageing, and has therefore 
brought telomeres to the attention of a wide spectrum of research disciplines.
Whilst the majority of cell types suffer the effects of end replication problem, there are marked 
exceptions. Cells with high replicative burdens, germ line cells, and cancer cells do not show the 
replicative restrictions of other cell types. These cell types overcome end replication problem, in the 
majority of cases, by activation of a ribonucleoprotein complex called telomerase. This specialised 
reverse transcriptase enzyme replaces lost telomere sequence and is responsible, in approximately 80% 
of human tumours, for the unlimited replicative potential that is one of the hallmarks of cancer cells. 
Furthermore, inhibition of this complex has resulted in senescence and apoptosis of malignant cells, 
and overall telomerase has proven to be an excellent tumour marker, with potential diagnostic and 
prognostic applications, and is considered one of the most promising targets for anti-cancer therapy 
currently under investigation.
The majority of telomere and telomerase research carried out to date has been directly or indirectly for 
the benefit of human medicine. Research in the veterinary field lags far behind, and very little 
information was available on basic parameters such as telomere length and distribution of telomerase 
activity in dogs and cats at the beginning of the project. The first experiments carried out were 
therefore concerned with investigating mean telomere lengths in a wide age and tissue range of both 
the dog and cat. The protocol used for telomere length assessment was based on a DNA probe. 
Southern Blot and chemiluminescent technique referred to as Terminal Restriction Fragment analysis. 
Telomere lengths in peripheral blood samples taken from 112 dogs and 30 cats were found to range 
from 4.7 to 20.6 kb, and 9.6 to 23.5 kb respectively. These are similar to telomere lengths typically 
found in human samples (5-15 kb). The telomere lengths in a panel of normal canine and feline organ
samples, tumour samples, and primary fibroblast cultures also did not differ significantly from these 
values. Telomere lengths decreased significantly with increased age in both species, and whilst gender 
did not have a significant effect in either species, an intriguing finding was that breed of pedigree dog 
had a significant effect on telomere length. Primary canine and feline fibroblasts were found to cease 
replicating and assume a senescent phenotype in vitro after an average of 10 and 16 population 
doublings respectively. Over the course of these population doublings, telomere attrition was shown to 
occur in both canine and feline cells, and averaged 175 and 130 bp/cell division respectively. In 
summary, telomeres in the dog and cat are of a similar size to that found in humans, and telomeric 
attrition has been shown to occur in both species in vivo and in vitro. Furthermore, loss of telomeric 
sequence is associated with the triggering of a senescent phenotype in both canine and feline 
fibroblasts in vitro.
Telomerase activity studies used a commercially available assay, referred to as the Telomeric Repeat 
Amplification Protocol (TRAP). Telomerase activity was strongly down regulated in a wide range of 
somatic tissues of the dog and cat. Conversely, telomerase activity was detected in all canine and 
feline tumours assayed (19/19), and was also present in a panel of immortalised canine cell lines. 
These data linked telomerase with immortalisation and malignancy in the dog and cat, and have 
identified telomerase as a potential target for novel cancer chemotherapeutics in companion animals. 
A pilot study to assess the efficacy of a reverse transcriptase inhibitor (azidothymidine triphosphate) as 
a telomerase inhibitor in two canine telomerase dependant cell lines produced inconsistent inhibition 
of telomerase and no discernable effect on telomere lengths. However, future use of this drug in 
combination with agents that utilise different modalities for targeting telomerase may produce more 
favourable results. Such combinational therapies are currently producing the most promising results in 
the human field.
Expression of the catalytic component of human telomerase (liTBRT) is sufficient to reconstitute 
telomerase activity and prevent senescence in a number of human tissues. This is definitive proof of a 
link between telomere attrition and senescence in humans. The canine and feline homologues of 
hTERT were not available to carry out this investigation in the dog and cat; however, heterologous 
expression of hTERT using a mammalian expression vector was used in canine fibroblasts to 
investigate the control of telomerase activity and the links with senescence in that species. Expression 
of hTERT mRNA was confirmed in the primary canine fibroblasts by reverse transcriptase PCR and 
sequence analysis; however the cells remained telomerase negative, and entered senescence normally. 
This may be due to sequence differences in the catalytic components of canine and human telomerase 
rendering hTERT ineffective in canine cells. Interestingly, telomerase activity was briefly 
reconstituted in an equine primaiy fibroblast culture that was subject to the same procedure. 
Telomerase was also successfully reconstituted in a human telomerase independent control cell line. 
The studies described above went some way to addressing the biology of telomeres and telomerase in 
canine and feline cells, however, the wider implications of telomere attrition and telomerase
reactivation within cells remained unknown. The importance of an understanding of the possible 
knock-on effects of telomere length reduction on the transcriptome of the cell is important as potential 
telomerase inhibitors are likely to operate through telomeric attrition. Furthermore, telomerase 
reactivation has been suggested as a possible therapy for conditions when loss of replicative potential 
is part of the pathology, such as liver cirrhosis. These strategies will rely on the absolute safety of 
telomerase reactivation in vivo, and will also require knowledge of the wider effects of telomerase 
reactivation within the cell. These issues were addressed by examining the changes in the 
transcriptome of canine primaiy fibroblasts as they switched from actively replicating to senescent. 
The effect of telomerase reactivation in canine and feline primary cells also needs to be addressed, 
however, as described above, it was not possible to reconstitute telomerase activity in those cells. 
Instead, the effect of telomerase reactivation was investigated in a human telomerase independent cell 
line, as it is likely that many of the down-stream effects will be conserved between species. The 
experiments utilised DNA microarray technology (Affymetrix, Santa Clara, CA), as this allowed 
changes in mRNA expression levels of many thousands of genes to be monitored simultaneously. The 
experiments identified a number of genes of interest that warrant further investigation. Chief among 
these was the finding that mRNA levels of the gene product epiregulin were up regulated greater than 
8-fold in telomerase positive, compared with telomerase negative cells. This is important, as epiregulin 
activity has been associated with cancer progression, and is therefore associated with a malignant 
phenotype. This immediately casts doubt over the safety of telomerase reactivation for therapeutic 
purposes. Genes of interest in senescent fibroblasts were thrombospondin-1, phosphatidic acid 
phosphatase type 2A, and ATPase, Na+/K+ transporting, beta 1 polypeptide. These gene products may 
be associated with inhibiting tumour angiogenesis, tumour inhibition, and regulation of senescent cell 
volume respectively. The upregulation of thrombospondin-1 and phosphatidic acid phosphatase type 
2A in senescent canine fibroblasts may provide evidence of additional anti-tumour mechanisms in 
senescent cells, and the down regulation of Na+/K+ transporting, beta I polypeptide, which encodes a 
component of the Na+/K+, ATPase osmotic ‘pump’ may have a part to play in the increased volume 
of senescent cells.
Overall, the findings of this project indicate that telomeres and telomerase are directly involved with 
cancer development and progression in the dog and cat, and identify telomerase as a promising target 
for the development of future cancer chemotherapeutics in companion animals.
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Chapter I 
General introduction and review 
of the literature
1.1 Abstract
Telomeres are nucleoprotein structures that cap the ends of eukaryotic 
chi'omosomes. Under normal circumstances, cell division results in an 
irretrievable reduction in telomere length that eventually triggers loss o f cellular 
proliferative potential. However, telomeres are occasionally maintained or even 
lengthened; in the vast majority o f cases this is facilitated by a specialised 
ribonucleoprotein, telomerase. Telomeres and telomerase have been associated 
with ageing and malignant transformation respectively, and this Chapter reviews 
current evidence for and against these associations. The bulk of research in the 
field of telomere biology to date has been human based, and the review reflects 
this bias, however where possible, special reference is given to research o f direct 
relevance to the dog and cat.
1.2 Telomere structure
Telomeres are specialised niicleoprotein structures that cap the ends of all 
eukaryotic chromosomes analysed to date. Telomeric DNA sequences and 
structure are highly conserved across otherwise wide species boundaries, and are 
based on a simple tandemly repeating unit. (Blackburn 1991) The sequence 
TTAGGG is the unit found in humans, other vertebrates, slime moulds and 
tiypanosomes, whilst a wide range of organisms adhere to a telomeric repeat 
based on the simple formula d(T/A)|.4 dGi_8 , examples include the GGGGTT and 
GGGGTTTT sequences found in the ciliate protozoans Tetmhymena and 
Eiiplotes respectively (Blackburn & Szostak 1984) (Moyzis, Buckingham, et al
1988) (Blackburn 1990).
The G rich strand of eukaryotic telomeres analysed to date are all orientated in 
the 5 ' to 3 ' direction towards the terminus, and work carried out initially in 
Oxytricha showed that this strand produces an overhang beyond the 
complimentary C rich strand. The length of this overhang is species specific, 
from the exact 16 base pairs (bp) in Oxytricha to a variable 50-100 bp in humans 
and the mouse (Klobutcher, Swanton, et al 1981) (Greider 1999). The basic 
stmcture of the mammalian telomere is shown diagrammatically in Figure 1-1.
The overall length o f telomeric sequence found in vertebrates typically mns to 
tens of thousands of base pairs, though there is considerable variation between 
species. Canine telomeres have been found in the range of 11 to 23 kilobases 
(kb) (Yazawa, Okuda, et al 2001) (Nasir, Devlin, et al 2001), and feline 
telomeres in the region of 12-23 kb (McKevitt, Nasir, et al 2003). Human germ 
line telomeres are 15-20 kb, whilst the laboratory mouse {Mus musculus) has 
unusually long telomeres ranging from 30 to >50 kb (Allshire, Dempster, et al
1989) (Campisi, Kim, et al 2001). The closely related interfertile species Mus 
spretus has telomeres that are slightly shorter than in humans, usually reaching
5-15 kb (Smogorzewska, van Steensel, et al 2000), illustrating the wide variation 
found between even closely related species. Aside from interspecies variation, 
diversity in telomere lengths is found at an organismal, tissue, cellular and even
chl'omosomal level, albeit with less marked variety, and telomere length is 
affected by cellular replicative history. Takubo et al demonstrated that telomere 
lengths are not significantly linked to tissue renewal times in humans. For 
example there is no typical telomere length for human myocardial tissue at a 
given age, despite this tissue being relatively static with respect to cellular 
turnover (Takubo, Izumiyama-Shimomura, et al 2002) (Cameron 1970). 
Furthermore, an individual with longer than average telomeres in one tissue is 
likely to have longer than average telomeres in a number o f different tissues, 
illustrating telomere length variation at an individual organism basis around a 
species average (Takubo, Izumiyama-Shimomura, et al 2002).
Germ line cells have the ability to maintain or increase their telomere lengths, 
however the mean telomere lengths found in germ line cells remains constant for 
any given species (Kipling & Cook 1990) (Wright, Piatyszek, et al 1996 160 
/id).
Figure 1-1. Structure of the mammalian telomere. Telomeres are specialised 
nucleoprotein structures found at chromosome ends, as shown diagrammatically 
below. The duplex telomeric DNA sequence is based on a repeating hexamer, 
and a single stranded G-rich 3' overhang o f variable length is found at the 
terminus.
AGGGTTAGGGTTAGGGTTAGGGTTAGGG 3 ’ 
ATCCCAATCCCAATCCC 5 ’
1.2.1 G-quartets
The G-quartet is the defensive structure hypothesised to be formed from the 
single stranded !>' overhang at the end of the telomere, and it is believed to shield 
chromosome ends from the attentions of DNA repair complexes (Williamson, 
Raghuraman, et al 1989).
The suspicion that a specific telomeric sequence structure may be present at the 
telomeric terminus was initially aroused by the observation that oligonucleotides 
formed from the G-rich strand of telomeric sequence had greater electrophoretic 
mobility than would be expected for their size. Furthermore, the oligonucleotide 
Tet-4 formed from four Tetrahymena telomeric repeats, d(TTGGGG ) 4  has been 
shown to contain G-G base pairs. (Henderson, Hardin, et al 1987). Experimental 
work based on these data has implied that in vitro, such G-G base pairs lead to 
the formation o f the stmcture that has been termed the G-Quartet, under the 
influence of certain cations at physiological concentrations; the implication 
being that such stmctures may exist in vivo (Williamson, Raghuraman, et al
1989). The proposed structure is shown diagrammatically in Figure 1-2, and in 
this arrangement the common telomeric sequence elements, the G-strings (for 
example GGG in the human telomere) are the basis of the G-Quartet, whilst the 
variable elements, the T/A bases fonn loop regions around the Quartets. This 
stmcture has the potential to accommodate the telomeric sequences of a number 
of different species, as G-strings are a common feature in telomeric DNA 
(Blackburn & Szostak 1984).
1.2.2 Telomere associated proteins
In addition to a DNA repeat sequence, a number of proteins are also associated 
with the telomere. These telomeric proteins are believed to play important 
stmctural roles, and are integral to the proper functioning of the telomere 
(Greider 1999).
Figure 1-2. Proposed structure of the G-quartet. The diagram shows two G- 
quartets (linked by dashed lines) utilising the telomeric sequence of Oxytricha 
sp. d(TTTTGGGG). Variations in the telomeric sequence may be accommodated 
by variation in the number o f stacked quartets, and by changes in the length of 
the connecting DNA loops. Every fifth base is numbered, and the 
deoxyguanosine residues involved in the quartets are shaded to clarify the 
arrangement of bases in the structure.
1.2.2.1 TRFl
(TTAGGG repeat binding factor 1) is a double stranded telomeric DNA binding 
factor that binds along the length o f duplex telomeric DNA and was first 
identified and cloned in 1995. The discovery of TRTl was the first evidence that 
telomeres form nucleoprotein complexes in vertebrates (Chong, van Steensel, et 
al 1995). The protein is described as being related to the proto-oncogene Myb 
due to its Myb-like DNA binding domain at its carboxy terminus, and acidic 
amino terminal domain. It is a ubiquitous protein, and has been found associated 
with telomeres at all stages of the cell cycle (Broccoli, Smogorzewska, et al
1997). Telomeric DNA has been shown to recruit TRFl in the form of a 
tetramer, and at high protein concentrations in vitro will coat the entire length of 
available telomeric sequence with a 10 nm thick array o f bound proteins. In 
addition, the presence of TRFl attached to the telomere has the in vitro effect of 
promoting telomeric tracts to form pairs, with a strong bias for the parallel 
arrangement. (Griffith, Bianchi, et al 1998).
TRFl has been shown to act as a negative regulator of telomere length, and it is 
proposed to carry out this function by inhibiting the ribonucleoprotein 
telomerase (vanSteensel & de Lange 1997). When new telomeres are transfected 
into cultured cells, these stretches of DNA are elongated, presumably by 
telomerase until they reach the average length for that type o f cell. At this time, 
TRF1 is recruited to the new telomeres, and growth is halted. This provides an in 
vitro insight into the function and mode of action of TRFl (Smogorzewska, van 
Steensel, et al 2000).
1.2.2.2 TRF2
TRF2 was initially classified as a duplex DNA binding protein, and was first 
identified by Broccoli et al in 1997 (Broccoli, Smogorzewska, et al 1997). It is a 
distant homologue of TRFl and has a similar Myb like DNA binding motif at its 
carboxy terminus. Unlike TR Fl, however, it has a basic amino terminus. 
Inhibition of TRF2 has serious consequences for the cell, resulting in an
immediate threat of damage to the chromosomal ends by cellular activation of 
the ataxia telangectasia mutated (ATM)/p5 3-dependant DNA damage 
checkpoint pathway (Karlseder, Broccoli, et al 1999). Chromosomal end to end 
fusions follow, and the 3 ' G rich single stranded DNA overhang at the telomere 
end is lost (Griffith, Comeau, et al 1999). This indicates that TRF2 interacts with 
both single and double stranded DNA, and supports the idea that TRF2 is crucial 
for the proper functioning of the telomere. Griffith et al used electron 
microscopy to demonstrate that TRF2 is capable of remodelling linear telomeric 
DNA into large duplex loops in vitro (Griffith, Comeau, et al 1999). As the 
presence o f telomeric DNA per se is not enough to protect chromosomal ends 
from degradation, these telomeric DNA or ‘T ’ loops are proposed to be the 
additional structure necessary for protection of the chromosomal ends (van 
Steensel, Smogorzewska, et al 1998).
Currently, the proposed view of telomeric structure in vivo is that the 3% single 
stranded DNA overhang loops back to invade the duplex telomeric DNA and 
fonu a displacement loop in the order of a few hundred nucleotides. In many of 
the experimental cases the T-loops were very large and encompassed the entire 
length o f the telomere. Whether this is always the case is unknown (Griffith, 
Comeau, et al 1999). TRFl may also have a role to play in T-loop fonnation, as 
it has been shown to possess the ability to promote parallel pairing of telomeric 
tracts in vitro, which may help to stabilise the T-loop anangement (Griffith, 
Bianchi, et al 1998). The structure of the T-loop is shown in Figure 1-3.
The fact that inhibition of TRF2 has such an immediately deleterious effect on 
the cell; (cells expressing a dominant negative allele of TRF2 rapidly undergo 
apoptosis (Karlseder, Broccoli, et al 1999)) led to difficulty assessing any 
potential role o f this protein in regulation o f telomere length. Smogorzewska et 
al circumvented this problem by examining the effect o f over expression of 
TRF2, using a tetracycline inducible expression system in the human 
fibrosarcoma line HTC75. This study indicated that TRF2 is also a negative 
regulator of telomeric length, though in a transient way which is eventually 
corrected (Smogorzewska, van Steensel, et al 2000).
Figure 1-3. Structure of the T-loop. TRFl stabilises a loop structure formed by 
the telomere and allows TRF2 to mediate invasion of the duplex DNA at the 
base of the telomere by the 3' ssDNA overhang. This T-loop is thought to be 
important in allowing the cell to differentiate between a natural chromosomal 
end and a double stranded DNA break.
T-loop
TRFl and TRF2
D-loop
1.2.2.3 TANKl
TANKl, or tankyrase is a protein with homology to the catalytic domain of 
poly-adenosine phosphate ribose polymerase (PARP). This type of enzyme 
activity is usually associated with DNA repair (de Murcia & de Murcia 1994), 
and recombinant TANKl has demonstrated PARP activity in vitro. TANKl has 
been found to interact with TRFl in vitro, and binding o f TANKl to TRFl 
diminishes the ability o f TRFl to bind to telomeres. The long term over­
expression of tankyrase in telomerase positive cell lines results in a gradual and 
progressive lengthening of telomeres, whilst PARP deficient forms of TANKl 
do not demonstrate this effect. This suggests TANKl regulates the negative 
effect of TRFl on telomere length via ribosylation of TRFl, though it is possible 
TANKl may act on other, as yet unidentified telomere associated factors as well 
(Smith, Giriat, et al 1998) (Smith and de Lange 2000). Tankyrase is likely to act 
by causing a structural change in the telomere end, which allows the enzyme 
telomerase access to the telomere sequence.
1.2.2.4 TANK2
This protein is a recently identified second tankyrase with telomere associations. 
This protein has a very similar amino acid identity to TANKl, but has a unique 
N-terminal domain. TANK2 also interacts with TRFl, however over expression 
of TANK2 leads to rapid cell death by necrosis, with loss of mitochondrial 
membrane potential. The PARP inhibitor 3-aminobenzamide blocks this effect in 
vitro, linking this activity with the cell death. If this is the case, it may be that the 
PARP activity of TANKl is more efficiently regulated than that of TANK2, or 
that TANK2 acts on substrates that are not a target for TANKl (Kaminker, Kim, 
et al 2001). This idea is supported by the fact that both TANK2 and TANKl are 
not restricted to the telomere alone; both these proteins are abundant in the 
nuclear periphery and in the Golgi. It is therefore possible that they carry out 
non-telomere related activities in the cell, and so act on other substrates 
(Campisi, Kim, et al 2001).
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1.2.2.5 Ku70 and Ku86
These proteins are components of DNA-dependant protein kinase (DNA-PK). 
DNA-PK is a trimeric complex that is essential for the repair of double stranded 
DNA breaks in the cell. Ku binds and stabilises the broken ends of DNA, and 
then recruits the catalytic component o f the DNA-PK to carry out the necessary 
repair. Ku70 has been shown to specifically bind TRFl, and deficiency of Ku86 
in mice causes genetic instability due to frequent telomere-telomere fusions. 
This is similar to the effect of TRF2 deficiency, however Ku86 deficiency is not 
associated with loss of the 3'' overhang, or loss of telomere sequence overall. 
This indicates that as well as its documented role in DNA repair, Ku is also 
important for protection o f the terminal telomeric structure and that fusions 
associated with Ku deficiency are not mediated by loss of TRF2 function 
(Samper, Goytisolo, et al 2000).
1.2.2.6 TIN2 and HRAPl
TIN2 and HRAPl also appear to be exclusively sited at the telomere, but in 
association with other proteins rather than the telomere directly. TIN2 interacts 
with TRFl, and HRAPl with TRF2, and whilst their precise functions are 
unknown, they both play important roles in regulating telomere length (Campisi, 
Kim, et al 2001).
1.2.2.7 POTl
POTl is a recently identified single stranded DNA binding protein first isolated 
in yeast. The human homologue, hPOTl has been shown to bind specifically to 
the G-rich telomere strand, and acts as a positive regulator of telomere length in 
a telomerase dependant manner (Baumann, Podell, et al 2002), (Colgin, Baran, 
et al 2003).
11
1.3 Telomere function
A primary role of the telomere is to protect the integrity of chromosome ends. 
This idea was first proposed by McClintock (McClintock 1941) and later works 
have demonstrated the importance o f this function in a wide variety of species 
(Cervantes & Lundblad 2002). It is likely this faculty evolved in response to the 
development of natural chromosomal ends that may be mistaken within the cell 
as double stranded DNA breaks (Zakian 1989) (Souffler, Morgan, et al 1996).
Telomeres prevent loss o f genetic information during replication of 
chromosomes by providing a non-coding DNA buffer that is expendable in the 
face of ‘end replication problem,’ (Blackburn & Szostak 1984) and they promote 
correct mitotic separation o f sister chromatids during cell division (Kirk, 
Harmon, et al 1997).
1.3.1 End replication problem and telomere loss
End replication problem describes the difficulty encountered by a cell containing 
linear chromosomes in dealing with the established mechanics of cell division, 
specifically DNA replication. The semi-conservative mechanism of DNA 
replication describes how the strands of the DNA double helix separate and each 
acts as a template to direct the synthesis of a complementary daughter strand 
(Meselson & Stahl 1958). The point at which the DNA strands separate and 
synthesis of new DNA begins is termed the replication fork, two of which 
proceed bi-directionally from each other from an origin of replication. These 
single units of replicating DNA are referred to as replicons, and the typical 
mammalian cell may contain 50,000 to 100,000 of them with a size range of 40- 
200 kb. The DNA polymerases responsible for carrying out the replication are 
unidirectional in action in the 5 ' to 3 ' direction, and they require a short, labile 
tract of RNA to act as a primer. Whilst leading strand replication may proceed in 
the 5 ' to y  direction to the end o f the chromosome, lagging strand replication 
may only occur in the 5 ' to 3 ' direction in short fragments, termed Okazaki 
fragments. The Okazaki fragment includes the newly formed segment of
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daughter strand DNA along with its RNA primer arranged 5'-RNA-DNA-3' 
(Sugino & Okazaki 1973). The removal o f these individual RNA primers leaves 
multiple internal gaps in the DNA sequence. These internal gaps are filled in by 
extension of the DNA and ligation, however a 5' gap is left in the newly 
synthesised DNA strand as there is no terminal primer allowing it to be filled in 
(Olovnikov 1973) (Blackburn 1991). Despite the difficulty caused by end 
replication problem linear chromosome development may have facilitated the 
advent of meiosis, and the genetic diversity this enabled may well explain the 
evolutionaiy advantage provided by this otherwise unstable system (Griffith, 
Comeau, et al 1999) (Naito, Matsuura, et al 1998).
The model of telomere attrition by incomplete lagging strand synthesis predicts 
that 50% of chromosomes will have a G-rich overhang, and that chromosomal 
shortening will proceed at a rate of approximately 8-12 bases per cell division, a 
figure which is based upon the size o f the RNA primer (Tseng, Erickson, et al
1979). However, experimental work using a variety of cell types has reported 
long overhangs of between 130-210 bases in >80% of the telomeres tested 
(Makarov, Hirose, et al 1997). In addition it is known that the telomeres of 
human fibroblasts shorten by 31-85 bp per cell doubling. (Harley, Futcher, et al 
1990). This suggests that incomplete lagging strand replication is not alone in 
producing G-rich overhangs. Leading strand replication requires only one RNA 
primer, allowing DNA replication to proceed directly to the end o f the sequence 
and resulting in no DNA sequence loss. To account for this, a revised model of 
telomere shortening has been proposed in which DNA is lost from both ends of 
the chromosome due to degradation of both 5' strands of the DNA at the time of, 
or shortly after replication. This is termed the strand degradation hypothesis. A 
5 '-3 ' exonuclease has been isolated from calf thymus tissue and advanced as the 
likely cause of the missing bases. This exonuclease may be active by itself or as 
a component of DNA polymerase, and it has been shown to act specifically on 
single strands o f duplex DNA (Siegal, Turchi, et al 1992). The G-rich overhang 
may have developed at both ends o f the chromosome to allow protection o f the 
chromosome ends by T-loop formation (Campisi, Kim, et al 2001) (Klapper, 
Parwaresch, et al 2001).
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1.3.1.1 Other causes of terminal sequence loss
Factors not considered in the strand degradation hypothesis are also likely to 
contribute to terminal sequence loss. Recent work has shown that oxidative 
damage is repaired less efficiently in telomeric DNA than elsewhere in the cell, 
and that oxidative stress accelerates telomeric attrition (von Zglinicki 2002). The 
converse has also been shown to be true, namely antioxidant (such as ascorbic 
acid 2“0 “phosphate) treatment of cell lines attenuates telomere sequence loss 
(Furumoto, Inoue, et al 1998). These data have led some obseiwers to the 
opinion that oxidative stress is an important modulator of telomeric attrition, and 
that telomere driven replicative senescence itself is primarily a stress response 
(von Zglinicki 2002). Evidence in support of this is found in data showing that 
some fibroblast cell lines lose as few as 10-20 bp per cell division, indicating 
that strand degradation and end replication problem may not always be the major 
determinant of telomeric sequence loss. It is possible that in those cell lines that 
are affected by greater sequence loss (and have higher peroxide levels) the major 
factor at work is oxidative stress (Lorenz, Saretzki, et al 2001). This additional 
factor does help explain the huge heterogeneity in replicative potential of 
clonally derived cell lines identified by Smith and Whitney (Smith & Whitney
1980). Evidence o f such a stress response has been identified in vivo in the 
shortened replicative capacity of fibroblasts from subjects with Fanconi anaemia, 
a condition that is known to result in chronic oxidative stress, (von Zglinicki, 
Serra, et al 2000). It is likely that the effect o f oxidative damage on the rate of 
telomeric attrition allows the individual cell to ‘fine tune’ entry into senescence 
to account for the greater risk of mutation, and therefore malignancy associated 
with higher levels o f oxidative stress. This view appeals from an evolutionaiy 
standpoint, as it is a tumour suppressor mechanism by which those cells most at 
risk from malignant transformation may be removed from the replicating 
population more swiftly than would result from end replication problem alone.
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1.3.2 Role of telomeres in chromosome separation
Kirk et al have demonstrated that telomeres are essential for chromosomal 
stability during mitosis in an experiment focused on the ciliated protozoan 
Tetrahymena. Telomeric DNA mutants were produced by expression of a 
telomerase RNA with an altered template sequence, and this prevented division 
of the germline nucleus in anaphase, consistent with a physical block to 
separation of the telomeres (Kirk, Harmon, et al 1997).
1.3.3 Role of telomeres in gene silencing
A transcriptional silencing mechanism has been proposed that is caused by 
proximity to the telomere. This has been termed the telomere position effect 
(TPE), and was first identified in Saccharomyces cerevisae where TPE can cause 
reversible gene silencing by a mechanism that is dependant both on telomere 
length and the proximity of the gene to the telomere (Tham & Zakian 2002). 
This has prompted investigations to identify if this effect can be demonstrated in 
mammalian cells. Promising results have been obtained using HeLa clones in 
which a luciferase reporter adjacent to a newly formed telomere expressed 10 
times less luciferase than controls that have been randomly incorporated. 
Furthermore, lengthening of the telomere produced further reduction in reporter 
activity in the telomere adjacent reporters but not in the controls (Baur, Zou, et 
al 2001). Attempts to reproduce this effect in natural telomeric genes have not 
met with the same success; telomere length alone is not sufficient to deteimine 
the expression status of the genes investigated (Ning, Xu, et al 2003). However, 
this study has also identified a discontinuous pattern of gene expression during 
telomere shortening that may be related to senescence. Further work is necessary 
to clarify to what extent telomeres affect the expression level of genes located 
near to them, though the present evidence suggests that such proximity is a 
factor governing expression, and suggests another important role for the 
telomere in the mammalian cell.
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1.4 Replicative senescence
Senescence is the final phenotypic state adopted by a cell in response to several 
distinct physiological processes including proliferation, oncogene activation and 
oxygen free radical toxicity. In the context of this study, the qualified term 
replicative senescence is used to avoid confusion in cases where cells might for 
example be described as ‘senescent’ because they were derived from an aged 
individual, or because they are derived from post-mitotic tissue demonstrating 
age related decline in function.
The behaviour of individual cells in culture was initially thought to display 
immortality. The first flawed experiments in this field were carried out by 
Carrell in 1912, using cells dissociated from chicks and sub cultured in a 
medium derived from chick embryo extract. Carrell claimed these cells could be 
sub cultured indefinitely, and that organismal ageing and therefore mortality was 
a function of multicellularity. The cells cultured were in fact mortal, being 
sensitive to a wide variety o f poor growth conditions and noxious substances. 
They were also being replenished regularly with a medium that was 
contaminated with fresh cells, and the cultures correspondingly underwent 
phases of growth when new, presenescent cells were added with the growth 
medium (Cristofalo & Pignolo 1993) (Hayflick 1965). Since then and despite 
advances in the field. Carrel’s results have never been duplicated despite several 
attempts (Hayflick 1965) (Witkowski 1980). However, the view that the 
individual cell is inherently immortal persisted until the landmark experiments of 
Hayflick and Moorehead in 1961 and 1965, which proved conclusively that 
normal human fibroblasts have only a limited capacity for division. The process 
that eventually limits cell division has been termed replicative senescence, and 
with the exception of cells in the germ line and some stem cell types it affects all 
mammalian cells (Hayflick 1965) (Hayflick & Moorhead 1961) (Hayflick 1997). 
Olovnikov first proposed that loss o f chromosomal end genes, or ‘telogenes’ was 
the trigger for Playflick’s limit, and linked telomeres to replicative senescence 
(Olovnikov 1973).
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Replicative senescence occurs in two distinct phases in human fibroblasts, 
mortality stages 1 and 2 (M l and M2, shown in Figure 1-4), and this model is 
the accepted sequence of events that occur in normal somatic cells approaching 
replicative exhaustion (Wright & Shay 1992). M l probably occurs when 
telomeres are sufficiently short that they can no longer be effectively ‘masked’ 
from cellular DNA repair machinery and are treated as double stranded DNA 
breaks (Harley 1991). The replicative block that occurs at M l is mediated by cell 
cycle checkpoint proteins that are associated with response to DNA damage, 
such as the p53 and pl6/pRb pathways (Kohn 1999). As such, mutations or 
transfonning oncogenes that inactivate these checks allow frirther cell division 
with concomitant telomeric attrition until M2 is reached (Lundberg, Hahn, et al 
2000).
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Figure 1-4. Two step hypothesis of cellular immortality. Germ line cells and 
pluripotent stem cells are telomerase positive, although pluripotent stem cells do 
not maintain their telomere lengths. Normal somatic cells are telomerase 
negative and undergo telomeric attrition. At a critical length this erosion triggers 
a replicative block termed Hayflick’s limit, or mortality stage 1 (M l). 
Abrogation o f cell cycle checkpoints such as p53 or pl6/pRb allows further cell 
division and concomitant telomeric loss until a genetic crisis, or mortality stage 
2 (M2) is triggered characterised by massive cell death. Almost all the rare cells 
that survive beyond this stage contain mutations that have led to telomerase 
reactivation.
Germ  line ce lls
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M2 (crisis) represents the end result o f critically short telomeres, and is 
characterised by end-to-end fusions, and chromosome breakage fusion cycles 
resulting in apoptosis (Wright & Shay 2000). The stringency with which 
replicative senescence is adhered to varies between species, for example whilst 
there are no confirmed reports of either human or chick fibroblasts from normal 
donors spontaneously immortalising, this occurs relatively frequently in cells 
derived from mice (Ponten 1971).
The onset of replicative senescence is determined by the number o f times the 
cells divide, and not by calendar time. It is characterised by irreversible growth 
arrest in the G1 phase of the cell cycle and the ability to survive and remain 
metabolically active in this condition for a period of time that may extend to 
several years, despite an inability to synthesise DNA (Matsumura, Zerrudo, et al 
1979). Senescent cells also appear enlarged and flattened, and express a (3- 
galactosidase activity at pH6 (Dimri, Lee, et al 1995). These criteria are few, 
partly as other changes that occur in senescence are also seen in the reversible 
state of quiescence into which some cultured cells fall in the absence of growth 
factors (Berube, Smith, et al 1998). Even very young cultures are found to 
contain a small proportion of cells that are senescent, and this proportion slowly 
increases thi'oughout the life span of the cell line until all the cells are affected.
It has been found that human fibroblasts, when treated with high concentrations 
of hydrogen peroxide stop dividing and become enlarged. This has been 
interpreted as a means by which replicative senescence may be triggered for 
experimental purposes. However as other cell states (such as terminal 
differentiation) may mimic the senescent phenotype, this means of inducing 
senescence should be treated with caution; at least until the underlying control 
mechanisms are more fully understood (Chen & Ames 1994) (Smith & Pereira- 
Smith 1996). In contrast, a recognised means for delaying the onset of 
replicative senescence is via cellular expression of DNA tumour viral genes, 
such as simian virus 40 (SV40) T antigen. SV40 acts as a dual inactivator o f the 
genes p53 and RBI. The same effect is seen by treatment with antisense 
oligonucleotides to the tumour suppression genes p53 and RBI, or by expression
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of a dominant negative p53 mutant (Smith & Pereira-Smith 1996). These 
treatments allow cells an extra 10-20 doublings compared to controls, though 
they are only effective if  carried out on pre-senescent cells, as senescent cells 
cannot be stimulated to divide (Sager, Tanaka, et al 1983). After the extra 
population doublings treated cells will enter senescence normally, with the 
exception of SV40 treated cells, which will instead undergo a period of genetic 
crisis, usually leading to cell death.
1.4.1 How is senescence triggered?
When considering this subject, it should first be noted that whilst the finite 
replicative potential of nonnal somatic cells is now as much a central dogma as 
CaiTel’s view of cellular immortality was before 1961, there are still dissenting 
voices. Notably Harry Rubin states that the concept of a genetically 
predetermined number of human fibroblast replications, and its implied 
extension to other cells, is based on an artefact resulting from the damage 
accumulated by the explanted cells during their replication in the radically 
foreign environment of cell culture (Rubin 1998). Rubin is not alone in this 
view, and it must be accepted that the cell culture environment, improved though 
it is from the days of Carrel’s work does represent a radically alien and crude 
environment for the cells grown within it; as such the true nature of cellular 
replicative potential may not lend itself entirely to one view or the other but lie 
somewhere between the two camps. That aside, replicative senescence as a 
phenomenon is widely accepted (Kipling & Wyndford-Thomas 1999), and 
explanations of how it is triggered usually fall into two broad camps. First, the 
cell is considered to play a passive role, having senescence tluust upon it as the 
result o f accumulation of errors associated with, for example, imperfect repair of 
DNA damage and inadequate scavenging o f haraiflil free radicals. Second, 
senescence is considered an active, progiammed cellular process, and implies 
cellular ageing is part o f an intrinsic genetic programme.
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1.4.1.1 Mechanisms under consideration
Several hypotheses have been advanced to explain the link between telomeric 
attrition and replicative senescence. First, telomeres might bind transcription 
factors necessary for triggering senescence that are released upon loss of enough 
repeats. Whilst there is as yet no fmn evidence for this in mammalian cells, this 
idea is based on experimental work earned out in yeast, where the telomere 
associated Rapl protein sequesters silencing factors that normally act at non- 
telomeric sites (Marcand, Buck, et al 1996).
Second, the heterchromatic structure of DNA near the telomere may act to 
silence genes necessary for triggering the senescent phenotype. These genes 
would then become derepressed as telomeric sequence is lost, and 
heterochromatin diminishes. Again, the evidence put forward in support of this 
hypothesis is yeast-based research where there is strong evidence of desilencing 
of loci near telomeres (Shore 1995).
Finally, short telomeres may cause a DNA damage response that leads to cell 
cycle arrest, and replicative senescence. The key to this mechanism is believed 
to be the T-loop structure identified by Griffith et al and described previously 
(Griffith, Comeau, et al 1999). T-loops allow the telomere end to be sequestered 
from DNA repair complexes, and it is possible that loss of this loop forming 
ability due to telomeric attrition is the mechanism through which the senescence 
response is initiated. This is likely to occur through a p53 mediated DNA 
damage response.
1.4.1.2 Evidence in favour of a genetic basis to replicative 
senescence
Smith et al exploited in vitro hybrids between young and old cells to investigate 
how replicative senescence is controlled. Such hybrids were found to have no 
greater replicative potential than the old set of parental cells from which they 
were partly derived. This suggests that the senescent phenotype is dominant.
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Further evidence of this is the observation that hybrids of two old cell lines never 
show greater replicative potential than their parental cells. In addition, fusion of 
immortal and mortal human fibroblasts produce hybrids that are invariably 
mortal, indicating that cellular immortality arises due to recessive mutations that 
allow escape from senescence (Pereira-Smith, Robetorye, et al 1990).
1.4.2 Replicative senescence and ageing
The link between replicative senescence and ageing was first postulated by 
Hayflick (Hayflick 1965), who linked the aged appearance o f senescent cells to 
organismal ageing, and suggested replicative senescence may therefore play a 
part in the many phenotypic changes that occur during this process. This proved 
a popular idea, as it provided a mechanism by which cell culture studies could 
contribute to the investigation o f the ageing process. The study o f ageing, and 
more specifically age related disease is extremely important in the human field 
as we live in a world with an ageing population (HMSO 1995). Many of the 
improvements in human healthcare that have produced this effect have filtered 
into the veterinary field resulting in an increased demand for treatments for age 
related disease such as cancer (Bronson 1982). Hayflick’s original hypothesis of 
ageing through the mechanism of replicative senescence indicates a cellular, 
genetic programme for how we age, but does not address why this might have 
evolved. The question of why we age is engaged more recently in the concept of 
antagonistic pleiotropy, which has the central tenet that evolutionary pressure 
does not have any effect on the post-reproductive age organism. This fits 
conveniently with Hayflick’s idea, as replicative senescence would be strongly 
selected for as a potent anti-cancer mechanism and if any deleterious effects 
were co-selected they would be unchecked by the forces of evolution if they 
occurred in the older post-reproductive organism. The supposition is therefore 
that ageing may be the price paid for a cancer free reproductive lifespan 
(Krtolica, Parrinello, et al 2001).
A second idea is the disposable soma theory of ageing, in which evolution is 
viewed as the force behind the most efficient use of resources between
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reproduction and somatic tissue repair (Kirkwood 1996). The theory is well 
illustrated by the mouse, a creature with a short lifespan, high fecundity and high 
predation rate. According to the theory, evolution has allocated the lion’s share 
of resources to reproduction rather than a long-lived body, as a mouse with a 
body designed to live to for fifty years will in its natural environment most likely 
be eaten after two. Therefore the life spans of species may be a reflection of a 
logical use of resources in the face o f predation and disease.
Aside from the hypotheses about why we age, Hayflick’s idea about how this 
might happen has yet to be tested critically. Even if proved to play a part in the 
ageing process, replicative senescence cannot be the sole mechanism involved, 
as it does not provide an explanation for the age related changes that are clearly 
documented in post-mitotic tissues such as neurones (Smith & Whitney 1980). 
Yet cell culture has provided indirect evidence of a link between the two 
processes. First, a number o f in vitro studies have shown an inverse relationship 
between donor age and the number o f population doublings (PDs) until 
replicative senescence (Allsopp, Vaziri, et al 1992). Second, interspecies studies 
have shown a correlation between species life span and the replicative potential 
of fibroblast cell cultures derived from them. For example, whilst murine 
fibroblasts senescence after only 10-15 PDs, fibroblasts cultured from the long- 
lived Galapagos tortoise routinely undergo more than 100 PDs before exhausting 
their replicative potential (Soldstein 1974). This points to an overlap in the genes 
governing replicative senescence and organismal ageing (Rohme 1981). Allied 
to this data is the observation that cell lines derived from sufferers o f the human 
progeric syndromes Werner’s syndrome and Hutchinson-Gilford exhibit 
decreased proliferative potential compared to age matched controls. Such 
decreased proliferative potential is also found in Down’s syndrome patients 
(Oshima, Campisi, et al 1995) (Goldstein & Harley 1979). Furthermore, recent 
research has demonstrated an association between loss of replicative potential 
and premature cardiac ageing in humans (Chimenti, Kajstura, et al 2003).
At a molecular level correlations have been uncovered between replicative 
senescence and ageing. The ability to respond to stressors by induction of heat 
shock protein 70 is attenuated in both senescent human fibroblasts and aged
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rodent tissue (Choi, Lin, et al 1990) (Fawcett, Sylvester, et al 1994). Such 
observations are circumstantial only, but add to the overall weight o f evidence.
Finally, a senescence associated marker enzyme ((3-galactosidase activity at pH6, 
Dimri, Lee et al 1995) has been found to be more prevalent in cells from 
physiologically aged tissue of the Rliesus monkey {Macaca mulatto) than young 
equivalents, providing the first in situ evidence that replicative senescent cells 
accumulate in aging tissue. Crucially, this enzyme activity is not displayed in 
reversibly arrested cells, such as young, growing cells that have been affected by 
removal o f growth factors. This allows clear differentiation between quiescence 
and true replicative senescence (Pendergrass, Lane, et al 1999).
The above evidence is not without contradiction; for example Cristofalo et al 
could not demonstrate an age effect on fibroblast replicative potential using a 
health screened donor population, and pointed out that weaknesses in candidate 
selection may give rise to false correlations (Cristofalo, Allen, et al 1998). One 
example o f this is a study that could demonstrate an inverse relationship between 
the two parameters only when diabetics and pre-diabetics were included in the 
study gi’oup, even though diabetes is a disease that is known to increase cell 
turnover (Goldstein, Moennan, et al 1978).
Furthermore, whilst the decreased growth potential of cultures from patients 
with progeric syndromes would appear to provide strong circumstantial evidence 
of a link between replicative senescence and ageing, closer examination of early 
senescent cells from donors with perhaps the most documented condition, the 
Werner syndrome are found not to repress c-fos, which is a hallmark of normal 
senescence (Oshima, Campisi, et al 1995).
Perhaps most crucially of all, whilst the above evidence supports the idea of 
replicative senescence and ageing being co-dependent variables this does not 
imply causality; thus whilst telomeric attrition is associated with ageing it has 
not been shown conclusively that it is the major cause of ageing.
24
1.4,3 Senescence as a tumour suppressor mechanism
The ability of cells to replicate is essential for repairing and renewing the tissues 
of multi cellular organisms throughout life. However, this capacity to divide is 1
also an opportunity for mutations to develop, and such mutations can lead to j
malignant transfonnation. The risk o f malignant transformation increases with I
oxidative stress, environmental insults and errors in DNA replication. This is ■
because all these factors cause damage to the genome, which increases the risk 
of mutation. It is mutation that may cause a genome to become unstable 
(hypermutable), and confer a growth or other survival advantage over normal 
cells that allows the development of cancer (Campisi 2001a). i
The dividing cell has two strategies for dealing with the risk of malignant ‘
transformation. First, apoptosis or programmed cell death eliminates at risk cells |
from the population. Second cellular senescence eliminates risk by irreversibly j
arresting growth. The term ‘cellular senescence’ is used specifically in this case I
to denote a senescent phenotype that may be induced by a range of factors other |
than telomeric attrition, such as DNA damage, chromatin remodelling and strong !
mitogenic signals (Campisi 2000). Evidence linking cellular senescence and |
tumour suppression has been uncovered both in vitro and in vivo. DNA damage |
in the form of double strand breaks or oxidative damage will induce a senescent ;
phenotype, and oxidative stress is known to shorten telomeres (von Zglinicki I
2002). Agents that open or unravel chromatin stmcture will induce a senescent 
phenotype (Young & Smith 2001), and such agents have the capacity to cause 
loss of the gene silencing capacity of chromatin. Over expression of both the 
growth stimulatoiy transcription factor E2F1 and activated forms of the growth 
factor signal transducing protein Ras will induce a senescent phenotype (Dimri,
Itahana, et al 2000) (Serrano, Lin, et al 1997). Malfunctions of these factors may 
contribute to the development of cancer; and this points to senescence being a 
general tumour suppressor mechanism with the capacity to respond to a wide 
range of signals from different sources within the cell.
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The genes controlling cellular senescence give further insight into the 
importance of this process as a tumour suppressor mechanism. Genes governing 
cellular senescence encode two proteins that are at the heart o f the two most 
important tumour suppressor pathways in the cell. Together, flmctional loss of 
the tumour suppressors p53 and pRb are the most disabled in mammalian 
cancers (Hickman, Moroni, et al 2002), and such ffinctional loss has been shown 
to occur in canine cancers, for example canine melanoma (Koenig, Bianco, et al 
2002). p53 controls the expression of genes that respond to genomic damage 
through cell cycle arrest or apoptosis, and p53 levels are increased in senescent 
cells (Bringold & Serrano 2000) (Lundberg, Hahn, et al 2000). pRb does a 
similar job of policing the genes controlling cell cycle progression and cellular 
differentiation, though by the indirect route of interacting with transcription 
factors such as E2F (Berube, Smith, et al 1998). Other oncogenes, such as c- 
myc, and the viral oncogenes E6 and E7, also act by overcoming senescence, 
underlining the importance of this process for tumour suppression in the cell 
(reviewed in Campisi, Dimri, et al 1996).
In vivo evidence o f the link between senescence and tumour suppression has 
been demonstrated in the highly cancer prone state of mice that have been 
engineered to produce inactive p53 or pl6*^ ^^ "^ ‘‘ proteins (Ghebranious & 
Donehower 1998). Conversely, premature senescence of mammary epithelial 
tissue suppresses the development of mammary cancer in young mice exposed to 
the mouse mammary tumour virus (Boulanger & Smith 2001).
Finally, a clear piece o f evidence for the importance o f replicative senescence as 
a tumour suppressor mechanism is the fact that cells with a finite replicative life 
span are orders o f magnitude less likely to form tumours than immortal cells 
(Campisi 1997).
1.4.4 Cellular senescence as a facilitator of tumorigenesis
In light of the above evidence, it may appear strange to describe senescent cells 
as a cancer risk factor, however recent evidence shows this to be the case; not by
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any direct action of the senescent cells themselves, but via adjacent cells that still 
have replicative potential (Ki'tolica, Parrinello, et al 2001).
Cellular senescence has been described as an example of antagonistic pleiotropy 
(Campisi 2001a). Therefore whilst replicative senescence may have evolved to 
provide the advantage of tumour suppression to organisms of breeding age, it 
may also have selected for undesirable characteristics, one o f which may be a 
tendency to develop cancer in the older, post-reproductive organism. Krtolica et 
al using in vitro human fibroblast cultures provided the main experimental 
evidence of this effect. This work showed that both premalignant and malignant 
epithelial cells are stimulated to proliferate by senescent fibroblasts via factors 
that are at least in part secreted by the senescent cells (Krtolica, Parrinello, et al 
2001). This effect was observed when the senescent cells comprised only 10% of 
the cell population as a whole, and was unaffected by the method by which 
senescence was induced (replicative exhaustion, oncogenic RAS, pl4^^^^, and 
hydrogen peroxide).
1.5 Telomerase structure
Not all mammalian cells undergo telomeric attrition; for example germ-line cells 
and cancer cells do not. However these cells possess linear chromosomes, and 
are therefore prey to the end replication problem. The solution is the 
ribonucleoprotein telomerase, a complex composed of an RNA sequence that is 
complimentary to the telomere sequence, a catalytic component, and several 
other associated structural proteins with an estimated total molecular mass of 
1000 kilodaltons (kDa) (Dhaene, Van Marck, et al 2000). Telomerase was 
identified in 1985, and the earliest purification o f the active components 
occurred in Enplotes aedictilattis (Greider & Blackburn 1985) (Lingner & Cech 
1996). Telomerase activity allows maintenance of telomere length despite cell 
division, and accordingly activity is strongly associated with immortalised and 
cancerous tissues (Kim, Piatyszek, et al 1994) (Shay & Bacchetti 1997).
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Telomerase is frequently described as a ‘specialised’ reverse transcriptase, and 
there are three main reasons for granting it specialised status. First, and 
unusually for a reverse transcriptase, telomerase utilises only a part of its RNA 
subunit functionally. Second, during the processive synthesis of telomeric 
repeats, the substrate translocates from one end of the template to the other by an 
unknown mechanism, and finally, the RNA subunit of telomerase is stably 
associated with the protein complex as a whole.
Telomerase acts by using the RNA sequence as an internal template, guiding the 
addition o f nucleotides to the 3 ' end o f the telomere by the catalytic component, 
telomerase reverse transcriptase. The complex is then repositioned at the new 
telomere terminus and the process is repeated until the effects of end replication 
problem have been negated (Buys 2000). Accordingly, telomerase activity 
should be absent from those cell types that undergo telomeric attrition, and this 
is indeed the case (Reviewed in Dhaene, Van Marck, et al 2000).
1.5.1 Telomerase RNA
This component was first cloned in Tetrahyinena thermophila, and the human 
analogue is referred to as liTR (human telomerase RNA component). In humans, 
the hTR transcript is 451 nucleotides in length and lacks polyadenylation. It 
contains a ‘template’ sequence that is complimentary to the telomere repeat, and 
in humans this sequence is II  nucleotides in length (5’-CUAACCCUAAC-3’) 
(Feng, Funk, et al 1995). Mammalian telomerase RNAs resemble small 
nucleolar RNAs (snoRNAs) due to the presence of a H/ACA box in their 3' 
domain (Mitchell, Cheng, et al 1999). The vital nature of the RNA component to 
telomerase function was revealed first in Tetmhymena, where disruption of 
telomerase RNA was shown to lead to progressive telomere shortening (Ahmed, 
Sheng, et al 1998).
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1.5.2 Telomerase reverse transcriptase
The telomerase reverse transcriptase gene (the human analogue is referred to as 
hTERT) consists of 16 exons and 15 introns and extends over 40 kb (Wick & 
Hagen 1999). O f the three major subunits that comprise the telomerase 
ribonucleoprotein, the hTERT gene product is considered to be the most 
common rate-limiting determinant of activity. This is due primarily to studies 
connecting telomerase activity directly with transcriptional activity of hTERT at 
all stages during the process of malignant transformation, in contrast with the 
hTR subunit that is expressed in many tissues irrespective of telomerase activity 
(Avilion, Piatyszek, et al 1996) (Wisman, De Jong, et al 2000). The reverse 
transcriptase domain has been shown to be essential for telomerase activity 
(Weinrich, Bodnar, et al 1997), however in humans both the amino and carboxyl 
terminus also have important functional roles to play, and even minor deletions 
in these regions may lead to loss of telomerase activity (Beattie, Zhou, et al
2000) (Banik, Guo, et al 2002).
The importance of the TERT component is further supported by studies 
demonstrating that forced expression of hTERT in telomerase negative cells is 
enough to reconstitute telomerase activity and extend replicative life span 
(Bodnar, Ouellette, et al 1998). This work was subsequently extended by 
Takakura et al, who showed conclusively that hTERT is significantly activated 
in cancer cells, but repressed in normal primary cells (Takakura, Kyo, et al
1999).
1.5.3 Human telomerase associated protein 1
TEPl, or hTEPl in humans (human telomerase associated protein 1), is a 240 
kDa protein which is associated with telomerase activity, but in common with 
hTERT, expression of this protein alone in a cell does not imply telomerase is 
active (Harrington, McPhail, et al 1997). hTEPl is the human homologue of p80 
in Tetrahymena, p80 being one of the first telomerase associated proteins 
identified. This protein was initially thought to be the catalytic component of
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telomerase before TERT was identified (Dhaene, Van Marck, et al 2000). Some 
light has been shed on the possible function o f this protein by recent work that 
has shown TEPl to be identical to the 240 kDa vault protein. Vault proteins are 
large cytoplasmic ribonucleoprotein complexes, and whilst their function is as 
yet unknown the sharing o f TEPl between vault proteins and telomerase 
suggests TEPl may play a stmctural role in ribonuceloproteins, or aid generally 
with their function or assembly (Kickhoefer, Stephen, et al 1999). In the same 
study, Kickhoefer et al demonstrated that vault proteins themselves display no 
detectable telomerase activity,
1.6 Telomerase activity
Many human tissues display telomerase activity during early embryonic 
development, however this period is short lived, and telomerase activity is 
repressed in most normal human somatic tissues after birth (Kim, Piatyszek, et al 
1994) (Shay & Bacchetti 1997). Telomerase activity may still be found in 
specific tissues throughout adult life, and this pattern correlates with tissues that 
require a large replicative potential due to functional demand. For example, 
Tahara et al detected telomerase activity in normal colonic glandular epithelial 
crypt cells (Tahara, Yasui, et al 1999). Telomerase activity is induced by antigen 
activation of mature resting lymphocytes, (Weng, Palmer, et al 1997) and germ 
cells are telomerase positive, along with normal endometrial tissue (Dhaene, Van 
Marck, et al 2000).
1.7 Regulation of telomerase activity
1.7.1 Transcriptional regulation of the hTERT gene
As TERT is the primary determinant for telomerase activity the regulation of 
TERT expression has been the focus of many studies. The isolation and 
characterisation o f the hTERT promoter (Wick & Hagen 1999) (Cong, Wen, et 
al 1999) led to transient transfection experiments that used hTERT promoter- 
luciferase constmcts to show promoter inactivity in mortal and transformed
30
preimmortal cells, but activity in immortal cells, highlighting the importance of 
transcriptional control (Takakura, Kyo, et al 1999).
Regulation of hTERT promoter activity is likely to be a key point that is 
controlled at a number o f different levels. The large numbers of transcription 
factor binding sites within the hTERT promoter provide evidence for this. O f 
these, several have been implicated in the control of hTERT expression and may 
be defined as transcriptional activators or repressors (Cong, Wen, et al 1999).
1.7.1.1 TERT transcriptional activators
1.7.1.1.1 C-Myc
C-myc is a well-characterised oncogene that promotes growth, proliferation and 
apoptosis (Grandori, Cowley, et al 2000). Alterations in the structure or 
expression of this gene have been linked to a wide variety of human cancers. 
The link between c-myc and hTERT transcription are the two E-box recognition 
sequences in the hTERT promoter sequence. This sequence (5'-CACGTG-3') is 
recognised and bound by heterodimers formed by c-myc and the Max protein 
(Grandori, Cowley, et al 2000). C-myc has been shown to induce hTERT 
expression and telomerase activity in primary fibroblasts (Wang, Xie, et al 
1998). These data provide clear evidence of a direct effect o f c-myc on hTERT 
activation.
1.7.1.1.2 Spl
Spl is a general transcription factor that binds to specific sequence areas of 
promoters termed GC boxes. It helps to initiate transcription of a large number 
of genes, particularly by aiding transcription of promoter sequences that are 
without the TATA-box binding protein, which is part of the general transcription 
machinery of the mammalian cell. The hTERT promoter is TATA-less, and Spl 
has been shown to cooperate with c-myc to activate transcription of hTERT in a 
cell-type dependant manner (Kyo, Takakura, et al 2000).
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1.7.1.1.3 Human papillomavirus 16 E6 protein
Telomerase activity can be induced in a number o f human cell types by the 
human papillomavii-us 16 E6 protein, via up regulation o f hTERT transcription. 
The mechanism by which E6 causes hTERT up regulation is as yet unknown, 
however it occurs independent of any interactions with either p53 or c-Myc 
(Klingelhutz, Foster, et al 1996).
1.7.1.1.4 Steroid hormones
Initial studies focusing on telomerase activity in normal human ovarian and 
endometrial tissues identified telomerase activity at those stages o f the menstmal 
cycle that are under the influence of oestrogen. It has been recognised for some 
time that certain types of cancers are oestrogen dependant (Henderson, Ross, et 
al 1993), and so research has been directed at identifying whether a causal link 
between oestrogen influence and telomerase activity can be identified. Kyo et al 
were the first to demonstrate that oestrogen activates telomerase, and that this 
phenomenon is due to direct transcriptional regulation of hTERT expression in 
hormone sensitive tissues (Kyo, Takakura, et al 1999).
1.7.1.2 TERT transcriptional repressors
The cmcial importance of TERT expression for reconstituting telomerase 
activity has been outlined above, and in accordance with the finding that 
telomerase activity is absent from most normal post-embryonic human somatic 
tissues it is considered likely that repression of hTERT transcription in these cell 
types is a key control point. Consistent with this hypothesis, fusion between 
normal somatic cells and some immortal telomerase positive cells results in 
repression of telomerase activity (Ishii, Tsuyama, et al 1999). Furthermore, 
down regulation of telomerase activity in cancer cells has been achieved via 
repression of hTERT expression by the transfer of specific chromosomes from 
normal cells, implying that normal cells express negative regulators of hTERT 
expression (Oshimura & Barrett 1997). To date several hTERT repressors have
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been identified including M adl, p53, pRb, E2F1, W Tl, and anti-proliferation 
agents, as detailed below.
1.7.1.2.1 M adl
The proteins c-Myc, Max and M adl are crucial to the proper cellular control of 
growth and differentiation. As has been described in Section 1.7.1.1.1 the 
heterodiiners formed by c-myc and max have a positive effect on hTERT 
transcription. Mad/Max dimers act as the counterbalance to this relationship and 
produce downregulation of hTERT transciption through competitive inhibition 
of the c-myc/Max dimers (Xu, Popov, et al 2001).
1.7.1.2.2 p53
p53 is a tumour suppressor protein that acts by inducing cell cycle arrest or 
apoptosis and can respond to a variety of types of cellular damage. The 
importance of this protein is reflected in the fact that it is functionally disabled in 
50% of human tumours (Asker, Wiraan, et al 1999). Recent evidence has shown 
that p53 down regulates hTERT expression directly, and therefore its anti 
telomerase effects are not dependant on its cell cycle arrest or apoptosis 
flinctions (Xu, Wang, et al 2000) (Kusumoto, Ogawa, et al 1999).
1.7.1.2.3 pRb and E2F1
Over expression of both pRb and E2F1 resulted in repression o f telomerase 
activity in a number of human cancer cell lines. The exact mode o f action of this 
effect has yet to be elucidated, and whether pRb and E2F1 act independently or 
cooperate (Ying C.Henderson,, et al 2000) (Nguyen & Crowe 1999).
1.7.1.2.4 Wilms’ tumour 1 tumour suppressor (W Tl)
W Tl is a tissue specific (kidney, gonad and spleen) repressor of the hTERT 
promoter, inactivation of which may contribute to activation of telomerase 
during tumorigenesis in its target tissues (Oh, Song, et al 1999).
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1.7.1.2.5 Antiproliferation and differentiation agents
Telomerase activity is reduced by cellular differentiation and cell cycle exit, 
therefore focus has been given to identifying possible inhibitory effects by 
factors governing these cellular changes on hTERT activity. Both Interferon-a 
and autocrine transforming growth factor p have been shown to exert a direct 
inhibitory effect on TERT expression in cell lines derived from human 
malignant cancers. Both these factors are involved in control o f cellular 
proliferation, and it is possible many more such factors exert similar influence 
(Yang, Kyo, et al 2001).
1.7.2 Epigenetic regulation of TERT gene
DNA méthylation is a common, programmed alteration of genomic sequences 
that has been shown to be essential for normal development (Reik & Dean
2001). The possibility that abnonnal méthylation may lead directly to up 
regulation of hTERT activity exists though whether this occurs remains to be 
resolved. It is clear that abnormal méthylation down regulates tumour 
suppressors such as p l6  and pRb and is associated with human cancers and so 
such a relationship may be implied (Laird & Jaenisch 1994). In addition, a 
reverse correlation has been shown between the degree of méthylation of the 
hTERT promoter and telomerase activity in B-cell lymphocytic leukaemia 
(Bechter, Eisterer, et al 2002); it is possible such relationships are not rarities, 
but are as yet undiscovered.
1.7.3 Other TERT controls
Transcriptional regulation of hTERT is undeniably important for the regulation 
of telomerase activity in cells. However, the large volume of work that has been 
dedicated to categorising the telomerase activity status of normal human tissues 
has revealed other points of control. For example full-length hTR and hTERT 
mRNA are readily detectable in human lymphocytes, tonsils, peripheral B and T
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cells and ovarian tissue without the presence of detectable telomerase activity 
(Ulaner, Hu, et al 2000) (Liu, Schoonmaker, et al 1999). This posttranscriptional 
control is likely to relate to phosphorylation o f hTERT by serine/protein kinases, 
which is a modification necessary for activity that has been demonstrated by a 
number of different workers (Akiyama, Hideshima, et al 2002) (Minamino & 
Kourembanas 2001) (Haendeler, Hoffmann et al 2003). Interestingly, 
phosphoiylation regulation of hTERT may exert control over telomerase activity 
in part by influencing the location of hTERT within the cell. hTERT tyrosine 
phosphorylation at position 707 has been linked with nuclear export of hTERT, 
and increased antiap opto tic activity (Haendeler, Hoffmann et al 2003). This also 
indicates novel effects of TERT within the eytosol that are unrelated to 
telomerase actvity, and demonstrate clearly that regulation of telomerase and its 
components is more complex than initially thought. Furthennore, the finding of 
hTERT transcripts in foetal tissues and tumour cell lines that would result in a 
truncated or inactive protein indicate that alternative splicing also has a role to 
play in regulating telomerase activity. These include an a transcript which lacks 
36 nucleotides from the 5' end of exon 6, the p transcript, which lacks exons 7 
and 8 entirely, both a  and p spliced transcripts and a number of insertional 
alternative transcripts (Ulaner, Hu, et al 1998) (Ulaner, Hu, et al 2001) (Ulaner, 
Hu, et al 2000) (Yokoyama, Wan, et al 2001).
The exact repressor gene or genes responsible for suppressing hTERT 
transcription have yet to be identified, however a gene/number o f genes on the 
short ai-m of chromosome 3 suppress telomerase activity, (Tanaka, Shimizu, et al
1998) and produce permanent growth arrest in breast cancer cells (Cuthbert, 
Bond, et al 1999). Antagonism of growth hormone releasing hormone also 
produces down regulation of the hTERT gene in human glioblastomas, but the 
mechanism o f suppression is not known (Kiaris & Schally 1999).
Initial investigations into the location of the telomerase gene placed it at a sub- 
telomeric region of the short aim of chromosome 5p (Bryce, Morrison, et al
2000). This data led workers to speculate that telomere position effect (TPE) 
might be the key to explaining transcriptional regulation. TPE has been 
characterised in both yeast and human cells, and refers to the reversible silencing
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of a gene near the telomere (Tham & Zakian 2002) (Baur, Zou, et al 2001). 
More recent data indicates that the hTERT gene is positioned more than 2 Mega 
bases from the telomere, and so it is likely other control mechanisms are at work 
(Leem, Londono-Vallejo, et al 2002).
1.8 Telomeres, telomerase and cancer
The unchecked cellular division that is a feature of cancer cells indicates these 
cells have evolved a way to overcome the end replication problem. Telomerase 
reactivation is the most common way in which cancer cells overcome end 
replication problem, and telomerase activity in a growing mass is a strong 
indicator of malignancy (Shay and Bacchetti 1997). Bodnar et al described the 
first direct evidence of the ability of telomerase to extend the replicative life 
span of a cell line. This showed conclusively that forced expression o f the 
catalytic component o f human telomerase, hTERT was sufficient to reconstitute 
telomerase activity in the test cells, and that the newly telomerase positive cells 
were capable o f dividing well beyond their accepted replicative limits. In 
addition to this the telomerase positive clones had elongated telomeres, and 
reduced p-galactosidase activity compared with their telomerase negative 
counter parts (Bodnar et al 1998).
A number of telomerase positive cell lines have shown continued telomeric 
attrition after immortalisation, which has lead to the opinion that another 
property of telomerase beyond telomere maintenance may contribute to the 
process of immortalisation (Zhu, Wang, et al 1999). Stewart et al examined the 
capacity of oncogenic H-Ras to transform previously immortalised cells and 
provided experimental evidence for this. Expression of H-Ras in a cell line 
immortalised by an alternative pathway did not cause transformation, however 
when these cells where forced to express hTERT and the experiment repeated 
successful transformation occuiTed and the cells developed a tumorigenic
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phenotype. Crucially, this was also possible using a mutant form of hTERT that 
retains catalytic activity, but cannot maintain telomeres; providing clear 
evidence for a non-telomere based contribution of telomerase to tumorigenesis 
(Stewart, Hahn, et al 2002).
Whilst these data indicate telomerase activity acts as a facilitator of malignancy, 
telomerase activity per se is not sufficient to cause cancer, i.e. telomerase is not 
an oncogene. This is borne out by the obseiwation that certain germ line cells and 
stem cells are telomerase positive, but are not cancerous (Kim, Piatyszek, et al 
1994) (Broccoli, Smogorzewska, et al 1997). Telomerase activity does however 
confer unlimited replicative potential on a cell, which allows for the 
accumulation of mutations that may eventually lead to malignancy.
1.8.1 The Alternative Lengthening of Telomeres (ALT) 
pathway
Not all tumours, or tumour derived cell lines are telomerase positive. As many as 
10% of human tumour derived cell lines are telomerase negative and rely on an 
alternative mechanism of telomere maintenance termed ‘Alternative 
Lengthening of Telomeres,’ (ALT) (Bryan & Reddel 1997). The mode of action 
of the ALT pathway is poorly understood, however cell fusion experiments have 
shown that ALT is triggered by recessive mutation(s) (Perrem, Bryan, et al
1999). The initial insight into the mechanism of ALT was gained by Murane et 
al, whose experimental work demonstrated fluctuations in telomere lengths of 
ALT positive cells consistent with a recombination mechanism (Murnane, 
Sabatier, et al 1994).
Human cells with an active ALT pathway characteristically have widely vaiying 
telomere lengths within the same cell, including telomeres so short as to be 
undetectable, and those so long as to be considered abnormal for that particular 
cell type (Grobelny, Godwin, et al 2000). This is in contrast to the situation in 
telomerase positive human cell lines, where mean telomere length is relatively 
homogenous around 5 kb (Chu, Piatyszek, et al 2000). The two modes of
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telomere length maintenance are not mutually exclusive, and both telomerase 
activity and the ALT mechanism have been demonstrated in the same human 
cell line (Cerone, Londono-Vallejo, et al 2001).
Many ALT cell lines have also been found to contain nuclear structures referred 
to as ALT associated PML bodies (APBs) (Yeager, Neumann, et al 1999). PML 
(promyelocytic leukaemia) nuclear bodies (PNBs) have been implieated in 
oncogenesis and viral infection. They are usually 0.3-1 (im in diameter, and a 
typical mammalian nucleus may contain 20-30 such structures. (Ruggero, Wang, 
et al 2000) (Boisvert, Hendzel, et al 2000). APBs are disc or ring shaped PMLs 
with ALT specific contents, such as telomeric DNA and TRFl and TRF2. APBs 
are the first PBLs found to contain DNA (Yeager, Neumann, et al 1999). In 
addition they have been found to contain a range of proteins involved in DNA 
replication and recombination (reviewed in Henson et al 2002). It is possible 
APBs may gather or modify the proteins required for functioning of the ALT 
mechanism. Recent work has shown that APBs may localise at nuclear foci in 
response to DNA damage, in association with factors that are associated with 
DNA repair such as RAD51 (Bischof, Kim, et al 2001).
Presently there are four proposed mechanisms by which homologous 
recombination may result in telomere replication. The first proposes inter- 
telomeric recombination events as the mechanism by which ALT maintains 
telomeres (Dunham, Neumann, et al 2000). As this mechanism involves the 
fondation of a displacement loop, it raises the second possibility that the 
displacement loops created by the formation of the T-loops identified by Griffith 
et al (Griffith, Comeau, et al 1999), and described previously may be the basis 
o f another mechanism of recombination dependant replication; in essence a self- 
replicating telomere (Henson, Neumann, et al 2002). The third and fourth 
hypotheses are based on an extra-chromosomal step involved in the copying of 
telomeric sequence. This mechanism involves extrachromosomal telomeric 
repeats (ECTR) in either a linear or circular format. ECTR have been identified 
in various types of cells, however they are generally restricted to ALT positive 
cells (Ogino, Nakabayashi, et al 1998). Circular ECTR has been utilised by K.
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lactis to extend its telomeres, and linear ECTR has been identified in all ALT 
cell lines that have been tested (McEachern 2001) (Yeager, Neumann, et al 
1999).
An important recent development in ALT research is the finding that ALT 
positive cell lines failed to produce macroscopic lung tumours even seven weeks 
after tail vein injection in mice using five different cell lines. By contrast once 
telomerase activity had been reactivated, the same five cell lines produced 
tumours large enough to kill the injected mice after 5 weeks. The conclusion 
reached is that ALT positive tumours, whilst capable of producing locally 
aggressive lesions appear to lack the ability to metastasise. This could be of great 
importance for the targeting of fiiture cancer therapies based on anti telomerase 
therapy (Chang, Khoo, et al 2003).
1.8,2 Telomerase as a therapeutic target
The clear evidence linking telomerase activity to cellular immortalisation and 
cancer development makes telomerase an attractive target for anti-cancer 
therapeutic research (Yan, Coindre, et al 1999). The aim of this therapy would 
be to restore mortality to telomerase positive cancers via telomerase inhibition, 
allowing telomeric attrition to lead to cell senescence, or preferably a genetic 
crisis resulting in cell death. The therapeutic strategy is outlined in Figure 1-5. 
One of the main attractions of this type of therapy and a potential advantage over 
traditional methods is the very low levels of telomerase activity in normal 
tissues, allowing selective targeting o f cancer cells with a minimum of toxic side 
effects (Bearss, Laurence, et al 2000). As previously mentioned, a range of 
normal tissues do retain telomerase activity, however selective tumour cell 
killing is still feasible as the majority of tumours investigated have shorter 
telomeres and higher proliferation rates than normal proliferating cell 
populations (Hastie, Dempster, et al 1990), (Bacchetti 1996). Thus, targeted 
anti-telomerase therapy aimed at a tumour cell population known to possess 
short telomeres would only require a short number of cell divisions before a 
therapeutic effect is seen, and this period of therapy should not effect the
39
telomere functions of the subject’s population of germ and stem cells. The 
corollary of this is that anti-telomerase therapy may be ineffective in tumours 
with long telomeres, as the tumour may have progressed to a fatal outcome 
before senescence is triggered. It is possible that such tumours, whilst having 
substantial mean telomere lengths may have telomeres on specific chromosomes 
that are short enough to trigger a swift growth check. Despite this, the reality is 
that it is very unlikely all tumours will lend themselves to this type o f therapy. 
These drawbacks, particularly the lag before therapeutic effect mean that 
antitelomerase therapy is unlikely to be a first line treatment for cancer, rather at 
present it is envisioned that these drugs will be deployed after primary therapy 
(such as surgery, radiotherapy, traditional chemotherapy) in a ‘mopping up’ role 
against surviving cancerous cells. Such therapy would be aimed at increasing 
remission times in clinical cases, or perhaps to affect a cure if the cancer was 
particularly sensitive to the agent (i.e. had short telomeres). In this regard, 
tandem research using existing therapies will focus on identifying which o f these 
agents increase cancer cell vulnerability to telomerase inhibitors (Corey 2002).
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Figure 1-5. Strategy for anti-telomerase cancer therapy. The aim of anti- 
telomerase therapy is to cause telomeric attrition in treated cancer cells, leading 
to senescence, or more favourably cell death. Such therapy is likely to be used as 
an adjunct to traditional treatment strategies, and the specificity of such agents 
will likely mean this therapy is particularly useful against metastatic disease and 
after primary debulking of a tumour.
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1.8.3 Telomerase inhibitors
1.8.3.1 Reverse transcriptase inhibitors
The catalytic component of telomerase functions as a reverse transcriptase, and 
some of the earliest telomerase inhibition studies investigated the effects of 
drugs that are known to inhibit retroviral reverse transcriptase. The dmgs used 
included Azidothymidine triphosphate, dideoxyguanosine, arabinofiiranyl- 
guanosine, dideoxyinosine, dideoxy adenosine, didehydrothymidine and 
phosphonoformic acid. Whilst all these drugs are known inhibitors o f retroviral 
reverse transcriptase, the emerging results with hTERT are not encouraging. 
Prolonged exposure of telomerase positive immortalised B- and T-cell lines to 
the panel o f drugs resulted in telomerase inhibition in only two cases; with 
azidothymidine and dideoxy guano sine. O f these two, only dideoxyguanosine 
translated this effect into telomere shortening in every test culture, but cmcially 
it had no effect on population doubling or cell survivability, even when drug 
exposure was extended to almost a year. The results indicated that the drug 
effect is caused by dideoxyguanosine binding to and competing for the 
nueleoside triphosphate binding site, and the results were not made more 
favourable by using combinations of the test drugs (Strahl and Blackburn 1996).
1.8.3.2 Telomerase RNA targeting
The majority o f antitelomerase therapy tested to date has been directed against 
hTR. These agents are stably transfected antisense complementary DNA 
(cDNA), synthetic modified oligonucleotides with antisense polarity, targeted 
ribozymes and RNA interference (Feng, Funk, et al 1995), (Mata, Joshi, et. al 
1997), (Yokoyama, Takahashi, et al 1998).
1.8.3.2.1 Oligonucleotides
The RNA template region is considered a good target for antisense 
oligonucleotides for several reasons. First, the necessity of telomerase RNA to 
base pair with the telomere sequence for telomerase function indicates that this
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region of the ribonucleoprotein must be accessible externally, and therefore it is 
a relatively available target within the cell. This is particularly the case when 
using oligonucleotides, as previous experience has given rise to compounds with 
favourable pharmacokinetics for cellular uptake, and furthermore chemically 
similar oligonucleotides have similar pharmacokinetics regardless of their target 
sequence (Corey 2002). Second, as the 11 base pair sequence of the RNA 
template region o f hTR is known, design of the oligonucleotide itself is simple. 
Third, there are commercially available sources of oligonucleotides with widely 
varying chemical properties that may assist in achieving therapeutic effect, and 
as this is not a nascent technology, previous experience in this field will assist in 
development of clinical trials. Finally, use o f oligonucleotides containing 
mismatched bases provides a convenient control of target specificity. An 
example of oligonucleotide technology already in development as an anti-cancer 
therapy is ‘Gentasense,’ being developed by Genta Corp. to target Bcl-2. This 
drug has shown promising results in trials against a number o f different cancers 
(Dias & Stein 2003).
A hexameric phosphorothioate oligonucleotide has inhibited telomerase activity, 
lengthened cell-doubling time and induced apoptosis in a Burkitf s Lymphoma 
derived cell line in vitro. Using a xenograft human-nude mouse model to assess 
in vivo efficacy, this oligonucleotide caused a significant reduction in tumour 
size and splenic metastasis compared with mismatched sequence and saline only 
negative controls (Mata, Joshi, et al 1997). These results show that despite the 
drawbacks associated with telomerase inhibition therapy it is an area with 
potential for considerable success in the future.
1.8.3.2.2 Ribozymes
Preliminary results using hammerhead ribozyme technology have also gained 
promising results. Flammerhead ribozymes are small RNA motifs that have the 
ability to catalyse cleavage of the RNA phosphodiester chain at defined sites 
(Blount & Uhlenbeck 2002). Ludwig et al have reported the use of a 
hammerhead ribozyme that cleaved telomerase (hTERT) mRNA in vitro 
(Ludwig, Saretzki, et al 2001). This compound was stably expressed in a breast
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cancer tumour cell line (MCF-7) using a mammalian expression vector delivery 
system, and in addition to resulting in reduced telomerase activity caused 
telomere reduction, growth inhibition and apoptosis.
1.8.3.2.3 RNA interference
RNA interference (RNAi) is a recent innovation that utilises cellular machinery 
that has evolved to target parasitic RNAs, including RNA viruses (Hutvagner & 
Zamore 2002). The mechanism is triggered by dsRNA, which becomes 
processed by double strand specific RNase to shorter RNA fragments. The 
shorter RNA fragments become incorporated into, and confer sequence 
specificity upon an RNase protein complex termed RISC that then targets the 
homologous RNA sequence for degradation (Hammond, Boettcher, et al 2001). 
The system may be triggered by artificially generated short dsRNAs, and these 
short interfering RNAs (siRNAs) have been tried against hTERT and the 
telomerase template RNA. Both agents reduced telomerase activity in a variety 
of human cancer cell lines, and although the effect was minor and short-lived, 
the result is interesting as it represents a success against a target thought to be 
restricted to the nucleus by a modality thought only to be effective in the 
cytoplasm (Kosciolek, ICalantidis, et al 2003).
1.8.3.3 Telomerase specific gene therapy
Recent studies have focussed on the potential to exploit the significant 
correlation between TERT promoter activity and telomerase activity to target 
telomerase specific suicide gene therapy (Gu, Kagawa, et al 2000). Considerable 
success has been achieved using a bacterial nitroreductase system under the 
control of the telomerase gene promoter for hTERT. This strategy has been 
shown to result in cell death in vitro in cell lines with high promoter activity, and 
result in significant tumour reduction in vivo using a xenograft model (Plumb, 
Bilsland, et al 2001).
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1.8.3.4 Other compounds
Non-nucleoside low molecular weight molecules that interact with the proposed 
G-quadmplex structures have also been tested. One such molecule, a pentacyclic 
acridine (RHPS4) is a potent telomerase inhibitor. Such therapies target the four- 
stranded G-quadruplex structure formed by single stranded telomeric DNA. 
These drugs have been shown to be efficacious, and are hypothesised to act by 
stabilising a quadruplex structure formed by the first few hexanucleotide repeats 
synthesised by telomerase. This is inhibitory because telomerase requires a 
single stranded telomeric primer for positioning, and thus folding o f the target 
sequence in a four-stranded structure prevents this (Gowan, Heald, et al 2001).
1.9 Mice as models for human telomerase studies
As described previously, the frequency of spontaneous immortalisation of 
human fibroblasts is vanishingly small (Wright & Shay 2000), and this is linked 
to the tight cellular controls on telomerase activity. However, telomerase activity 
is widespread in murine tissue, and yet murine cell lines that are telomerase 
negative actually immortalise with approximately ten million fold greater 
frequency than normal human cells. Furthermore, although the telomeres of the 
laboratory mouse, Mus musculus are several times the size of human telomeres 
(40-60 kb versus 5-15 kb), cell lines derived from these mice develop, after 10- 
15 population doublings, the characteristic phenotype and biochemical markers 
of senescent cells. This occurs in both wild type (telomerase positive) and 
murine telomerase RNA knockout (mTR'^') mice, and would seem to provide 
direct evidence to refute the idea of a telomere driven replicative senescence that 
may be overcome by telomerase activity (Artandi and DePinho 2000) (Blasco, 
Lee, et al 1997 36 /id).
Closer examination of this data reveals that mice may not represent a paradox 
after all. The postulated role o f telomerase in cancer development is that 
telomerase activity allows the additional divisions necessary for genetic 
mutation to lead to full-blown malignant transformation. Such a mechanism is
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only necessary if  telomeric attrition represents an effective block to these extra 
replications. As pointed out by Wright and Shay (Wright and Shay 2000), this is 
clearly not the case in an animal with the large telomeric reserve of the mouse, 
and so telomerase down regulation has not evolved in normal murine tissue, as it 
would be ineffectual as an anti-cancer mechanism in this species.
In addition, it would appear murine tissue does not follow the established M l, 
M2 growth blocks that occur in human tissue, as M2 in the mouse appears to 
contribute to, rather than help to prevent tumour formation. Fifth and sixth 
generation mTR'^' mice with noimal p53 activity provide the evidence for this. 
By the fifth generation, these mice have sufficiently short telomeres to produce a 
growth check, however the frequency of escape from crisis in sixth generation 
mice approaches 100%. This contrasts sharply with the figure of 10"^  for human 
cells that are telomerase negative at the equivalent crisis/M2 stage (Chin, 
Artandi, et al 1999) (Shay & Wright 1989).
The evolutionary advantage long telomeres confer on an organism is thought to 
be the facility to efficiently align chromosomes during meiosis, and is therefore 
completely independent of any cellular division counting mechanism (Wright & 
Shay 2000). It is postulated that telomerase repression evolved in tandem to 
maintain telomeres at the appropriate size for this function. Further to this line of 
argument, it is postulated that shorter telomeres, and the co-existent telomere 
driven growth arrest would be of little use to the mouse, first because the 
restriction on tissue repair would outweigh any potential anti-eancer benefit in 
an animal with a short life-span, and second, in an organism the size of a mouse 
a telomere based growth arrest with a lag period encompassing many rounds of 
cell division is unlikely to be of benefit when even a small mass in any part of 
the body is life-threatening (Wright & Shay 2000) (Takahashi, Kuro, et al 2000).
This intriguing explanation for the unusual telomere length and telomerase 
activity found in the mouse is based on work carried out in highly inbred 
laboratory strains, and has recently been countered by new evidence that 
inbreeding causes a net increase in telomere length with strain specific 
significant variation, and therefore the traditional mean telomere length o f the
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mouse (40-60 kb) may be an artefact (Hemann & Greider 2000) (Manning, 
Crossland, et al 2002). If this is proven to be the case, then the view of Wright et 
al (Wright & Shay 2000) that long telomeres are the evolutionary result of small 
size and short life span will need to be reviewed.
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1.10 Aims of the project
There is much evidence to suggest that telomeres and telomerase are key 
components in the process of immortalisation and cancer progression, and 
possibly the ageing process. However, the majority of research carried out to 
date has been in the human field, and relatively little is known of the biology o f 
telomeres and telomerase in the dog and cat. The aims of this project were to 
carry out a comprehensive investigation of telomere and telomerase biology as it 
relates to companion animals along three broad themes.
1. Telomere studies
The aims were to assess telomere lengths in a wide range o f normal canine and 
feline tissues, peripheral blood samples, tumours and immortalised cell lines, 
and examine the effect o f age, breed, and gender on telomere length in the dog 
and cat in vivo, whilst telomere attrition was also investigated in vitro using 
primary fibroblast cultures.
2. Telomerase studies
The aims were to assess the distribution of telomerase activity in a wide range of 
normal canine and feline somatic tissues, tumour samples, immortalised cell 
lines and primary cultures. The effects of a potential telomerase inhibitor were 
assessed in telomerase dependant canine cell lines, and the link between 
telomere attrition and senescence in the dog and cat was investigated using 
heterologous expression o f the catalytic component o f human telomerase in 
canine and feline primary cultures.
3. Gene expression studies
The aims were to cany out an investigation of changes in the transcriptome of 
ageing canine fibroblasts using a DNA microarray platform. The same 
technology was used to assess changes in gene expression levels concurrent with 
reactivation o f telomerase in a human ALT cell line.
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Materials and Methods
2.1 Materials
Materials in regular use such as equipment and general solutions are detailed in 
this section.
2.1.1 Cell culture materials
2.1.1.1 Sources of cell lines
CMT3, CMT7 and CMT8 cells were donated by G. Ruttemann, Department of 
Clinical Sciences of Companion Animals, Faculty o f Veterinary Medicine, 
University of Utrecht, PO Box 80.154, 3508 TD Utrecht, The Netherlands. 
GM847 cells were donated by W. N. Keith, Department o f Medical Oncology, 
Beatson Laboratories, University of Glasgow.
S22, SFA and EQl cultures were all generated from post mortem skin biopsy 
samples taken with informed owner consent at Glasgow University Veterinary 
School. The 3132T and GHK cell lines were generated from post-mortem biopsy 
samples taken with informed owner consent at GUVS.
CCL-176, CMLIO, MDCK, 293T, MCF7, D-17 and A-72 cells were all supplied 
by the American Type Culture Collection (ATCC), Manassas, VA.
AG08075, AG07906, AG07648 and AG08157 primary cultures were all 
supplied by Coriell Cell Repositories (CCR), 403 Fladdon Ave., Camden, NJ 
08103.
2.1.1.2 Plasticware
Tissue culture flasks, 6, 12, 24 well plates, Falcon conical centrifuge tubes (15 
and 50 ml), and pipettes (5, 10, 25, and 50 ml) were supplied by Greiner 
(Gloucestershire, UK). Ninety-six well plates were supplied by Packard 
(Berkshire, UK).
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2.1.1.3 Solutions, media and supplements
Gibco BRL Life Technologies and Sigma Genosys supplied all solutions and 
media, unless otherwise stated.
2.1.1.3.1 Media
All the following media were delivered as sterile solutions and stored at 4‘’C- 
Dulbecco’s Minimum Essential Medium (MEM) with Glutamax-L and 4500 
mg/L glucose and pyridoxine
MEM-Alpha, with ribonucleosides and deoxyribonucleosides 
MEM with Earle’s salts
MEM with Earle’s salts and NaHCOs without L-Glutamine 
RPMI 1640 medium without L-glutamine.
2.1.1.3.2 Supplements
Foetal Calf Serum (FCS): virus and mycoplasma screened, FCS was stored in 50 
ml aliquots at ~20°C, and was used both with and without heat inactivation. 
When heat inactivation was required this was carried out at 56°C for 30 minutes 
before storage in aliquots.
L-glutamine: supplied as a 200 mM (lOOx) stock, and stored at -20°C in 5 ml 
aliquots.
Penicillin/streptomycin (P/S): supplied as a lOOx stock of 10,000 units penicillin 
and 10,000 units streptomycin per ml and stored in 5 ml aliquots at -20°C.
G418 antibiotic: supplied as a 50 mg/ml solution and stored in 800 pi aliquots at 
-20°C. G-418 is an aminoglycoside antibiotic produced by Streptomyces that 
induces cytotoxicity by blocking translation.
Fungizone (Amphotericin B): supplied as a lOOx stock solution and stored in 5 
ml aliquots at -20°C, at a working concentration of 1.25 pg/ml.
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Non-essential amino acids: supplied as a lOOx stock solution and stored at 4°C. 
Concentrations and constituents of the Ix working solution are available from 
the supplier (GibcoBRL, Catalogue number 11140)
Trypsin-EDTA: supplied as a lOOx stock solution and stored in 5 ml aliquots at - 
20°C.
Essential amino acids: supplied as a 50x stock solution and stored at 4°C. 
Concentrations and constituents of the Ix working solution are available from 
the supplier (GibcoBRL, Catalogue number 11130)
Sodium pymvate: supplied as a 100 mM stock solution and stored at 4°C. 
Vitamins for MEM media: supplied as a lOOx stock solution and stored at 4®C.
2.1.2 General chemicals
Chemicals used were of analytic, ultrapure or molecular grade quality and were 
supplied by a range of companies.
2.1.3 Complete kits
QIAquick® Gel Extraction kit (QIAGEN, UK)
QIAamp® DNA blood midi and maxi kits (QIAGEN, UK)
EndoFree® Plasmid Maxi Kit (QIAGEN, UK)
TOPO TA Cloning® (Invitrogen, UK)
DNA Sequencing Kit Big Dye™ Terminator Version 3.0 Cycle Sequencing 
Ready Reaction (ABI, UK)
TeloTTAGGG  PCR ELISA*'^^^ Kit (Roche, UK)
RNeasy Total RNA Isolation Kit (QIAGEN, UK)
ENZO® Bioarray HighYield RNA transcript labelling kit (Affymetrix, CA)
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2.1.4 Bacterial strains
2.1.4.1 E.COÜ  One Shot* TOPIO
Chemically competent E.coli cells (>1 x 10  ^ colony forming units/pg) 
(Invitrogeii). Genotype: F mcrA à{mrr-hsdKMS-mcrBC)<^SO /acZAMlS 
AlacX74 deoR recA l ardD\?>9 à{ara-leu)7691 gallJ galK rpsh (Str^) endAl 
nupG
2.1.5 DNA
Plasmid, molecular weight markers and oligonucleotide DNAs were stored at - 
20°C.
2.1.5.1 Plasmid vectors-PCI-neo Mammalian Expression Vector
PCI-neo Mammalian Expression Vector is supplied by Promega UK, and is 
derived from the pGEM®-3Zf(+) vector and contains a cytomegalovirus (CMV) 
immediate-early enhancer/promoter region with a downstream chimeric intron, 
T7 and T3 RNA polymerase promoters, an SV40 late polyadenylation signal and 
a neomycin phosphotransferase selectable marker which confers resistance to the 
antibiotic G-418, causing antibiotic inactivation through phosphorylation.
2.1.5.2 Molecular size standards
Molecular size standards used include a 1 kb DNA ladder (size range: 75-12,216 
bp), 1 kb Plus DNA ladder^M (size range: 100-12,000 bp), 100 bp DNA Ladder 
(size range: 100-2072 bp), and a Low DNA Mass™ Ladder (size range: 100- 
2000 bp and 5-400 ng) all supplied by GIBCOBRL Life Technologies, and a 
CHEF DNA Ladder supplied by BIO-RAD Ltd (size range: 8-48.5 bp).
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2.1,5.3 Oligonucleotide primers
Oligonucleotides for polymerase chain reaction (PCR) and cycle sequencing 
were supplied by both MWG Biotech and Sigma-Genosysis, and were delivered 
as lyophilised DNA. Primers were reconstituted in distilled water (dH20) and 
stored at -20°C in 20 pi aliquots at 10 pM.
2.1.6 Enzymes
All enzymes were stored at -20°C and were removed from storage immediately 
before use.
2.1.6.1 Restriction enzymes
All enzymes and their associated buffers were supplied by GIBCO BRL (UK) 
and Invitrogen (UK). Details of restriction enzymes, their restriction sites and 
reaction conditions are shown in Table 2-1.
2.1.6.2 T4 DNA Ligase
T4 DNA ligase was provided by Promega UK, with a ligation buffer (used at a 
final concentration of 30 mM Tris-HCl (pH 7.8), 10 mM MgCh, 10 mM DTT 
and 1 mM ATP) to catalyse the joining o f two strands o f DNA between the 5 '- 
phosphate and the 3 '-hydroxyl groups of adjacent nucleotides in either a 
cohesive-ended or blunt-ended configuration.
2.1.6.3 Ready-To-Go^^ PCR beads
Ready-To-Go™ PCR beads (Amersham, Pharmacia) are premixed and pre­
dispensed reactions for PCR applications. When brought to a final volume of 25 
pi, each reaction contains Taq DNA Polymerase (1.5 units), 10 mM Tris-HCl 
(pH 9.0), 50 mM KCl, 1.5 mM MgCh, 200 pM of each dNTP and Bovine 
Serum Albumin (BSA).
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Table 2-1. Restriction enzymes.
Restriction
enzyme
Restriction site Buffer Incubation Temp 
CC)
H M l [5 '-G iA N T C-3'] REACT® 2 37
Rsa I [5'-GTiAC-3'] r e a c t ® 1 37
EcoR  1 [5 '-G iAA TT-3'l Buffer 6 37
Xho 1 [5'-CiTCGAG-31 Buffer 6 37
S a li [5'-GiTCGA-3'] r e a c t ® 10 37
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2.1.6.4 Murine Moloney Virus Reverse Transcriptase
Murine Moloney Virus Reverse Transcriptase (MMLV-RT) enzyme 
(GIBCOBRL) uses single stranded RNA in the presence of a primer to 
synthesise a complementary DNA strand. This enzyme is isolated from E.coli 
expressing a portion o f the po l gene of the MMLV on a plasmid.
2.1.6.5 DNase I: DNA-/re^TM
DNase I (Ambion) is a deoxyribonuclease I enzyme that cleaves both double 
stranded and single stranded DNA. Cleavage occurs preferentially adjacent to 
pyrimidine (C or T) residues, and the enzyme is therefore an endonuclease. 
Major products are 5 '-phosphorylated di, tri and tetranucleotides. In the presence 
of Magnesium ions, DNase I hydrolyses each strand of duplex DNA 
independently, generating random cleavages. In the presence of Manganese ions, 
the enzyme cleaves both DNA strands at approximately the same site, producing 
blunt ends or fragments with 1-2 base overhangs. DNase I does not cleave RNA.
2.1.7 Equipment
2.1.7.1 Major Equipment
PCR Machines: GeneAmp PCR System 2400, 2700, and DNA Thermal Cycler 
480 (Perkin Elmer, Boston MA, USA)
Stirrer: Magnetic StitTcr Hotplate (Stuart Scientific, Surrey, UK)
Balance: Précisa 100A-300M (Précisa Balances Ltd, Buckinghamshire, UK) 
Power packs: PAB 35-0.2 (Kikusui electronics corporation, Yokohama, Japan) 
Gel systems: Hoefer HE 33 Mini Horizontal Submarine Unit, CHEF system 
(Biorad, Hertfordshire, UK)
Incubator: B5042 (Heraeus, Surrey, UK)
Horizontal orbital shaker: 4628-ICE Labline Instruments Inc. (IL, USA)
Gel documentation system: Uvi tec (Thistle Scientific, Glasgow, UK)
Ultraviolet trans-illuminator: T2201 (Sigma Chemical Company, Surrey, UK)
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Pipettes: Finnpipette Techpette (0.5-10, 5-40, 40-200, 200-1000 pi, UK) 
Automatic Sequencing Apparatus: ABI 3100 (Amersham, UK) 
Spectrophotometer: GeneQuant pro  RNA/DNA calculator, Agilent 2100 
Bioanalyzer, Nanodrop ND-1000 (Cheshire, UK)
Water baths: Sub36, and W6 (Grant, Cambridge, UK)
Microcentrifuges: Centrifuge 5402, 5415R and Minispin (Eppendorf, Cambridge 
UK)
Benchtop centrifuge: CPR Centrifuge (Beckman, Buckinghamshire, UK) 
Biological safety cabinet (Microflow, Andover, UK)
Affymetrix: GeneChip® station and HGU133-A GeneChip® (Affymetrix UK)
2.1.7.2 Consumables
Eppendorf tubes: Flip-top and screw-top in both 1.5 ml and 0.5 ml sizes 
(Thermo Life Sciences, Basingstoke, UK)
Pipette tips: (Greiner, Gloucestershire, UK)
Filter tip pipette tips: A range of capacities (10, 100, 200, 1000 pi) supplied by
Finntip (Thermo Lab Systems, Basingstoke, UK)
Petri dishes: (Sterilin, Staffordshire, UK)
Bijoux: (Greiner, Gloucestershire, UK)
Universals: (Greiner Gloucestershire, UK)
Scalpel blades: Schwann-Morton (Sheffield, UK)
Parafilm: (Sigma, Surrey, UK)
Phase lock gel: Eppendorf, Basingstoke, UK
2.1.8 Buffers, solutions and growth media
2.1.8.1 Water
Water for the preparation of general solutions and media was provided by a 
Vivendi Water systems (USE ELGA) filter system. Sterile water for more
sensitive procedures such as PCR was supplied by Baxter Ltd.
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2.1.8.2 Buffers and solutions
50x TAE buffer solution: 2M Tris base, 50mM Na%EDTA, IM glacial acetic 
acid. pH adjusted to 8.15 using glacial acetic acid and made up to a 2 litre 
volume.
TBE buffer solution: 0.09 M Tris Borate, 0.002 M EDTA 
1 M Tris HCl: 121 g Tris base, 800 ml dH20. Adjusted to the desired pH with 
concentrated HCl and made up to 1 litre.
TE buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA
Ix Phosphate buffered saline (PBS): 140 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HP04, 1.8 mM KH2 PO4  (pH 7.3)
20x SSC: 3 M NaCl, 0.3 M Sodium citrate, pH 7.0
lOx DNA Gel loading buffer: 20% w/v Ficoll 400, 0.1 M Na2 EDTA (pH 8.0), 
1% w/v sodium dodecyl sulphate, 0.25% bromophenol blue. Stored at room 
temperature and used at a 1:10 dilution.
Ethidium bromide: made to a working dilution of 10 mg/ml with dH20 in a fume 
cupboard. Stored away from light.
Transfast™ transfection reagent: Supplied as a dried lipid fdm to be 
reconstituted with 400 pi of water per vial to form multi-lamellar vesicles. 
Storage of dried and reconstituted reagent is at -20°C. (Promega) 
LipofectamineT'^ transfection reagent: Supplied in liquid form at a concentration 
of 2 mg/ml and stored at 4°C. (Invitrogen, UK)
DEPC water: 0.5 ml of Diethylpyrocarbonate was added to 500 ml water, left 
overnight in a fume cupboard and then autoclaved before storage at 4°C.
Lysis mix: 0.32 M sucrose, 10 mM Tris, 5 mM MgCl, 1% Triton X, pH of 
solution adjusted to 7.5 and stored at 4°C.
Nuclei lysis mix: 10 mM Tris, 0.4 M NaCl, 2 mM EDTA (pH 8.0), stored at 
room temperature.
2.1.8.3 Bacteriological media
Media were sterilised by autoclaving at 12UC for 15 minutes.
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LB medium: 20 g tryptone, 20 g NaCl, 10 g yeast extract made up to 2 L with 
dHaO, pH then adjusted to 7.0 with NaOH
SOC medium: 2% tiyptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCh, 10 mM MgS0 4 , and 20 mM glucose. (Invitrogen, UK)
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2.2 Methods
Methods used commonly tluoughout the thesis are detailed in this section whilst 
more specific methods are dealt with in the relevant chapter. Many of the 
methods described here are based on standard protocols that are detailed in 
Current Protocols in Molecular Biology Volumes 1 & 2 (Ausubel, Brent, et al 
1994).
2.2.1 Growth of mammalian cells
2.2.1.1 Basic technique
All procedures involving mammalian cells were carried out in a laminar flow 
hood using standard aseptic procedures.
2.2.1.1.1 Cell counting
Cells were counted in a haemocytometer as follows. Cell pellets were suspended 
in an appropriate volume of media (usually 5 ml) to allow ease of counting in the 
haemocytometer chamber. A 25 pi volume o f the cell suspension was then 
diluted 1:1 in 0.4% trypan blue (Sigma) and incubated at room temperature for 1 
minute. The suspension was then introduced to the haemocytometer chamber 
and cell counts made using an inverted microscope with a 4 x 10 objective. Cells 
lying on the top and right side of the marked squares were not included in the 
count, those lying on the bottom and left perimeters were. Cell concentrations 
(cells/ml) were calculated by multiplying the mean numbers of cells per large 
marked square by 10'^  to account for the volume of the haemocytometer chamber 
and 2 to correct for the dilution factor. Dead cells were differentiated by uptake 
of the trypan blue stain and appear blue.
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2.2.1.1.2 Passage and cryopreservation of cells
Stocks of cells for long-temi storage were preseiwed over liquid nitrogen. Cells 
to be preserved were haiwested using 0.05% Trypsin- 0.53 mM EDTA at mid­
log phase growth and removed to a sterile 15 ml centrifuge tube. Cells were 
centrifuged at 1200 g for 2 minutes and the supernatant discarded. The cells 
were then re-suspended in freeze medium at a concentration of approximately 2 
X 10  ^ cells/ml. Freeze medium consisted of 45% culture medium, 45% foetal 
bovine serum, and 10% DMSO as a cryoprotectant. Cells were transferred in 1 
ml aliquots to labelled ciyovials (NALGENE'^'^) and brought to -70®C at a 
controlled rate of -1“C per minute using a NALGENE™ Cryo DC Freezing 
container (NALGENE, USA). The vials were then transferred to a liquid 
nitrogen freezer. Cell stocks were revived by rapid thawing in a 37"C water bath 
and used following standard techniques as described. All cell lines were 
reseeded at a concentration of 1 xlO^ cells/ml after passaging.
2.2.1.2 Cell lines
All cell lines form an adherent monolayer in culture, and were cultured in 75 
c n f  tissue culture flasks kept at 37“C and in 5% CO2 unless otherwise stated.
2.2.1.2.1 MDCK
S.H. Madin and N.B. Darby established the MDCK cell line from the kidney of 
an apparently normal female Cocker Spaniel in September 1958 (Gaush, Hard et 
al 1966). The cells were maintained in 20 ml Dulbecco’s MEM with glutamax-1 
medium supplemented with 10% FCS, 100 international units (IU)/ml penicillin 
and 100 lU/ml streptomycin and 1.25 pg/ml fungizone. Cultures were split, 
typically 1:9 every 3-4 days when sub-confluent. Cells were trypsinised and 
seeded into new flasks as described above.
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2.2.1.2.2 AG07648
The primary canine fibroblast culture AG07648 was established from a post­
mortem skin biopsy taken from the thorax area of a 6 year old female Beagle in 
May 1984. The species of origin was confirmed by chromosomal analysis; the 
karyotype was normal diploid female, 78XX. The cells were maintained in 
MEM Eagle medium with Earle’s salts, 2 times normal concentration of 
essential and non-essential amino-acids (Section 2.1.1.3.2), MEM Vitamins, 2 
mM L-glutamine, 100 lU/ml penicillin and 100 lU/ml streptomycin and 1.25 
pg/ml fungizone and 20% FBS. Cultures were split, typically 1:5 every 5-7 days 
when sub-confluent. Cells were trypsinised and seeded into new flasks as 
described.
2.2.1.2.3 AG07906
The primary equine fibroblast culture AG07906 was established from a post­
mortem sample taken from a skin biopsy sited at the right inner thigh of a 3 year 
old female thoroughbred horse. The sample was taken in June 1984. The species 
o f origin has been confirmed by chromosome analysis, and the karyotype is 
confirmed as normal diploid female, 64XX. The cells were maintained in MEM 
Eagle medium with Earle’s salts, 2 times nonnal concentration of essential and 
non-essential amino-acids (Section 2.1.1.3.2), MEM Vitamins, 2 mM L- 
glutamine, 100 lU/ml penicillin and 100 lU/ml streptomycin and 1.25 pg/ml 
fungizone and 20% FBS. Cells were trypsinised as standard, and reseeded at a 
ratio of approximately 1:5.
2.2.1.2.4 AG08075
The AG08075 primary canine fibroblast culture was established from a post­
mortem skin biopsy from the abdomen o f a 14-year-old female Beagle taken in 
March 1985. The species o f origin and karyotype were established by 
chromosome analysis; the karyotype was normal diploid female (78XX). The 
cells were maintained in MEM Eagle medium with Earle’s salts, 2 times normal 
concentration of essential and non-essential amino-acids (Section 2.1.1.3.2),
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MEM Vitamins, 2 mM L-gliitamine, 100 lU/ml penicillin and 100 lU/ml 
streptomycin, 1.25 pg/ml fungizone and 20% FBS. Cultures were split, typically 
1:5 every 5-7 days when sub-confluent. Cells were trypsinised and seeded into 
new flasks as described.
2.2.1.2.5 GM847
The GM847 cell line is an SV40 transformed human fibroblast cell line. The 
cells were grown in DMEM medium supplemented with 10% FCS, 100 lU/ml 
penicillin and 100 lU/ml streptomycin and 1.25 pg/ml fungizone. Cells were 
tiypsinised as standard every 3-4 days, and reseeded at a ratio of approximately 
1:5.
2.2.1.2.6 CCL-176
The primary feline fibroblast culture CCL-176 was established from a post­
mortem biopsy taken from the tongue of an embryonic female domestic cat. The 
cells were propagated in MEM Eagle medium with Earle’s salts supplemented 
with a normal concentration of non-essential amino-acids (Section 2.1.1.3.2), 
and 10% FBS. Cultures were split, typically 1:5 every 3-4 days when sub­
confluent.
2.2.1.2.7 CMT7
CMT7 is an immortal cell line established from a canine mammary tumour. 
CMT7 cells were maintained in RPMI medium supplemented with 10% FCS, 
100 lU/mi penicillin and 100 lU/ml streptomycin and 1.25 pg/ml fungizone. 
Cells were trypsinised as standard every 3-4 days, and reseeded at a ratio of 
approximately 1:5.
2.2.1.2.8 SFA
The canine primary fibroblast culture SFA was derived from a post-mortem 
flank biopsy from a 13 year old male Staffordshire Bull Terrier at GUVS. Cells
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were maintained in MEM-alpha medium supplemented with 10% FCS, 100 
lU/ml penicillin and 100 lU/ml streptomycin, 1,25 pg/ml fungizone and 2 mM 
L-glutamine. Cells were passaged routinely after 5-1 days. The culture was 
confirmed to be canine in origin by RT-PCR and sequence analysis for canine 
cyclophilin.
2.2.1.2.9 S22
The feline primary fibroblast culture S22 was derived from an eight week old 
female DSH cat from a flank skin biopsy. Cells were maintained in MEM-Eagle 
medium supplemented with 10% FCS, 100 lU/ml penicillin and 100 lU/ml 
streptomycin, 1.25 pg/ml fringizone and 2 mM L-glutamine. Cells were passaged 
routinely after 5-7 days growth in culture.
2.2.1.2.10 293T
A human derived, SV40 transformed cell line sourced from renal epithelial cells. 
Cells were maintained in DMEM medium supplemented with 10% FCS, 100 
lU/ml penicillin and 100 lU/ml streptomycin, 1.25 pg/ml fungizone and 2 mM 
L-glutamine. Cells were passaged routinely after 3-4 days growth in culture.
2.2.1.2.11 MCF7
The MCF7 cell line comprises epithelial-like cells derived from a human 
Caucasian breast adenocarcinoma patient. The cells were maintained in DMEM 
medium supplemented with 10% FCS, 100 lU/ml penicillin and 100 lU/ml 
streptomycin and 1.25 pg/ml fungizone. Cells were trypsinised as standard every 
3-4 days, and reseeded at a ratio of approximately 1:5.
2.2.1.2.12 AG08157
This canine primary fibroblast culture was established from a post-mortem skin 
biopsy taken from a 42-day-old male Beagle dog in 1985. The cell line was 
maintained in MEM Eagle medium with Earle’s salts, 2 times normal
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concentration of essential and non-essential amino-acids (Section 2.1.1.3.2), 
MEM Vitamins, 2 mM L-glutamine, 100 lU/ml penicillin and 100 lU/ml 
streptomycin, 1.25 pg/ml fungizone and 20% FBS. Cultures were split, typically 
1:5 every 5-7 days when sub-confluent. Cells were trypsinised and seeded into 
new flasks as described.
2.2.1.2.13 CMT8
CMT8 is an immortal cell line established from a canine mammary tumour. 
CMT7 cells were maintained in RPMI medium supplemented with 10% FCS, 
100 lU/ml penicillin and 100 lU/ml streptomycin and 1.25 pg/ml fungizone. 
Cells were trypsinised as standard every 3-4 days, and reseeded at a ratio of 
approximately 1:5.
2.2.1.2.14 CMT3
CMT3 is also an immortal cell line established from a canine mammary tumour. 
Conditions for culture were as for CMT8.
2.2.1.2.15 CMLIO
This canine cell line contained epithelial-like cells and was derived from a 
melanoma biopsy taken from a 10-year-old female dog. The cells were 
maintained in DMEM medium supplemented with 10% FCS, 100 lU/ml 
penicillin and 100 lU/ml streptomycin and 1.25 pg/ml fungizone. Cells were 
trypsinised as standard every 3-4 days, and reseeded at a ratio of approximately 
1:5.
2.2.1.2.16 D17
A canine osteosarcoma cell line derived from an eleven year old female poodle. 
Cells were maintained in DMEM medium supplemented with 10% FCS, 100 
lU/ml penicillin and 100 lU/ml streptomycin and 1.25 pg/ml fungizone. Cells
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were trypsinised as standard every 3-4 days, and reseeded at a ratio of 
approximately 1:5.
2.2.1.2.17 A72
An immortal canine cell line comprising cells of fibroblast morphology derived 
from an 8 year old female dog. Cells were maintained in DMEM medium 
supplemented with 10% FCS, 100 lU/ml penicillin and 100 lU/ml streptomycin 
and 1.25 pg/ml fungizone. Cells were trypsinised as standard every 3-4 days, and 
reseeded at a ratio of approximately 1:5.
2.2.1.2.18 GHK
A cell line comprising renal epithelial cells derived from a greyhoimd at GUVS, 
age and gender unknown. Cells were maintained in DMEM medium 
supplemented with 10% FCS, 100 lU/ml penicillin and 100 lU/ml streptomycin 
and 1.25 pg/ml fungizone. The cells were trypsinised as standard every 3-4 days, 
and reseeded at a ratio of approximately 1:5.
2.2.1.2.19 3132T
This immortal canine cell line comprised cells of an epithelial morphology and 
was derived from a lymphoma sample taken from a 10-year-old female dog. The 
cells were maintained in RPMI medium supplemented with 10% FCS, 100 
lU/ml penicillin and 100 lU/ml streptomycin and 1.25 pg/ml fungizone. Cells 
were trypsinised as standard every 3-4 days, and reseeded at a ratio of 
approximately 1:5.
2.2.1.2.20 EQl
This primary equine fibroblast culture was derived from a skin biopsy taken 
from a 7 year old male neutered horse at GUVS. Cells were maintained in 
MEM-alpha medium supplemented with 10% FCS, 100 lU/ml penicillin and 100 
lU/ml streptomycin, 1.25 pg/ml fungizone and 2 mM L-glutamine. Cells were
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passaged routinely after 5-7 days growth in culture. Species of origin was 
confirmed by RT-PCR and sequence analysis for equine major 
histocompatability complex class II, DQB locus (Szalai, Bailey, et al 1993).
2.2.2 Preparation of DNA from blood samples
2.2.2.1 Phenol/chloroform/isoamyl alcohol extraction and ethanol 
precipitation
To each 3 ml blood sample 10 ml of lysis mix (Section 2.1.8.2) was added 
followed by gentle mixing and incubation on ice for 10 minutes. Samples were 
then centrifuged at 2800 g for 10 minutes at 4°C, the supernatant decanted and 
pellets resuspended in 500 pi o f nuclei lysis mix (Section 2.1.8.2) and 
thoroughly mixed. A 100 pi volume o f 10% SDS and 50 pi of proteinase K were 
then added and the samples were incubated at 37°C overnight. Samples were 
then deproteinised with an equal volume of a phenol/chloroform/isoamyl alcohol 
extraction mixture (25:24:1), followed by centrifugation at 2800 g for 10 
minutes to separate the samples into aqueous and organic phases. The upper 
aqueous phase of each sample was then carefully transferred to a sterile 1.5 ml 
eppendorf tube and the DNA recovered by precipitation in an equal volume of 
molecular biology grade 100% ethanol. DNA was pelleted by centrifugation at 
2800 g for 10 minutes at 4°C followed by a wash step in 70% ethanol. DNA was 
again pelleted and allowed to air diy, before resuspension in an appropriate 
volume of TE buffer (usually 50 pi) and storage at -20°C
2.2.2.2 DNA extraction using the QIAamp® DNA kit (QIAGEN, 
UK)
Both the Midi and Maxi kits were used for DNA extraction as per 
manufacturer’s instructions. These kits are used for total DNA purification from 
1-2 ml and 5-10 ml of whole blood respectively. Briefly, the protocol involved a 
lysis step, followed by adsorption of nucleic acid to a membrane contained 
within a specially designed QIAamp spin column through which lysate was
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forced by centrifligal force. DNA bound to the membrane was then washed in 
two fiirther centrifugation steps before elution in a concentrated form in elution 
buffer. All centrifugation steps were carried out at room temperature, and at 
3000 rpm.
2.2.3 Recombinant DNA techniques
2.2.3.1 Storage and growth of bacteria
Plasmid DNA was maintained and stored in the E.coli strain One Shot®. 
Glycerol stocks were prepared from these bacteria and their transformants for 
long-temi storage as outlined below.
The desired bacterial culture was streaked onto a 1.5% agar plate (15g agar in 1 
litre LB medium); as the plasmid conferred ampicillin resistance the medium 
was supplemented with 50-100 pg/ml ampicillin. The plate was then incubated 
overnight at 37°C and the following day single colonies were picked using a 
sterile pipette tip into a sterile universal containing 3-5 ml LB medium 
supplemented with 50-100 pg/ml ampicillin. These cultures were then incubated 
at 37°C overnight in a horizontal orbital incubator at 225 rpm. Confirmation that 
this overnight culture was derived from bacteria containing the correct plasmid 
was confirmed by DNA isolation and restriction digestion. Glycerol stocks were 
prepared by addition of 90 pi of 50% glycerol to 210 pi o f culture broth to 
produce a 15% glycerol mixture. These glycerol stocks were then stored at -  
20"C and -70°C. Bacterial stocks were subsequently revived by taking a surface 
sample of the glycerol stock and streaking this onto an agar plate.
2.2.3.2 Extraction and purification of plasmid DNA
2.2.3.2.1 Large-scale plasmid preparation
Large quantities of highly pure, endotoxin free plasmid necessary for 
applications such as transfections and sequencing were prepared using the 
EndoFree® Plasmid Maxi Kit (Qiagen,UK). A starter culture in 3-5 ml of LB 
broth was used to seed an overnight multiplier culture in 250 ml of LB broth
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incubated at 37®C with constant agitation. These exponentially growing bacteria 
were haiwested by centrifligation o f the culture broth in 50 ml sterile centrifuge 
tubes at 2800 rpm. The remainder of the protocol was perfomied according to 
the manufacturers instructions. DNA was stored at -20°C.
2.2.3.2.2 Small-scale plasmid preparation
Requirements for small amounts of plasmid DNA, such as sequencing, were met 
using the QIAprep® PCR Spin Miniprep Kit (QIAGEN, UK). This kit isolated 
plasmid DNA from 4 ml LB broth cultures o f exponentially growing bacteria. 
The bacteria were harvested by centrifugation (2800 rpm for 10 minutes), and 
the manufacturers protocol was then followed. The method involved lysis of the 
bacterial cells to release the DNA constructs, which were then haiwested after 
centrifugation, filtration and wash steps into 50 pi of sterile water. DNA storage 
was at -20°C.
2.2.3.3 Determination of nucleic acid concentration and quality
2.2.3.3.1 Determination by spectrophotometry
Nucleic acid samples were diluted 1:20 by addition of 5 pi of resuspended 
nucleic acid in 95 pi of dH^O. Optical density readings were taken at 260 nm 
and 280 nm, using blank dH20 as a comparison. An optical density reading of
1.0 at 260 nm conesponds to an approximate nucleic acid concentration of 50 
pg/ml for double stranded DNA, 40 pg/ml for RNA and 33 pg/ml for single 
stranded oligonucleotides. The ratio of the readings taken at 260 nm and 280 nm 
(OD2 6 0 /OD2 8 0 ) was used to give an estimate o f the purity of the nucleic acid. 
Pure preparations of DNA and RNA have an OD2 6 0 /OD2 8 0  of L8 and 2.0 
respectively; a lower value suggests contamination, typically with protein or 
phenol.
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2.2.3.3.2 Estimation of double stranded DNA concentration and quality by 
agarose gel electrophoresis.
This method was used when there were insufficient amounts of dsDNA for 
spectrophotometry, or when purity of a particular DNA fragment needed to be 
investigated. Agarose gel electrophoresis was carried out by standard methods as 
detailed elsewhere (Section 2.2.3.5), and the intensity of the fluorescence of the 
unknown DNA was compared to that of a known size marker (Low DNA 
Mass™ Ladder) following staining with ethidium bromide and visualisation by 
UV transillumination. Smearing of a DNA band indicated degi'adation of the 
sample and resulted in exclusion of that DNA from further analysis.
2.2.3.4 Restriction endonuclease digestion
The required amount of DNA was digested in a volume of 20 pi containing 
appropriate buffer for the restriction endonuclease(s), 4 units of each enzyme per 
microgram of DNA and dHzO to make up the volume. The reactions were 
incubated at the appropriate temperature for a minimum of 1 hour.
2.2.3.5 Electrophoresis of DNA
DNA fragments of 0.1-22 kb were separated and identified by agarose gel 
electrophoresis using a Hoefer HE 33 Mini Submarine Electrophoresis Unit 
(Amersham Pharmacia Biotech, San Franciso, CA.). Typically 0.5 g of agarose 
was added to 50 ml of 0.5% TBE buffer and heated in a microwave oven for 1-2 
minutes to produce a 1% gel. This was allowed to cool to 55''C before addition 
of 1.5 pi of 100 mg/ml ethidium bromide. The gel was then mixed and poured 
into a casting tray containing a comb with a suitable number of wells (10-20). 
After solidification the gel was transferred to the electrophoresis unit containing 
chilled 0.5% TBE buffer and the comb was carefiilly removed. DNA samples 
and molecular size standards were prepared by addition of a suitable amount of 
lOx DNA loading buffer (Section 2.1.8.2) and introduced to the wells using a 
micropipette. Gels were imn at 100 V for approximately 20 minutes, then
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removed from the electrophoresis unit and the DNA visualised using a UV 
transilluminator (Uvi tec, Thistle Scientific) and photographed using a 
Mitsubishi P91 photographic unit.
2.2.3.6 Purification of restriction enzyme fragments
When purification of DNA fragments was required for construction of 
recombinant plasmids, the DNA was purified from agarose gels using the 
QIAquick® Gel extraction kit (QIAGEN). DNA fragments of interest were cut 
from an agarose gel using a clean scalpel blade and the protocol was then 
performed according to the manufacturers instructions.
2,23.1 Ligation of vector and insert DNA
Fragments of DNA generated by restriction digestion were ligated with 
approximately 50-100 ng of vector DNA using T4 DNA ligase (Promega) 
according to the manufacturers instructions. The quantities of vector and insert 
DNA to be used were calculated to produce a molar ratio of between 1:1 and 1:5 
using the equation:
X ng of vector x Y kb of insert x insert : vector ratio = ng of insert required 
Z kb of vector
Vector and insert were mixed with ligation buffer and 1 unit of DNA ligase in a 
total volume of 10 pi. Ligation reactions proceeded at 16°C overnight.
2.2.3.8 Transformation of bacteria with plasmid DNA
The TOPIC cells used in transformation experiments were stored in volumes of 
25-50 pi in microcentrifrige tubes at -80°C. Aliquots were thawed on ice, and 
0.5-5 pi of ligation reaction was added to the cells representing 1-20 ng of DNA. 
Mixing was carried out very gently to avoid damage to the bacterial cells. The 
cells were then left on ice for 30 minutes, followed by a 30 second heat shock at
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42”C. The cells were then quenched on ice for 2 minutes, 200 pi of SOC 
medium was added and the tubes were incubated at 37°C for 1 hour with shaking 
at 225 rpm. The cells were streaked onto LB agar plates containing ampicillin at 
100 mg/ml. The addition of ampicillin enabled selection o f transformants as the 
plasmid used in this project conferred ampicillin resistance on the host bacteria.
2.2.4 Preparation of total RNA
The unstable nature of isolated RNA and the necessity for very pure isolates for 
downstream applications required that all materials used in RNA preparation be 
totally free from ribonuclease (RNAse) activity. RNAse is a very stable, 
ubiquitous enzyme that degrades RNA requiring no cofactors for function. 
Inhibition of this enzyme was carried out using RNAse ERASE (ICN 
Biomedicals Inc., Ohio), followed by rinsing with DEPC treated water. All 
plastic-ware used for RNA storage was pre-treated by an overnight soak in 
DEPC treated water followed by autoclaving and drying. Solutions were also 
prepared using DEPC treated water only, and gloves were used in all procedures 
involving RNA.
2.2.4.1 RNA extraction using RNAwiz^i^
Various methods have been described for the isolation of undegraded RNA, and 
progress in the field have led to the development of single step methods for the 
procedure (Chirgwin, Przybyla, et al 1979) (Chomcyznski & Saachi 1987). 
RNAwiz'^*'  ^ is a combination of dénaturants and RNAse inhibitors for the 
isolation of total RNA, and it is effective for animal, plant and microorganism 
based RNA. The samples used for RNA isolation in this project were cell pellets 
harvested from tissue culture experiments, stored in 1.5 ml DEPC treated 
eppendorf tubes, as described above. These were homogenised directly in 
RNAwiz™ by simply pipetting vigorously several times. One ml of RNAwiz™ 
was used per 10  ^ cells. The homogenate was then incubated at room temperature 
for 5 minutes to allow dissociation of nucleoproteins from the nucleic acids. 
Chloroform was then added (0.2x starting volume), and thorough mixing was
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carried out by shaking the tube vigorously for approximately 20 seconds. The 
chloroform used was free from isoamyl alcohol and any other additives. The 
mixture was then centrifuged at 13000 rpm at 4“C for 15 minutes to allow 
separation of the mixture into three distinct phases, an upper aqueous phase 
containing the RNA, a semi-solid interphase containing most of the DNA, and a 
lower organic phase. The upper aqueous phase was removed carefully by 
pipetting and transferred to a clean DEPC treated 1.5 ml tube. RNase-free water 
was then added (0.5x starting volume), and thorough mixing carried out. This 
was followed by addition of Ix starting volume of isopropanol, mixing, and 
incubation of the sample at room temperature for 10 minutes. The RNA was then 
pelleted by centrifugation at 13000 rpm for 15 minutes at 4‘^ C. The supernatant 
was decanted, and a wash step using 75% ethanol was carried out, followed by 
centrifligation as noted above.
The RNA samples were stored at -20°C in 70% ethanol until required. When 
required, the RNA samples were pelleted by centrifugation as above and the 
supernatant decanted. The pellets were then allowed to air dry for no longer than 
10 minutes (complete diying of the pellet makes resuspension very difficult) and 
resuspended in 40 pi of DEPC water.
2.2.4.2 Assessment of RNA using agarose gel electrophoresis
An aliquot of each RNA sample was run on a 1% agarose TAE gel (lOg agarose 
in 1 litre TAE buffer). Assessment of RNA quality was earried out by checking 
the integrity of the I8S and 28S ribosomal subunit bands, and examining their 
rate o f migration in comparison to a 100 bp molecular weight standard (GIBCO 
BRL).
2.2.4.3 DNase treatment of RNA
RNA samples were freed from contaminating DNA by use o f the DNA-free'^M 
kit (Ambion). O.lx volume of I Ox DNase buffer and 2 units of DNase 1 were 
added directly to RNA samples, mixed and incubated at 37°C for 30 minutes.
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The enzyme reaction was then halted by addition of 5 pi of well-mixed slimy of 
DNase Inactivation Reagent followed by a 2-minute incubation at room 
temperature. The inactivation reagent was then pelleted by centrifugation at
10,000 g for one minute and the RNA sample transferred to a clean DEPC 
treated eppendorf for storage.
2.2.5 Amplification of DNA by polymerase chain 
reaction
The polymerase chain reaction (PCR) is a technique that allows the 
amplification of a specific sequence of DNA and is effective even when the 
target DNA is very scarce. The technique was developed by Mullis et al, and 
allows large amounts of a single copy gene to be generated from genomic or 
viral DNA (Mullis, Faloona, et al 1986) (Mullis & Faloona 1987) (Saiki, 
Gelfland, et al 1988) (Kwok, Mack, et al 1987). The initial procedure used the 
Klenow fragment of DNA polymerase I. This enzyme needed to be replaced at 
each cycle as it was denatured by the reaction conditions. Efficiency was greatly 
improved by introduction of a thermostable Taq polymerase isolated from 
Thermits aquaticiis, as this allowed automation of the procedure (Saiki, 
Gelfland, et al 1988).
PCR allows the amplification of any unknown DNA sequence by the 
simultaneous extension of primer pairs flanking the unlmown sequence, each 
complementary to opposite strands of the DNA. An overview of PCR and its 
applications is available (Innis & Gelfland 1990), and although the basic 
technique has been developed to include other applications such as cloning 
(Scharf 1990), basic PCR remains widely used. An outline of the procedure is 
provided below.
2.2.5.1 Primer design
Primers were designed following the guidance of a standard text (Innis & 
Gelfland 1990). The goal of primer design is to produce an oligonucleotide that
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will hybridise efficiently with the DNA sequence of interest, and not hybridise 
with any other sequence. The amount of sequence permissible between primers 
is flexible, and up to 10 kb is possible, however beyond 3 kb efficiency is 
decreased (Jeffreys, Wilson, et al 1988). The disadvantages of minimising the 
distance between the primers include reducing the ability to re-amplify the 
sequence using nested internal oligonucleotides, and short distances between 
primers result in less sequence information being gained from the PCR. For any 
given pair of primers, the annealing temperatures (Tm) and GC content were 
balanced.
Whilst in many PCR applications the primer design will be exactly 
complementary to the template DNA, in some cases, such as efforts to clone or 
detect homologues when sequence information is lacking, mismatches will be 
unavoidable. Independent of the reason for mismatches between template and 
primer DNA, it is best if these are located close to the 5 ' end of the primer. The 
closer a mismatch is to the 3 ' end of the primer the more likely it will prevent 
extension, as DNA polymerase will be acting in a 5 ' to 3 ' direction.
The annealing portion of primers should generally be between 18 and 30 
nucleotides in length; any increase in size beyond this is unlikely to improve 
primer specificity significantly and this size of primer is sufficient for sequence 
as complex as the human genome. Other potential features of the primer 
sequence, such as restriction enzyme sites should be engineered onto the 5  ' end 
of the primer. Such additions can have a detrimental effect on primer specificity 
at low temperatures, and so are best used when amplifying from a single 
template vector. Primer GC content should match that of the template as closely 
as possible. Unusual stretches o f sequence such as internal complementarities 
can lead to secondary structures and a loss of annealing efficiency, and so should 
be avoided.
A common artefact in PCR is the fonuation of primer-dimers. A primer-dimer is 
the product o f primer extension annealing on itself or on the other primer in the 
PCR. Since the primer-dimer product contains one or both primer sequences and 
their complementary sequences it provides an excellent template for further
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amplification. Given the small size of the product, and that small products are 
copied more efficiently, primer-dimers can swamp the PCR and sequester primer 
from the real target on the template DNA. These can be avoided by not using 
primers with complementary sequences in the 3 ' region. Primer dimers can be 
minimised by optimising the M gC f concentration.
2.2.5.2 Preparation of PCR reactions
The sensitive nature o f PCR means that very stringent steps must be taken if 
contamination is to be avoided. First, physical separation o f the PCR area from 
bench space used for other work is recommended. In the case of PCRs carried 
out in this project, a dedicated PCR suite isolated from the main laboratory was 
used. In addition, a set of instruments used to aliquot reagents (micropipettes and 
their tips) were kept within the PCR suite and restricted to PCR use. Filter tip 
pipette tips were used to reduce the chance o f carryover from one step to the 
next, and master mixes of reagents were used whenever possible to reduce the 
number of pipetting steps required per reaction. Reaction components including 
primers were aliquoted prior to use and stored at -20°C.
2.2.5.3 Reaction conditions
A number of PCR amplification kits containing all the necessary reagents were 
used according to the manufacturers’ instructions. The reaction mixes were 
made up to either 50 or 25 pi and contained variable concentrations of primers, 
dATPs, dCTPs, dTTPs, dGTPs, MgCC, DNA polymerase, and Ix PCR buffer 
containing Tris-HCl, KCl, and gelatin. To this was added an appropriate volume 
o f DNA or cDNA template. Two thermal cyclers were used; a Perkin Elmer 480 
which requires a layer of mineral oil to be placed over the reaction mixes, and a 
Perkin Elmer 2400 with a heated lid that does not require any mineral oil. 
Reactions were placed in these machines in 0.5 ml and 0.2 ml thin walled 
eppendorf tubes respectively. The exact parameters of the reactions varied, but 
generally consisted of an initial dénaturation at 94°C for five minutes followed 
by 25-45 cycles of the following; dénaturation at 94°C for one minute, annealing
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at 55-72°C for one minute, extension at 72°C for one minute thirty seconds 
followed by a final extension step at 72°C for 4-30 minutes. Reaction products 
were visualised using agarose gel electrophoresis using 5-10 pi of the reaction 
mix.
2.2.5.4 Purification and assessment of PCR products
Single PCR products were purified following the QIAquick® PCR purification 
kit protocol (QIAGEN). Briefly, the DNA band of interest was removed from 
the agarose gel with a sharp scalpel. Visualisation was by UV transillumination. 
The DNA binds to the filter within the column, facilitating separation from all 
other components o f the mixture by a series of washing steps. The PCR products 
are finally eluted in 30-50 pi of sterile water, 4 pi of which was assessed by 1% 
TAE agarose gel electrophoresis against a 100 bp molecular weight standard 
(GIBCO BRL).
2.2.5.5 First strand DNA synthesis for reverse transcriptase 
(RT)-PCR
Analysis of gene expression requires accurate determination of mRNA levels, 
but as PCR is based on amplification of DNA, the process of amplifying RNA 
sequence requires an initial step of conversion of the RNA to cDNA by reverse 
transcription. The MMLV reverse transcriptase enzyme was used to mediate the 
formation cDNA for RT-PCR in the experiments detailed in this thesis. Reverse 
transcriptase synthesises a DNA strand complementary to an RNA template 
when provided with a primer that is base paired to the RNA and has a free 3 
OH group. Three types of primers are used, namely random primers, gene 
specific primers (GSP) and oligo-dT primers. Oligo-dT primers pair with the 
poly A sequence found at the 3 '-end o f most eukaryotic mRNA molecules. All 
of the above primers can be used to initiate the synthesis of cDNA strands in the 
presence of the four dNTPs. The RNA-DNA hybrid is subsequently hydrolysed 
by either raising the pH (as DNA, unlike RNA is resistant to alkaline 
hydrolysis), or by using a ribonuclease. The 3 ' end of the newly synthesised
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DNA strand forms a hairpin loop that primes the synthesis o f the complementary 
DNA strand. The hairpin loop is then removed by digestion with SI nuclease, 
which recognises unpaired nucleotides.
The specific conditions used involved first a dénaturation step of the RNA (in 9 
pi of DEPC water) at 65“C for 5 minutes to ensure no secondary RNA structure 
remained that might interfere with the process. The sample was then quenched 
on ice, and the first strand synthesis was carried out in a total reaction volume of 
25 pi containing the heat treated RNA, the MMLV reverse transcriptase enzyme 
and its buffer, DL-Dithiothreitol (DTT), dNTPs, an RNAse inhibitor and 
primers. The reaction conditions vary between protocols. A Perkin-Elmer 
thermal cycler 480 was used for the reaction, and the reaction mix was kept on 
ice immediately before use or at -20°C for more long-term storage.
2.2.6 DNA sequence analysis
2.2.6.1 Automated sequencing
Sanger dideoxy DNA sequencing is the most commonly used method for DNA 
sequencing, particularly for large-scale genomic sequencing (Sanger, Nicklen, et 
al 1977). A variation of automated DNA sequencing using dye-labelled 
teiininators, in which the dyes are attached to the terminating dideoxynucleoside 
triphosphates has been used in this project (Prober, Trainor, e/ a/ 1987).
2.2.6.1.1 Sample preparation
During sample preparation, DNA fragments in a sample are chemically labelled 
with fluorescent dyes. The dyes facilitate the detection and identification of the 
DNA. Typically each DNA molecule is labelled with one dye molecule, but up 
to five dyes can be used to label the DNA sample. More specifically, PCR 
reactions were performed using DNA samples (200-500 ng) in a total volume of 
20 pi containing 0.5 pM of primers, 40 mM Tris-HCl, 1 mmol/1 M gCb and 4 pi 
of Big Dye™ Terminator Cycle sequencing Ready Reaction (ABI Prism). 
Samples were prepared in the PE 2400 thermal cycler incoiporating 25 cycles of
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amplification, each cycle consisting of a denaturing step at 96”C for 10 seeonds 
followed by an annealing temperature of 50°C for 5 seconds, and an elongation 
step o f 60°C for 4 minutes. DNA was then purified by precipitation using 
ethanol (95%). Pelleted DNA (14000 rpm for 20 minutes) was washed in ethanol 
(70%) and repelleted before all ethanol was removed and the pellet dried at 90°C 
for 1 minute. Template Suppression Reagent (25 pi) was then added and the 
mixture heated to 95"’C for 5 minutes and chilled before transfer to genetic 
analyser sample tubes.
2.2.6.1.2 Sample sequencing
Samples were loaded and run on the ABI PRISM® 3100 Genetic Analyzer (PE 
Applied Biosystems, UK) under standard sequencing conditions for generation 
o f automated sequence data. The ABI PRISM® 3100 Genetic Analyzer is a 
multi-colour fluorescence-based DNA analysis system using the proven 
technology of capillary electrophoresis with 16 capillaries operating in parallel. 
The 3100 Genetic Analyzer is fully automated from sample loading to data 
analysis.
2.2.6.1.3 Sequence evaluation
The length of read is 750 bases at the 98.5% base calling accuracy with less than 
2% ambiguity. The output is in the fonn of a chromas file. A series of different 
computational software were utilised for sequence analysis including the ‘Blast’ 
search engine within the NCBI database, Genetics Computer Group (GCG) and 
ClustalW (http://www.ch.embnet.ore/software/CliistalW.html) .
2.2.7 Estimation of protein concentration
Protein concentrations were estimated using a bicinchoninic acid (BCA, Sigma, 
UK) method (Smith, Kiohn, et al 1985). The protocol combines the reduction of 
Cu^^ to Cu'^ caused by protein in an alkaline environment with the capability of 
BCA to fonn an intense purple complex with Cu*’*’. The complex produced from
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this reaction is stable and increases in a proportional fashion over a broad range 
of increasing protein concentration. It is also water-soluble and exhibits a strong 
absorbance at 562 nin, thus allowing the spectrophotoinetric quantification of 
protein in aqueous solution. A standard panel of 6  bovine serum albumin (BSA) 
dilutions from a 2 mg/ml stock solution (Sigma, UK) were used as a standard 
against which protein samples of unknown concentration could be compared. 
Standard concentrations were 80, 100, 200, 400, 1000, and 2000 ]ag/ml. A 10 p.1 
volume of each standard solution was added in duplicate to individual wells of a 
96 well plate. An additional 3 wells were used as blanks (ie. contained 10 |ul of 
dHiO). A 1:10 dilution of each protein sample to be tested was then made in 
dH 20 and 10 ql of each diluted sample added to the test wells in duplicate 
according to a predetennined pipetting scheme.
The developing solution was a mixture of 5 ml of BCA and 100 |ul o f CUSO4  
(Copper (II) Sulphate pentahydrate, 4% w/v solution, Sigma, UK). A 200 |il 
volume o f this solution was added to each of the standard, blank and test wells 
and the test plate then incubated at 37°C for 45 minutes to allow for colour 
development. Absorbance of wells was then measured using a microtitre plate 
reader and concentrations of test samples determined by comparison with the 
standard dilutions.
2.2.8 Electroblotting of DNA fragments to a positively 
charged nylon membrane
Electroblotting was necessary for the transfer of DNA fragments after 
polyacrylamide gel electrophoresis (Section 4.3.2.5) to a nylon membrane, as the 
small pore size of polyacrylamide gels does not allow the effective transverse 
diffusion of DNA required for successful Southern blotting.
After electrophoresis, the polyacrylamide gel was removed from its glass 
backing by laying a piece o f wet Whatmann 3MM filter paper slightly larger 
than the gel onto the gel surface, being careful to avoid air bubbles. This allowed
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the gel to be lifted safely from its backing without risk of breakage. Two Scotch- 
Brite pads and a farther 7 pieces of 3MM Whatmann filter paper o f the same 
size as the gel were presoaked for 15-30 minutes in 0.5% TBE, carefully 
removing air pockets from the Scotch-Brite pads by repeated squeezing and 
agitation. These pieces were necessary for building up a sandwich around the gel 
for electroblotting.
Electroblotting experiments carried out in this thesis used the Mini-PROTEAN® 
II cell (Bio-Rad) and non-denaturing polyacrylamide gels. The electroblot 
apparatus contains a gel holder consisting of hinged grey and black panels on 
which the components of the sandwich are built up on the grey panel as follows; 
Scotch Brite pad, 3x filter papers, filter paper with gel (gel surface uppermost), 
prewetted positively charged nylon membrane (Amersham, UK), followed by 
the remaining 4 pieces of filter paper and the second Scotch Brite pad. At each 
stage any air bubbles are carefully removed from between the layers, and the 
filter paper carrying the gel and the gel surface itself are flooded with 0.5% TBE 
before they are put into place. The gel holder is then closed and placed in the 
transfer cell with the grey panel facing the cathode. An ice block is included to 
prevent overheating of the transfer buffer. The cell is then filled with 0.5% TBE 
and electroblotted for 4 hours at 30 V. Following this the membrane is removed 
and denatured for 10 minutes, DNA side up in 0.4 M NaOH. The membrane is 
then rinsed in 2x SSC and is ready for downstream applications.
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Chapter III 
In vivo and in vitro canine and feline 
telomere studies
3.1 Abstract
The majority of telomere research carried out to date has focussed on humans, 
and has established links between telomere attrition and senescence. Senescence 
has been associated with organismal ageing, and failure or bypass of senescence 
has been associated with immortalisation and malignancy. Telomeres are 
therefore of great interest to both oncologists and gerontologists, however, 
despite a small number of studies demonstrating similarities between companion 
animal and human telomeres, the amount o f information available to veterinary 
researchers is relatively very small. The experiments detailed in this Chapter 
describe investigations to establish the typical range of telomere lengths found in 
the dog and cat in both healthy tissues and tumour samples. Possible associations 
between age, gender, breed, life expectancy and telomere length were 
investigated. A separate set of experiments aimed at demonstrating and 
quantifying telomeric attrition in vitro in the dog and cat using primary fibroblast 
cultures were carried out, and senescent cells in both species were characterised 
using a number of established biomarkers. The major aim of this research was to 
investigate possible links between telomere attrition, senescence and ageing in 
the dog and cat and thereby establish the importance of telomere biology to 
current veterinary research.
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3.2 Introduction
The study o f canine and feline telomeres is still a relatively new area. Interest in 
this subject has been spurred by advances in human telomere biology that have 
identified telomeres and their cellular functions as being important to the process 
of malignant transformation, and perhaps ageing itself (Artandi & DePinho 
2000) (Bearss, Laurence, et al 2000) (Corey 2002), and reviewed in (Campisi, 
Kim, et al 2001). In contrast to the large volume of work already dedicated to 
human telomere biology relatively little work has been carried out in other 
species, with the exception of the laboratory mouse. The experiments detailed in 
this chapter aim to improve understanding o f canine and feline telomere biology 
as it relates to organismal ageing and cancer.
Yazawa et al in 2001 were the first to provide telomere length data for canine 
tumours and somatic tissues (Yazawa, Okuda, et al 2001). This study 
investigated telomere lengths by restriction endonuclease digestion and Southern 
blot and in a panel of 27 mammary gland tumours found telomere length to vary 
from 11.0 to 21.6 kb. A panel of 12 normal mammary gland sections were found 
to have slightly longer telomeres but the gi'oups could not be compared, as a 
significant age difference existed between them. Increasing age was negatively 
correlated with telomere length in the control dogs, whilst such a relationship 
was not found in the tumour tissue sections. These data imply that the canine 
tumour samples investigated contained an active telomere length maintenance 
mechanism that is not found in the corresponding non-cancerous tissue (Yazawa, 
Okuda, et al 2001). Biummendorf et al examined the telomere lengths in 
peripheral blood leukocytes of cats ranging in age from newborn kittens to 1 0  
year old animals using fluorescence in situ hybridisation and flow cytometry and 
again could demonstrate that the older animals had shorter telomeres in the cell 
types examined (Brummendorf, Mak, et al 2002).
A negative correlation between age and telomere length has been a major finding 
in human telomere research (Lindsey, McGill, et al 1991) (Hastie, Dempster, et 
al 1990), and these preliminary investigations of telomere biology in the dog and
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cat have revealed similarities with human telomere biology, and represent an 
encouraging start. These data have also raised the possibility of using telomere 
length measurement as a novel way of determining age in wildlife, and a pilot 
study has produced promising results in birds (Haussmann & Vleck 2002). 
However studies to date have assumed a uniform rate of telomeric attrition with 
age for a given species, and as reeent work has detailed that other, variable 
factors such as oxidative stress affect telomeric decline these initial data must be 
treated with caution (von Zglinicki, Pilger, et al 2000) (von Zglinicki 2002).
The study o f ageing and age related disease is o f major importance in human 
medicine, and the centrepiece of most theories of the ageing process revolves 
around DNA damage. Telomeric loss, such as that noted to occur in dogs and 
cats can lead to DNA damage and this fact has lead some researchers in the 
human field to conclude that the ageing process begins in the embryo when 
telomerase activity is repressed in the majority o f human somatic tissues 
(Skulachev 1997) (Ahmed & Tollefsbol 2001). Evidence of an actual link 
between telomere length dynamics and the characteristic phenotypic changes 
associated with ageing is circumstantial only, so for example associating 
decreasing telomere length in human fibroblasts and B- and T- lymphocytes with 
the clearly age related changes of decreased wound healing and impaired 
immune function may be a case of confusing sequence with consequence 
(Allsop, Chang, et al 1995) (Weng, Levine, et al 1995).
There is also evidence o f telomere association with age related disease. However 
the short telomeres found in artherosclerotic blood vessels and endothelium 
under haemodynamic stress, compared with healthy tissue coimteiparts, may be 
an effect of the disease process, rather than the cause of it. Such associations 
may be useful in future diagnostic protocols; for example telomere length has 
been found to be inversely proportional to arthers cl erotic grade (Okuda, Khan, et 
al 2000). Recent work has also shown short telomeres in human peripheral blood 
leukocytes (PBLs) to be associated with an increased risk for the development of 
carcinomas in a number o f organs (Wu, Amos, et al 2003).
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Despite the lack of firm evidence of a link between telomeric attrition and 
ageing, it is interesting to hypothesise how such a relationship might work. A 
recent idea advances the prospect that the telomeric contribution to phenotypic 
ageing may revolve around a mosaic effect (Toussaint, Rem ade, et al 2002), 
Accumulation of functionally impaired senescent cells may cause a reduction in 
the ‘vitality’ of the tissue as a whole that is sufficient to produce a phenotypic 
effect and yet does not have a large impact on mean telomere length of the cell 
population.
The ability to accurately identify senescent cells in vitro and in vivo is therefore 
central to telomere-based studies of ageing. The most commonly used biomarker 
is senescence associated P-galactosidase activity at pH 6.0, useflil both in vitro 
and in vivo (Dimri, Lee, et al 1995). The expression o f the cyclin dependant 
kinase inhibitor p2 1  increases as cells near senescence, and p i 6 '^ '^"'^ “ has been 
shown to accumulate in senescent cells, is also a cyclin dependant
kinase inhibitor, and acts as an inhibitor of cell replication through its interaction 
with the retinoblastoma gene product pRb (Huschtscha & Reddel 1999) This 
interaction results in the maintenance of pRb in a hypophosphorylated form in 
senescent cells, and this has been advanced as additional means by which 
senescent cells may be identified in vitro (Alcorta, Xiong, et al 1996).
More than one method has been described to determine telomere length. The 
bulk of telomere length research carried out to date, and all the experiments 
detailed in this chapter use a Southern Blot and hybridisation approach, though 
recent studies reflect a trend towards variations on the original technique or use 
o f completely new methodologies. A discussion o f the other methods currently 
in common usage is detailed in Section 3.2.1.
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3.2.1 Alternative methods for determining telomere 
length in mammalian cells
3.2.1.1 Hybridisation protection assay
The hybridisation protection assay (HPA) is a rapid (45 minutes) and sensitive 
way to determine telomere lengths directly by a chemiluminescent method. Cell 
lysate or DNA solution is mixed with a hybridisation solution containing a light 
emitting (acridium ester labelled) telomere specific probe. A selection buffer 
then differentially hydrolyses unhybridised probe, allowing chemiluminescence 
of the sample to correlate directly with the amount of telomere repeats it 
contains (Nakamura, Hirose, et al 1999). As only telomeric DNA is included in 
the analysis, the concern over inclusion of sub-telomeric DNA that has been 
raised with reference to the Southern Blot method is avoided (Saldanha, 
Andrews, et al 2003). Shearing o f the sample DNA has no effect on the result, 
and the DNA used does not require purification either from cells or tissue 
lysates. The entire procedure can be performed in a reaction tube. Results 
obtained using the HP A method compare favourably with those obtained by 
Southern Blot; however in common with Southern Blot this method does not 
allow measurement of telomeres in individual cells. The equipment required for 
the HP A method is not specialised beyond that available in most laboratories so 
it is not an expensive method to adopt (Nakamura, Hirose, et al 1999).
3.2.1.2 Fluorescent in situ hybridisation (FISH)
The original theme of the FISH method consisted of hybridising fixed cells to a 
fluorescent peptide nucleic acid probe that is complementary to the telomere 
sequence. This method has the advantage over the HP A method that the 
telomere lengths of individual cells may be assessed; the usefulness of it is 
clearly demonstrated by the number o f variations that have been created. The 
variants in cuiTent use include quantitative FISH (Q-FISH), quantitative flow 
cytometry (Q-FISH''^^) and flow cytometry and FISH (flow FISH) (Hultdin, 
Gronlund, et al 1998). The direct labelling of the telomere sequence with the 
fluorescent probe and its visualisation allows for greater accuracy in
85
measurement of telomere length than other methods, however the method 
requires the use of metaphase spreads thus introducing an inherent bias to the 
method as senescent cells are excluded from the sample population. The addition 
of flow cytometry allows small subsets o f cells to be included in the analysis on 
an individual basis, however another level of complexity is added to an already 
technically demanding technique. The most complex variant includes the use of 
digital fluorescence microscopy in a technique. This method utilises
both a telomere specific fluorescent PNA probe and the 4', 6-diamidino-2- 
phenylindole (DAPI) dye specific for chiomosomes allowing accurate telomere 
length measurements of individual chromosomes within the same cell to be 
performed.
3.2.1.3 Telomeric-oligonucleotide ligation assay (T-OLA)
This method is comparatively less complex than FISH derived methods, 
however telomeric DNA must be isolated from sub-telomeric sequence, a large 
amount o f DNA (approximately 30 pg) is required, and the method requires the 
use o f an electron microscope. The assay involves hybridisation o f a highly 
specific ^^aP-labelled oligonucleotide to non-denatured DNA. The 
oligonucleotide binds in the presence of ligase to single stranded DNA with high 
base pairing specificity and the products are resolved on a denaturing 
polyacrylamide gel. The probe specificity for single stranded portions of non­
denatured DNA allow this method to be used to estimate the length o f the 3' 
single stranded overhang found at the telomere terminus, and has an effective 
range from 24-650 nucleotides. As this method involves the use of radioactive 
nucleotides, safety is more of a concern than with the other procedures 
(Huffman, Levene, et al 2000) (Cimino-Reale, Pascale, et al 2001).
A summary o f the methods detailed above is provided in Table 3-1.
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Table 3-1. Methods currently used to measure telomere lengths and G-rich 
overhang. Southern Blot is the least complex technique and requires the least 
specialist equipment, however the higher throughput capabilities of the newer 
methods reduce time constraints and improve accuracy.
Technique Summaiy
Southern Blot Time consuming, labour intensive
HPA Simple rapid and sensitive
Q-FISH Labour intensive and more complex than Southern Blot and HPA
rFCM Similar complexity to Q-FISH, however process takes 
approximately 30 hours
Q-FISH"
Q-FISH^*^^ and Use of digital fluorescence microscopy reduces time required,
digital fluorescence 
microscopy
T-OLA
however very complex technique
Less complex than FISH based methods, used primarily to 
measure G-rich overhangs
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3.2.2 Chapter aims
The aims o f the experiments detailed in this chapter were to evaluate telomere 
lengths in a number of different breeds of dogs and the domestie shorthaired cat 
(DSH) across a wide age range o f individuals. This study allowed the effect of 
age, breed and gender on telomere length in the dog and cat to be investigated. 
In vitro studies aimed at exploring the replicative potential of a number of 
primary fibroblast cell lines and the interrelationship between replicative 
potential and the age o f the donor animals concerned. In addition, the analysis of 
telomere lengths of necropsy specimens from healthy tissues, and a panel of 
canine and feline tumour specimens were carried out.
3.3 Materials and Methods
3.3.1 Sample details
3.3.1.1 Blood samples
Five ml jugular blood samples were taken from dogs and cats kept in 
environmentally enriched housing at the Waltham Centre for Pet Nutrition 
(WCPN). Samples also included excess blood from 2 ml jugular samples taken 
from clinical cases for routine biochemical analysis at GUVS. A total of 112 
dogs and 30 cats were sampled. Sampling carried out at WCPN was in 
accordance with WALTHAM® research ethics guidelines. Cats ranged in age 
from 1 to 17 years and were all Domestic Shorthaired (DSH). Dogs sampled 
were aged from <1 to 15 years from five recognised breeds, the Labrador 
Retriever {n = 24), Miniature Schnauzer {n = 16), Beagle {n = 10), Golden 
Retriever {n = 22), and Great Dane {n = 4), and 37 dogs described as cross breed. 
All animals were clinically healthy at the time of sampling following a routine 
health inspection by a veterinary surgeon.
3.3.1.2 Necropsy specimens
Tissue samples were collected from canine and feline necropsy cases at GUVS. 
In all cases animals had either been euthanased for unrelated medical reasons at 
GUVS prior to necropsy or had been delivered for necropsy to the pathology 
department. All necropsies performed at the school are carried out with infoixned 
owner consent.
Approximately 1 cm^ tissue samples were taken under aseptic conditions from as 
many organs as the particular necropsy would allow and immediately flash 
frozen in liquid nitrogen (LNO2 ) before storage at -70°C. Details of individual 
animals are shown in Table 3-2.
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Table 3-2. Details of necropsy sample animals. Canine (a) and feline (b) 
necropsy sampling was carried out with informed owner consent on each of the 
animals detailed. Tissue samples of approximately 1 cm^ were harvested from as 
many organs as the particular necropsy would allow. Any evidence o f post­
mortem DNA degradation (OD2 6 0 /OD2 8 0  <1.7, or evidence of smearing after 
agarose gel electrophoresis) resulted in exclusion o f the particular sample from 
the study.
(a)
Breed Age (years) Gender Cause of death
CNl English
Bulldog
0.25 Female Aspirational
pneumonia
CN2 Yorkshire
terrier
0.75 Male Tracheal
collapse
CN3 Dachshund 6 Male Vertebral disc 
collapse
CN4 Cross breed 11 Female
neuter
Neoplasia
CN5 Staffordshire 
Bull terrier
13 Male Trauma
(b)
FELINE Breed Age (years) Gender Cause of death
FNl DSH 1 Male neuter Trauma
FN2 DSH 1.5 Male neuter Trauma
FN3 DSH 3 Male neuter Protein losing 
nephropathy
FN4 DSH 13 Female neuter Intestinal
carcinoma
FN5 DSH 15 Male Trauma
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3.3.1.3 Tumour samples
Tumour samples were collected from two sources; necropsies carried out at 
GUVS and samples from excisional biopsies harvested at the time of surgeiy at 
the Peoples’ Dispensary for Sick Animals (PDSA) hospital, Shamrock Street, 
Glasgow. All necropsies were carried out with informed owner consent, and 
decisions to perform excisional biopsies were made solely on clinical grounds 
and with informed owner consent, the samples used in this project representing 
surplus tissue beyond that required for histological diagnosis of tumour type as 
part of routine diagnostic work-up. Samples were flash frozen in LNO2 at time 
of harvesting before storage at -70°C. A total of 21 tumour samples were used in 
this study, 17 canine and 4 feline. All tumours were identified by histopathology 
carried out at the pathology department of GUVS, and samples included 
examples of anaplastic sarcoma, chondrosarcoma, fibrosarcoma, 
haemangiosarcoma, leiomyosarcoma, liposarcoma, lymphoma, nephroblastoma, 
neurofibrosarcoma, rhabdomyosarcoma, spindle cell tumour, synovial cell 
sarcoma, mammary carcinoma and squamous cell carcinoma.
3.3.1.4 Cell lines
Cells used in this chapter include the SFA, AG08157, AG07648, AG08075, 
CCL-176 and S22, all o f which are primary fibroblast cell cultures as detailed in 
Section 2.2.1.2. Cells were grown in T75 flasks and passaged routinely upon 
reaching approximately 80% confluence. The timing of passage is particularly 
important for telomere length studies, as evidence exists that prolonged 
confluence may affect telomeric attrition rate (Sitte, Saretzki, et al 1998). Cell 
numbers were counted (Section 2.2.1.1.1) upon harvesting, and all cell lines 
were seeded at 1 xlO^ eells/ml. 2  xlO^ cells were retained at each passage, 
transferred to 1.5 ml eppendorf tubes and pelleted at 500 g for 5 minutes. The 
growth media was discarded and the pellets washed in sterile PBS. A further 5- 
minute centrifugation step was perfoiined; PBS was carefully aspirated from the 
cell pellet, which was then flash frozen in LNO2  before storage at -70°C. DNA 
extracted from these pellets was used for telomere length estimation.
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Cell counts at harvesting were used to generate growth curves for the cell lines 
according to the fomiula:
Tc- 0.3T 
Log (ri/rio)
Where % represents the doubling time for the cell population, T is the time 
elapsed, A is the number of cells at the time of harvesting and Aq is the number 
of cells at an initial point (Wieder 1999).
3.3.2 DNA extraction
3.3.2.1 Isolation of DNA from peripheral blood samples
Canine DNA was isolated from 5 ml blood samples using either the QIAamp 
DNA blood maxi kit, or phenol/chloroform extraction as detailed in Section 
2.2.2. DNA was resuspended in 50 pi TE buffer, and DNA quality and quantity 
were estimated using spectrophotometry (GeneQuant), and quality of all DNA 
isolates was confirmed by 1% agarose TBE gel electrophoresis (Section 2.2.3.3). 
DNA samples were then stored at -20°C in screw-top 1.5 ml Eppendorf tubes 
until required for analysis.
3.3.2.2 Isolation of DNA from necropsy specimens and cell pellets
Cell lysis and digestion was carried out in 1.5 ml eppendorf tubes using either 2 
xlO^ cells or approximately 100-200 mg of tissue. Tissue samples were cmshed 
in the eppendorf tubes using a sterile pestle. Digestion buffer consisted of 100 
mM NaCl, 10 mM Tris HCl (pH 8 ), 25 mM EDTA (pH 8 ), 0.5% sodium 
dodecyl sulphate (SDS) and 0.1 mg/ml proteinase K (Roche). Approximately 1 
ml o f digestion buffer was used per tissue sample, whilst cell pellets required 
only 0.3 ml per sample. All samples were incubated with shaking at 50°C for 
between 12 and 16 hours in tightly capped tubes. Deproteination was achieved 
by equal volume phenol/chloroform/isoamyl alcohol (25:24:1) extraction. 
Separation of the phases was achieved by a 10 minute centrifugation at 1700 g;
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separation was further aided by eariying out this step in 15 ml tubes containing 
Phase Lock gel (eppendorf) which forms a stable barrier between the upper, 
DNA containing aqueous phase and the lower organic phase. This allowed the 
aqueous phase to be easily transferred to a fresh tube for precipitation of the 
DNA in 2x(original) volumes o f 100% ethanol and K volume of 7.5 M 
ammonium acetate. This precipitation step in the presence o f high salt 
concentration helps reduce the amount of RNA in the DNA sample. The DNA 
was then pelleted by centrifugation at 1700 g for 2 minutes. A frirther wash step 
in 70% ethanol was then carried out before again pelleting the DNA, decanting 
the alcohol and allowing the DNA to ah dry. DNA samples were then 
resuspended in 50-100 |ul o f TE buffer and quality and quantity checked as 
described in Section 2.2.3.3.
3.3.3 Telomere length analysis
3.3.3.1 Digestion of DNA with HiniHRsal
The selection of the restriction endonucleases H inli and Rsal was based on the 
fact that these enzymes do not contain recognition sequences that cut within 
mammalian telomeric sequence. These enzymes are not alone in this respect, 
however, they are the most commonly used in the literature (Nakamura, Hirose, 
et al 1999) (Lauzon, Dardon, et al 2000). The use of these enzymes allows 
complete digestion of non-telomeric DNA, up to the first recognition site for the 
enzymes. The remaining intact telomeric DNA is referred to as a Telomere 
Restriction Fragment (TRF). Three p.g of DNA was digested per sample at 4U of 
enzyme mix/jig of DNA for 12-16 hours at 37°C.
3.3.3.2 DNA fragment separation
3.3.3.2.1 Agarose gel electrophoresis and Southern blot
Separation of digested DNA was achieved by 0.8% agarose gel electrophoresis 
in Ix TAE buffer using highly pure agarose (SIGMA) following a standard 
protocol (The DIG system user's guide for filter hybridisation 2003) (Southern 
1979). A DIG molecular weight marker was used (23.1 kb- 0.12 kb, Roche UK).
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Equal amounts of sample DNA were mn in each lane, and each sample was mn 
in duplicate. Individual samples were made up to 20 p.1 using dHzO and 2 ql of 
lOx DNA loading buffer (Section 2.1.8.2). Samples were mn at 5 V/cm for 
between 4 and 5 hours until the loading dye was approximately 2 cm from the 
base of the gel.
Southern transfer (Southern 1975) o f the digested DNA was canied out by 
capillary action using 20x SSC as a transfer buffer following a standard protocol 
(Current protocols in molecular biology) to a high quality positively charged 
nylon membrane (Amersham, UK). Gels were pre-treated first by submersion in 
0.25 M HCl for 5-10 minutes; completion o f this step was indicated by a change 
in colour of the bromophenol blue loading dye from blue to yellow. Following a 
rinse in dH2 0  the gels were submerged in dénaturation solution (0.5 M NaOH, 
1.5 M NaCl) for 30 minutes, with a change of solution after 15 minutes. This 
step was not complete until the loading dye colour had changed from yellow to 
blue. After a further rinse in H 2 O the gels were submerged in a neutralisation 
solution (0.5 M Tris-HCl, 3 M NaCl at pH 7.5) for 30 minutes with a change to 
fresh solution after 15 minutes. All pre-treatment steps were canied out at room 
temperature and with gentle agitation using a rocking table (Luckham, UK).
Gels were flipped before Southern transfer as this reduced the likelihood of 
irregularities in the upper gel surface resulting in uneven DNA transfer. Transfer 
was carried out overnight, and the DNA was then UV cross linked with 120 
mJoules of energy using a trans-illuminator (Sigma) to the nylon membrane. 
After twice washing the membrane with 2x SSC the blot was ready for probe 
hybridisation and chemiluminescent detection (Section 3.3.3.3).
3.B.3.2.2 Pulsed field agarose gel electrophoresis
Pulsed field electrophoresis was carried out using a CHEF-DR® II system 
(Biorad). This system allows resolution of large DNA fragments (approximately 
1 0 - 2 0 0 0  kb) beyond the capacity of simple gel electrophoresis and is necessary 
for resolution of DNA fragments beyond approximately 25 kb in size (Carle,
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Frank, et al 1986). The pulsed field electrophoresis used in this Chapter is 
described as ‘contour clamped homogenous electric field’ (CHEF). In this 
system the gel is surrounded by a set of electrodes that allows alternation of the 
electric field to be coupled with a uniform direction of DNA migration (Chu, 
Vollrath, et al 1986). One percent agarose gels in 0.5% TBE as buffer were used 
in all procedures, and the apparatus includes a pump and cooling system to keep 
the buffer temperature steady at 14°C for the duration of the electrophoresis. The 
gels were run at 6  V/cm with a 1 to 6  second ramped switch time and a total mn 
time of 15 hours. These parameters are within that recommended by the 
manufacturer to resolve DNA of 1-100 kb in length. An 8-48 kb CHEF DNA 
size standard (Bio-Rad) was used consisting o f 13 bands; 8.3, 8 .6 , 10.1, 12.2, 15, 
17.1, 19.4, 22.6, 24.8, 29.9, 33.5, 38.4 and 48.5 kb.
Following electrophoresis, gels were stained for 30 minutes in 1.0 jag/ml 
ethidium bromide to visualise the DNA size standard that was then 
photographed with the aid of UV transillumination (Uvi, Thistle Scientific, UK). 
These photographs allowed the position of the DNA marker bands to be 
accurately recorded on the final autoradiographs. Gels were UV treated in a UV 
cross-linker with 60 mJoules of energy to cleave the separated DNA fragments; 
this is necessary to allow efficient Southern transfer of fragments gi*eater than 
approximately 20 kb. The gels were pre-treated in 0.4 M NaOH, 1.5 M NaCl for 
15 minutes to reduce background and increase transfer efficiency then Southern 
blotted using the same solution as a transfer solvent onto a positively charged 
nylon membrane overnight. Following this the nylon membranes were 
neutralised in 0.5 M Tris, pH 7.0 for 5 minutes, then briefly rinsed in 2x SSC 
(Section 2.1.8.2) before proceeding with hybridisation. The hybridisation and 
chemiluminescent method are common to the standard and CHEF 
electrophoresis protocols.
3.3.3.3 Hybridisation and chemiluminescent detection
All hybridisation steps were caiTied out using a Hybaid Maxi hybridisation oven 
(Hybaid) and standard hybridisation flasks on a rotary mount. Pre-hybridisation
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was carried out at 42°C for 45 minutes using 25 ml of DIG Easy Hyb solution 
(Roche, UK). This solution was then discarded and replaced with 10 ml of DIG 
Easy Hyb containing 2 jil o f digoxigenin (DIG) labelled telomere probe 
(TTAGGG?). Hybridisation was carried out at 42°C for 3 hours.
Two stringency washes were carried out; the first consisted of two washes in 2x 
SSC, 0.1% SDS for 5 minutes each at room temperature. This was followed by 2 
washes in 0.2x SSC, 0.1% SDS at 50°C for 20 minutes each. Gentle agitation of 
the membrane was carried out during both stringency washes and throughout the 
detection procedure.
Membranes were rinsed in a washing solution (0.3% w/v Tween® 20, 0.1 M 
maleic acid, 0.15 M NaCl, pH 7.5) for 5 minutes at room temperature followed 
by a 30-minute incubation at room temperature in freshly prepared blocking 
buffer (Roche, UK) dissolved in maleic acid buffer solution (0.1 M maleic acid, 
0.15 M NaCl, pH 7.5). Blots were then incubated with a DIG specific antibody 
(750 units/ml Anti-Digoxigenin, Fab fragments) covalently coupled to alkaline 
phosphatase (Anti-DIG-AP) (Roche, UK). The Anti-DIG-AP working solution 
was prepared to a final concentration of 75 mU/ml (1:10,000) in blocking buffer 
(Roche, UK). The antibody solution was centrifuged for 5 minutes at 13000 ipm 
before careful pipetting from the surface of the liquid to avoid background signal 
being generated by aggregated antibody.
Incubation in the antibody solution was followed by two further 15-minute 
washes at room temperature in wash buffer (Roche, UK), followed by a 5- 
minute incubation in detection buffer (100 mM Tris-HCl, pH 9.5, 100 mM 
NaCl). Excess detection buffer was briefly blotted from the membrane by 
placing it DNA side up on a piece of 3MM Whatman filter paper. The blot was 
then placed on an acetate sheet and approximately 3 ml of substrate solution 
placed di'op wise onto the DNA side before overlaying with another acetate. The 
system used the chemiluminescent alkaline phosphate substrate CSPD® (25 mM 
Disodium 4-chloro-3-(4-methoxyspiro( 1,2-dioxetane-3,2 ’-(5 ’-
ehioro)tricycio[3.3.1.1^’^ ]decan)-4-yl) phenyl phosphate) (Roche, UK) diluted
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1:100 in detection buffer. Any bubbles were carefully removed from between the 
sheets and the composite was incubated at room temperature for 10 minutes. 
Exeess substrate solution was then squeezed out and the two plastic sheets sealed 
with sellotape. The sealed membrane was incubated at 37°C for a further 10 
minutes to aid the chemiluminescent signal. The membranes were then used to 
generate autoradiographs. Exposure time varied between 5 and 20 minutes to 
achieve optimum image quality for analysis.
3.3.3.4 Analysis of autoradiographs
Autoradiographs were analysed by densitometry using TotalLab v2.01 software. 
Mean TRF (kb) values were determined from the densitometric readings 
according to the formula:
TRF (kb) = EfOdiLii 
Z(Odi)
Where Od; is the chemiluminescent signal and Li is the length of the TRF 
fragment at position i. The calculation takes into account the higher signal 
intensity from larger TRF fragments because of multiple hybridization of the 
telomere specific probe. Duplicate analyses were carried out on each sample.
3.3.4 Confirmation of senescence
Replicative senescence in primary cultures was marked by cessation of cellular 
replication and morphological changes of the senescent cells, involving an 
increased cell size and a rounded, flattened appearance. In addition to these 
visual indicators, a number o f biomarkers were employed to confirm the 
presence of senescent cells in cultures, and these are detailed below.
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3.3.4.1 Senescence associated p-galactosidase (SA-p-GAL) 
staining at pH 6
Replicative senescence was detected in cell lines by staining for the presence of 
a senescence associated p-galactosidase activity at pH 6.0. This method was 
developed from that originally outlined by Dimri et al (Dimri, Lee, et al 1995) 
and detects SA-p-GAL using the compound X-Gal, which forms a perinuclear 
blue precipitate upon cleavage (Miller 1972). Cells were stained in situ in tissue 
culture flasks or grown on cover slips contained in 6 well plates, and were first 
washed three times in PBS, then fixed for 10 minutes at room temperature in 2% 
fonnaldehyde/0.2% glutaraldehyde in PBS. Cells were then washed a further 
three times in PBS and incubated at 37°C (without CO2 ) in fresh SA- p -GAL 
staining solution consisting of 40 mM citric acid/sodium phosphate buffer 
(pH6.0), 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM 
sodium chloride, 2 mM magnesium chloride and 2 rag/ml X-gal dissolved in 
dimethylformamide all made up in distilled water.
Staining was evident after 2-4 hours and maximal after 12-16 hours. Five fields 
o f at least 100 cells were counted, and cells positive for SA- p -G A L activity 
expressed as a percentage of the total number counted. Staining was recorded by 
digital photography.
3.3.4.2 Immunocytochemistry
Immunocytochemistry (ICC) is a technique that allows identification o f cellular 
or tissue antigens by means of a specific antigen-antibody interaction. The 
method has been greatly refined since the initial direct labelling experiments that 
employed a primary antibody conjugated directly to a fluorochrome (Coons, 
Creech, et al 1941). A common variation that uses an indirect 
immunoperoxidase labelling approach is used in these experiments (Sternberger, 
Hardy, et al 1970). This method involves a dual antibody system in which an 
unlabelled primary antibody is bound to a secondary biotinylated ‘bridging’ 
antibody. A complex formed from strept-avidin and horseradish peroxidase
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(HRPO) is then conjugated to this secondary antibody to provide signal 
amplification at the site of the primaiy antibody. The final substrate for the 
HRPO is 3,3 diaminobenzidine (DAB) (Sigma, USA) which produces a brown 
end product at the antigen site that is highly insoluble in alcohol and other 
inorganic solvents. This method was used to identify the presence of p i 
and p21 in cells grown on cover slips in the primary canine culture SFA and the 
primary feline culture S22 (both detailed in Section 2.2.1.2). The primary 
p2giNtc4a antibody used was the H-156 purified rabbit polyclonal antibody (Santa 
Cruz Biotechnology) raised against a recombinant protein corresponding to 
amino acids 1-156 representing full length pl6^ '^^^^“ of human origin. The p21 
antibody, SX118 (murine IgGi) was sourced from BD PharMingen and is raised 
against the final 20 amino acids of human p21.
Accumulation of both p i6'^ ^^ "*^  and p21 has been associated with replicative 
senescence in human cultures (Alcorta, Xiong, et al 1996) (Huschtscha & 
Reddel 1999). Alcorta et al found that p21 accumulated as human fibroblasts 
approached senescence (in the last few passages), and then reduced in the 
senescent cells, concomitant with an increase in p i jgygjg (Alcorta, Xiong, 
et al 1996). The staining carried out on the SFA and S22 cultures detailed in this 
chapter were on the final passages (p i2 and plO respectively) and the cells had 
been senescent, as determined by SA-p-GAL activity, for two weeks before 
staining was canied out.
3.3.4.2.1 Staining optimisation
This procedure involves identifying a concentration of primary antibody that 
provides the maximum amount of specific staining with the least amount of 
background. A range of dilutions (1/50, 1/100, 1/200, 1/400) is used to stain a 
positive control tissue for each antigen to be investigated. Repeating this 
procedure and omitting the primary antibody provides negative controls. 
Evaluation o f control slides by light microscopy identified the most favourable 
dilution for each antibody, which was then used on all subsequent test cells. The 
H-156 (p i6) antibody has previously been shown to cross react with canine 
pj^[Nic4a fibroblasts (Koenig, Bianco, et al 2002), and the MCF7 cell line
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(Section 2.2.1.2) was used as a positive control for the p21 antibody as 
recommended in the product datasheet.
3.3.4.2.2 Immunocytochemical staining procedure
The antibody diluent used in this study consisted of 0.1 g BSA (BDH, UK) and 
0.01 g sodium azide (BDH, UK) in 100 ml o f 0.01 M TBS (pH 7.5). Test cells 
were incubated with primary antibodies for two hours at room temperature 
followed by three five minute wash steps in the wash buffer (Tween20, 0.01 M 
TBS at pH 7.5). A standard 1/200 dilution o f the appropriate secondary antibody 
(polyclonal swine anti-goat/mouse/rabbit, biotinylated, Dako, UK) was then 
applied for a 45-minute incubation at room temperature. This was followed by 
another thi’ee five minute washes in wash buffer before signal amplification was 
achieved by a 45-minute incubation with the HRPO conjugated strept-avidin 
complex (Dako, UK). The chromagen DAB was reconstituted in 5 ml tap water 
as per manufacturers instructions as ions contained in the tap water enhance the 
reaction and improve the intensity o f the final staining. The chromagen was then 
applied for 5 minutes to produce the stable brown insoluble product that may be 
viewed by light microscopy. Couterstaining was performed using Gills’ 
haematoxylin followed by washing of the stained cells in water, dehydration via 
a series of graded alcohols and clearing in Histo-Clear (AGTC Bioproducts). 
Cover slips were then permanently mounted using DPX mountant (BDH, UK) 
onto microscope slides before examination by light microscopy.
100
3.4 Results
3.4.1 DNA quantity and quality
Genomic DNA was isolated from PBLs using both phenol/chloroform extraction 
with ethanol precipitation, and also using the QIAamp DNA blood maxi kit 
(QIAGEN, UK). Good quality DNA samples were obtained and checked by 
spectrophotometry to have an A2 6 0 /A2 8 0  value o f >1.7. Agarose gel assessment 
was also carried out revealing intact, high molecular weight DNA with no 
evidence o f smearing associated with DNA degradation, as shown in Figure 3- 
la. Complete digestion of the DNA was confirmed by agarose gel 
electrophoresis to reveal a smear of DNA with no evidence of residual high 
molecular weight DNA. An example of a post digestion gel is shown in Figure 
3-lb.
3.4.2 Comparison of CHEF electrophoresis and standard 
agarose gel electrophoresis
A number of samples were analysed using both standard agarose gel 
electrophoresis and CHEF electrophoresis (Figure 3-2). TRF results were found 
to be comparable in size using the two methodologies (average difference 0.6 kb, 
standard deviation 0.44). All future TRF investigations were performed using 
standard agarose gel electrophoresis.
3.4.2.1 Analysis of autoradiographs
A TRF value was deteiinined for each sample as detailed in Section 3.3.3.4. 
Duplicate analysis was carried out for each sample, and the average difference 
between samples was 0.42 kb with a standard deviation of 0.42. A representative 
autoradiograph with telomere length analysis is shown in Figure 3-3.
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Figure 3-1 (a) 1% agarose gel electrophoresis of genomic DNA isolated from 
canine PBLs, and (b) canine DNA after a 2-hour digestion with 4 iu/|Lig of H inï 
I and Rsa I. Both gels include a 100 bp marker (100-2072 bp, Invitrogen)
(a) (b)
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Figure 3-2. Comparison of CHEF and standard agarose gel electrophoresis
The autoradiographs below demonstrate comparable telomere smears generated 
using both CHEF and standard agarose gel electrophoresis. Both 
autoradiographs show necropsy samples from an 11 -year-old female crossbred 
bitch. The autoradiograph shown on the left contains smears generated from 
specimens using CHEF electrophoresis as described in Section 3.3.3.2.2. The 
samples shown are duplicates of skeletal muscle (lanes 1 and 2), liver (3 and 4) 
and kidney (5 and 6). The same samples were re-analysed to produce the 
autoradiograph shown on the right using the same protocol except that these 
smears were separated by standard agarose gel electrophoresis as outlined in 
section 3.3.3.2.I. Skeletal muscle is shown in lanes 1 and 2, liver in lanes 3 and 
4 and kidney in lanes 7 and 8. Lanes 5 and 6 contain a lung sample. Averages of 
the duplicates were taken to demonstrate that for each of the three samples the 
telomere lengths were comparable. Skeletal muscle was estimated at 22.7 kb 
using CHEF and 22.4 kb using standard gel electrophoresis, liver at 21.5 kb by 
CHEF and 20.4 kb by standard gel electrophoresis and kidney at 17.4 kb by 
CHEF and 17.8 kb by standard agarose electrophoresis.
1 2 3 4 5 6
48.5kb«
8.3kb
2 3 .lk b
2.3kb
2.0kb
1 2 3 4 5 6 7 8
9.4kb
6.6kb
4.4kb
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Figure 3-3. Autoradiograph of feline TRFs highlighted by 
chemiluminescence. Lanes order is as follows- Lane 1, DNA molecular weight 
marker II (Roche); lane 2, control DNA (3.9 kb, Roche, UK); lanes 3 and 4, 10 
year old mean TRF 5.0 kb; lanes 5 and 6; 1 year old mean TRF 7.3 kb; lanes 7 
and 8, 9 years old, mean TRF 6.4 kb; lanes 9 and 10, 9 years old, TRF 7.2 kb; 
lanes 11 and 12, 4 years old, TRF 16.3 kb; lanes 13 and 14, 1 year old, TRF 13.3 
kb; lane 15, second marker lane.
1 2  3 4 5 6 7 8 9 10 11 12 13 14 15
23.1 kb
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6.6kb
4.4kb
2.3kb
2.0kb
104
3.4.3 In vivo telomere length studies
3.4.3.1 TRF analysis of PBL samples in the dog
Duplicate TRF analysis was canied out on a total of 112 canine PBL DNA 
samples. The final mean TRF value was then determined by averaging each pair 
of analyses. Canine samples were derived from five distinct breed groups and 36 
cross breed dogs revealing a heterogeneous population o f telomeres ranging 
from 9.6 kb to 23.5 kb. O f these individuals, 24 animals were Labrador 
Retrievers, comprising 15 females and 9 males with an age range of <1 to 13 
years, and mean TRF values o f 14.7 to 19.7 kb. Sixteen dogs belonged to the 
Miniature Schnauzer breed comprising 7 females and 9 males with an age range 
of <1 to 9 years and a mean TRF range of 9.7 to 19.9 kb. Two females and 8 
males represented the Beagle breed, with an age range of 4 to 13 years and a 
mean TRF range of 14.9 to 22.3 kb. Four Great Dane dogs were also included, 1 
female and 3 males, age range 2 to 3 years and TRF values of 10.7 to 18.5 kb. 
Gender data was unavailable for the Golden Retriever and crossbreed group. 
Golden Retrievers numbered 22, aged from 1 to 13 years and with mean TRFs 
ranging from 9.6 to 22.1 kb. Thirty-six crossbreed dogs made up the remainder 
of the canine PBL samples, ranging in age from 1 to 15 years and with a mean 
TRF range of 12 to 23.5 kb. TRF results for individual dogs are shown in Tables 
3-3, 3-4, 3-5, 3-6, 3-7 and 3-8, corresponding to Labrador Retrievers, Miniature 
Schnauzers, Golden Retrievers, Beagles, Great Danes, and Crossbreeds 
respectively.
These data were used to examine the effect of age, breed and gender on telomere 
length in the dog. Regression plots of age against TRF in the canine PBL 
samples are shown in Figures 3-4 and 3-5. An analysis o f covariance for all 112 
dogs revealed no trend o f changing telomere length with age (Figure 3-6), 
however a significant association between decreasing telomere length and 
increasing donor age was identified in all pedigree dogs (p = 0.001) when these 
were analysed in isolation. In contrast, the crossbreed group showed a trend of 
increasing telomere length with increasing age. An analysis of covariance 
including the five pedigree breed groups (Beagle, Great Dane, Golden Retriever,
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Labrador Retriever and Miniature Schnauzer) revealed breed to have a highly 
significant effect on telomere length (p = <0.0001). This is the first report of 
breed specific differences in telomere length in the dog. There was no significant 
interaction between age and breed in the analysis, so the age distributions of the 
individuals within each breed group did not contribute to the breed effect on 
telomere length. A Least Squares means analysis was carried out on the pedigree 
dog PBL samples as shown in Table 3-9. This revealed that when mean TRF 
values are corrected for age the Great Dane group had the shortest telomeres, 
and that the telomeres o f the Great Danes and the Miniature Schnauzers were 
significantly shorter than the Golden Retriever and Beagle gi’oup (p <0.05). The 
Miniature Schnauzer breed also displayed significantly shorter telomeres than 
the Labrador Retrievers (p <0.05).
Gender had no effect on telomere length within the canine PBL sample 
population.
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Table 3-3. TRF analysis of PBL DNA isolated from Labrador Retrievers; 15
females (F), 9 males (M) ranging in age form <1 to 13 years old. TRFs in this
gi'oup ranged from 14.7 to 19.7 kb.
Sample number Age (years) Gender Mean TRF (kb)
1 <1 F 14.8
2 <1 F 18.5
3 <1 F 19.5
4 1 M 15.8
5 1 M 18.2
6 1 F 16.9
7 3 M 17.4
8 3 M 14.7
9 3 M 17.5
10 3 M 18.2
11 3 F 18.2
12 3 F 17.1
13 4 F 16.3
14 4 M 18.5
15 5 F 17.7
16 5 F 17.1
17 5 M 14.8
18 5 F 14.8
19 6 M 16.3
20 6 F 19.7
21 7 F 17.7
22 8 F 17.9
23 13 F 15.2
24 13 F 15.8
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Table 3-4. TRF analysis of PBL DNA isolated from Miniature Schnauzers; 7
females (F), 9 males (M) ranging in age from <1 to 9 years. TRFs in this group
ranged from 9.7 to 19.9 kb.
Sample number Age (years) Gender Mean TRF (kb)
1 < 1 F 15
2 < 1 M 14
3 < 1 M 14.6
4 < 1 F 15.2
5 2 F 19.2
6 2 F 19.9
7 5 M 15.4
8 6 F 15.8
9 6 M 16.9
10 6 F 14.5
11 6 M 15.1
12 6 M 10.6
13 7 M 12
14 9 M 12.6
15 9 M 10.3
16 9 F 9.7
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Table 3-5. TRF analysis of PBL DNA isolated from Golden Retrievers;
ranging in age from 1 to 13 years, gender information for this group is not
available. TRFs in this group ranged from 9.6 to 22.1 kb.
Number Age (years) Mean TRF (kb)
1 1 18
2 2 17.8
3 2 17.7
4 2 17.4
5 4 17.9
6 4 17.8
7 5 20.6
8 5 19.7
9 5 18.4
10 6 18.5
11 7 21.3
12 8 19.7
13 9 20.4
14 9 16.7
15 9 22.1
16 10 19.1
17 10 16.4
18 11 16.7
19 12 15.1
20 12 10.2
21 13 9.6
22 13 18
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Table 3-6. TRF analysis of PBL DNA isolated from Beagles; 2 females (F)
and 8 males (M), with an age range o f 4 to 13 years, represent the breed. TRFs in
this group ranged from 14.9 to 22.3 kb.
Number Age (years) Gender Mean TRF (kb)
1 4 M 21.7
2 4 M 16.3
3 5 M 21.6
4 6 F 22.3
5 6 M 18.7
6 7 F 14.9
7 9 M 15.1
8 12 M 18.7
9 12 M 16.7
10 13 M 18.1
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Table 3-7. TRF analysis of PBL DNA isolated from Great Danes, 3 males 
(M) and one female (F). TRFs ranged from 10.7 to 18.5 kb.
Number Age (years) Gender Mean TRF (kb)
1 2 M Î&5
2 2 M 13.5
3 2 F 10.7
4 3 M 16.5
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Table 3-8. TRF analysis of PBL DNA isolated from crossbreeds; gender 
information for this group is not available, ranging in age from 1 to 15 years. 
TRFs in this group ranged from 12 to 23.5 kb.
Number Age (years) Mean TRF (kb)
1 1 16
2 1 20
3 1 19.8
4 1 12
5 1 17.9
6 1 14
7 1 19.2
8 2 19.4
9 2 16.9
10 2 12.3
11 3 16.3
12 4 19.1
13 4 21.7
14 5 19.2
15 6 19.2
16 7 21.2
17 7 20.8
18 7 20.4
19 7 14.8
20 8 21.8
21 8 20.9
22 8 2T5
23 8 20.9
24 9 21.9
25 9 23
26 9 21.5
27 9 21.6
28 10 19.9
29 10 21.9
30 10 21.7
31 10 22
32 11 23,5
33 12 19.4
34 12 18.7
35 12 16
36 15 17.3
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Figure 3-4. Regression plot of TRF against age for the Golden Retriever, 
Beagle and Crossbreed dogs. A regression plot of TRF against age for the 
Golden Retriever and Beagle PBL DNA samples both show a trend of 
decreasing TRF with increased age. However the group of 36 cross breeds show 
a trend of increasing TRF with increasing age. It is believed this is an artefact 
caused by a breed effect on TRF, therefore the apparent increase in TRF with 
increasing age is considered to reflect the breed backgrounds within the sample 
population and is not a true reflection of the effect o f age on telomere length.
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Figure 3-5. Regression plot of TRF length against age for Miniature 
Schnauzer and Labrador Retriever PBL DNA samples. In this case both 
breeds show a trend o f decreasing TRF with increased age.
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Figure 3-6. Regression plot of TRF length against age for all canine PBL 
DNA samples combined, including and excluding crossbreed animals.
Analysis of all samples together does not reveal any trend o f decreasing TRF 
with increasing age. However, removal of the crossbreed dogs from the analysis 
reveals an association between decreasing telomere length and increasing age (p 
= 0.001) in pedigree dogs. These data are likely a reflection o f large genetic 
diversity in the crossbreed group, in effect some individuals inheriting longer 
than average telomeres, others shorter than average telomeres. Although it is not 
possible to examine whether there is any interaction between breed inheritance 
and age within the crossbreed dogs such an interaction could cause an 
overshadowing of the age effect on telomere length. These data underscore the 
importance of removing breed as a variable when examining the effect of age on 
telomere length in the dog.
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Table 3-9. Least Squares Means analysis of canine PBL TRF length from 
the five pedigree breed groups. Great Dane and Miniature Schnauzers had 
significantly shorter TRFs than the Golden Retriever and Beagle groups, and the 
Miniature Schnauzer group had significantly shorter TRFs than the Labrador 
Retrievers. Groups with overlapping confidence limits are denoted with the same 
superscript letter.
Breed Mean TRF 95% confidence limits
Great Dane^'’ 13.8 11.4-16.3
Miniature Schnauzer'^ 14.2 13.0-15.4
Labrador Retriever"^ 16.7 15.7-17.7
Golden Retriever^ 18.2 17.1-19.2
Beagle^ 19.0 17.5-20.6
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3.4.3.2 TRF analysis of PBL samples in the cat
All thirty feline PBL DNA samples were derived from cats belonging to the 
DSH breed group. O f these, 12 were female and 18 male with ages ranging from 
1 to 17 years and mean TRF values ranging from 4.7 to 20.6 kb. TRF results for 
individual cats are shown in Table 3-10. A regression plot o f TRF against age 
(Figure 3-7) showed a significant association between decreasing TRF length 
and increased donor age (p -0.001).
An analysis o f covariance was also carried out on the 30 feline samples to 
investigate the effect of age and gender on telomere length in the cat. Breed was 
not included in the analysis as all the cats were DSHs. Again age was shown to 
have a significant effect on telomere length {p = 0.001), whilst gender did not 
affect telomere length at a significant level. In addition the cats had significantly 
different PBL TRF values to the dogs sampled {p = <0.01).
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Table 3-10. TRF analysis of PBL DNA samples taken from 30 DSH cats, 12
female (F) and 18 male (M). TRF values range from 4,7 to 20.6 kb.
Number Age (years) Gender TRF (kb)
1 1 F 14.5
2 1 M 14.9
3 1 M 9.2
4 1 M 7.6
5 1 M 13.3
6 1 M 20.6
7 1 M 4.7
8 1 M 9.5
9 1 M 12.6
10 4 F 10.8
11 4 M 9.4
12 4 F 9.2
13 4 M 9.2
14 9 FN 11.4
15 9 M 10.4
16 9 FN 7.2
17 9 M 6.9
18 9 MN 11.3
19 9 FN 6.4
20 9 M 8.9
21 10 FN 5
22 10 M 7.1
23 10 FN 4.8
24 10 FN 11.3
25 10 F 7.4
26 12 M 6.1
27 12 M 6.1
28 12 M 7.6
29 12 F 6.1
30 17 FN 5.6
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Figure 3-7. Regression plot of TRF length against age for the feline PBL 
DNA samples. The cats sampled all belong to the DSH breed type, with an age 
range of 1 to 17 years, TRFs ranged from 4.7 to 20.6 kb, and show an 
association of decreasing size with increasing age {p = 0.001).
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3.4.3.3 TRF analysis of necropsy samples in the dog and cat
3.4.3.3.1 Normal tissue
Tissue samples were harvested from 5 dogs and 5 cats necropsied at GUVS for 
unrelated medical reasons. Details of donor animals are shown in Table 3-2. 
After DNA extraction and quality assessment as detailed in Section 2.2.2, 48 
DNA samples were considered fit for duplicate TRF analysis comprising 26 
canine and 22 feline samples. The canine samples included cardiac muscle {n = 
2), liver {n ~ 4), skeletal muscle {n = 4), lung {n = 2), kidney {n = 4), small 
intestine {n = 3), spleen {n = 2), stomach {n = 3), testis (« = 1) and ovary { n ^  1). 
The feline samples included brain {n = 2), cardiac muscle {n = 2), liver {n = 5), 
skeletal muscle {n = 3), lung {n = 4), kidney {n = 3), small intestine {n = 2), and 
testis {n = 1). TRF values for each sample are shown in Table 3-11. Regression 
plots of TRF against age of donor animal are detailed In Figures 3-8, 3-9, 3-10 
and 3-11. These are included in cases where more than 2 samples per organ are 
available for comparison.
When all canine organ samples were analysed together (TRFs ranged from 11.6- 
22.8 kb) no trend in telomere length between the different ages o f animal is 
visible, however when tissue samples were analysed individually the liver, 
kidney and small intestine samples showed a trend of decreasing TRF with 
increased age of donor animal. A repeat of this analysis using only the feline 
samples (TRFs ranged from 8.5-26.3 kb) revealed a trend of decreasing TRF 
with increased donor age even when the different tissue types were included in 
the same analysis. The canine and feline necropsy sample TRFs were not 
significantly different from the range of TRFs found in canine (9.6-23.5 kb) , 
and feline (4.7-20.6 kb) PBLs.
3.4.3.3.2 Tumour tissue
A total of 21 tumour samples, 17 canine and 4 feline were subjected to TRF 
analysis. TRFs ranged from 7.2 to 22.2 kb for the canine samples and 11.6 to
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18.3 kb for the feline samples. Details o f individual results are shown in Table 3- 
12 .
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Figure 3-8. Regression plot of TRF length against age for canine necropsy 
specimens (1). A trend of decreased TRF with increased donor age is present in 
both the canine liver (range 13.5 to 22.7 kb) and kidney samples analysed (range 
14.8 to 22.8 kb). Both liver and kidney trends may reflect cell turnover in these 
organs. No such trend is seen with canine skeletal muscle samples, reflecting the 
post-mitotic nature of this tissue. The increased TRF in the samples from older 
animals may reflect individual variation in donor animals.
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Figure 3-9. Regression plot of TRF against age for canine necropsy 
specimens (2). A trend o f decreased TRF with increased donor age is present in 
the canine small intestine samples (range 11.6 to 20.3 kb), but not in the stomach 
samples (range 13.7 to 18.6 kb). A regression plot of TRF length against age for 
the entire canine necropsy samples combined displays no trend of changing TRF 
with age. This may reflect breed variation in the sample population.
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Figure 3-10. Regression plot of TRF length against age for feline necropsy 
specimens (1). Feline liver (range 9.2 to 22.7 kb), lung (range 11.5 to 26.3 kb) 
and skeletal muscle (range 11.3 to 19 kb) all show a trend of decreased TRF 
length with increased age of donor animal.
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Figure 3-11. Regression plot of TRF against age for feline necropsy 
specimens (2). Feline kidney (range 13.7 to 22.8 kb) samples show a trend of 
decreasing TRF length with increased age of donor. Combining all feline organ 
samples (range 9.4 to 26.3 kb) reveals the same trend.
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Table 3-12. TRF analysis of canine (a) and feline (b) tumours sampled 
during biopsy and at post-mortem examination. Matched normal tissue 
samples from each individual case were unavailable.
(a)
Number Tumom- type TRF (kb)
1 Anaplastic sarcoma 18.3
2 Chondrosarcoma 17.6
3 Fibrosarcoma 20.9
4 Haemangiosarcoma 20
5 Leiomyosarcoma 14.7
6 Leiomyosarcoma 17.5
7 Leiomyosarcoma 19.4
8 Leiomyosarcoma 16.7
9 Liposarcoma 21.4
10 Lyphoma 19.1
11 Nephroblastoma 14
12 N eurofibrosarcoma 7.2
13 Rhabdomyosarcoma 15.5
14 Spindle cell tumour 22.2
15 Spindle cell tumour 19.5
16 Spindle cell tumour 12.8
17 Synovial cell sarcoma 222
(b)
Number Tumour type TRF (kb)
1 Mammary carcinoma 14.9
2 Squamous cell 11.6
carcinoma
3 Squamous cell 14.9
carcinoma
4 Squamous cell 18.3
carcinoma
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3.4.4 In vitro telomere studies
3.4.4.1 Growth of primary fibroblast cultures
The canine primary fibroblast cultures AG08075, AG08157, AG07648, SFA and 
the feline primary fibroblast culture S22 (all detailed in Section 2.2.1.2) were 
maintained in culture until cell replication ceased. Growth curves were generated 
for each cell line and used to determine how many population doublings 
occurred in the cell population before replication arrest. This ranged from 4.7 to
16.6 population doublings, as shown in Figures 3-12 and 3-13. The AG08075, 
AG08157, AG07648 and SFA cultures were then maintained in the growth 
medium of the S22 culture, as it displayed the greatest replicative potential (16.6 
PDs). The change of growth medium did not increase the replicative potential of 
the other cultures beyond that which had already been achieved.
3.4.4.2 TRF analysis of primary fibroblast cultures
Telomere length analysis was carried out on selected passages of the SFA, S22 
and AG07648 cell lines, as shown in Figures 3-14 and 3-15. The SFA canine 
primary fibroblast culture underwent a reduction in mean TRF from 20.5 kb at 
passage 2 to 17.5 kb at passage 13 during which the culture underwent 13.3 
population doublings. This equates to a telomere loss of approximately 220 bp 
per cell division. The S22 feline fibroblast culture demonstrated telomere loss 
from 10.6 kb at passage 3 to 9.3 kb at passage 10, during which the cell line 
underwent 16.6 population doublings, in this case equating to approximately 80 
bp per cell division. The AG07648 cell line also underwent telomere loss, from 
11.0 kb at passage 2 to 9.7 kb at passage 15. This occurred over 10.1 population 
doublings, and thus equates to a telomere loss of approximately 130 bp per cell 
division. No correlation between age of donor animal and replicative potential of 
the in vitro culture derived from it could be identified.
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Figure 3-12 Growth curves for canine primary fibroblast cultures SFA, 
AG07648, and AG08157. These cell lines underwent 13.3, 10.1 and 8.9 
population doublings respectively before cell replication ceased.
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Figure 3-13. Growth curves for the canine primary fibroblast culture 
AG08075 and the feline primary fibroblast culture S22. These cell lines 
underwent 4.7 and 16.6 population doublings respectively before replication 
ceased.
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Figure 3-14. Autoradiographs demonstrating teiomeric attrition in the SFA 
and AG07648 cell cultures. Lanes 1 ,2 ,3 , 4, and 5 in the SFA autoradiograph 
represent passages 2, 4 ,7 , 10 and 12 respectively, and equate to telomere lengths 
of 20.5, 20.1, 19.7, 18.9, and 17.5 kb. The SFA cell culture ceased replicating at 
passage 13 after a total of 38 days in culture. Lanes 1 and 2 both represent 
passage 2 and lanes 3 and 4 passage 14 of the AG07648 cell culture and equate 
to telomere lengths o f 11.0 and 9.7 kb respectively. The AG07648 culture was in 
culture a total of 98 days. Lane 5 is a standard TRF marker lane (DNA molecular 
weight marker II, Roche, UK).
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AG07648
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Figure 3-15 Autoradiograph demonstrating teiomeric attrition in the S22 
feline fibroblast culture. Cells were maintained in MEM Eagle medium 
(Sigma) supplemented with 10% heat inactivated PCS, penicillin-streptomycin 
and fungizone and passaged routinely upon reaching approximately 80% 
confluence. The cell line was initially seeded with 2 xlO  ^ cells, and reseeded 
after passage at a concentration of 1x10  ^ cells/ml. After 66 days in culture the 
cell line ceased replication and the majority of cells within it were shown to be 
senescent by SA-p-GAL staining. Autoradiograph lanes 1 and 2 show teiomeric 
smears generated from passage 3 cells, 3 and 4 correspond to passage 5, 5 and 6 
to passage 7 and lanes 7 and 8 to passage 9. These teiomeric smears represent 
mean telomere lengths of 10.6, 10.7, 9.9 and 9.3 kb respectively.
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3.4.4.3 Detection of senescence in vitro
SA-p-GAL staining was the main method by which the accumulation of 
senescent cells in vitro was recorded. Presence of a perinuclear blue dye 
indicates that a cell is senescent, and staining was found to be clear and easily 
interpreted in the cell lines used, as illustrated by Figure 3-16. Staining of the 
SFA primary culture was carried out at passage 2, 4, 10 and 12. For comparison 
pui'poses all other cell cultures were stained initially, again at passage 10 and 
when the culture had effectively stopped replicating. The S22 and AG08075 cell 
cultures did not grow beyond passage 10 and were therefore stained only twice. 
In addition, the replicatively immortal human cell line GM847 was stained as a 
negative control.
Initial staining, carried out as soon as possible after the cell lines were 
introduced to culture conditions revealed varying percentages of senescent cells. 
Both the SFA and S22 cultures contained less than 5% senescent cells, 
increasing to 20% at passage 4 in the SFA culture. The other cell cultures 
contained 14, 16 and 21% SA-P-GAL positive cells at passage 2 in the 
AG08157, AG08075 and AG07648 cultures respectively. The S22 and 
AG08075 lines were the first to cease replicating, and at passages 10 and 7 
respectively both these cell lines contained >95% SA-p-GAL positive cells. At 
passage 10 AG08157, SFA and AG07648 were 43%, 80% and 65% SA-P-GAL 
positive, and these cell lines stopped replicating and reached >95% SA-P-GAL 
positive status at passages 14, 12 and 17 respectively. The GM847 cell line, as 
expected did not contain any SA-P-GAL positive cells.
Further confirmation of senescence in the primary fibroblast cultures was 
determined by ICC for p i6'^ '^^ '^ ''' and p21, as detailed in Section 3.3.4.2. Working 
dilutions of 1/50 were used for both the H-156 (p i6) and the SX118 (p21) 
antibodies. ICC was carried out on the final passage of each culture tested, (p i2 
and plO for SFA and S22 respectively). The test cells had been in a state of 
replicative senescence for 2 weeks prior to ICC, and had previously been shown 
to be SA-P-GAL positive, as described above. In both cell cultures, ICC for
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pj i^N[C4a in Strong nuclear, and moderate cytoplasmic staining,
indicating the accumulation of in the senescent cells. A representative
image o f this staining for the S22 culture is shown in Figure 3-17. In both cases 
the cultures were found to be negative for p21, as shown in Figure 3-18. These 
results follow the pattern noted by Alcoita et al in senescent human fibroblasts 
(Alcorta, Xiong, et al 1996).
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Figure 3-16. Senescence associated p-galactosidase activity at pH 6. A stable 
perinuclear blue dye allows visual identification of cells that have entered 
replicative senescence, as indicated in image (a) by arrows. Five fields of at least 
100 cells were counted, and cells positive for SA- p -GAL activity expressed as 
a percentage o f the total number counted. Percentage positive varied greatly 
depending on the replicative age of the cell line, as shown in image (b), 
indicating the canine primary fibroblast cell line SFA at p4 with 20% of cells 
estimated to be SA-p-GAL positive and image (c), generated from the same cell 
line at p i2, where 100% of the cell population appear to be SA- p -GAL  
positive.
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Figure 3-17. ICC for in late passage S22 primary feline fibroblasts.
Image (a) shows the presence of the brown insoluble DAB end product in 
passage 10 S22 feline fibroblasts using the H-156 anti-pl6 primary antibody 
(Santa Cruz Biotech). This culture entered replicative arrest 2 weeks before 
staining was carried out, and staining was strongest in the nuclei o f the senescent 
cells. Image (b) is taken from the same passage cells with omission of the 
primary (H-156) antibody. No uptake of stain is apparent, implying that the stain 
is binding specifically to the primary antibody. Counterstaining of nuclei used 
Gills haematoxylin. Both images are at 200x magnification.
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Figure 3-18. ICC detection of p21 in late passage canine and feline 
fibroblasts. Both the passage 12 canine fibroblasts from the SFA culture (a), and 
the passage 10 feline fibroblasts from the S22 culture (b) entered replicative 
senescence 2 weeks before staining. No DAB stain is visible in either culture, 
implying an absence of p21 in both cell cultures. Image (c) shows staining of the 
positive control cell line (MCF7), illustrating that the primary antibody (SXl 18, 
BD PharMingen) was working effectively. All images are at 400x magnification.
(a)
(b)
(c)
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3.5 Discussion
The primary aims of this chapter were to investigate telomere lengths in the dog 
and cat and to determine what if any effect the variables of age, breed and 
gender have on telomeres in these two species. An analysis o f 112 canine PBL 
DNA samples demonstrated that PBL telomeres range from 9.6 to 23.5 kb in the 
dog. Analysis of the same cell types from 30 DSH cats revealed a similar range, 
from 4.7 to 20.6 kb. Furthermore, this study found telomere lengths in a panel of 
26 canine and 22 feline somatic tissues to range from 11.6 kb to 22.8 kb, and 8.5 
kb to 26.3 kb respectively. These ranges are very similar to those typical of 
human telomeres (Blackburn 1990) (Harley 1995), and are in contrast with the 
much longer telomeres found in the mouse, which is a species commonly used to 
model human telomere biology (Kipling & Cook 1990).
3.5.1 Age effect on PBL telomere length in the dog and 
cat
This study has shown age to have a significant effect on telomere length in five 
pedigree dog breeds and the DSH cat, (p = 0.001 for both species). This age 
effect supports previous reports documenting the effect of age on telomere 
length in human PBLs (Ruler, Bmmmendorf, et al 1999), in canine mammary 
tissue (Yazawa, Okuda, et al 2001) and feline blood cells (Bmmmendorf, Mak, 
et al 2002).The rate o f telomere loss in human PBLs is not linear thi oughout life, 
instead telomere loss appears accelerated in infancy. In granulocytes this 
corresponds to 3052 bp/year for the first 6 months of life, compared with an 
average of 39 bp/year over a human lifespan (Rufer, Bmmmendorf, et al 1999). 
Such a pattern is not apparent for the dog and cat PBLs investigated in this 
study; however the priority in this investigation was to encompass a broad age 
range of animals, and particularly in the cat this has resulted in the majority of 
the samples being from either old or young individuals. The use of animals from 
the tails of the age distribution is a powerful tool to investigate the relationship 
between age and telomere length as this experimental design emphasizes the
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contribution of age to the variation in telomere length. The results indicate that 
old dogs and cats have shorter telomeres than young individuals. This implies 
that telomere length reduces with increasing age; however flirther work will be 
required to reveal whether this relationship is linear or more complex.
3.5.2 Breed effect on telomere length in the dog
In addition, this study has considered the effect of breed on canine telomere 
length. We have shown breed to have a significant effect in the pedigree canine 
PBL sample population {p = <0.0001). This is interesting as it correlates with 
findings in human research that have determined telomere length to be a 
heritable trait (Slagboom, Droog, et al 1994) (Jeanclos, Schork, et al 2000), and 
also because breed has an effect on lifespan in the dog. An age corrected 
analysis of the breeds examined revealed the Great Dane population to have the 
shortest mean TRFs, and the Beagle breed to have the longest. O f the five 
pedigree breeds examined the Great Dane also has the shortest life expectancy 
(Maynagh 1983) (Michell 1999). The same sources of breed specific data also 
credit the Beagle breed with the longest life expectancy (Maynagh 1983) 
(Michell 1999).
These correlations between breed specific telomere length and life expectancy 
provide evidence of a link between telomere length and ageing in the dog, albeit 
circumstantial evidence from a relatively small population, but nevertheless 
adding to the growing list o f such evidence linking telomere dynamics with the 
ageing process (Rohme 1981) (Oshima, Campisi, et al 1995) (Benetos, Okuda, 
et al 2001). In addition these data provide an area for further investigation in 
canine telomere studies. It would be interesting to investigate if selective 
breeding such pedigrees on the basis of longer than average telomeres in the 
parental stock would result in an increased life expectancy in the progeny. It is 
realised such a study would require careful selection of candidates to avoid 
interference with existing breeding programmes aimed at reducing the 
prevalence of inherited disease.
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3.5.3 Gender effect on telomere length in the dog and cat
Gender did not have a significant effect on telomere length in the sample 
population for which gender data was available. This is interesting as a gender 
effect on telomere length has been identified in humans (Benetos, Okuda, et al 
2001), and more recently rats (Cherif, Tarry, et al 2003). In both these studies, 
males were found to have shorter telomeres than females in an age corrected 
analysis. This provides a novel mechanism for the gender related differences in 
lifespan that are known to exist in both humans and rats; in both species females 
have a greater life expectancy (Cherif, Taiiy, et al 2003). The results of studies 
on the effect of gender on canine lifespan are complicated by factors such as 
entire versus neutered, and natural death versus euthanasia within the sample 
population. Michell found entire female dogs to have the greatest natural life 
expectancy in a panel of over 3000 individuals (Michell 1999), and whilst 
Moore et al found castrated male dogs to have the greatest life expectancy in a 
different study, this sample population o f 927 military animals did not include 
any entire females (Moore, Burkman, et al 2001). Thus the effect of gender on 
canine lifespan is still unclear, and therefore the lack of gender effect on 
telomere length in the canine samples in this study does not add or detract from a 
possible link between telomere length and life expectancy in the dog.
The author is unaware o f any research on the effect of gender on life expectancy 
in the DSH cat, and so the lack o f relationship between telomere length and 
gender in the DSH population cannot be correlated with life expectancy at 
present.
3.5.4 Telomere length analysis of normal canine and 
feline organ samples
Necropsy sample analysis showed a trend of TRF length reduction with 
increased donor age in canine liver, kidney and small intestine, and all the feline 
samples for which a comparison was possible, including liver, lung, skeletal 
muscle and kidney. Tissue renewal times are not available for canine and feline
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tissues, however these results correlate with findings in the adult, non-growing 
mouse where only neurones and myocardium were found to be static with 
respect to cell turnover (Cameron 1970). Other tissues would be expected to 
undergo a decline in telomere length proportional to their renewal rates. Human 
liver and renal cortex also show a trend of decreased telomere length with 
increased donor age (Takubo, Izumiyama-Shimomura, et al 2002), as does 
gastric mucosa, small and large intestinal mucosa and the spleen (Furugori, 
Hirayama, et al 2000) (Hiyama, Hiyama, et al 1996) (Takubo, Izumiyama- 
Shimomura, et al 2002). However, given the small sample size the experiment 
primarily provides an insight into the average size of telomeres in these organs 
in the dog and cat, as the trends noted may simply be a reflection of natural 
variation in the telomere lengths o f the individuals concerned. This is clearly 
illustrated in the canine gastric mucosal samples. If tissue renewal times are 
similar in the dog and the mouse a gi'eater teiomeric loss would be expected in 
gastric mucosa than any of the other tissues examined, yet no such trend is 
displayed. This may simply be a reflection o f individual variation and the small 
sample size {n -  3). However, it is also possible that the unusually high turnover 
of gastric mucosa may be key to explaining the lack of appreciable telomere loss 
with age. Telomerase activity has been detected in gastrointestinal mucosa in 
humans and in dogs (Section 4.4.1) (Bachor, Bachor, et al 1999), and so it is 
possible that transient telomerase activity in canine gastric mucosa counteracts 
the effect of end replication problem brought on by high cell turnover. This is 
also likely to be the case in human gastric mucosal samples, as despite what 
must be a higher cell turnover in this tissue, telomere loss is not significantly 
greater in gastric mucosa than any other human tissues that have been examined 
(Takubo, Izumiyama-Shimomina, et al 2002).
3.5.5 Telomere length analysis of canine and feline 
tumours
Telomere lengths in a panel of canine and feline tumours were also examined to 
determine if a quantifiable reduction in telomere length of the cancerous tissue 
had occurred before transformation. Unfortunately matched normal tissue
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samples from the same individual were not available for comparison, and so it is 
not possible to gauge how many cell divisions were undergone in each case 
before transformation occurred. It is only possible to state that the tumours 
examined did not show any significant difference in telomere length to normal 
canine and feline organ or PBL samples.
Recent work has identified short PBL telomeres as a risk factor for the 
development of a number of diseases in humans, including cancer and 
myocardial infarction (Wu, Amos, et al 2003) (Reviewed in Wong & dePinho, 
2003). This raises the possibility that assessment of telomere length in PBLs 
may provide a non-invasive aid to diagnosis of a range of diseases (Reviewed in 
Wong & dePinho, 2003). Furthermore, this research in the human field raises the 
possibility that a genetic predisposition to short telomeres may predispose a 
canine breed to, for example, cancer development. Whilst the situation in vivo 
will be more complex than this simple relationship it would be interesting to 
discover whether this single factor is important by determining whether a breed 
with an increased cancer risk also tends to display shorter than average PBL 
telomeres. If such an association were discovered, this would have great 
potential for use in evaluating disease risk in individuals, or aid non-invasive 
diagnosis.
3,5.6 In vitro telomere studies
The in vitro study earned out using canine and feline primary fibroblast cultures 
revealed these cultures to have much less replicative potential than their human 
counterparts. Normal human primary fibroblast cultures will enter replicative 
senescence after approximately 50 population doublings (Harley 1995), however 
the greatest replicative potential of any of the canine or feline primary cultures 
used was only 16.6 population doublings. Replicative potential of canine and 
feline primary fibroblast cell cultures has not been investigated before and it is 
possible the reduced proliferative potential of the cell lines studied in this project 
represent a genuine species difference between companion animals and humans. 
Rohme et al (Rohme 1981) demonstrated a correlation between species lifespan
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and replicative potential of fibroblasts in a study that included mammalian 
species with a wide range o f life expectancy; those findings indicate that the 
shorter the lifespan o f the species the poorer the replicative potential o f the 
fibroblast cell line derived from it. These data fit well with our findings, and 
provide an explanation for the comparatively poor replication of our canine and 
feline primary cultures.
Furthermore, no clear coiTelation between age of donor and replicative potential 
of cell line could be demonstrated in this study. Although the cell line with the 
gi'eatest replicative potential was derived from an eight-week-old feline, a cell 
line derived from a six-week-old canine had less replicative potential than one 
derived from a thirteen year old dog. Whilst studies have presented evidence that 
a negative conelation between age and replicative potential does exist (Bruce, 
Deamond, et al 1986) (Cristofalo & Pignolo 1993), a more recent evaluation has 
not been able to repeat the findings (Cristofalo, Allen, et al 1998). It must also 
be borne in mind that the in vitro environment is a cmde simulacmra of the 
situation encountered by the cell in vivo; even the best regulation of culture 
conditions and the constituents of growth media lag far behind physiological 
regulation in the living organism. It is therefore possible that the variation in 
replicative potential of the primary fibroblast cultures may be in part the product 
of sub-optimal conditions, or ‘culture shock’ (Sherr & dePinho 2000).
In addition, it is possible that the initial telomere length o f the specific cell from 
which a culture is derived is the more important factor in determining its 
proliferative potential (Allsopp, Vaziri, et al 1992), however applying these 
criteria did not reveal any insight into the varying potentials of the cell lines 
studied. The S22 cell line initially contained mean TRFs o f 10.6 kb, and 
although these were eclipsed by the mean TRF of the SFA cell line at the first 
passage (20.5 kb), the SFA cell line imdei-went 3.3 fewer population doublings 
before senescence. It is possible that inclusion of a larger number of cell lines in 
the experiment might reveal a relationship between initial mean telomere length 
o f a culture and its replicative potential, however far fewer canine and feline 
primary fibroblast cell lines are available than human equivalents, and make 
such an analysis beyond the scope o f this project.
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All primary cell cultures demonstrated SA-P-GAL staining that increased with 
passage number and approached 100% once replicative exhaustion had been 
reached. Furthermore, >95% positive SA-p-GAL staining was shown to 
correlate with an accumulation o f p i i n  primary canine and feline 
fibroblast cultures, thus confirming that senescence was the cause of the 
replicative arrest rather than quiescence (Dimri, Lee, et al 1995) (Alcorta, 
Xiong, et al 1996) (Huschtscha & Reddel 1999).
Telomere attrition was detected in vitro in the SFA, S22 and AG07648 cell lines 
despite the small number o f population doublings before senescence. At 220, 80 
and 130 bp per cell division respectively, only the SFA cell line demonstrated 
telomere loss greater than that usually detected in human cells in vitro (estimated 
at 30-200), and only by a small margin (Harley 1995). It is also likely that these 
values overestimate the rate at which teiomeric attrition would occur under 
normal circumstances in vivo, as this has been shown to be the case in human 
tissues where a realistic estimate is closer to 10-50 bp per cell division (Harley 
1995).
The choice of TRF analysis for these telomere length studies was governed by 
the fact that this is still widely regarded as the method o f choice (Saldanha, 
Andrews, et al 2003), and also by the practical consideration o f available 
equipment and expertise. However, the TRF method is not without its critics, 
and the chief query regarding the accuracy of the technique lies in the inclusion 
of sub-telomeric repeats in the analysis, up to the first restriction enzyme cutting 
site in the target DNA. Typically comments on the subject refer to a study 
earned out by Hultdin et al that estimated this sub-telomeric DNA component to 
average 3.2 kb in a number of human cell lines and cell suspensions by 
comparing a Southern Blot analysis with a fluorescence in situ hybridisation and 
flow cytometry (Q-FISH^^^) protocol developed for the purpose (Hultdin, 
Gronlund, et al 1998). Given these data it must be conceded that the telomere 
length values presented in these experiments will encompass a small proportion 
o f sub-telomeric DNA. However, the same study found that results gained by Q-
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coiTelated significantly with those gained by Southern blotting. This is 
evidence that the sub teiomeric DNA content was consistent given the same 
experimental conditions across the whole sample population, and therefore does 
not exclude the use of TRF analysis for the accurate investigation o f telomere 
length changes.
Without comparison of TRF analysis with telomere length estimation methods 
beyond the scope of this project it is impossible to state the actual amount of 
sub-telomeric DNA included in the canine and feline telomere length results 
documented, however human sub teiomeric DNA has been found to vary 
between 2.5 and 4 kb in a review carried out by de Lange (de Lange 2003).
The TRF analysis method has been found to give reproducible results that meet 
the demands of the project, however it is clear that the labour intensive nature of 
the technique make it less suitable for larger scale applications. From receiving a 
tissue, blood or cell pellet sample to getting a TRF value takes three to four days, 
and the technique is prone to complications such as uneven transfer o f DNA to 
the membrane, uneven probe and chemiluminescent substrate distribution, and 
high, uneven or mottled background all of which can interfere with analysis of 
the final blot and result in exclusion of a blot from the study. Even with 
experience o f the technique and due attention paid to optimisation, the multi-step 
nature o f the Southern Blot and chemiluminescent detection will inevitably 
result in loss of a number of blots to these complications. Whilst an investigation 
of the newer techniques for telomere length analysis has not been carried out in 
our laboratory it is envisioned that if  techniques such as the hybridisation 
protection assay (Section 3.2.1.1) compare favourably with Southern Blot in 
ternis of sensitivity and repeatability then the TRF method will not remain in 
common use for large scale telomere length analysis.
The decision to examine mean telomere length rather than investigate telomere 
length on individual chromosomes was again based on what was practically 
achievable within the scope of the project, however it is noted that although 
mean telomere length decreases as the canine and feline cells investigated divide 
it is likely, given research carried out in the mouse that the trigger for entering
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senescence is the shortest telomere within a particular cell, rather than the 
average length of all the telomeres (Hemann, Strong, et al 2001).
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3.6 Summary
The experiments described in this Chapter have determined the range of 
telomere lengths that are found in both canine and feline PBLs and normal, 
healthy organ samples taken from a wide spectrum of ages using a standard TRF 
method. A TRF analysis of PBL samples taken from 112 dogs of various breeds, 
and 30 DSH cats found TRFs to range from 4.7 to 20.6 kb, and 9.6 to 23.5 kb 
respectively. PBL telomere lengths in both the pedigree dog and DSH cat have 
been shown to decrease significantly with increased age, and whilst gender did 
not have a significant effect in either species, an intriguing finding was that 
breed o f pedigree dog had a significant effect on telomere length. An age 
coiTected analysis revealed that the shortest mean PBL TRFs in the sample 
population were sourced from the breed with the shortest life expectancy. 
Telomere lengths in a panel of canine and feline tumours were not found to be 
significantly different from telomere lengths o f PBL or healthy organ origin. In 
vitro telomere length studies determined that the replicative potential o f four 
canine primary fibroblast cultures was an average of 10 population doublings, 
whilst a feline primary fibroblast culture had a replicative potential of 16 
population doublings. Once replicative potential had been exhausted, the cells 
adopted an enlarged and rounded appearance typical of senescence, were 
positive for SA-^-GAL activity and plb*^’^ '^ ". Telomere attrition was 
demonstrated in vitro in primary fibroblast cultures of canine and feline origin, 
and averaged 175 and 130 bp/cell division respectively. The in vivo and in vitro 
datasets have demonstrated that teiomeric attrition occurs in both the dog and 
cat; that the telomere lengths of companion animals are similar to humans, and 
the data supports the idea that the telomere may be involved in companion 
animal ageing.
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Chapter IV 
In vivo and in vitro canine and 
feline telomerase studies
4.1 Abstract
Activity of the ribonucleoprotein telomerase is absent from the majority of 
normal human somatic tissues, however telomerase activity has been detected in 
approximately 80% of human malignancies. These findings have established a 
clear link between telomerase activity and cancer in humans. However, very 
little research has been carried out on the biology of telomerase in companion 
animal species, and the experiments described in this Chapter aim to address this 
lack of information. First, an investigation was canied out to detemiine if 
telomerase is active in noiinal canine and feline somatic tissues. Second, an 
investigation of telomerase activity in a panel of canine and feline tumour 
samples, and immortalised canine cell lines was undertaken to determine if 
telomerase activity in dogs and cats is associated with immortalisation and 
malignancy. Further to this work, a study on the potential use of a reverse 
transcriptase inhibitor to inhibit telomerase activity in two immortalised canine 
cell lines is described. Finally, an attempt was made to transfect the human 
telomerase reverse transcriptase sequence into primary canine and feline 
fibroblasts to reconstitute telomerase activity in those cells. This was undertaken 
in a bid to extend the replicative lifespan of the fibroblasts, and thereby provide 
direct evidence of a link between teiomeric attrition and replicative senescence 
in the dog and cat.
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4.2 Introduction
The ribonucleoprotein telomerase has been a major focus for research since its 
telomere specific DNA polymerase activity, initially identified in Tetrahymena 
was confirmed to have a specific association with immortal cells and cancer 
(Greider & Blackburn) (Kim, Piatyszek, et al 1994). This initial study led to a 
large volume of research aimed at determining exactly where this polymerase 
activity could be found in normal, pre-malignant and malignant tissues (for 
review see Dhaene, Van Marck, et al 2000). The conclusion of this large volume 
of work was, that with the exception o f germ cells and the stem cells of 
renewable tissues, telomerase is not readily detectable in normal human tissue. 
In contrast telomerase activity is found in the vast majority of human cancers 
(Shay & Bacchetti 1997) and this has led to the identification o f telomerase as a 
promising molecular target for therapeutic intervention in the field o f oncology. 
At present this is one of three main applications that have been identified with 
respect to telomerase, the other two being cancer diagnosis and prognosis, and 
tissue engineering (Kelland 2001).
4.2.1 Telomerase and cancer
The six hallmarks of cancer are described as being a self-sufficiency in growth 
signals, insensitivity to antigrowth signals, avoidance of programmed cell death, 
sustained angiogenesis, invasion and metastasis and finally, limitless replicative 
potential (Hanahan & Weinberg 2000). The trait of limitless replicative 
potential, acquired by all cancer cells, is dependant in the majority of cases on 
telomerase and for this reason it has become a key player in cancer research 
today. In fact, less than 20 years after its discovery, the ectopic expression of its 
catalytic subunit is one of only three conditions required to successflilly produce 
direct tumorigenlc conversion of nonual human epithelial and fibroblast cells 
(Hahn, Counter, et al 1999).
The strategies for targeting telomerase have been outlined elsewhere (Section 
1.8.2), and the significant advances that have been made in the field appear to at
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least partly justify the initial optimism with which researchers approached the 
subject. A number of companies involved in drug discovery have made 
significant investments into targeting telomerase for new cancer dmgs. Geron 
Corporation has produced an oligonucleotide telomerase inhibitor (GRN163) 
that targets the template region of liTERT, and has been shown to inhibit 
telomerase activity and has passed initial safety tests. Geron is also in the 
process of developing a telomerase vaccine with Phase I clinical trials already 
underway (Goldman 2003). Isis phannaceuticals, a drug discovery company that 
focuses entirely on RNA targeting have a number of oligonucleotide based anti- 
telomerase therapies in various stages of development, several of which have 
reached Phase II clinical trials (Corey 2002). In addition, telomerase positive 
cancer cells have been targeted using an adenovims vector containing bacterial 
nitroreductase under the control of the hTR and liTERT promoters. Bacterial 
nitroreductase bioactivates the prodmg CB1954 into an active cytotoxic 
alkylating agent, and this approach has produced favourable results in both 
telomerase positive cell lines and in vivo (Bilsland, Anderson, et al 2003).
One of the major criticisms levelled at anti-telomerase therapies is termed the lag 
effect, meaning the time required after telomerase inhibition for natural telomere 
attrition to lead to senescence or apoptosis. For instance, one of the earliest 
strategies employed an antisense vector directed against hTR in the cervical 
cancer cell line HeLa; this did result in teiomeric attrition and crisis (M2) 
however the strategy required up to 26 population doublings in the transfected 
cells to be effective. In vivo such a degree of tumour growth would almost 
certainly result in death of the patient before destruction of the transformed cells 
(Feng, Funk, et al 1995).
These data imply that it will be necessary to assess telomere length in individual 
cancers before the decision to use antitelomerase therapy can be made. Whilst 
this is certainly a drawback, a survey of telomeres across 60 human tumour cell 
lines in the US has revealed mean telomere length to be only 5 kb (Chu, 
Piatyszek, et al 2000), implying that a large proportion of human telomerase 
positive tumours would lend themselves to such therapy. In addition it has been 
found that functional p53 is not required for telomere driven apoptosis to occur,
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thus allowing telomerase therapy to be effective in a much broader range of 
cancers, given that p53 function is Icnown to be abrogated in a wide range of 
human malignancies (Zhang, Mar, et al 1999).
A second major concern over telomerase as a target for cancer therapy is the 
potential that the selection pressures such therapy would cause could result in the 
emergence o f an ALT competent phenotype that would be resistant to the 
treatment. This may well be a problem in individual cases, however a number of 
studies already carried out have found no evidence that such a switch from 
telomerase to ALT under the selection pressure of antitelomerase therapy occurs 
(Herbert, Pitts, et al 1999) (Zhang, Mar, et al 1999). Furthermore, telomerase 
inhibitors that target the G-rich single strand overhang at the end o f the telomere 
(G-quadruplex interacting compounds) may be less susceptible to ALT as a 
resistance mechanism as they target the substrate of telomerase, and do not 
interfere with the enzyme itself. An example o f such a compound is telomestatin, 
which has shown favourable results in vitro using a number o f human leukaemia 
cell lines (Tauchi, Kazuo, et al 2003). An important feature of this compound is 
that it appears to act at least partly by inducing telomere dysfunction rather than 
shortening, and therefore does not suffer a Tag effect’ in its mode of action 
(Tauchi, Kazuo, et al 2003). This may make it ideal choice to combine with 
other types of telomerase inhibitor, which may be potent but not immediate in 
their effect, for an overall improved efficacy.
4.2.2 Telomerase as a tumour marker and prognostic 
indicator
It is not surprising that the greatest part of research that has been carried out in 
this area has focussed on humans and the traditional model species, the mouse. 
However, a number of investigators have begun to examine the extent of 
telomerase activity in the tissues of the dog and cat, and this research has already 
uncovered interesting parallels between human, canine and feline telomerase 
biology (Nasir, Devlin, et al 2001) (Argyle & Nasir 2003) (Biller, Kitchell, et al 
1998) (McKevitt, Nasir, et al 2002). Yazawa et al detected telomerase activity in
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26/27 examples of mammary carcinoma in the dog, compared to telomerase 
activity in 4/12 examples of normal canine mammary tissue (Yazawa, Okuda, et 
al 2001). Fiinakoshi et al also investigated the telomerase activity of canine 
mammaiy tumours, and found telomerase activity in all the adenomas, benign 
mixed tumours and adenocarcinomas examined. In contrast to the findings of 
Yazawa, Funakoshi also found telomerase activity to be entirely absent from 
normal and hypeiplastic canine mammary tissue, though interestingly telomerase 
activity was also absent from two malignant mixed tumours (Funakoshi, 
Nakayama, et al 2000). This is evidence that an ALT pathway may be present in 
a subset of canine cancers. In addition there was a relatively greater level of 
telomerase activity in the adenocarcinomas than any of the other positive tissues, 
raising the possibility that relative telomerase activity (RTA) could be used as a 
prognostic indicator. These findings are also reflected in the human literature, 
were telomerase is considered a useful marker for the detection of cancer cells, 
and in cancers were telomerase becomes up regulated during tumour progression 
telomerase is considered a usefiil prognostic indicator (reviewed in Hiyama & 
Hiyama 2003).
Telomerase activity is considered to be absent from normal human somatic 
tissues (Forsyth, Wright et al 2002), and this has been linked to the fact that the 
majority of mammalian somatic tissues do not require gi*eat replicative potential, 
and so telomerase activity has been tightly down regulated as an anti-cancer 
mechanism. However Leri et al have detected telomerase activity in a large 
proportion of canine cardiac myocytes (up to 20%) (Leri, Barlucchi, et al 2001). 
The animals included in the study were all suffering from a fonn of dilated 
cardiomyopathy, and these data alone raise an interesting question mark over the 
simple association between telomerase activity in somatic tissue and malignancy 
(Kim, Piatyszek, et al 1994). These data also imply that canine myocytes from 
non-growing adults are capable of division, as even in cells that are telomerase 
competent telomerase activity appears to be tightly correlated with entry into the 
cell cycle and replication (Chadeneau, Siegal, et al 1995).
In this context the intriguing findings of Leri et al (Leri, Barlucchi, et al 2001) 
underscore the importance of considering health screening of samples for
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telomerase activity assays and make it clear that a simple association between 
telomerase activity, immortalisation and malignancy is by no means all 
encompassing. Indeed, the discovery of telomerase activity in the heart has been 
a substantial addition to the evidence calling into question the dogma that the 
heart is one of the two major organs in the body that are unable to undergo 
physiological repair (the other being the brain), due to the inability of myocytes 
and neurones to divide (Kajstura, Leri, et al 1998) (Horner & Gage 2000).
A number of studies have also investigated telomerase activity in the tissues of 
the cat. Cadile et al (Cadile, Kitchell, et al 2001) examined the potential of using 
telomerase activity as a marker for malignancy in feline tissues. The results are 
encouraging; 1/22 benign samples and 29/31 malignant samples were positive 
for telomerase activity, translating to a sensitivity and specificity for cancer 
detection of 94 and 95% respectively. In addition telomerase activity has been 
detected in normal feline lenses, and a number of feline immortalised cell lines 
(Colitz, Davidson, et al 1999) (Muleya, Nakaichi, et al 1998).
4.2.3 Telomerase therapy
Not all potential therapeutic interventions involving telomerase are concerned 
with switching off the enzyme. The ability of telomerase to extend the 
proliferative life of a cell population has lead to the possibility of using 
telomerase to intervene in disease states where the pathogenesis includes failure 
of cellular proliferation. A potential application for this approach is in the 
treatment of liver cirrhosis; a common disorder, which, left unchecked, results in 
end-stage liver failui'e and ultimately death (Williams & Iredale 1998). A major 
component of liver cirrhosis is the failure of hepatocyte proliferation, and it is 
likely that telomere attrition has a large part to play in this because the sustained 
hepatocyte turnover associated with liver disease results in accelerated telomere 
loss compared with a healthy organ (Miura, Horikawa, et al 1997). Rudolph et al 
have shown that adenoviral delivery of mTR inhibited the development of 
experimental liver cinhosis in mTR' " mice by enabling hepatocytes to overcome 
the proliferative block imposed by short telomeres (Rudolph, Chang, et al 2000).
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The telomeres of human cirrhotic patients have been shown to be short enough 
to produce a proliferation check, and so it is feasible that a variation of this 
technique could be used to treat liver cirrhosis in humans, and that such an 
approach could be extended to the veterinary field (Rudolph, Chang, et. al 2000).
Another area where therapeutic use of telomerase activity has already shown 
great promise is in bone regeneration and repair. A new and very effective 
treatment for large bone defects beyond the capacity of normal healing is the use 
o f bone marrow stromal stem cells (BMSSCs). These are defined as pluripotent 
progenitor cells with the ability to differentiate into osteoblasts, chondrocytes, 
adipocytes, muscle and neural cells (Caplan & Binder 2001). These cells must 
be expanded ex vivo to produce the large numbers necessaiy to aid bone repair 
upon cell transplantation to the site of a defect. The major restriction to the 
application of the technique is the limited replicative potential o f BMSSCs in 
cell culture, coupled with a gradual loss of osteogenic potential (Bianco, 
Riminucci, et al 2001). Shi et al have demonstrated that ectopic expression of 
hTERT in these cells extended their lifespan and maintained their osteogenic 
potential (Shi, Gronthos, et al 2002). Again, clear potential exists to exploit this 
application of telomerase in both the medical and veterinary medical fields.
A major concern over the use of telomerase for therapeutic intervention is the 
potentially increased risk of malignant transfoiination in the target tissue (Kim, 
Piatyszek, et al 1994). In the examples described here, it is envisioned that the 
risk o f developing cancer secondary to telomerase therapy will be slight. For 
example, when considering telomerase for the treatment of human liver cirrhosis 
it is likely that any telomerase therapy will be used only to prolong the life of a 
patient until such time as a liver transplant becomes possible, therefore 
minimising the long-term risk of exposure to the initial therapy. Furthermore, 
Shi et al have been able to show that the bone generated by their telomerase 
expressing stem cells is of a normal architecture (Shi, Gronthos, et al 2002). This 
is an important finding as lack o f normal architecture and failure to differentiate 
would be indicative of genetic instability and therefore risk of malignant 
transformation. However, not all findings in this area have been so encouraging. 
Recent work carried out by Mondello et al found that ectopic expression of
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hTERT resulted in karyotype instability and anchorage independent growth in 
human fibroblast cell lines (Mondello, Chiesa, et al 2003). These results indicate 
that a case-by-case approach will be necessary when assessing the safety of 
telomerase therapy in the future, and that such therapy might not be entirely 
without risk.
All these studies based on the analysis o f telomerase activity have utilised a 
protocol originally designed by Kim et al teimed the Telomeric Repeat 
Amplification Protocol (TRAP) (Kim, Piatyszek, et al 1994). Initially this 
technique was qualitative only, utilising an oligonucleotide primer as a substrate 
for telomerase. If the telomerase enzyme is active in a sample then telomeric 
repeats are synthesised and added to the 2>' end of the primer. These extension 
fragments are subsequently amplified by PCR and may be detected by 
polyacrylamide gel electrophoresis. The assay is sensitive enough to detect one 
telomerase positive cell in 10,000 negatives. The original technique has been 
modified and updated to improve sensitivity and quantification (Kim & Wu 
1997), and Roche molecular biochemicals have produced a variant that includes 
an enzyme linked immunosorbent assay (ELISA) to allow semi-quantification of 
telomerase activity and more accurate comparison between samples.
Whether the TRAP assay can be used as the basis for clinical applications of 
telomerase testing is still debatable. Tseng et al deteiinined the TRAP assay to 
be 100% sensitive and 90% specific in relation to the detection of malignant 
ascites secondary to ovarian cancer in a series of 97 cases. These results 
compared favourably to the 96% sensitivity and 100% specificity of cytology, 
and led the authors to recommend telomerase activity testing as an adjuvant to 
cytopathological methods (Tseng, Jain, et al 2001). Braunschweig et al earned 
out a similar test of the assay as a marker o f malignancy in cytological effusions 
and in a total of 291 cases determined the TRAP assay to perfonn relatively 
poorly; only 76% sensitive and 82-91% specific (Braunschweig, Guilleret, et al 
2001) when compared to routine histopathological diagnosis. The TRAP assay is 
vulnerable to false negatives caused by inadequate handling and storage of 
material for the assay. To ensure integrity o f the telomerase RNA subunit it has
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been proposed that samples should be snap frozen in liquid nitrogen and stored 
at “80°C within 20 minutes of collection, as the assay relies on the presence o f 
functionally intact RNA (Cadile, Kitchell, et al 2001).
Telomerase is not an oncogene (Harley 2002), and therefore coupling a 
telomerase activity assay with other markers o f abnormal behaviour in a tissue 
may be necessary to reduce the potential for false positives when associating 
telomerase activity with malignancy. Work carried out by Chu et al (Chu, Lin, et 
al 2001) on canine transmissible venereal tumour (CTVT) is a good example o f 
why such a strategy may be necessary. CTVT occurs in two phases, a 
progressive growth phase (P-phase) followed by spontaneous regression (R- 
Phase). Telomerase activity is present in both phases of the disease, but is higher 
in P-phase tissue samples. These samples also have a greater mitotic index. 
However, despite the fact that P-phase tissue has high telomerase activity and an 
increased mitotic index, it inevitably regresses to the R-phase. Therefore whilst 
telomerase activity is broadly acceptable as a marker of malignancy it will be 
necessary to validate results in a case-by-case approach before the results o f 
telomerase testing are used as a basis for making clinical decisions (Chu, Lin, et 
al 2001).
4.2.4 Chapter aims
4.2.4.1 To investigate telomerase activity in normal canine and 
feline somatic tissue and tumour samples
As described, to date only limited information is available on telomerase activity 
in the tissues of the dog and cat. In light of this, an investigation of telomerase 
activity was conducted encompassing a wide variety of tissue samples taken 
from healthy organs o f the dog and cat. In addition telomerase activity was 
assessed in a panel of canine and feline tumour samples to ascertain if  the 
widespread dependence on telomerase reactivation found in human tumours was 
mirrored in the dog and cat, such that telomerase status may be o f 
diagnostic/prognostic significance in companion animals.
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4.2.4.2 To assess if telomerase inhibition could be achieved using 
a potential telomerase inhibitor in vitro
Some of the earliest anti-telomerase strategies tested in human immortalised cell 
lines involved the use of reverse transcriptase inhibitors (RTIs) (Strahl & 
Blackburn 1996). A number of these dmgs were found to be capable of 
inhibiting telomerase activity and reducing telomere length in vitro. In this 
chapter, the effect o f the reverse transcriptase inhibitor 3'-Azido-3'- 
deoxythymidine triphosphate (AZT-TP) on telomerase activity was assessed in 
two telomerase positive canine cell lines.
4.2.4.3 Telomerase reactivation study
It is known that ectopic expression of the catalytic component of human 
telomerase, hTERT, greatly extends the lifespan of primary human cell cultures 
in vitro by causing reconstitution of telomerase activity in the transformed cells 
(Bodnar, Ouellette, et al 1998). Whilst at the time o f this study the canine and 
feline homologous sequences to hTERT were not known, an investigation was 
conducted to determine if ectopic expression of hTERT in primary canine and 
feline cell lines is capable of reconstituting telomerase activity using 
heterologous gene expression, and whether this is sufficient to expand 
replicative potential in vitro.
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4.3 Materials and Methods
4.3.1 Sample details
4.3.1.1 Normal somatic tissues
Normal somatic tissue samples were collected from the same animals that were 
described in Chapter III for telomere length assessment. These were 5 dogs 
(CN1-CN5) and 5 cats (FN1-FN5). Details including age, sex, breed and cause 
o f death of individual animals from which samples were taken are presented in 
Table 3-2. The 26 canine samples included kidney (n = 4), liver (/? = 5), ovary {n 
= 1), skeletal muscle {n = 4), small intestine {n = 4), stomach {n = 2), cardiac 
muscle {n = 3), lung {n ^  2) and testis {n = 1). The 25 feline samples included 
brain {n = 4), cardiac muscle {n = 3), liver {n = 5), skeletal muscle {n = 4), lung 
{n = 4), small intestine {n = 3), testis {n = 1) and kidney {n = 1).
4.3.1.2 Tumour tissues
A total of 19 tumour tissue samples were collected from 15 dogs and 4 cats 
during necropsy examination at GUVS and surgical biopsy at the PDSA 
hospital, Shamrock Street, Glasgow. The canine samples included 10 examples 
of mammary carcinoma, 3 fibrosarcomas and 2 squamous cell carcinomas. The 
four feline samples included 1 mammary carcinoma and 3 squamous cell 
carcinomas. The tumour types were confirmed by routine histopathological 
examination canied out at GUVS, and all samples were haivested with informed 
owner consent. Each o f the tissue samples was snap frozen in LNO2  at the time 
of collection to ensure integrity o f the telomerase RNA until required.
4.3.1.3 Primary cultures and cell lines
Primaiy fibroblast cultures o f canine (SFA and AG08157), feline (S22 and CCL- 
176) and equine (EQ l) origin, and a human immortalised cell line (GM847) 
were used in the telomerase reactivation study. Additionally, a number of
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immortal cell lines of both canine and human origin (results shown in Table 4- 
14) were used for telomerase activity testing. Two cell lines from this panel 
(MDCK and CMT7) were subsequently used to test the efficacy o f a potential 
telomerase inhibitor in vitro. The sources of each of these cells are provided in 
Section 2.1.1,1, and individual details including culture requirements are 
provided in Section 2.2.1.2. Additional details of the investigation o f telomerase 
activity in cell lines and the telomerase reactivation study are provided below.
4.3.1.3.1 Telomerase reactivation study
Primary fibroblast cell cultures were utilised for this study. These included the 
canine cultures SFA and AG08157 and the feline cell cultures S22 and CCL- 
176. All the primary fibroblast cultures were at passage 2 at the beginning of the 
experiment to preserve the greatest possible replicative potential for the 
experimental procedure. The human ALT competent cell line GM847 and the 
primary equine fibroblast culture EQl were included, GM847 as a positive 
experimental control and EQl as a further species control for the specificity of 
the hTERT sequence. A full-length hTERT clone was kindly donated by Robert 
Weinberg (Whithead Institute for Biomedical research, Cambridge, MA), and 
the mammalian expression vector PCIneo (Promega, UK), detailed in Section
2.1.5.1 was used as the vehicle for entry of hTERT into the test cells.
4.3.1.3.2 Telomerase inhibition study
The ability of a RTI to reduce telomerase activity was assessed in two 
immortalised canine cell line lines that were found to be telomerase positive in 
the telomerase activity study. The RTI AZT-TP was used in this study. The drug 
was supplied as a 10 mM solution of the tetralithium salt in water (Calbiochem, 
La Jolla CA), and was stored in a tightly closed container in aliquots o f 60 pi at - 
70°C, and protected from light when not in use. The drug is considered toxic and 
was used only with appropriate safety precautions (within a Rime cupboard and 
wearing protective clothing and gloves).
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4.3.2 The TRAP assay
TRAP assay testing of all samples in this project used the TeloTAGGG 
Telomerase PCR ELISA^^^^ kit available commercially from Roche, UK.
4.3.2.1 Sample preparation for the TRAP assay
Samples used for telomerase activity analysis included cell pellets derived from 
cultured cells and protein extracts derived from tissue samples. Cells were 
harvested and counted as described elsewhere (Section 2.2.1). A total of 2 x 10^  
cells were harvested for each assay. Cells were pelleted at 3000 g for 5 minutes 
at 4°C, the supernatant decanted, and following a brief resuspension in 100 pi of 
PBS the cells were again pelleted and the supernatant carefully removed. Cell 
pellets were then resuspended in 200 pi ice-cold lysis reagent (Roche, UK) and 
incubated on ice for 30 minutes. The lysate was then centrifuged at 16000 g for 
20 minutes at 4°C and the supernatant carefully removed with a micropipette, 
taking care not to disturb the pellet o f cellular debris. To facilitate this, only 175 
pi was removed per sample. Cell extracts were then either used immediately for 
the TRAP assay or snap frozen in LNO2 and stored at -80°C for later use.
Normal tissue samples and tumour samples were placed in tumour pots and snap 
frozen in LNO2 immediately after harvesting. Samples were then stored at - 
80°C. Such precautions in tissue handling were necessary to safeguard the 
integrity of telomerase RNA and catalytic subunit and thus reduce the likelihood 
of false negative results (Cadile, Kitchell, et al 2001). Thin slices of frozen 
samples were then removed (approximately 10 slices being sufficient) using 
sterile scalpel blades on disposable petri dishes and immediately transferred to 
1.5 ml eppendorf homogenisation tubes containing 200 pi o f ice-cold lysis 
reagent (Roche, UK). Samples were then thoroughly homogenised using a sterile 
pestle and stored on ice for 30 minutes to achieve thorough lysis.
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Following lysis, samples were centrifuged at 16000 g for 20 minutes at 4°C and 
the protein rich supernatant carefully removed with a micropipette, as described 
for cell pellets. Protein concentration was then determined using a standard 
protocol, as described in Section 2.2.7. The tissue extracts were either 
immediately used for the TRAP assay or snap frozen in LNO2 and stored at - 
80°C for later use.
4.3.2.2 Primer elongation and amplification
All preparation steps for the TRAP PCR procedure were canied out on ice, 
including the thawing of frozen samples prior to analysis. Unless othenvise 
indicated sample numbers were limited to six per individual assay to minimise 
the potential cost in reagents of failure o f any assay. Master mixes were made up 
for all samples and controls consisting of 25 pi of a 2x reaction mixture (Roche, 
UK) and 5 pi of an internal standard (Roche, UK). A 30 pi volume of the mix 
was placed into a PCR tube for each sample and to this was added 1 pi of the 
cell extract or a volume equivalent to 5 pg of total protein. A 1 pi volume o f two 
separate positive controls, one of high and one of low telomerase activity were 
used, and 1 pi of lysis buffer alone was used as a negative control. Analysis of a 
heat-inactivated version of each test sample provided an additional level of 
control. Heating these control samples to 85°C for 10 minutes inactivates 
telomerase protein within the sample and ensures any positive result is specific 
to telomerase activity. All reactions were then made up to a total volume of 50 
pi using nuclease-free water (Roche, UK) and transferred to a DNA Thermal 
Cycler (Perkin Elmer) for the combined primer elongation/amplification 
reaction. Reaction conditions are shown in Table 4-1.
4.3.2.3 Hybridisation and ELISA
Hybridisation steps were carried out in 0.5 ml eppendorf tubes placed in colour 
coded racks to differentiate between test, internal standard and negative 
(including heat inactivated) controls. A 2.5 pi volume of amplification product 
from the previous step was added to 10 pi of a dénaturation reagent (Roche, UK)
161
in the corresponding eppendorf tube. These mixtures were then incubated at 
room temperature for 10 minutes before addition of 100 pi of either a test 
hybridisation buffer (to test and control samples) or an internal standard buffer 
(to internal control samples). These buffers contained DIG-labelled detection 
probes specific for telomeric repeats and the internal standard respectively. 
Thorough mixing of the contents of all Pibes was ensured by vortexing before 
100 pi of the contents of each was removed and placed in a corresponding well 
o f a streptavidin precoated microtitre plate (Roche, UK) according to a 
predetermined pipetting scheme. A plate contained 12 modules of 8 wells each, 
and modules could be removed to facilitate separate analysis such that more than 
one assay could be performed per kit.
The microtitre plate wells were then clearly labelled, covered with an adhesive 
strip to prevent evaporation and incubated at 37°C on a heated plate shaker 
(Dynatech, UK) rotating at 300 rpm for 2 hours. This allowed immobilisation of 
the telomerase and internal standard products with their corresponding detection 
probes to the streptavidin-coated walls of the plate wells, via the biotin label of 
the kit primer. Following hybridisation the solutions were completely removed 
from the wells, following which the wells were washed three times for a 
minimum of 30 seconds per wash with 250 fil of wash buffer, (Roche, UK) 
ensuring complete removal of the buffer from the wells between steps.
The anti-DIG working solution was a polyclonal antibody (Roche, UK) raised in 
sheep conjugated to HRP that was diluted to a concentration of 10 mU/ml in a 
conjugate dilution buffer (Roche, UK). A 100 |ul volume of this anti-DIG-HRP 
working solution was then added to each of the wells that were again covered 
with adhesive film and incubated for 30 minutes at room temperature on a plate 
shaker rotating at 300 rpm. The working solution was then removed completely 
from the wells and five, 30-second wash steps carried out as described 
previously. Following this, 100 pi o f a substrate solution, equilibrated to room 
temperature and containing the HRP sensitive compound 3,3% 5,5'-
tetramethylbenzidine (TMB) was added to each well and the plate covered and 
incubated for colour development at room temperature for 10 minutes with
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rotation at 300 rpm. Without removal of the substrate solution from the well, 100 
pi o f a stop reagent (< 5 %  sulphuric acid, Roche, UK) was then added; this 
stopped the reaction and in addition caused a colour change o f the reacted HRP 
substrate from blue to yellow, which increased the sensitivity o f the reaction. 
The absorbance of the samples was then immediately measured at 450 nm, with 
a reference wavelength o f 690 nm using a microtitre plate reader (Dynex 
Technologies, UK). An oveiwiew of the TRAP assay procedure is provided in 
Figure 4-1.
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Table 4-1. Telomerase primer elongation/ampliücation reaction protocol
Step Time Temerature Cycle
Primer elongation 20 minutes 25°C
Telomerase inactivation 5 minutes 94°C
Amplification
Denaturing 30 seconds 94°C 30 cycles
Annealing 30 seconds 50°C 30 cycles
Polymerisation 30 seconds 72“C 30 cylces
10 minutes 72°C 
Hold 4°C
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Figure 4-1. Overview of the TRAP assay. In the first step, telomerase adds 
telomeric repeats (TTAGGG) to the 3' end of the biotin labelled synthetic primer 
(green rectangle). These elongation products, as well as the internal standard 
included in the same reaction vessel are amplified by PCR. The PCR products 
are split into two aliquots, denatured and hybridised separately to DIG labelled 
detection probes, specific for telomeric repeats (blue) and internal standard (red), 
respectively. The resulting products are immobilised to the streptavidin-coated 
microtitre plate wall via the biotin label. The immobilised amplicons are then 
detected with an antibody against DIG that is conjugated to HRP and the 
sensitive peroxidase substrate TMB.
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4.3.2.4 Quantification of telomerase activity
The level of telomerase activity in positive samples was determined from the 
absorbance of each test sample and the absorbance obtained from 1 pi of the 
control templates. The control templates (TS8) were identical to a telomerase 
elongation product of 8 telomeric repeats and were at a concentration of 0.001 
amol/ml (low activity) and 0.1 amol/ml (high activity). As amplification of the 
telomerase specific products and internal standards were competitive, both low 
and high controls were used in each experiment to cover for a potentially broad 
range of telomerase activity in the test samples. The most appropriate control 
was then used depending on the level of telomerase activity in the test samples. 
In practice this meant use of the high activity control in the majority of cases. 
RTA in a sample was then determined using the foiinula:
(As-Aso)/As,is
RTA =   X 100
( A t S 8 -A  TS8,o) / A tS8,IS
where,
As = absorbance o f sample
Aso = absorbance of heat-treated sample
As,IS = absorbance of the internal standard of the sample
Ats8 = absorbance o f the control template (TS8)
A ts8 ,o  = absorbance of lysis buffer
A t s 8 ,i s  = absorbance of the internal standard of the control template
The values ( A j s s - A  t s 8 ,o ) /A t s s , i s  obtained using 1 pi of the high and low control 
templates were considered acceptable if within the range o f 2.0-4.0 and 0.2-0.5 
respectively after 10 minutes o f substrate reaction. Test samples with absorbance 
readings greater than three times the background reading (mean absorbance of 
the heat treated samples) were considered to be telomerase positive.
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4.3.2.5 Detection of telomerase mediated DNA-Iadder
The biotin labelled primer used in the TRAP assay allowed identification of the 
amplification products by polyaciylamide gel electrophoresis (PAGE). The Mini 
PROTEAN 3 vertical gel electrophoresis system (Bio-rad) was used for this 
procedure. First, 20 pi of the PCR product was mixed with a loading dye 
containing bromophenol blue and xylene cyanol. Separation o f amplification 
products was achieved using a precast 12% non-denaturing polyacrylamide gel 
(Bio-Rad, Hertfordshire, UK) run for 30 minutes at 100 V. After electrophoresis, 
products were transferred by electroblotting (Section 2.2.8) to a positively 
charged nylon membrane (Amersham, UK), which was then blocked with a 2% 
blocking reagent (Roche, UK) for 30 minutes at room temperature to prevent 
binding at non-specific sites. Blocking solution was then discarded and the 
membrane incubated with 20 ml of a streptavidin-alkaline phosphate conjugate 
which bound to the biotin labels on the DNA fragments. Following this the 
membrane received two 15-minute rinses in 100 ml of wash buffer (0.1 M 
Maleic acid, 0.15 M NaCl pH 7.5; 0.3 v/v Tween 20) at room temperature before 
equilibration with 20 ml of detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, pH 
9.5) for 2-5 minutes. The membrane was then placed DNA side up on an acetate 
sheet and 1 ml of CSPD ready-to-use (Roche, UK) applied drop wise. (CSPD 
ready-to-use is a chemiluminescent substrate for alkaline phosphatase at a 
concentration of 0.25 mM). A second acetate sheet was placed over the 
membrane, ensuring no air bubbles were trapped in the process, to help 
distribute the substrate solution evenly over the surface after which there was a 5 
minute incubation at room temperature before excess CSPD solution was 
squeezed out and the acetate sheets sealed with sellotape. At this point an 
incubation o f the damp membrane at 37°C for 10 minutes helped to enhance the 
chemiluminescent reaction. The membrane was then exposed to X-ray film for 
15-20 minutes to produce an autoradiograph.
4,3.3 Telomerase inhibition study
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The effect of the RTI AZT-TP on telomerase activity of canine cells was 
investigated in vitro using the immortalised canine cell lines MDCK and CMT7 
(detailed in Section 2.2.1.2). An initial investigation assessed the toxicity of the 
dmg to the test cells before any telomerase inhibitory effects could be examined.
4.3.3.1 Investigation of acute cytotoxic effect
Both test cell lines were maintained in two-fold dilutions of AZT-TP in a 96 well 
plate format to assess cytotoxicity o f the dmg. Each cell line was seeded at 1 
xlO^ cells/ml in triplicate and allowed to settle overnight before exposure to 
concentrations of 480, 240, 120, 60, 30, 15, 7.5 and 3.75 pM AZT-TP in 
complete culture medium for a period o f 7 days. Treated medium was replaced 
with fresh, dmg containing solution after 3 days, following nonnal practice for 
growth medium replacement. Parallel cultures of the test cell lines, seeded at the 
same concentration were maintained in complete culture medium without the 
addition of the test dmg. These cultures also received fresh medium after 3 days. 
This experiment allowed the identification o f AZT-TP concentrations that did 
not kill the test cells outright, and the experiment was then repeated in duplicate 
using the identified concentrations of AZT-TP in a T25 flask format, as this 
allowed easier harvesting and counting o f cells, given the relatively greater 
numbers. This second stage was used to identify the highest concentration of 
AZT-TP that did not effect cell morphology or growth rate, and this 
concentration was duly selected for the main study.
4.3.3.2 Investigation of effect of AZT-TP on telomerase activity
MDCK and CMT7 cells were maintained in T75 flasks under normal culture 
conditions. Each cell line was initially seeded at 1 x 10  ^ cells/ml, and two 
batches of each cell line were maintained. One batch of each cell line was 
exposed to AZT-TP at a concentration previously determined not to exert any 
acute cytotoxic effects on the cells. A second batch was maintained in parallel in 
AZT-TP free medium. Cells were passaged normally as described elsewhere 
(Section 2.2.1) upon reaching 80% confluence, and at each passage cells were
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counted (Section 2.2.1.1.1) and 2 xlO^ and 2 xlO*^  cells from each treated and 
control cell line haivested and retained for analysis. These cells were pelleted at 
3000 g for 5 minutes to facilitate removal of the culture medium. The pellets 
were then briefly resuspended in cold PBS, repelleted as described and the 
supernatant decanted to remove the last traces of culture medium. These 
precautions were necessary due to the theoretical possibility of the presence of 
Taq DNA polymerase inhibitors in the media used to culture the cells. Pellets 
were then snap frozen in LNO 2 and transferred to -80°C storage. The 2x10^ cell 
pellet was subsequently used to assess telomerase activity in the sample by the 
TRAP assay, and the 2 xlO^ pellet used for telomere length analysis. In addition, 
growth curves were generated for each cell line and any difference in growth 
rate between test and control cells noted. The techniques used for telomere 
length analysis and the production of growth curves have been detailed 
elsewhere (Sections 3.3.3 and 3.3.1.4).
4.3.4 Telomerase reactivation study
4.3.4.1 Cell lines
In addition to the canine and feline primary cultures used in this study (Section 
4.3.1.3) a number of other cell lines were included as controls. Telomerase 
activity has been successfully reconstituted in the human ALT positive cell line 
GM847 by ectopic expression of hTERT (Perrem, Colgin, et al 2001), and this 
cell line was therefore included to ensure the experimental protocol was working 
effectively. In addition, the ability o f hTERT to reconstitute telomerase activity 
was investigated in an equine primary fibroblast culture, EQ l. The aim here was 
to use equine cells as an additional control to determine whether heterologous 
TERT expression is sufficient to activate telomerase in a range of mammalian 
cells. Currently, there are no published data on the feline, equine or canine 
TERT sequences which limits the investigation o f homologous TERT 
reconstitution analyses. However, during the preparation o f this thesis, our group 
have isolated and cloned the cDNA encoding the canine TERT sequence 
(submitted for review, Nasir, Gault, et al 2004).
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4.3.4.2 Cloning of hTERT cDNA into a mammalian expression 
vector
The PCIneo mammalian expression vector (Section 2.1.5.1) was selected to act 
as the plasmid for introducing hTERT into the test cells as it is designed 
specifically for mammalian gene expression studies and includes a strong, 
constitutively active CMV promoter, and has the capacity for selection of 
transfected cells via its neomycin phosphotransferase sequence. Furthermore, 
PCIneo has been successfully used to transfect several canine cell lines within 
the laboratory. PCIneo required linearization to facilitate insertion of the hTERT 
cDNA, and this was achieved by a 2-hour digestion of 5 pg o f PCIneo with 4 
lU/pg each of EcoR 1 and Sal I at 37°C. As these restriction enzymes have one 
recognition site each within the PCIneo sequence (at nucleotide positions 1096 
and 1120 respectively), they were ideal for linearising the vector. Following 
digestion, linearised vector was subjected to 1% agarose gel electrophoresis 
(Section 2.2.3.5) with a 1 kb DNA ladder to confirm integrity of the DNA and 
size of fragment. The band containing the vector was visualised using a UV 
transilluminator (Sigma, UK), removed from the gel using a sterile scalpel blade 
and purified using the QIAquick® Gel extraction kit (QIAgen, UK) following the 
manufacturers recommended protocol. Concentration of plasmid DNA was then 
determined by a standard protocol (Section 2,2.3.3.2).
A full-length hTERT clone (Table 4-2) was kindly donated by Robert Weinberg 
(Whithead Institute for Biomedical research, Cambridge, MA), supplied cloned 
into the pBABE-puro retroviral vector. The hTERT cDNA was isolated from 
this vector using the same enzymes as described for the PCIneo, and vector and 
insert DNA were then ligated using T4 DNA ligase (Promega, UK) following 
the protocol detailed in Section 2.2.3.7. A molar ratio of vector: insert DNA of 
1:3 was used. A 1 pi volume o f the ligation products from each reaction were 
then used to transform E. coli TOP 10 bacterial cells as described in Section 
2.2.3.8. After overnight growth on agar containing ampicillin at 100 mg/ml 
individual colonies were picked and gi*own as described in section 2.2.3.1.
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Table 4-2. hTERT done sequence
ORIGIN
1 GCAGCGCTGC GTCCTGCTGC GCACGTGGGA AGCCCTGGCC CCGGCCACCC CCGCGATGCC 
6 1  GCGCGCTCCC CGCTGCCGAG CCGTGCGCTC CCTGCTGCGC AGCCACTACC GCGAGGTGCT
1 2 1  GCCGCTGGCC ACGTTCGTGC GGCGCCTGGG GCCCCAGGGC TGGCGGCTGG TGCAGCGCGG
1 8 1  GGACCCGGCG GCTTTCCGCG CGCTGGTGGC CCAGTGCCTG GTGTGCGTGG CCTGGGACGC
2 4 1  ACGGCCGCCC CCCGCCGCCC CCTCCTTCCG CCAGGTGTCC TGCCTGAAGG AGCTGGTGGC
3 0 1  CCGAGTGCTG CAGAGGCTGT GCGAGGGCGG CGCGAAGAAC GTGCTGGCCT TCGGCTTCGC
3 6 1  GCTGCTGGAC GGGGCCCGCG GGGGCCCCCC CGAGGCCTTC ACCACCAGCG TGCGCAGCTA
4 2 1  CCTGCCCAAC ACGGTGACCG ACGCACTGCG GGGGAGCGGG GCGTGGGGGC TGCTGCTGCG
4 8 1  CCGCGTGGGC GACGACGTGC TGGTTCACCT GCTGGCACGC TGCGCGCTCT TTGTGCTGGT
5 4 1  GGCTCCCAGC TGCGCCTACC AGGTGTGCGG GCCGCCGCTG TACCAGCTCG GCGCTGCCAC
6 0 1  TCAGGCCCGG CCCCCGCCAC ACGCTAGTGG ACCCCGAAGG CGTCTGGGAT GCGAACGGGC
6 6 1  CTGGAACCAT AGCGTCAGGG AGGCCGGGGT CCGCGTGGGC CTGCCAGCCC CGGGTGCGAG
7 2 1  GAGGCGCGGG GGCAGTGCCA GCCGAAGTCT GCCGTTGCCC AAGAGGCCCA GGCGTGGCGC
7 8 1  TGCCCCTGAG CCGGAGCGGA CGCCCGTTGG GCAGGGGTCC TGGGCCCACC CGGGCAGGAC
8 4 1  GCGTGGACCG AGTGACCGTG GTTTCTGTGT GGTGTCACCT GCCAGACCCG CCGAAGAAGC
9 0 1  CACCTCTTTG GAGGGTGCGC TCTCTGGCAC GCGCCACTCC CACCCATCCG TGGGCCGCCA
9 6 1  GCACCACGCG GGCCCCCCAT CCACATCGCG GCCACCACGT CCCTGGGACA CGCCTTGTCC
1 0 2 1  CCCGGTGTAC GCCGAGACCA AGCACTTCCT CTACTCCTCA GGCGACAAGG AGCAGCTGCG
1 0  8 1  GCCCTCCTTC CTACTCAGCT CTCTGAGGCC CAGCCTGACT GGCGCTCGGA GGCTCGTGGA
1 1 4 1  GACCATCTTT CTGGGTTCCA GGCCCTGGAT GCCAGGGACT CCCCGCAGGT TGCCCCGCCT
1 2  0 1  GCCCCAGGGC TACTGGCAAA TGCGGCCCCT GTTTCTGGAG CTGCTTGGGA ACCACGCGCA
1 2 6 1  GTGCCCCTAC GGGGTGCTCC TCAAGACGCA CTGCCCGCTG CGAGCTGCGG TCACCCCAGC
1 3  2 1  AGCCGGTGTC TGTGCCCGGG AGAAGCCCCA GGGCTCTGTG GGGGCCCGCG AGGAGGAGGA
1 3  8 1  CACAGACCCC CGTCGCCTGG TGCAGCTGCT CCGCCAGCAC AGCAGCCCCT GGCAGGTGTA
1 4 4 1  CGGCTTCGTG CGGGGCTGCC TGCGCCGGCT GGTGCCCCCA GGCCTCTGGG GCTCCAGGCA
1 5 0 1  CAACGAACGC CGCTTCCTCA GGAACACCAA GAAGTTCATC TCCCTGGGGA AGCATGCCAA
1 5 6 1  GCTCTCGCTG CAGGAGCTGA CGTGGAAGAT GAGCGTGCGG GACTGCGCTT GGCTGCGCAG
1 6 2 1  GAGCCCAGGG GTTGGCTGTG TTCCGGCCGC AGAGCACCGT CTGCGTGAGG AGATCCTGGC
1 6 8 1  CAAGTTCCTG CACTGGCTGA TGAGTGTGTA CGTCGTCGAG CTGCTCAGGT CTTTCTTTTA
1 7 4 1  TGTCACGGAG ACCACGTTTC AAAAGAACAG GCTCTTTTTC TACCGGAAGA GTGTCTGGAG
1 8  0 1  CAAGTTGCAA AGCATTGGAA TCAGACAGCA CTTGAAGAGG GTGCAGCTGC GGGAGCTGTC
1 8  6 1  GGAAGCAGAG GTCAGGCAGC ATCGGGAAGC CAGGCCCGCC CTGCTGACGT CCAGACTCCG
1 9 2 1  CTTCATCCCC AAGCCTGACG GGCTGCGGCC GATTGTGAAC ATGGACTACG TCGTGGGAGC
1 9  8 1  CAGAACGTTC CGCAGAGAAA AGAGGGCCGA GCGTCTCACC TCGAGGGTGA AGGCACTGTT
2 0 4 1  CAGCGTGCTC AACTACGAGC GGGCGCGGCG CCCCGGCCTC CTGGGCGCCT CTGTGCTGGG
2 1 0 1  CCTGGACGAT ATCCACAGGG CCTGGCGCAC CTTCGTGCTG CGTGTGCGGG CCCAGGACCC
2 1 6 1  GCCGCCTGAG CTGTACTTTG TCAAGGACAG GCTCACGGAG GTCATCGCCA GCATCATCAA
2 2 2 1  ACCCCAGAAC ACGTACTGCG TGCGTCGGTA TGCCGTGGTC CAGAAGGCCG CCCATGGGCA
2 2  8 1  CGTCCGCAAG GCCTTCAAGA GCCACGTCCT ACGTCCAGTG CCAGGGGATC CCGCAGGGCT
2 3 4 1  CCATCCTCTC CACGCTGCTC TGCAGCCTGT GCTACGGCGA CATGGAGAAC AAGCTGTTTG
2 4 0 1  CGGGGATTCG GCGGGACGGG CTGCTCCTGC GTTTGGTGGA TGATTTCTTG TTGGTGACAC
2 4 6 1  CTCACCTCAC CCACGCGAAA ACCTTCCTCA GCTATGCCCG GACCTCCATC AGAGCCAGTC
2 5 2 1  TCACCTTCAA CCGCGGCTTC AAGGCTGGGA GGAACATGCG TCGCAAACTC TTTGGGGTCT
2 5 8 1  TGCGGCTGAA GTGTCACAGC CTGTTTCTGG ATTTGCAGGT GAACAGCCTC CAGACGGTGT
2 6 4 1  GCACCAACAT CTACAAGATC GTCCTGCTGC AGGCGTACAG GTTTCACGCA TGTGTGCTGC
2 7 0 1  AGCTCCCATT TCATCAGCAA GTTTGGAAGA ACCCCACATT TTTCCTGCGC GTCATCTCTG
2 7 6 1  ACACGGCCTC CCTCTGCTAC TCCATCCTGA AAGCCAAGAA CGCAGGGATG TCGCTGGGGG
2 8 2 1  CCAAGGGCGC CGCCGGCCCT CTGCCCTCCG AGGCCGTGCA GTGGCTGTGC CACCAAGCAT
2 8 8 1  TCCTGCTCAA GCTGACTCGA CACCGTGTCA CCTACGTGCC ACTCCTGGGG TCACTCAGGA
2 9 4 1  CAGCCCAGAC GCAGCTGAGT CGGAAGCTCC CGGGGACGAC GCTGACTGCC CTGGAGGCCG
3 0 0 1  CAGCCAACCC GGCACTGCCC TCAGACTTCA AGACCATCCT GGACTGATGG CCACCCGCCC
3 0 6 1  ACAGCCAGGC CGAGAGCAGA CACCAGCAGC CCTGTCACGC CGGGCTCTAC GTCCCAGGGA
3 1 2 1  GGGAGGGGCG GCCCACACCC AGGCCCGCAC CGCTGGGAGT CTGAGGCCTG AGTGAGTGTT
3 1 8 1  TGGCCGAGGC CTGCATGTCC GGCTGAAGGC TGAGTGTCCG GCTGAGGCCT GAGCGAGTGT
3 2 4 1  CCAGCCAAGG GCTGAGTGTC CAGCACACCT GCCGTCTTCA CTTCCCCACA GGCTGGCGCT
3 3 0 1  CGGCTCCACC CCAGGGCCAG CTTTTCCTCA CCAGGAGCCC GGCTTCCACT CCCCACATAG
3 3 6 1  GAATAGTCCA TCCCCAGATT CGCCATTGTT CACCCCTCGC CCTGCCCTCC TTTGCCTTCC
3 4 2 1  ACCCCCACCA TCCAGGTGGA GACCCTGAGA AGGACCCTGG GAGCTCTGGG AATTTGGAGT
3 4  8 1  GACCAAAGGT GTGCCCTGTA CACAGGCGAG GACCCTGCAC CTGGATGGGG GTCCCTGTGG
3 5 4 1  GTCAAATTGG GGGGAGGTGC TGTGGGAGTA AAATACTGAA TATATGAGTT TTTCAGTTTT
3 6 0 1  G
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Plasmid DNA was then purified from each individual clone using the QIAprep® 
PCR Spin Miniprep Kit (QIAGEN, UK, detailed in Section 2.2.3.2.2). This kit 
allowed isolation of plasmid DNA from 4 ml LB broth cultures of exponentially 
growing bacteria. The bacteria were harvested by centrifugation (2800 rpm for 
10 minutes), and the manufacturers protocol was then followed. The method 
involved lysis of the bacterial cells to release the DNA constructs, which were 
then harvested by centrifugation, filtration and wash steps into 50 pi o f sterile 
water. DNA was stored at -20°C.
A 5 pi volume of each plasmid was then digested with 4 lU/pg of EcoR 1 and 
Sal I as described previously, and the digests run out on a 1% agarose gel to 
confirm the correct size of plasmid and insert. Plasmids found to contain the 
hTERT insert were then used to produce bulk stocks of purified PCIneo/hTERT 
(Section 2.2.3.2.1) and glycerol stocks o f bacteria containing the construct as 
described in Section 2.2.3.1.
4.3.4,3 Stable transfection of cell cultures
Transfections were carried out using Trans Fast™ (Promega, UK) and 
Lipofectamine™/Plus'^‘'^  transfection reagents (Invitrogen life technologies, UK). 
Test cell cultures were transfected with PCIneo/hTERT and PCIneo empty 
vector as a control.
4.3.4.3.1 TransFast^^ reagent
The Trans Fast transfection reagent relies on interaction between liposomes and 
DNA to facilitate entry of the nucleic acids into mammalian cells. Liposomes are 
lipid bilayers that form colloidal particles in an aqueous medium. The lipids 
contained in TransFast include the synthetic cationic lipid, (+)-N,N [bis (2- 
hydroxyethyl)-N-methyl-N-[2,3-di(tetradecanoyloxy)propyl] ammonium iodide, 
and the neutral lipid L-dioleoyl phosphatidyethanolamine (DOPE).
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The incubation of cationic lipid containing liposomes and nucleic acids results in 
rapid association and compaction of the nucleic acid; this is thought to be caused 
by electrostatic interactions between the negatively charged nucleic acid and the 
positively charged head group of the synthetic lipid. Thus the negative charge o f 
the nucleic acid is shielded, allowing closer association with the target cell 
membrane. Entry of the liposome into the cell may then occur by either 
endocytosis or fusion with the cell membrane (Gao & Huang 1995). The neutral 
lipid DOPE, which allows the complexes to escape from endosomes and 
lysosomes into the cytoplasm, enhances this process (Farhood, Serbina, et al 
1995). It is not laiown how the transfected DNA of DNA/liposome complex 
gains entry to the nucleus.
4.3.4.3.Z Transfection protocol using TransFast™ reagent
Cells were plated at normal concentration (1 xloVml) the day before transfection 
and allowed to settle overnight. The TransFast reagent was reconstituted with 
400 pi of water on the same day to result in a 1 mM concentration o f lipid. The 
reagent was then vortexed thoroughly to resuspend the lipid film and stored at - 
20°C overnight. The first stage of the transfection process involved optimisation 
of the conditions. This involved a trial o f different amounts of DNA in the 
transfection reaction, and different charge ratios of TransFast reagent to DNA. 
This was done in a 24 well plate format, and for each cell line to be transfected, 
0.25, 0.5, 0.75 and 1.0 pg of DNA was used with a 1:1, 2:1 and a 3:1 charge 
ratio. Each combination was also tested in complete medium, and medium 
without the addition of FCS. The conditions resulting in the most effective 
transfection were then adopted for the main study.
Master mixes adequate for 6 replicates o f each DNA concentration and charge 
ratio were made up. First the required amount of medium (with or without FCS, 
and prewanned to 37°C) was combined with the requisite amount of DNA and 
voitexed. To this was added the amount of TransFast reagent indicated by the 
charge ratio. For a 24 well plate fonnat, the total volume of these 3 constituents 
was 200 pi per well. The mixture was allowed to incubate for 15 minutes at
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room temperature, then growth medium was carefully aspirated from the test 
cells and after a final vortex the TransFast/DNA mixture was added to the cells, 
which were then incubated under normal culture conditions for 1 hour.
At the end of the incubation period the cells were overlaid with prewarmed 
complete medium (1 ml per well in the 24 well plate format). Cells were then 
returned to the incubator and left undisturbed for 48 hours. At the end of this 
period, selection for transfected cells was achieved by the addition of fresh 
medium containing the antibiotic G418 at a concentration previously determined 
to select strongly for transfected cells. In general, mammalian cells require a 
concentration of 400-600 pg/ml of G418 to achieve the selection criteria of 
>90% cell death in control cells within 5-7 days (Manufacturer’s transfection 
guidelines). As such, control (untransfected) cells from each cell line were 
exposed to concentrations of 300, 350, 400, 500 and 600 pg/ml of G418 initially 
to determine the concentration of drug required for adequate selection.
Test cells were maintained in selective medium for 3-4 weeks with twice-weekly 
changes of medium to eliminate dead cells and debris until, if stable 
transfectants were achieved, distinct colonies of suiwiving cells appeared. At this 
point surviving cells were haiwested and pooled to produce a cell line containing 
stable transfectants only. These were maintained in selective medium and 
otherwise cultured normally. In addition a parallel transfection with empty 
plasmid vector was can ied out, to provide a negative control.
4.3.4.3.3 Lipofectamine'*'^ and PIus^^ reagents
Lipofectamine is a different liposome formulation consisting of the polycationic 
lipid 2,3-dioleyloxy-N-[2(spenninecarboxamido)ethyl]-N,N-dimethyl-1 -
propanaminium trifluoroacetate (DOSPA) and DOPE. It has the same mode of 
action as TransFast™, and it is recommended for use with the proprietary Plus^'^ 
reagent (Invitrogen, UK). The Plus reagent is used for precomplexing with DNA 
and has been found to enhance cationic lipid-mediated transfection. Optimisation
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of conditions using Lipofectamine was determined in the same manner as 
detailed for the TransFast reagent.
4.3.4.3.4 Transfection using the Lipofectamine/Pius reagents
Cells were plated at normal concentration (1 xlO^/ml) the night before the 
procedure such that they would be 60-80% confluent at the time of transfection. 
Plasmid DNA was precomplexed with the Plus reagent; for each well of a 24 
well plate format this involved dilution of 0.4 pg of DNA in 25 pi of medium 
without semm before the addition of 4 pi of the Plus reagent to the mixture, a 
thorough mixing of the components and a 15 minute incubation at room 
temperature.
A 1 pi volume of Lipofectamine reagent was then diluted in 25 pi of serum free 
medium in a second tube and mixed before this was added to the tube containing 
the precomplexed DNA. After a thorough mixing there then followed another 
15-minute incubation at room temperature. During this incubation, the growth 
medium covering the test cells was replaced with 0.2 ml of transfection medium 
(normal or without FCS) per well. The DNA-Plus/Lipofectamine complexes 
were then added to the test wells, mixed gently and incubated under normal 
culture conditions for 3 hours. After the incubation, transfection medium was 
completely removed and replaced with nonnal growth medium for each o f the 
cell types. Cells were then incubated under normal growth conditions for 72 
hours, after which growth medium was replaced with selective medium 
containing G 418 at the previously determined concentration.
Cell lines were maintained under nonnal gmwth conditions in the selective 
medium and passaged upon reaching 80% confluence. At each passage, cell 
pellets were retained for TRP and TRAP analysis, as described previously for 
the telomerase inhibition study (Section 4.3.3.2) Cell counts at passage were 
monitored and used to constmct growth curves for each surviving test cell line.
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43.4.4 Confirmation of transfection
Successful transfection of the hTERT gene sequence into test cell lines was 
confirmed by RT-PCR (Section 2.2.5). Any possible DNA contamination in the 
isolated RNA samples was removed by inclusion of an RNAse-free DNAse 1 
digestion step for each sample before RT-PCR (Section 2.2.4.3). First strand 
cDNA synthesis was carried out using both random primers and the gene 
specific primers detailed below. The use of oligo-dT primers was not appropriate 
in this case as the mature hTERT transcript is not polyadenylated. The gene 
specific primer sequences were 5'-ACTGTTCAGCGTGCTCAACTA-3' 
(DNHTOOl) and 5 -TCATTCAGGGAGGAGCTCTGCT-3 ' (DNHTOOIR), 
corresponding to nucleotide numbers 1980-2000 and 2378-2399 respectively on 
the Homo sapiens telomerase reverse transcriptase mRNA sequence, accession 
number NM 003219. The PCR was then carried out at 95"C for 5 minutes 
followed by 25 amplification cycles of 94”C for 30 seconds, 55°C for 30 
seconds, and 72°C for 30 seconds. The final polymerisation incubation at 72”C 
was canied out for 7 minutes, after which the PCR products were held at 4°C 
until Rirther analysis. The PCR products were visualised by agarose gel 
electrophoresis to confirm they were o f the coixect size, and then gel purified 
before sequencing using the ABI PRISM® 3100 Genetic Analyzer (Section 
2.2.6) and confinning the origin of the sequence using the ‘B lasf search engine 
(Section 2.2.6.1.3).
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4.4 Results
4.4.1 Telomerase activity profile of normal canine and 
feline tissues
Telomerase activity was assessed in a panel of tissues (26 canine and 25 feline) 
sampled from 5 dogs (CNl-5) and 5 cats (FNl-5) as detailed in Table 3-2. Not 
all the tissue types sampled were available from each of the 10 animals, due to 
the individual nature of each necropsy examination. RTA values were generated 
from absorbance readings of test, control and internal standard wells as detailed 
in the Materials and Methods (Section 4.3). A sample was described as 
telomerase positive if the value determined by subtraction of background 
absorbance (average of the absorbance o f the heat inactivated samples. Ago) 
from the absorbance of the sample. As resulted in a value greater than twice the 
background; i.e. As - Aso / Ago > 2.0. To reduce the likelihood of false 
negatives due to this highly stringent standard, samples with As - Ago / Ago > 1- 
2 were said to contain low, or borderline telomerase activity. These samples 
contained telomerase activity that was between two and three times greater than 
the background. Background readings of less than 0.1 were acceptable, any 
higher reading indicated inadequate heat inactivation and resulted in repetition of 
the experiment. All experiments utilised the high activity positive telomerase 
control, and (Ajss-A t s 8,o) / A t s 8,is values after 10 minutes of colour development 
were between 2.0 and 4.0.
RTA values determined for the canine tissue samples from subjects CN l, CN2, 
CN3, CN4 and CN5 are shown in Tables 4-2 to 4-6. In all the subjects where 
kidney tissue samples were available for analysis, these were negative for 
telomerase activity. Similarly, no activity could be detected in liver, cardiac 
muscle, lung or skeletal muscle samples isolated from several dogs. Small 
intestinal tissue samples were available for analysis in 4 subjects and low levels 
of telomerase activity could be detected in 2 cases (CN2 and CN3). Similarly, 
low levels of activity were identified in a stomach sample from CN1, however a
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stomach sample from CN5 was negative for telomerase activity. One ovarian 
sample was available for analysis (CNl), however this sample was negative. A 
single testis sample was also analysed (CN5), and this sample showed the 
presence of low levels of activity.
RTA values determined for the feline tissue samples from subjects FNl,  FN2, 
FN3, FN4 and FN5 are shown in Tables 4-7 to 4-11. O f the feline samples 
examined, telomerase activity was not detected in the following tissue samples 
from several subjects; brain, cardiac muscle, liver, skeletal muscle, lung and 
small intestine. Telomerase activity was also absent from the single feline kidney 
specimen (FN5). The one sample that was telomerase positive out of the 25 
examined was a testis sample taken from subject FN5.
The telomerase positive and low telomerase activity results for both dogs and 
cats were all confirmed by repeat TRAP analysis.
4.4.2 Telomerase activity profile of canine and feline 
tumour samples
Telomerase activity was assessed in a panel of 15 canine and 4 feline tumours 
utilising the same criteria as described above for normal tissues, including the 
use of the high activity positive control for all experiments. Canine tumours 
sampled included fibrosarcoma {n = 3), mammary carcinoma {n = 10), and 
squamous cell carcinoma (/? = 2). Feline tumour samples included mammary 
carcinoma {n = 1), and squamous cell carcinoma {n = 3). All tumour samples 
were identified by histopathology carried out at the Pathology department at 
GUVS. All tumour samples were either harvested during surgical biopsy and 
immediately flash frozen in LNO2 , or in the case of tumours harvested post­
mortem, the necropsy was carried out the same day as euthanasia.
High levels of telomerase activity were detected in 4 of 4 (100%) feline tumour 
samples, and in 15 of 17 (88%) canine tumour samples. The remaining two 
canine tumour samples contained low levels of telomerase activity, which was
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confirmed by repeat TRAP analysis. The TRAP results for the canine and feline 
tumour samples are shown in Tables 4-12 and 4-13 respectively.
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Table 4-2. TRAP analysis of necropsy specimens from canine CNl. As is the
absorbance o f the sample, Aso the absorbance of the heat inactivated version of 
the sample, AAg was determined by subtraction of the mean of the heat 
inactivated samples ( Aso or backgi'ound) from As, AAs / Aso is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAs) was greater than twice the backgi'ound activity (AAs / Aso > 2.0). 
Samples contained low telomerase activity if  AAs / Aso was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEC) for telomerase activity. The CNl assay gave a 
background absorbance of 0 . 0 4 4 ,  and a ( A t s s - A  t s s ,o) / A t s 8,is value of 2 . 5 2  after 
10 minutes o f colour development using the high activity positive control.
CNl As Aso AAs M s
Aso
RTA Result
Kidney 0.042 0.05 0 0 0 NEC
Liver 0.054 0.046 0.01 0.23 4 NEC
Ovary 0.076 0.043 0.032 0.73 3 NEC
Skeletal 0.041 0.042 0 0 0 NEC
muscle
Small 0.041 0.036 0 0 6 NEC
intestine
Stomach 0.090 0.046 0.044 1.05 3 LOW
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Table 4-3. TRAP analysis of necropsy specimens from canine CN2. As is the
absorbance o f the sample, Aso the absorbance of the heat inactivated version of 
each sample, AAs was deteimined by subtraction of the mean of the heat 
inactivated samples ( Aso or background) from As, AAs / Ago is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAs) was greater than twice the background activity (AAs / Ago > 2.0). 
Samples contained low telomerase activity if AAs / Ago was between i and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The CN2 assay gave a 
background absorbance of 0.046, and a (Apss-A t s 8,o) / A t s 8,is value of 2.14 after 
10 minutes of colour development using the high activity positive control.
CN2 As Aso AAs AAs
Ago
RTA Result
Cardiac
muscle
0.042 0.045 0 0 0 NEG
Kidney 0.041 0.046 0 0 0 NEG
Liver 0.041 0.045 0 0 0 NEG
Small
intestine
0.101 0.048 0.055 1.20 3 LOW
1 8 1
Table 4-4. TRAP analysis of necropsy specimens from canine CN3. As is the
absorbance of the sample, Aso the absorbance of the heat inactivated version of 
each sample, AAs was determined by subtraction of the mean of the heat 
inactivated samples ( Aso or backgi'ound) from As, AAs / Aso is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAs) was greater than twice the background activity (AAs / Aso > 2.0). 
Samples contained low telomerase activity if  AAs / Aso was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The CN3 assay gave a 
background absorbance of 0.052, and a (Apsg-A t s s , o ) / A t s 8 , i s  value of 3.58 after 
10 minutes of colour development using the high activity positive control.
CN3 As Aso AAs AAs
Aso
RTA Result
Cardiac
muscle
0.032 0.037 0 0 0 NEG
Kidney 0.063 0.073 0.011 0.2 0 NEG
Liver 0.034 0.037 0 0 0 NEG
Lung 0.091 0.042 0.039 0.75 5 NEG
Skeletal
muscle
0.033 0.037 0 0 0 NEG
Small
intestine
0.388 0.086 0.336 6.5 172 POS
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Table 4-5. TRAP analysis of necropsy specimens from canine CN4. As is the
absorbance of the sample, Aso the absorbance of the heat inactivated version of 
each sample, AAs was deteimined by subtraction of the mean of the heat 
inactivated samples ( Aso or backgi'ound) from As, AAs / Aso is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAs) was greater than twice the background activity (AAs / Aso > 2.0). 
Samples contained low telomerase activity if AAs / Aso was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The CN3 assay gave a 
background absorbance of 0.055, and a ( A t s s - A  t s 8 , o ) / A t s 8 , i s  value of 2.35 after 
10 minutes of colour development using the high activity positive control.
CN4 As Aso AAs AAs
Aso
RTA Result
Cardiac
muscle
0.071 0.067 0.016 0.3 <1 NEG
Kidney 0.061 0.070 0.006 0.1 0 NEG
Liver 0.058 0.038 0.003 0.1 3 NEG
Lung 0.086 0.063 0.031 0.6 3 NEG
Skeletal
muscle
0.072 0.060 0.017 0.3 7 NEG
Small
intestine
0.072 0.031 0.017 0.3 3 NEG
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Table 4-6. TRAP analysis of necropsy specimens from canine CN5. As is the
absorbance of the sample, Aso the absorbance of the heat inactivated version of 
each sample, AAs was determined by subtraction of the mean o f the heat 
inactivated samples ( Aso or background) from As, AAs / Aso is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAs) was greater than twice the backgi'ound activity (AAs / Aso > 2.0). 
Samples contained low telomerase activity if AAs / Ago was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The CN5 assay gave a 
background absorbance of 0.062, and a (Ajss-A t s 8 , o ) / A t s s , i s  value o f 3.00 after 
10 minutes of colour development using the high activity positive control.
CN5 As Aso AAs AAs
Aso
RTA Result
Liver 0.070 0.069
Skeletal 0.059 0.068
muscle
Stomach 0.062 0.052
Testis 0.152 0.059
0.008
0
0
0.09
0.1
0
0
1.5
<1
0
0
< 1
NEG
NEG
NEG
LOW
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Table 4-7. TRAP analysis of necropsy specimens from feline FN l. As is the
absorbance of the sample, Aso the absorbance of the heat inactivated version of 
each sample, AAs was deteimined by subtraction of the mean of the heat 
inactivated samples ( Ago or background) from As, AAs / Ago is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if  the difference in absorbance 
(AAg) was greater than twice the backgi'ound activity (AAg / Ago > 2.0). 
Samples contained low telomerase activity if  AAg / Ago was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The FNl assay gave a 
background absorbance of 0.063, and a ( A t s s ' A  t s 8 , o ) / A t s 8 , i s  value o f 3.00 after 
10 minutes of colour development using the high activity positive control.
FNl As Ago AAg AAs
Ago
RTA Result
Brain 0.069 0.070 0 0 0 NEG
Cardiac 0.063 0.053 0.01 0.2 2 NEG
muscle
Liver 0.072 0.067 0.005 0.1 <1 NEG
Skeletal 0.103 0.059 0.04 0.6 8 NEG
muscle
Lung 0.119 0.063 0.056 0.9 22 NEG
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Table 4-8. TRAP analysis of necropsy specimens from feline FN2. As is the
absorbance o f the sample, Ago the absorbance of the heat inactivated version of 
each sample, AAg was deteimined by subtraction of the mean o f the heat 
inactivated samples ( Ago or background) from Ag, AAg / Ago is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAg) was greater than twice the background activity (AAg / Ago > 2.0). 
Samples contained low telomerase activity if  AAg / Ago was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The FN2 assay gave a 
background absorbance of 0.063, and a (Ajss-A T S 8 ,o )/A T S 8 ,ts  value of 3.00 after 
10 minutes o f colour development using the high activity positive control.
FN2 Ag Ago AAg AAg
Ago
RTA Result
Brain 0.071 0.067 0.004 0.1 <1 NEG
Cardiac 0.063 0.072 0 0 0 NEG
muscle
Liver 0.056 0.041 0.015 0.24 3 NEG
Lung 0.066 0.061 0.005 0.1 1 NEG
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Table 4-9. TRAP analysis of necropsy specimens from feline FN3. Ag is the
absorbance of the sample, Ago the absorbance o f the heat inactivated version of 
each sample, AAg was deteimined by subtraction of the mean of the heat 
inactivated samples ( Ago or background) from Ag, AAg / Ago is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAg) was greater than twice the background activity (AAg / Ago > 2.0). 
Samples contained low telomerase activity if AAg / Ago was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The FN3 assay gave a 
background absorbance o f 0.038, and a (A-rss-A TS8,o)/ATg8,is value of 2.27 after 
10 minutes of colour development using the high activity positive control.
FN3 Ag Ago AAg AAs
Ago
RTA Result
Lung 0.037 0.046 0 0 0 NEG
Cardiac 0.033 0.032 0 0 1 NEG
muscle
Brain 0.043 0.032 0.005 0.13 <1 NEG
Liver 0.039 0.035 0.001 0.03 5 NEG
Skeletal 0.037 0.033 0 0 5 NEG
muscle
Small 0.052 0.052 0.014 0.37 0 NEG
intestine
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Table 4-10. TRAP analysis of necropsy specimens from feline FN4. Ag is the
absorbance of the sample, Ago the absorbance of the heat inactivated version of 
each sample, AAg was deteimined by subtraction of the mean of the heat 
inactivated samples ( Ago or backgi'ound) from Ag, AAg / Ago is the ratio of 
sample to background activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAg) was greater than twice the background activity (AAg / Ago > 2.0). 
Samples contained low telomerase activity if  AAg / Ago was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The FN4 assay gave a 
background absorbance o f 0.030, and a (A-pgg-A t s 8 ,o) / A t s 8 , i s  value of 3.97 after 
10 minutes of colour development using the high activity positive control.
FN4 Ag Ago AAg AAg
Ago
RTA Result
Liver 0.025 0.035 0 0 0 NEG
Skeletal 0.040 0.035 0.005 0.17 <1 NEG
muscle
Small 0.027 0.021 0.006 0.2 <1 NEG
intestine
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Table 4-11. TRAP analysis of necropsy specimens from feline FN5. Ag is the
absorbance of the sample, Ago the absorbance of the heat inactivated version of 
each sample, AAg was deteimined by subtraction of the mean o f the heat 
inactivated samples ( Ago or backgi'ound) from Ag, AAg / Ago is the ratio of 
sample to backgi’ound activity, and RTA the relative telomerase activity. 
Samples were considered telomerase positive if the difference in absorbance 
(AAg) was greater than twice the backgi'ound activity (AAg / Ago > 2.0). 
Samples contained low telomerase activity if AAg / Ago was between 1 and 2. 
Using these criteria samples were designated positive (POS), low activity 
(LOW) or negative (NEG) for telomerase activity. The FN5 assay gave a 
background absorbance of 0.043, and a (Aygg-A t s s ,o ) / A t s 8 , i s  value o f 2.69 after 
10 minutes of colour development using the high activity positive control.
FN5 Ag Ago AAg M s
Ago
RTA Result
Brain 0.048 0.043 0.005 0.12 <1 NEG
Kidney 0.041 0.042 0 0 0 NEG
Liver 0.041 0.040 0 0 0 NEG
Lung 0.044 0.044 0.001 0.02 0 NEG
Small 0.047 0.041 0.004 0.09 <1 NEG
intestine
Skeletal 0.037 0.047 0 0 0 NEG
muscle
Testis 0.171 0.047 0.128 2.98 7 POS
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Table 4-12. TRAP analysis of canine tumour samples. Ag is the absorbance of 
the sample, Ago the absorbance of the heat inactivated version of each sample, 
AAg was determined by subtraction o f the mean of the heat inactivated samples 
( Ago or background) from Ag, AAg / Ago is the ratio of sample to backgi'ound 
activity, and RTA the relative telomerase activity. Samples were considered 
telomerase positive if the difference in absorbance (AAg) is greater than twice 
the background activity (AAg / Ago > 2.0). Samples contained low telomerase 
activity if AAg / Ago was between 1 and 2. Using these criteria samples were 
designated positive (POS), low activity (LOW) or negative (NEG) for 
telomerase activity. The canine tumour assay gave a background absorbance of 
0.071, and a (Ajgs-A t s 8 ,o) / A t s 8 , i s  value of 2.10 after 10 minutes of colour 
development using the high activity positive control. Low telomerase activity 
results were confirmed by repeat analysis.
Tumour Ag A'so AAs AAg
Ago
RTA Result
Mammary carcinoma 0.335 0.07 0.264 3.72 11 POS
Mammary carcinoma 0.155 0.07 0.084 1.18 6 LOW
Mammary carcinoma 0.277 0.065 0.206 2.9 8 POS
Mammary carcinoma 0.301 0.07 0.23 3.24 14 POS
Mammary carcinoma 0.272 0.07 0.201 2.83 10 POS
Mammary carcinoma 0.256 0.075 0.185 2.61 7 POS
Mammary carcinoma 0.284 0.073 0.213 3.0 9 POS
Mammary carcinoma 0.15 0.064 0.079 1.11 3 LOW
Mammary carcinoma 0.709 0.074 0.638 8.99 29 POS
Mammary carcinoma 0.363 0.072 0.292 4.11 13 POS
Fibrosarcoma 0.835 0.067 0.764 10.8 54 POS
Fibrosarcoma 0.322 0.074 0.251 3.54 14 POS
Fibrosarcoma 0.646 0.073 0.575 8.10 36 POS
Squamous cell carcinoma 0.24 0.074 0.169 238 8 POS
Squamous cell carcinoma 1.428 0.072 1.357 19.1 81 POS
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Table 4-13. TRAP analysis of feline tumour samples. Ag is the absorbance of 
the sample, Ago the absorbance of the heat inactivated version of each sample, 
AAg was determined by subtraction of the mean of the heat inactivated samples 
( Ago or background) from Ag, AAg / Ago is the ratio of sample to background 
activity, and RTA the relative telomerase activity. Samples were considered 
telomerase positive if the difference in absorbance (AAg) is greater than twice 
the background activity (AAg / Ago > 2.0). Samples contained low telomerase 
activity if  AAg / Ago was between 1 and 2. Using these criteria samples were 
designated positive (POS), low activity (LOW) or negative (NEG) for 
telomerase activity. The feline tumour assay gave a background absorbance of 
0.04, and a (Ajgg-A t s 8 ,o) / A t s 8 , i s  value of 3.90 after 10 minutes of colour 
development using the high activity positive control.
Tumour Ag Ago AAg AAg
Ago
RTA Result
Mammary carcinoma 0.510 0.037 0.47 11.8 13 POS
Squamous cell carcinoma 0.232 0.040 0.192 4.8 4 POS
Squamous cell carcinoma 0.481 0.043 0.441 11.0 10 POS
Squamous cell carcinoma 0.477 0.039 0.437 10.9 11 POS
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4.4.3 Telomerase activity in immortalised cell lines
Telomerase activity was assessed in the canine immortalised cell lines CMLIO, 
MDCK, D17, A72, GHK, CMT3, CMT7 and CMT8, and in a number of 
immortalised cell lines of human origin (GM847, 293T and 3132T), which were 
included for comparison of telomerase activity levels. The canine primary 
fibroblast culture SFA was included as a negative control. Details of the entire 
panel of cell lines used are provided in Section 2.2.1.2, and the results of the 
TRAP assay are shown in Table 4-14. Telomerase activity was confirmed in all 
of the canine immortalised cell lines tested, with RTA values ranging from 3 in 
the A72 cells to 38 in the CMT3 cells. The human cell lines 293T and 3132T 
were also positive for activity, and with RTA values of 12 and 47 respectively, 
the human cell lines displayed a similar level of telomerase activity to their 
canine counterparts. No activity was detected in the human ALT competent cell 
line GM847 or the primary fibroblast culture, which were confirmed to be 
telomerase negative by repeat analysis. A representative autoradiograph showing 
TRAP PCR products form three immortalised canine cell lines is shown in 
Figure 4-2.
4.4.4 Effect of the RTI AZT-TP on telomerase activity in 
canine telomerase positive cells
Canine MDCK and CMT7 cells identified as positive for telomerase activity 
(Section 4.4.3) were used to test the telomerase inhibitory effects of AZT-TP. 
The initial step in this investigation was to assess the highest concentration of 
AZT-TP to which the test cell lines could be exposed without inducing an acute 
cytotoxic effect. To this end, cells were exposed to two-fold dilutions of AZT- 
TP in a 96 well plate format, whilst control cell cultures were maintained in dmg 
free medium. The initial screening ran for 7 days. Concentrations of 120 pM and 
above resulted in death of both the cell lines. An AZT-TP concentration of 60 
pM and below allowed survival of test cells, and the experiment was then 
repeated in a T25 flask format with cells seeded at 1 xlO^ cells/ml.
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Table 4-14. TRAP analysis of immortalised cell lines. Ag is the absorbance of 
the sample, Ago the absorbance of the heat inactivated version of each sample, 
AAg was determined by subtraction of the mean of the heat inactivated samples 
( Ago or background) from Ag, AAg / Ago is the ratio of sample to backgi'ound 
activity, and RTA the relative telomerase activity. Samples were considered 
telomerase positive if the difference in absorbance (AAg) was greater than twice 
the background activity (AAg / Ago > 2.0) On these criteria samples were 
designated positive (POS) or negative (NEG) for telomerase activity. The cell 
line assay gave a background absorbance of 0.060, and a (Argg-A t s 8 ,o) / A t s 8 , is  
value of 2.78 after 10 minutes of colour development using the high activity 
positive control.
Cell line Ag Ago AAg AAg
Ago
RTA Result
A72 0.287 0.062 0.225 3.75 3 POS
CMLIO 0.544 0.055 0.489 8.15 10 POS
CMT3 1.194 0.060 1.134 18.9 38 POS
CMT7 0.492 0.072 0.42 7 9 POS
CMT8 0.862 0.071 0.791 13.2 11 POS
D17 0.382 0.058 0.324 5.4 7 POS
GHK 0.605 0.057 0.548 9.1 11 POS
GM847 0.072 0.062 0.01 0.2 <1 NEG
MDCK 0.182 0.052 0.13 2.2 4 POS
SFA 0.064 0.066 0 0 0 NEG
293T 3.45 0.061 3.389 56.5 47 POS
3132T 1.190 0.060 1.13 18.8 12 POS
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Figure 4-3. Autoradiograph image of a representative PAGE of TRAP assay 
PCR products. LB indicates the lysis buffer only negative control, lanes 1 and 2 
are the CMLIO cell line, lanes 3 and 4 are from the CMT7 cell line, and lanes 5 
and 6 from the CMT3 cell line. The 216 bp internal standard is indicated. The 
banding pattern is caused by the presence of TTAGGG repeat sequences of 
varying length, produced by active telomerase in the samples.
216 bp
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This repetition was carried out to facilitate harvesting and counting o f cells, 
Cells were passaged upon reaching approximately 80% confluence, and the 
doubling time for each test and control flask noted. A concentration of 60 pM of 
AZT-TP caused an increase in doubling time and in the number of dead cells in 
the culture, as shown in Table 4-15, compared with the control cell lines for both 
MDCK and CMT7 cells. A 30 pM concentration of AZT-TP did not result in 
any acute cytotoxic effect to either cell line. This concentration was 
subsequently used for the main study with both cell lines.
4.4.4.1 Effects of AZT-TP on cell growth parameters
In the main study, test cells were grown in T75 flasks and exposed to 30 pM of 
AZT-TP throughout the course o f the experiment. Control cells were also 
maintained in T75 flasks in parallel with the test cultures and passage of each 
culture was carried out as normal. Cell counts and population doubling times for 
each of the cell lines were recorded at passage and are shown in Tables 4-16 and 
4-17. These data were used to generate growth curves for comparison between 
control and test cell lines, as shown in Figures 4-3 and 4-4. Control CMT7 cells 
reached 36.2 population doublings over the time course of the experiment (70 
days), whilst at 32.5 population doublings the AZT-TP treated CMT7 cells 
achieved only 3.7 fewer divisions. The more rapidly replicating MDCK control 
and test cells achieved 52.0 and 45.3 population doublings respectively, a 
difference o f 6.7 population doublings over the 70 days of the experiment. No 
significant difference in the growth rates between control cells and cells cultured 
in the presence of AZT were discernible in either the MDCK cells or the CMT7 
cells.
4.4.4.2 Effects of AZT-TP on telomerase activity
Telomerase activity was monitored in the control and AZT-TP treated versions 
of each cell line at a number of time points during the course of the experiment. 
These data were used to generate an RTA value for each cell type to allow a 
comparison between the telomerase activity of the control and treated cells, as
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shown in Tables 4-18 and 4-19. Figure 4-5 illustrates that AZT-TP exposure did 
not result in a sustained, demonstrable reduction in telomerase activity in the 
CMT7 cell line. The equivalent analysis for the MDCK cell line is also shown in 
Figure 4-5 and established that whilst the AZT-TP treated cells had a generally 
lower RTA value than the control cells suggestive of a telomerase inhibitory 
effect, they retained demonstrable telomerase activity. Telomerase activity was 
found to be lower in the control MDCK cell line than the control CMT7 cell line, 
and whilst all the AZT-TP treated CMT7 cell pellets assayed for telomerase 
activity remain telomerase positive (AAg / Ago > 2.0), passage 32, 44 and 49 of 
the treated MDCK cell line had AAg / Ago values of between 1 and 2, and are 
therefore classified as containing low telomerase activity.
4.4.43 Effects of AZT on telomere lengths
Telomere length was also monitored in the cell lines using 2 xlO^ cell pellets 
retained at passage. The analysis was carried out as described previously 
(Section 3.3.3) using standard agarose gel electrophoresis, and was undertaken 
to determine if  exposure to the RTI translated into any reduction in telomere 
length in the test cells. Mean TRF length was found to be 5.2 kb and 5.1 kb in 
the control MDCK cells at the first and last passages used in the experiment 
(passage 30 and passage 48). The AZT-TP treated cells had a mean TRF value 
of 5.0 kb at passage 30, and 4.9 kb at passage 48. A similar result was obtained 
for the CMT7 cells. In these cells, both the control and AZT-TP treated cells 
were found to contain mean TRFs o f 4.2 and 4.3 kb at the beginning and end of 
the experiment respectively (passage 49 to 67). Hence, no discernible change in 
telomere lengths could be detected in cells cultured in the AZT-TP. The TRF 
smears generated from the AZT-TP treated cells are shown in Figure 4-6.
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Table 4-15. Investigation of acute cytotoxic effect of AZT-TP on CMT7 and 
MDCK cells. Tc is the average doubling time in hours for cell lines maintained 
in 0, 30, and 60 pM AZT-TP counted at day 3 and 7 of the experiment; these 
values are followed by the average percentage of cells found to be dead during 
cell counting as defined by uptake of trypan blue stain (Section 2.2.1.1.1).
Cell line Tc 0 % dead Tc 30 % dead Tc 60 % dead
"CMT7 4Ô9 <5 353  <5 593  14
MDCK 19.4 <5 19.3 <5 29.3 9
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Table 4-16. Proliferation of CMT7 control and AZT-TP treated CMT7 cells.
All cell counts are xlO^, Tc indicates the doubling time of the cell populations in 
hours since the previous time point, and PD indicates the cumulative population 
doublings undergone by the control and AZT-TP treated cells during the course 
of the experiment.
Time
point
Cell
count
(control)
Cell
count
(treated)
Tc
(control)
Tc
(treated)
PD
(control)
PD
(treated)
1 3.6 3.0 25.7 30.2 1.9 1.6
2 2.6 3.6 52.1 38.8 3.3 3.5
3 3.2 2.0 42.8 71.8 5 4.5
4 3.0 2.8 60.4 64.4 6.6 6.0
5 3.6 2.0 38.8 71.8 8.5 7.0
6 3.2 3.4 57.0 54.2 10.2 8.8
7 2.7 2.4 50.1 56.8 11.6 10.1
8 6.2 4.6 45.4 54.3 14.2 12.3
9 3.2 3.6 28.5 25.9 15.9 14.2
10 3.4 2.6 81.3 104.1 17.7 15.6
11 2.0 2.0 95.7 95.7 18.7 16.6
12 5.6 5.4 19.2 19.7 21.2 19.0
13 4.2 3.4 34.7 40.6 23.3 20.8
14 7.0 6.6 42.6 43.9 26.1 23.5
15 6.0 5.4 64.8 68.8 28.7 25.9
16 1.6 1.6 105.8 105.8 29.4 26.6
17 6.6 6.6 35.1 35.1 32.1 29.3
18 3.4 3.2 40.6 42.8 33.9 31.0
19 4.8 2.8 31.7 48.3 36.2 32.5
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Table 4-17. Proliferation of MDCK control and AZT-TP treated MDCK 
cells. All cell counts are xlO^, Tc indicates the doubling time of the cell 
populations in hours since the previous time point, and PD indicates the 
cumulative population doublings undergone by the control and AZT-TP treated 
cells during the course o f the experiment.
Time
point
Cell
count
(control)
Cell
count
(treated)
Tc
(control)
Tc
(treated)
PD
(control)
PD
(treat
1 6.3 4.0 18.0 23.9 2.7 2.0
2 5.2 2.9 30.2 46.7 5.1 3.5
3 5.3 3.3 29.8 41.7 7.5 5.2
4 6.3 4.3 36.0 45.5 10.2 7.3
5 4.6 2.9 32.6 46.7 12.4 8.8
6 7.7 4.4 32.5 31.3 15.4 11.9
7 6.5 4.3 26.6 34.1 18.1 14.0
8 7.9 8.3 40.1 39.2 21.1 17.1
9 2.8 3.8 32.2 24.8 22.6 19.0
10 7.6 6.7 49.0 52.3 25.5 21.8
11 7.2 5.2 33.6 40.2 2K4 24.2
12 8.2 6.2 15.8 18.2 31.4 26.8
13 6.5 5.6 26.6 2K9 34.1 29.3
14 10.2 8.1 35.7 39.6 37.5 32.3
15 11.3 8.1 47.9 55.5 41.0 35.3
16 4.6 2.8 32.6 48.3 43.2 36.8
17 7.7 7.5 32.5 32.9 46.1 39.7
18 5.3 5.4 29.8 29.5 48.5 42.1
19 11.0 9.0 20.7 22.6 52.0 45.3
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Figure 4-4. Growth rates of control CMT7 cells and CMT7 cells exposed to 
30 pM AZT-TP. Population doubling o f the control cells are represented by 
blue squares, whilst green squares represent test cells. No significant difference 
existed between the growth rates o f the two cultures.
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Figure 4-5. Growth rates of control MDCK cells and MDCK cells exposed 
to 30 pM AZT-TP. Population doubling of the control cells are represented by 
blue squares, whilst green squares represent the AZT-TP treated test cells. No 
significant difference in growth rate existed between the two cultures.
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Table 4-18. Relative telomerase activity of AZT-TP treated and control 
CMT7 cells. As represents the absorbance o f the sample, Aso the absorbance of 
the heat inactivated control of the sample, As,is the absorbance of the internal 
standard of the sample and RTA the relative telomerase activity. (Tx) and (Cx) 
denote AZT-TP treated and control cells, respectively. The assay gave a 
background absorbance of 0 . 0 6 9 ,  and a (A ysrA  t s s .oV A t s s .is value of 2 . 1 1  after 
10 minutes of colour development using the high activity positive control.
Passage As
(Tx)
As
(Cx)
Aso
(Tx)
Aso
(Cx)
As,IS 
(Tx)
As, IS 
(Cx)
RTA
(Tx)
RTA
(Cx)
49 0.706 1.563 0.064 0.056 0.568 1.279 54 56
53 0.635 1.137 0.066 0.060 1.487 1.394 18 36
57 1.272 1.050 0.072 0.056 1.296 1.384 44 34
60 1.206 0.660 0.075 0.095 1.396 0.955 38 28
63 0.667 0.638 0.062 0.096 1.569 0.940 18 27
67 0.633 0.457 0.096 0.088 1.195 1.492 21 12
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Table 4-19. Relative telomerase activity of AZT-TP treated and control 
MOCK cells. As represents the absorbance of the sample, Aso the absorbance of 
the heat inactivated control of the sample, As,is the absorbance of the internal 
standard of the sample and RTA the relative telomerase activity. (Tx) and (Cx) 
denote AZT-TP treated and control cells, respectively. The assay gave a 
background absorbance o f 0.075, and a ( A t s s “ A  t s 8 ,o) / A t s s , i s  value of 2.05 after 
10 minutes of colour development using the high activity positive control.
Passage As
(Tx)
As
(Cx)
Aso
(Tx)
Aso
(Cx)
As,is
(Tx)
As,IS 
(Cx)
RTA
(Tx)
RTA
(Cx)
30 0.342 0.154 0.074 0.066 2.278 2.728 6 2
32 0.163 0.699 0.074 0.080 1.476 2.134 3 14
37 0.279 0.346 0.068 0.077 2.658 2.166 4 5
39 0.305 0.834 0.076 0.070 1.577 1.401 7 27
41 0.304 0.330 0.073 0.079 1.973 1.786 6 7
44 0.158 0.659 0.078 0.079 2.503 1.534 2 11
49 0.192 0.244 0.075 0.079 2.229 1.624 3 5
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Figure 4-6. Effect of AZT-TP on the RTA of CMT7 and MDCK cells.
Control cells are represented by blue squares, whilst green squares denote AZT- 
TP treated cells. Comparison o f RTA values established that AZT-TP is 
ineffective at reducing telomerase activity in vitro in the CMT7 cell line. Whilst 
RTA values of AZT-TP treated MDCK cells are generally lower than the 
matched control samples the test cells retain active telomerase.
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Figure 4-7. TRF analysis of first and last passage AZT-TP treated CMT7 
and MDCK cells. Lanes 2 and 3 show passage 30 and passage 48 respectively 
of the MDCK cell line, corresponding to mean TRFs of 5.0 and 4.9 kb. Lanes 4 
and 5 show passages 49 and 67 o f the CMT7 cell line, corresponding to TRFs of 
4.2 and 4.3 kb respectively. Lane 1 contains the DNA molecular weight marker 
II (Roche).
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4.4.5 Ectopic expression of hTERT in primary canine, 
feline and equine fibroblasts
4.4.5.1 Generation of a PCIneo/hTERT expression vector
Prior to embarking on the experiments aimed at reconstituting telomerase 
activity in canine, feline and equine primary fibroblasts, the hTERT DNA was 
cloned into the PCIneo mammalian expression vector. PCIneo vector DNA was 
linearised by EcoR  1 and Sail restriction digestion, as described in Section 
4.3.4.2, and visualised following agarose gel electrophoresis. This generated a 
fragment o f the expected size of approximately 5.6 kb that was then quantified 
by agarose gel electrophoresis using the Low DNA Mass Ladder (GibcoBRL) 
following gel purification, as shown in Figure 4-7. Purified hTERT clone was 
isolated from the pBABE-puro vector and quantified in the same manner and the 
expected size product of approximately 3.5 kb identified as shown in Figure 4-7. 
Vector and hTERT DNA were found to be at a concentration of 25 and 10 ng/jul 
respectively.
Following ligation and transformation, plasmid DNA was isolated from 12 
overnight bacterial cultures and the presence of hTERT insert confirmed by 
EcoR 1 and Sail digestion. Eleven of the 12 plasmids were confirmed to contain 
the hTERT insert as shown in Figure 4-8. The use of two different restriction 
enzymes ensured the correct orientation of the insert.
Following large sale purification of endotoxin free plasmid DNA (Section 
2.2.3.2.1), the DNA quantity and quality was confirmed by UV 
spectrophotometry. This process was also carried out using PCIneo empty vector 
to provide sufficient empty vector to act as an experimental control. Plasmid 
DNA concentration was determined to be 0.12 and 0.14 pg/pl for the empty 
vector and PCIneo/hTERT constmct respectively. A2 6 0 /A2 8 0  values for the 
suspensions were 1.71 and 1.79 respectively, indicating the plasmid DNA was of 
a sufficiently high quality to be used for transfection.
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Figure 4-8. Quantification of PCIneo vector and hTERT insert. A 2 pi
volume of the vector and insert were quantified by comparison with DNA 
fragments contained in the low DNA Mass^”^ Ladder (GibcoBRL). The ladder 
contained an equimolar mix of 6 blunt ended DNA fragments of 2000, 1200, 
800, 400, 200 and 100 bp. Electrophoresis o f a 2 pi volume of this ladder 
resulted in bands containing 100, 60, 40, 20, 10 and 5 ng of DNA respectively. 
Samples of unknown concentration were then subjectively quantified by 
comparing the intensity of the sample bands with the intensities of the bands in 
the ladder. By this method, the hTERT and vector samples shown were 
estimated to contain 10 and 25 ng/pl of DNA respectively. The 1 kb plus ladder 
illustrated that each fragment was of the correct size; 3.5 kb for hTERT and 5.6 
kb for PCIneo vector.
kh pIllN h l l K l  \I; lss  huklci
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Figure 4-9. Confirmation of ligation of hTERT with PCIneo vector. Plasmid 
DNA isolated from 12 transformed bacterial colonies was digested with EcoR 1 
and Sal I for 2 hours at 37 ®C to cut insert DNA from the PCIneo plasmid 
backbone. Digestion products were then separated by gel electrophoresis to 
confirm that a correctly sized insert (3.5 kb) was present in the plasmid samples. 
This process confirmed the presence of hTERT insert in all samples except 
number 4.
2 3 4 5 7 S u II)
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4.4.S.2 Transfection of PCIneo-hTERT into cells using the 
Transfast® reagent
Several cell cultures v/ere used to generate stable hTERT expressing cells. These 
included the canine primary fibroblasts (SFA, AG08157), feline primary 
fibroblasts (S22, CCL-176), equine primary fibroblasts (EQ l) and the human 
ALT cell line (GM847). Further information on these cultures is provided in 
Section 2.2.1.2. The cells were initially exposed to varying concentrations of 
G418 antibiotic to determine the concentration required to produce selection for 
transfected cells. This was carried out in a 24 well plate format. Untransfected 
SFA, AG08157, S22, CCL-176, GM847 and EQl cells were seeded at 1 xlO^ 
cells/ml and after settling overnight were exposed to concentrations of 300, 350, 
400, 500 and 600 pg/ml of G418. Control cells were maintained in parallel in 
drug free medium. In all cases, by day 7, a concentration o f 400 pg/ml or above 
of G418 had resulted in the death of >90% of the cells, and this concentration 
was adopted for all subsequent experiments.
Each cell line was transfected using a wide variety of conditions to offer the 
greatest chance of success. In a 24 well plate format, each cell line was 
transfected with 0.25, 0.5, 0.75, and 1.0 pg of plasmid DNA using a 1:1, a 2:1 
and a 3:1 charge ratio in serum free and complete growth medium as described 
in Section 4.3.4.3.2. After the application of selective medium containing 400 
pg/ml of G418, three weeks were allowed for the development of distinct islands 
o f surviving cells to form, representing clonal expansion of successfully stably 
transfected cells. Selective medium was replaced every 3 days during this period 
to facilitate removal o f dead cells and debris.
The GM847 (human ALT), SFA (canine) and EQl (equine) cell lines all 
developed islands of surviving cells within this timeframe, providing evidence 
for the generation of stable transfectants. The cells surviving in selective media 
were trypsinised and pooled to form new cell lines. Each o f these three cell lines 
produced successful transfectants using 1.0 pg of plasmid DNA and a 2:1 charge 
ratio (TransFast reagent to DNA) in medium containing semm, and the
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transfection was also successful in the GM847 cell line using 0.75 pg of plasmid 
DNA in a 2:1 charge ratio in serum containing medium, and 1.0 pg DNA, with a 
2:1 charge ratio in serum free medium.
Stable transfectants could not be generated in any of the other cell cultures 
(AG08157, S22 or CCL-176) using any of the varying conditions described 
above. Transfection of these cells was repeated in a 6 well plate format using the 
most successful conditions described above. This was carried out as the greater 
cell numbers provided a relatively improved opportunity for successful 
transfection. The repeat involved scaling the experiment up fivefold to account 
for the greater area of the wells in 6 well plates. Transfection time was reduced 
to 30 minutes in an attempt to reduce possible cell damage during the 
transfection process, but again after 3 weeks in selective medium, no 
successfully transfected cells were apparent in any of the cell lines, and all of the 
test cells had been killed by the selective medium. In summary, modifying 
various transfection protocol parameters including the quantity of DNA, the 
quantity of transfection reagent, transfection time, presence or absence of serum 
within the media and increasing the number of cells had no effect on transfection 
efficiency in the AG08157, S22 or CCL-176 cell cultures.
4.4.5.3 Transfection using the Lipofectamine and Plus reagents
For the cell cultures in which Transfast failed to generate stable transfectants, the 
transfection process was repeated using a second reagent to investigate if  a 
different liposome formulation would improve efficiency. The AG08157, S22 
and CCL-176 cell cultures were transfected as described in Section 4.3.4.3.4. 
After introducing selective medium to the test plates three weeks was again 
allowed for removal o f dead cells and the emergence of colonies of surviving 
cells. Using this methodology, cells of the AG08157 fibroblast culture were 
successfully transfected, however neither of the two feline cultures (S22 and 
CCL-176) suiwived the process. These cells exhibited cell death following 
transfection with Lipofectamine/Plus as obseiwed following transfection using 
Transfast reagent.
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4.4.5.4 Evaluation of hTERT expression in stably transfected 
cells
To further confirm the generation o f stable transfectants, the presence of hTERT 
mRNA was confirmed in the cells surviving in G418 supplemented medium by 
RT-PCR as detailed in Section 4.3.4.4, and shown in Figure 4-9. In all cells RT- 
PCR amplified a product of approximately 400 bp as expected, confirming 
expression of hTERT. This demonstrated that the transfection process had been 
successful in the SFA, GM847 and EQl cell lines. Too few cells remained after 
negative TRAP analysis of the hTERT-transfected AG08157 cells to carry out 
RT-PCR analysis for that cell line.
Further positive confinnation for the generation of hTERT expressing cells was 
provided by sequence analysis of the PCR products using the ABI PRISM® 3100 
Genetic Analyzer as detailed in Section 2.2.6. A BLAST homology search 
demonstrated that the sequences isolated from the cells showed 100% similarity 
to the hTERT mRNA sequence. The sequence data is shown in Figure 4-10.
4.4.5.5 Propagation of transfected cell lines and investigation of 
telomerase activity
Stably transfected cell lines were maintained in normal growth medium 
supplemented with 400 pg/ml of G418 and passaged normally. However, after 
pooling of the initial islands o f transfected cells, the SFA/hTERT and 
AG08157/hTERT cell lines did not require further passage as in both cases the 
cells developed a senescent appearance and ceased replicating before reaching 
confluence. TRAP analysis confirmed that both hTERT transfected canine cell 
lines remained telomerase negative.
The GM847/hTERT cell line and the EQl/hTERT cell line were passaged 
normally upon reaching approximately 80% confluence, and at each passage cell 
pellets were retained for TRAP analysis. The results o f this analysis for 
GM847/hTERT are shown in Table 4-20. The GM847/hTERT cell line was
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passaged for 80 population doublings post transfection, and was shown to 
maintain a high level of telomerase activity throughout this time. The replication 
rate of the cell line remained steady with a mean population doubling time of 58 
hours (standard deviation of 17.1 hours). In contrast, the EQl/hTERT cell 
exhibited increasing population doubling time with increased passage, and after 
23.2 population doublings replication ceased (Figure 4-11). An untransfected 
EQl culture maintained in parallel underwent 23.0 population doublings before 
entering senescence, as also shown in Figure 4-11. SA-p-GAL staining was 
carried out in the final passages of both these cell lines, which at 80 and 85% 
positive were found to contain a majority of senescent cells, as shown in Figure 
4-12. Whilst TRAP analysis of the EQl/hTERT cell line proved telomerase 
negative at three separate time points corresponding to passages 5, 9 and 15, 
duplicate TRAP analysis of first passage transfected EQl/hTERT cells was 
telomerase positive, as shown in Table 4-21. RT-PCR carried out on RNA 
isolated from the three telomerase negative passages confirmed that hTERT 
mRNA could not be detected in any of the three, as shown in Figure 4-13.
In summary, generation of stable transfectants was successf.il in the SFA, 
AG08157, EQl and GM847 cell lines, as confirmed by RT-PCR and sequence 
analysis. Whilst hTERT expression was sufficient to reconstitute telomerase 
activity in a human ALT cell line, no telomerase activity was detected in the 
hTERT transfected canine fibroblasts. hTERT expression in the equine 
fibroblasts did reconstitute telomerase activity briefly, but this was not 
maintained, and the cells subsequently returned to a telomerase negative status.
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Figure 4-10. RT-PCR confirmation of hTERT mRNA in SFA/hTERT, 
GM847/hTERT and EQl/hTERT cell lines. Duplicate analysis for each cell 
line was carried out, using both random primers and gene specific primers for 
the generation of cDNA. Lanes 1 and 2 represent SFA/hTERT, lanes 3 and 4 
GM847/hTERT, lanes 5 and 7 EQl/hTERT, lane 6 is a negative control and lane 
8 contains a 1 kb plus DNA ladder. The DNHTOOl forward and reverse primers 
used for the amplification of the cDNA produce a 380 bp product in the presence 
of hTERT mRNA, therefore the results indicated successful transfection o f the 
SFA, GM847 and EQl cell lines.
1(0(1 hp
 3(10 hp
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Figure 4-11. Sequence analysis of PCR products generated using the 
DNHTOOl forward and reverse primers for hTERT mRNA. In all three cases 
the sequence data shared 100% similarity with the hTERT mRNA sequence, 
confirming the expression o f hTERT mRNA in the EQl/hTERT, 
GM847/hTERT and SFA/hTERT cell cultures.
EQl/hTERT (nucleotide positions 2094-2454)
NGGNGGCGGGCGCCGGGCGTCCTGGGCGCCTCTGTGCTGGGCCTGGAACGATAT 
GGAGANTTNGGTGGGGGAGGTTGGTGGTGGGTGTGGGGGGGGAGGAAGGGGGGG 
GGTGAGGTGTAGTTTGTGAAGGTGGATGTGAGGGGGGGGTAGGAGAGGATGGGG 
GAGGAGAGGGT G AGGGAGG T GAT GGGGAGGAT GAT GAAAG G G GAGAAGAGGTAG 
TGGGTGGGTGGGTATGGGGTGGTCGAGAAGGGGGGGGATGGGGAGGTGGGGAAG 
GGGTTGAAGAGGGACGTGTGTAGGTTGAGAGAGGTGGAGGGGTAGATGGGAGAG 
TTGGTGGGTGAGGTGGAGGAGAGGAGGGGGGTGAGG
GM847/hTERT (nucleotide positions 2035-2422)
TAGTGTTGAGGGTGGTGAAGTAGGAGGGGGGGGGGGGGGGGGGGGTGGTGGGGG
GGTGTGTGGTGGGGGTGGAGGATATNGAGAGGGGGTGGGGGAGGTTGGTGGTGG
GTGTGGGGGGGGAGGAGGGGCGGGGTGAGGTGTAGTTTGTGAAGGTGGATNTNA
GGGGGGGGTAGGAGAGGATGGGGGAGGAGAGGGTGAGGGAGGTGATGGGGAGGA
TGATGAAAGGGGAGAAGACGTAGTGGGTGGGTGGGTATGGGGTGGTGGAGAAGG
GGGGGGATGGGGAGGTGGGGAAGNGGTTGAAGAGGGAGGTGTGTAGGTTGAGAG
AGGTGGAGGGGNAGATGGGAGAGTTTGGTGGCTGAGGTGGAGGAGAGGAGGGGG
TTGAGGGATG
SFA/hTERT (nucleotide positions 2084-2410)
AGGGTGNTNAAAGTAGGANGGGGGGGGGGGGGGGGGGGGGTTGGTGGGGGGGTG
TGTNGTGGGGGTGGAGGATATNGAGAGGNGGTGGGGGAGGTTGGTGGTGGGTGT
GGGGGGGGAGGAGGGGGGGGCTGAGGTGTAGTTTGTGAAGGTGGATGTGAGGGG
GGGGTAGGAGAGGATGGGGGAGGAGAGGGTGAGGGAGGTGATGGGGAGGATGAT
GAAAGGGGAGAAGAGGTAGTGGGTGGGTGGGTATGGGGTGGTGGAGAAGGGGGG
GGATGGGGAGGTGGGGAAGGGGTTGAAGAGGGAGGTGTGTAGGTTGNGANNGGT
GGG
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Table 4-20. Telomerase activity of GM847/liTERT cell line. TRAP analysis 
was carried out as described previously before transfection and at the passages 
indicated after transfection. RTA values are not included as the assays were 
carried out at different times. Telomerase activity was shown to be absent before 
transfection, and maintained at a high level after transfection. This human cell 
line control validated the suitability of the TransFast reagent for the transfection 
of PCIneo/hTERT. As represents the absorbance of the sample, and Aso the 
absorbance of the heat inactivated control of the sample.
Passage As Aso AAs AAs
Aso
Result
Pretransfection 0.072 0.051 0.021 0.4 NEC
3 2.039 0.050 1.989 3^8 POS
20 1.627 0.077 1.550 20.1 POS
25 2.197 0.084 2.113 25.2 POS
29 1.430 0.072 1.358 18.9 POS
48 1.557 0.053 1.504 2&4 POS
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Figure 4-12. Growth of untransfected and hTERT transfected EQl cells.
Both cell lines had equivalent replicative potentials o f 23 population doublings. 
The hTERT transfected cell line averaged 1.37 population doublings per passage 
(s.d. 0.51), whilst the untransfected cell line averaged 2.04 population doublings 
per passsage (s.d. 0.85).
EQl/hTERT
EQl
O) 25
n  20
5  20
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Figure 4-13. SA-p-GAL staining of EQl and EQl/hTERT ceil lines. Staining 
was carried out on the final passage (p i2) of the EQl cell line, shown in (a) 
below, and the final passage (p i7) o f the EQl/hTERT cell line shown in (b) 
below. These passages were found to contain 80 and 85% SA-P-GAL positive 
cells, confirming that both cultures were entering senescence.
(a) (b)
fT
' A , ' -  * . I - ' * '  -
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217
Table 4-21. TRAP analysis of EQl/hTERT cell line. As is the absorbance of 
the sample, Aso the absorbance of the heat inactivated version of the sample, 
AAs was determined by subtraction of the mean of the heat-inactivated samples 
( A so or background) from A s, and A A g / A so is the ratio of sample to 
background activity. Samples were considered telomerase positive if the 
difference in absorbance (A A s) was greater than twice the background activity 
(A A s / A so > 2 .0 ). Using these criteria samples were designated positive (POS) 
or negative (NEG) for telomerase activity. The assays were carried out at 
different times, however all assays used the high activity positive control, and 
(A ts8-A  ts8,o) /A ts8,is valucs were between 2 and 4  for each assay. RTA values 
are not included as results of different assays are shown together.
Passage A s A so A A s /  Aso Result
1 0 .1 8 4 0 .0 3 2 4 .7 5 POS
1 0 .1 1 3 0 .0 3 0 2 .7 7 POS
5 0 .0 6 5 0 .0 4 9 <1 NEG
9 0 .0 4 9 0 .0 4 7 <1 NEG
15 0 .0 4 6 0 .0 4 6 <1 NEG
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Figure 4-14. RT-PCR investigation of hTERT mRNA expression in the 
EQl/hTERT cell line. RT-PCR investigation o f hTERT mRNA expression in 
passages 5, 9 and 14 of the cell line EQl/hTERT, corresponding to lanes 2, 3, 
and 4 respectively. Random primers were used for the generation of cDNA, the 
production of which was confirmed by PCR for the equine major 
histocompatability complex. The DNHTOOl forward and reverse primers were 
then used for the amplification of the cDNA to produce a 380 bp product in the 
presence of hTERT mRNA. Lane 5 is a positive control (GM847/hTERT), and 
lane 1 shows the 1 kb plus DNA ladder. These results demonstrate that hTERT 
mRNA is not expressed in any of the three passages.
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4.5 Discussion
4.5.1 Assessment of telomerase activity in canine and 
feline somatic and tumour tissues
A primary aim o f this chapter was to investigate the distribution of telomerase 
activity in canine and feline somatic and tumour tissues. To identify tissue 
specific telomerase activity in these species, TRAP analysis of post-mortem 
healthy organ samples from 5 dogs and 5 cats was canied out. This investigation 
found telomerase activity to be absent from a wide range of normal canine 
tissues including canine liver, cardiac muscle, lung, skeletal muscle and kidney, 
and feline brain, cardiac muscle, liver, skeletal muscle, lung, small intestine and 
kidney. The only canine sample in which telomerase activity was detected, 
resulting in an A A s / A so value of >2 .0 , was taken from the small intestine o f a 
6 -year-old male dachshund. The positive feline sample was testicular tissue 
harvested from a 15-year-old DSH. In both these cases, the tissues in question 
have previously been found to harbour telomerase activity in human samples. 
Wright et al found the tissue of the human testis to be telomerase positive, whilst 
mature human spermatozoa were telomerase negative (Wright, Mieczyslaw , et. 
al 1996). Similarly, stem cells of the lower intestinal crypt have been found to be 
telomerase positive using an immunohistochemical method in human sections 
(Forsyth, Wright, et al 2002). Overall, these data reveal that telomerase activity 
is absent from the majority of canine and feline somatic tissues, and highlight a 
marked similarity between the distribution of telomerase activity in human 
somatic tissues (Shay & Bacchetti 1997), and the tissues of the dog and cat.
Telomerase activity in the small intestine is likely a reflection of the replicative 
demand placed upon basal intestinal cells, and as this high turn over is common 
to the intestinal tracts o f both species it is unsurprising that a canine sample was 
also shown to be telomerase positive. Telomerase activity in the intestine is 
likely to vary with the rate of cellular turnover, which in turn may vary 
depending on factors such as the constituents of the diet and the feeding patterns
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of the individual animals. It is possible that these variables are the cause of the 
lower absorbencies o f the six other small intestinal samples (four canine and two 
feline).
Given the function of the testis and ovary and considering previous findings of 
telomerase activity in human gonadal tissue, the telomerase positive result for 
feline testis was not surprising, however a canine testicular sample, and a canine 
ovarian sample were found to have AAs / Aso values of < 2.0. Aside from the 
issue of telomerase RNA integrity, it is important to note that for a sample to 
have met the standard for classification as telomerase positive the requirement 
was for telomerase activity that was at least three times the level o f background 
absorbance. This was a highly stringent system, and it would therefore be 
misleading to categorically declare all samples that did not meet this standard as 
telomerase negative. For example, the testicular sample mentioned had an A A s /  
Aso value of 1.5, meaning that this sample contained telomerase activity that 
was 250 % greater than the background. It is for this reason that the low 
telomerase activity (A A s / A so values of between 1 and 2 ) class was included. 
Included in this class were a stomach and small intestinal sample from dogs CNl 
and CN2 respectively, in addition to the second testicular sample.
Even with a two-tier classification scheme the ovarian sample from CNl was 
still telomerase negative, however rather than this being the permanent state for 
that particular tissue it is likely that the activity of telomerase in canine and 
feline ovarian tissues fluctuates with time. This idea is based on recent findings 
in human ovarian epithelium where it has been shown that it is incorrect to 
regard this tissue as simply telomerase negative or positive; instead its status is 
dependant upon the level of the sex hormone oestrogen. This interaction is 
facilitated by oestrogen receptors that interact directly with a specific set of 
DNA sequences, the oestrogen response elements (EREs). The EREs are located 
in the 5' flanking regions of hormone-regulated genes, and can cause 
transcriptional silencing or activation o f the target. An ERE has been identified 
within the hTERT promoter, and it has recently been shown that addition of 
oestrogen to human ovaiy epithelium cell cultures results in the induction of
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hTERT expression and telomerase activity (Misiti, Nanni, et al 2000). An 
equivalent hormonal control mechanism operating in the dog is likely to result in 
mostly telomerase negative results for canine ovarian tissue, given the long 
periods o f anoestms and associated periods of low oestrogen levels in the bitch 
(Johnson 2000). This applies directly to the ovarian sample from CN l, as the 
animal concerned was 3 months old at time of sampling and therefore still 
prepubescent with basal oestrogen levels.
Telomerase activity was also assessed in a panel of 15 canine and 4 feline 
tumour sections harvested during both necropsy examinations and at the time of 
excisional surgery. The specific association between malignancy and telomerase 
activity has long been established in the human literature (Kim, Piatyszek, et al 
1994), and a large scale survey has found telomerase to be active in the majority 
of human cancers (approximately 80%, Shay & Bacchetti 1997). Given this 
evidence, the results of the survey carried out in this chapter point to a very 
similar association between telomerase activity and malignancy in the dog and 
cat. High telomerase activity (AAs / Ago >2 .0 ) was found in 13/15 canine 
tumours, and 4/4 feline tumours, equating to 89% of the tumour sample 
population. These results indicate that telomerase is active in the majority of 
canine and feline tumours. The low telomerase activity (AAs / Ago 1-2) found in 
duplicate analyses o f the remaining two canine tumours is very likely to be 
sufficient for continued cell division, however as work carried out in this chapter 
and elsewhere (Perrem, Colgin, et al 2001) has shown that ALT and telomerase 
activity can coexist in vitro it is possible that the lower telomerase activity in the 
two samples may be supported by other telomere maintenance mechanisms.
It is also possible that partial degradation of telomerase RNA might have lead to 
the two lower telomerase results, however considering that all the tumour 
samples were handled in the same manner this is thought to be an unlikely 
explanation. In both cases the internal standard of the PCR reactions worked 
normally indicating there were no inhibitors of the PCR reaction active in the 
samples. A third possibility is that the particular sample contained too few 
malignant cells to be detected by the assay. Whilst there will be inherent
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variability in the cellular composition of different tumour samples this is not felt 
to be a major issue for two reasons; first all tumour sections were sampled by 
harvesting thin full transverse sections of the tissue thus ensuring that tumour 
cells in the core o f the section, and not surrounding normal tissues were 
analysed. Second, the PCR based TRAP assay is known to be highly sensitive 
and capable of detecting telomerase activity in as few as 10 positive cells (Shay 
& Bacchetti 1997). The most plausible explanation is that the Tow’ telomerase 
activity was simply sufficient for the replicative demands of the two tumour 
samples in question.
In addition, telomerase activity was assessed in a number of immortalised canine 
and human cell lines, and all of these were found to be telomerase positive with 
the exception o f the human cell line GM847, which is known to use an ALT 
mechanism for continued proliferation (Bryan, Englezou, et al 1995). In this 
case the RTA values were usehil in that they provided a semi-quantitative 
comparison of telomerase activities between the cell lines. This analysis showed 
that the CMT3 cell line had relatively the greatest telomerase activity of all the 
canine cell lines tested. The fact that a greater than 10-fold difference in RTA 
value between the canine cell lines with the highest and lowest activities (CMT3 
and A72 respectively) existed clearly demonstrated that relatively low 
telomerase activity can allow cellular replication to proceed. That such a broad 
range exists reinforced the idea that the two borderline tumour samples 
discussed above might well overcome end replication problem by telomerase 
activity alone.
Overall, the results of the TRAP analysis have demonstrated that telomerase 
activity is absent from the majority of canine and feline somatic tissues. Tissues 
that did contain telomerase activity either contained germ line cells, or were 
from tissues that are subject to a high replicative burden. In contrast, telomerase 
activity was detected in all the samples from a panel of canine and feline 
tumours, and all canine immortalised cell lines that were tested, linking 
telomerase reactivation in the dog and cat with immortalisation and malignancy.
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4.5.2 The in vitro inhibition of telomerase activity using 
the RTI AZT-TP
The use of RTIs to target telomerase in malignant cells is an approach that has 
recently shown some success in human leukaemia cell lines (Brown, Sigurdson, 
et al 2003). The experiment described in this chapter investigated the effect of a 
30 pM concentration of the RTI AZT-TP on two telomerase positive immortal 
canine cell lines, MDCK and CMT7 (cell lines detailed in Section 2.2.1.2). The 
ultimate goal of such a treatment is to reduce telomerase activity in the target 
cells to such an extent that end replication problem will eventually result in 
growth arrest or apoptosis via critically short telomeres. The concentration of 
drug used was determined in an initial calibration study, and corresponded to the 
highest concentration of drug to which the cells could be exposed without 
inducing an acute cytotoxic effect. This concentration was significantly less than 
the 100 pM of AZT-TP to which human immortalised cell lines were exposed in 
a similar study, (Strahi & Blackburn 1996). This is likely a reflection o f species 
differences between the human and canine cell lines.
The experiment ran over a course of 32.5 population doublings for the CMT7 
and 45.3 population doublings for MDCK AZT-TP treated cell lines. The 
experiment was discontinued at these points due to the economic consideration 
of the cost of AZT-TP, in addition to which data gained from further population 
doublings would be o f little relevance to the possible usefulness of the drug in 
the in vivo setting, as beyond these limits the majority of canine malignancies 
would have already proven fatal to the affected animal. The relatively poor 
effect of the drug on the replication rates of the treated cell lines, (i.e. 3.7 and 6.7 
fewer population doublings over the entire experiment for the CMT7 and 
MDCK cell lines respectively), was reflected in the negligible effect on the 
telomere lengths o f the treated cells. This is interesting as in the MDCK cell line, 
monitoring o f RTA values indicated that at several time points in the experiment 
telomerase activity was reduced in the AZT-TP treated cells compared with the 
controls. This indicated that residual telomerase activity in the treated cell lines 
was sufficient to maintain telomere length in the face of partial inhibition. This
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again indicated that a wide range of telomerase activity is capable of supporting 
replication in canine cell lines, and raised the potential that a successM single 
agent telomerase inhibitor may need to almost completely inhibit telomerase 
activity in target cells before this translates to a reduction in telomere length 
sufficient to result in growth arrest or cell death. Whilst these findings are 
disappointing, and similar to the results of an experiment carried out in human 
immortalised cell lines (Strahl & Blackburn 1996) it was important to determine 
that species differences did not effect the susceptibility of canine cells to the RTI 
inhibitor. Furthermore, the efficacy o f RTI inhibitors such as AZT-TP may be 
greatly enhanced by the conciiiTent use o f other agents that target the telomere 
itself (e.g. Telomestatin, Tauchi, Kazuo, et al 2003). The specific example of 
Telomestatin is given as this agent, which inhibits telomerase by the formation 
of stable G-quadruplexes at the telomere terminus, also appears to act at least 
partly by causing telomere dysfunction (Tauchi, Kazuo, et al 2003). This effect 
will complement the use of RTIs by helping to alleviate any Tag effect’ caused 
by the strategy of targeting telomerase alone.
4.5.3 Ectopic expression of hTERT in primary 
fibroblasts
The generation o f stable transfectants was successful in the SFA, AG08157, 
EQ l and GM847 cell lines, as confirmed by RT-PCR and sequence analysis. 
Whilst hTERT expression was sufficient to reconstitute telomerase activity in a 
human ALT cell line, no telomerase activity was detected in the hTERT 
transfected canine fibroblasts. hTERT expression in the equine fibroblasts did 
reconstitute telomerase activity briefly, but this was not maintained, and the cells 
subsequently returned to a telomerase negative status.
The successful entry of DNA into primary fibroblast cultures is difficult due to 
their limited replicative potential and relative resistance to DNA transfection 
(Quilliet, Chevallier-Lagente, et al 1996), however a number of different 
strategies have evolved to facilitate this process. These methods include lipid 
mediated transfection, calcium phosphate transfection, diethylaminoethyl
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(DEAE)"dextran transfection, electroporation, biolistics, polybrene, and virus 
mediated transduction, (reviewed in Sambrook & Russell 2001) and (Ausubel, 
Brent, et al 1994). All these methods rely on different strategies to negate the 
repulsion between the negatively charged DNA and the negatively charged cell 
membrane to allow successful DNA entry to the target cells, or they facilitate 
this entry by a physical (electroporation and biolistics) rather than a biochemical 
means. Lipid mediated transfer strategies were used in this chapter as these 
techniques are recommended for use in difficult situations (i.e. primary cultures) 
where other methods have proved unreliable (Thompson, Frazier-Jessen, et al 
1999).
Both of the liposome formulations used (TransFast and Lipofectamine) are 
commercially available, and both have been successful with a wide variety of 
cell types, including for the Lipofectamine reagent primary fibroblasts (Baker & 
Gotten 1997). The charge ratios and other conditions that were found to be 
successful for canine, equine and human cells were typical for those described in 
the manufacturer’s recommended protocols, and validate the choice of reagents. 
However the manufacturers also note that individual variation in cell lines can 
result in failure of tested methodologies in specific cases, and this was tme for 
the primary feline cell cultures. This particular type of culture has previously 
been shown to be resistant to transfection using a liposome formulation (Koksoy, 
Phipps, et al 2001). Furthermore, lipid mediated transfection is known to result 
in variable toxicity in different cell lines (Sambrook & Russell 2001), and the 
fact that the feline culture used in this project did not survive the procedure 
despite repeated attempts and the use of transfection medium that included 
semm would suggest that the feline fibroblast is at the upper end of this variable 
toxicity range.
As the main aim o f the experiment was to investigate the species specificity of 
the hTERT gene product, hirther work concentrated on the successfully 
transfected canine cell lines (SFA and AG08157). The fact that neither of the 
transfected cell lines required passage immediately suggested that telomerase 
activity had not been reconstituted and that the cells had entered senescence. 
TRAP analysis confirmed that both cell lines remained telomerase negative after
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transfection, and the phenotypic appearance o f the cells indicated they were 
senescent. This could not be confirmed by SA-p-GAL staining as the number of 
cells available never exceeded one sub confluent T25 flask for each culture, and 
the overriding priorities were the confirmation o f transfection and analysis for 
telomerase activity.
It is interesting that neither the SFA/hTERT or the AG08157/hTERT cell line 
required passage despite how each entered the experiment at passage 2 , with the 
majority of replicative potential intact. This may be explained by the very low 
transfection efficiency of the PCIneo/hTERT constmct. In each case, it was 
noted that only three or four distinct ‘islands’ of transfected cells repopulated the 
test flasks after transfection and the introduction of selective medium. 
Considering that each of these islands derived possibly from only one cell, it is 
not surprising that the cultures reached replicative exhaustion before confluence. 
However, this did not occur with the equine cell line, EQl/hTERT. This cell line 
underwent 17 passages before finally entering senescence, as confirmed by SA- 
P-GAL staining. This discrepancy is probably due to one or possibly two factors. 
First, as confirmed by the control EQl cell line (see Figure 4-11), the equine 
cells had almost twice the replicative potential of the two canine cell lines (see 
Figure 3-12). Second, transfection of the equine cell line was more efficient than 
the canine cell lines, resulting in a greater pool of cells to begin the new culture.
Despite the fact that telomerase activity was briefly detected in one early passage 
of the EQl/hTERT cell line, this did not increase the replicative potential, as 
shown in Figure 4-11. Why this cell line should subsequently revert to a 
telomerase negative status was investigated with further RT-PCR analysis for 
liTERT mRNA. The negative results from three later passages of post 
transfection EQl/hTERT cells implied that hTERT was no longer expressed in 
the cells, explaining the telomerase negative status. The reason for this loss of 
hTERT mRNA is likely due to the selection process that occurred after the 
introduction of selective medium containing G418. Despite the efforts made to 
confirm that the transfected vector contained the required insert (Figure 4-8) it is 
possible that some empty vector was also transfected into the primary equine 
cells, providing G418 resistance without expressing hTERT. These empty vector
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cells might have a survival advantage and overgrown hTERT-expressing cells in 
the culture. It is also possible that the PCIneo/hTERT construct removed the 
hTERT insert post-transfection, thus producing cells containing empty PCIneo 
vector. Alternatively, mutation in the primary culture could have enabled 
untransfected cells to survive in selective medium, and again overgrow hTERT- 
expressing cells.
The finding that hTERT had the capacity, albeit briefly to reconstitute 
telomerase activity in a primary equine culture raises the question o f why this 
was not possible in the primary canine cell lines in which hTERT mRNA was 
detected. The main issue surrounding this question is the fact that the experiment 
was earned out with the premise that hTERT regulation alone determined the 
telomerase status of the cell lines investigated. This was not an unreasonable 
presumption, given that ectopic expression of hTERT is sufficient to reconstitute 
telomerase activity in a number o f human tissues (Bodnar, Ouellette, et al 1998), 
and given the experimental success detailed in this project with the 
GM847/hTERT cell line. However, evidence exists that hTERT status is not 
alone in determining whether telomerase is active (Liu, Schoonmaker, et al
1999). Successful activation of telomerase in the canine cell lines would require 
that no post-transcriptional inhibition of hTERT mRNA was active, and that the 
hTERT gene product associated successfully with mature canine telomerase 
RNA in a process that would require the participation o f numerous cellular 
factors for both maturation o f the RNA and association o f this factor with the 
catalytic component (reviewed in Collins & Mitchell 2002). It is not 
unreasonable to suggest that one o f these many factors, including cleavage of the 
primary telomerase RNA transcript; primary and secondary structural 
rearrangements to facilitate association with the catalytic component (Mitchell & 
Collins 2000), and association with other protein elements necessary for 
maturation (Martin-Rivera & Blasco 2001) may have been inactive, inhibited or 
otherwise unsuited to the production of functionally active telomerase. That the 
experiment was transiently successful in an equine cell line underscores the 
point that differing status o f these co-factors, rather than species variation might 
be the cause of the continued telomerase inactivity in the hTERT transfected 
canine cell lines. An avenue for further investigation is to test this hypothesis by
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repeating the experiment using the recently cloned cTERT sequence (submitted 
for review Nasir, Gault, et al, 2004).
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4.6 Summary
The experiments detailed in this chapter have demonstrated that telomerase 
activity is strongly down regulated in a wide range of somatic tissues of the dog 
and cat. The only normal tissues found to contain telomerase activity at a low 
level were canine and feline testis, and canine small intestine and stomach. 
Telomerase activity in canine and feline tissues is however associated with 
immortalisation and malignancy; telomerase activity was detected in 19/19 
tumour samples analysed. Telomerase activity was also detected in a panel of 
canine immortalised cell lines, and the relative telomerase activity in these cell 
lines was similar to that detected in immortalised cell lines of human origin. The 
attempt to reconstitute telomerase activity in canine and feline primary 
fibroblasts was ultimately unsuccessful. Whilst the hTERT sequence was 
successfully transfected into primary canine fibroblast cultures, the cells 
remained telomerase negative and entered replicative senescence normally. This 
may be a product of significant differences between the human and canine TERT 
sequences. Overall, the biology of telomerase in the dog and cat is very similar 
to that found in humans, and the research described in this Chapter has identified 
telomerase as a promising target for the development of future cancer treatments 
for companion animals.
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Chapter V 
Gene expression profiling in 
association with telomerase 
reactivation and the onset of 
replicative senescence
5.1 Abstract
Telomeres and telomerase show considerable promise as targets for new anti- 
cancer treatments; flirthemiore they may provide insights into the mechanisms of 
phenotypic ageing, and therapeutic reactivation of telomerase may have 
applications for the treatment of conditions where loss of replicative potential is 
a major part of the pathology, such as liver cirrhosis. This wide range of 
potential applications is reflected in the availability of a wealth o f infoimation on 
the biology of telomeres and telomerase in the human literature; however there is 
a paucity of information regarding the wider effects of replicative senescence 
and telomerase reactivation on the transcriptome of the mammalian cell. A wider 
view of the effects of telomeric attrition and telomerase reactivation than is 
currently available will be necessary to assess the safety of any potential 
therapeutic intervention involving telomeres and telomerase. Recent
technological advances in the development of cDNA micro arrays, typified by 
Affymetrix GeneChips® have allowed researchers to take a global view of 
changes in gene expression in human cells, and this technology can be used to 
investigate the cellular consequences o f telomeric attrition and telomerase
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reactivation at the level of the transcriptome. The experiments detailed in this 
Chapter describe the use Affymetrix technology to carry out an investigation of 
the changes in mRNA expression levels as canine primary fibroblasts change 
from actively replicating to senescent, and following the reconstitution of 
telomerase activity in a human cell line.
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5.2 Introduction
Genome projects worldwide have vastly increased our knowledge of the 
genomic sequences of humans and other organisms, as well as the genes that 
they encode. However, until relatively recently the study of the regulation and 
function of these genes has been restricted to labour intensive step-by-step 
analysis of individual genes. The last decade has seen a major advance in the 
field with the advent of DNA microarrays, consisting of thousands of DNA 
probes immobilised on a solid surface and hybridised against fluorophore 
labelled cDNA or cRNA targets from template RNA sources. Although the 
technology is heralded as breakthiough it is in essence a variation of a standard 
Southern Blot (Southern 1979) with the traditional nitrocellulose membrane 
replaced by a glass slide. DNA microaiTays, along with Serial Analysis of Gene 
Expression (SAGE) (Patino, Mian, et al 2003) have become the core technology 
used in gene expression profiling, and are also o f major importance in the fields 
of comparative genomics and genotyping (Harrington, Rosenow, et al 2000). 
The main reason for the wide application of this technology is the growing 
awareness of the limitations imposed upon what may be extrapolated from 
research based around a ‘gene by gene’ approach, as typified by the Northern 
blot (Ausubel, Brent, et al 1994). If the aim of genomics is to advance 
understanding of the organisation and evolution of genomes (McKusick & 
Ruddle 1987) then attempting to place the relevance of each single gene 
individually is a hopelessly ineffective approach to a biological system with the 
complexity of a mammalian genome containing 30,000-40,000 genes (Venter, 
Adams, et al 2001) and with complexities such as polymorphic variation, time 
and place of expression of RNAs and intermolecular interaction of gene 
products.
DNA microarrays take a ‘global’ approach to gene expression studies, allowing a 
simultaneous readout of all the relevant components at a given time, thus 
allowing for rapid assessment of gene expression profiles in disease states and 
thereby representing a technological breakthrough in the analysis of biological 
specimens. The technology also allows researchers to take a broader view than
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was possible before the advent of the technology, and this global approach allows 
the identification of complex patterns of interaction that are invisible at the 
individual component level. In effect, the more genes and biological conditions 
studied simultaneously the more obvious the underlying organisation becomes.
5.2.1 Applications of microarray technology
Microarray technology, despite being relatively new, has already proved very 
useful to researchers and has lead to significant advances in the molecular 
classification of tumours and the discovery of subsets previously not known to 
exist. Notably, gene expression profiling using a DNA microarray has led to the 
discovery of two distinct forms of diffuse large B-cell lymphoma likely arising 
from two distinct non-transformed cellular progenitors. These two new groups 
are associated with significantly different prognoses, and thus the use of the 
technology has directly lead to more reliable predictions of the clinical course of 
the disease and the expected treatment response (Alizedeh, Risen, et al 2000).
Furthermore, use of a DNA microarray has allowed Sorlie et al to classify breast 
carcinomas by gene expression profile. This system is sufficiently robust to be 
used as a basis for judgements on prognosis in a subset of patients receiving 
uniform therapy and has lead to the identification of a subset of tumours based 
on an oestradiol receptor positive group not previously known to exist. This 
example is particularly interesting as it represents an advance in understanding 
directly attributable to the microarray approach where previous research based 
on individual genes in isolation could not correlate established findings with 
clinical outcome (Sorlie, Pérou, et al 2001). Microarray technology also has 
potential for use in dmg discovery applications by facilitating identification of 
novel di'Lig targets. The technology has already proved useful in antibiotic 
development (Ivanov, Schaab, et al 2000).
A clear application o f this technology to the field of telomere biology is the use 
o f micro arrays to help assess the safety of telomerase reactivation as a 
therapeutic approach to conditions such as liver cirrhosis (Rudolph, Chang, et al
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2000) and large bone defects (Shi, Gronthos, et al 2002). O f paramount 
importance to such a therapeutic strategy will be the safety o f reactivating 
telomerase in an already diseased tissue given the clear association between 
telomerase and cancer (Kim, Piatyszek et al 1994), Initial studies have identified 
an encouraging lack of cancer associated changes in the phenotype of telomerase 
immortalised cells (Jiang, Jimenez, et al 1999) (Morales, Holt et al, 1999), 
however an association between immortalisation by telomerase and activation of 
the oncogene c-myc has been found in human mammary epithelial cells 
(Wang,J, Hannon,G et al 2000). This study alone suggests that the use of 
telomerase reactivation for therapeutic puiposes must be approached with 
caution. To this end, the global view of the transcriptome provided by 
micro array technology provides an excellent tool with which to identify 
previously overlooked consequences of telomerase reactivation and telomeric 
attrition.
5.2.2 Microarray platforms
The two main forms of arrays are cDNA, ‘spotted’ arrays and oligonucleotide 
aiTays. The technology is essentially the same in both types, and consists of well 
characterised and annotated hybridisation probes arranged on glass microscope 
slides or nylon membranes, against which sample fluorophore labelled cDNA or 
cRNA is applied and allowed to hybridise. The advantage o f  the spotted arrays is 
that they may be manufactured in the laboratory, and therefore tailored to suit 
specific experimental needs. Such arrays are usually robotically spotted onto 
glass slides by a commercially purchased ‘arrayer’ robot. The main advantages 
o f the oligonucleotide arrays are that they are much more comprehensive; the 
manufacturing process allows significantly smaller individual spots to be 
produced (50-150 um in diameter, McGall, Barone, et al 1997) allowing 
approximately 15,000-20,000 genes to be accommodated on each array, rather 
than the several hundred genes usually represented on spotted arrays. This 
allows inteiTOgation of the entire transcriptome, allowing the detection of 
relevant changes that would be missed by a tailored anay. Second, as 
oligonucleotide arrays are available commercially, this technology facilitates 
comparison of results between laboratories. Oligonucleotide array technology is
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typified by Affymetrix GeneChip ' arrays, an overview of which is provided in 
Figure 5-1, As these arrays were used in all the experiments detailed in the 
chapter this technology will be the focus o f discussion.
5.2.3 Affymetrix GeneChip® arrays
The GeneChip® (Affymetrix, Santa Clara, CA) oligonucleotide arrays consist of 
high-density synthetic oligonucleotide probe sets on a 1.28 x 1.28 cm glass 
surface, with a capacity of up to one million probe sets per aiTay in experimental 
versions. The system has the advantage that sequence data alone is sufficient for 
array manufacture without intermediate steps such as cloning or FCR. In 
addition as little as 200 to 300 bases of sequence is required to generate 
independent, usually non-overlapping 25 base oligonucleotide probe sets unique 
to the target. The sequence chosen for oligonucleotide formation is usually 
selected from the 3' end of the gene sequence to reduce problems that might 
arise from the use of partially degraded mRNA.
A number of controls are built into the system to reduce the likelihood of false 
positives and interference from background signal. Crucial to the process is the 
use o f probe redundancy, meaning that a number of oligonucleotides of varying 
sequence are designed to hybridise to different regions of the same mRNA. The 
use of multiple detectors for the same molecule augments results by improving 
signal to noise ratios (due to averaging over the intensities of multiple array 
features) and improves the accuracy o f RNA quantitation (by averaging and 
outlier rejection). This greatly reduces the effects of cross-hybridisation and 
miscalls (Lipshutz, Fodor, et al 1999), and allows the system to provide an 
accurate representation of the relative abundance of each targeted transcript in 
the sample, referred to as the expression value.
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Figure 5-1. Overview of a GeneChip microarray experiment. The aim of
any microarray experiment is to detect a given mRNA species (transcribed 
genes) in a tissue or ceil type. In a GeneChip experiment this is achieved by 
reverse transcribing the RNA isolated from the sample to the more stable cDNA 
state. In vitro transcription is used to produce biotin labelled cRNA that is 
hybridised to the array surface, and stained with a fluorophore for detection.
Cell / tissue sample
Isolate total RNA
Reverse transcriptase
In vitro transcription
cDNA
Biotin labelling
cRNA
I
Hybridise to GeneChip arrayI
Stain with phycoerythrinI
Laser excitatation and image capture
237
A second control is the use of mismatch (MM) oligonucleotides for every perfect 
match (PM) contained on the array. MM oligonucleotide probes differ by only 
one base in a central position from their PM counterparts, and therefore allow a 
direct subtraction of background signal to be made for each probe set, in addition 
to providing another specificity safe-guard. The use of PM/MM probe sets are 
the best way to ensure that fluorescence signals are being generated by the 
intended target mRNA, and allow accurate quantification of the RNA molecule 
in the target solution (Lipshutz, Fodor, et al 1999).
5.2.3.1 Affymetrix data collection and normalisation
The fluorophore signal from the hybridised target cRNA (Figure 5-1) is 
stimulated by means of laser excitation directed through the back of the glass 
array support focussed at the interface of the array surface and the target 
solution. Fluorescence emission is collected by a lens coupled to a sensitive 
detector through a series of optical fibres allowing a two-dimensional image of 
hybridisation intensity to be obtained. These images must then be analysed to 
identify arrayed spots and measure the relative fluorescence intensities. A typical 
GeneChip® DNA array is the Human genome (HG)U133-A and B chipset, which 
contains over 1 million oligonucleotides targeting over 33,000 human genes in a 
two chip set. A representative scan image from a HGU133-A GeneChip is 
shown in Figure 5-2.
Each GeneChip® experiment presents researchers with a very large volume of 
information, so much so that initial problems with the technology tended to 
revolve around data analysis rather than experimental procedure. Data analysis 
software, designed to reliably extract biological information and aid meaningful 
interpretation has been developed in tandem with the technological hardware. 
The GeneChip® array images utilised in this chapter used Affymetrix® 
Microarray Suite software (MAS) for acquisition and processing of the 
GeneChip generated data. This software package also provides indicators of 
sample integrity, assay execution, and hybridisation performance through the 
assessment of control hybridisations. The MAS software evaluates the
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abundance of each transcript represented on the array and labels it as either 
present, absent or marginal. An algorithm identifies and removes contributions 
from stray hybridisation signals, and combines the results from probes that 
interrogated different fragments of the same transcript. The statistical 
significance of each detection call is indicated by an associated p-value.
The software allows for adjustments to be made to sensitivity and specificity as 
appropriate for a particular experimental design, for example if the main thmst 
of the experiment is high sensitivity the parameters may be changed, requiring a 
less stringent p-value for a positive call. This has the effect of increasing the 
sensitivity, however the number of miscalls is increased.
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Figure 5-2. Representative Affymetrix GeneChip array scan for HGUI33-A
chip. The chip contains a total of 22,283 oligonucleotide targets with which 
fluorescently labelled complimentary nucleic acid targets may bind. Subsequent 
laser excitation through the glass back o f the array cartridge produces 
fluorescent emission that is recorded as the final image. The complexity o f the 
resultant scan is only appreciable when magnified, as shown in the 12x- 
magnified image below on the right. Automated image capture and processing is 
carried out using microarray suite software (Affymetrix), and analysis of the 
processed results uses GD Expressionist Analyst and Refiner software 
(Genedata).
GeneChip
cartridge
Captured array scan image 12x magnified
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InteiTOgation of the processed results is then performed using GD 
Expressionist^^ Refiner and GD Expressionist^M Analyst software (Genedata, 
Basel, Switzerland). The Expressionist software is a bundle of client seiwer 
based programs that are specifically for use with Affymetrix technology (for 
tutorial see http:/AYWvv.msi.umn.edu/software/expressionist/). The Refiner is a 
tool for assessing, standardising and tracking microarray data. It allows quality 
control when comparing data from different GeneChip microarrays, identifying 
and highlighting errors in individual microarrays and standardising the data 
quality from all arrays in the experiment. The Analyst component allows user 
defined investigation o f the biological context of the standardised data. For 
example, this program allows a direct comparison of gene expression levels at 
different time points in an experiment using data obtained from separate 
microarrays.
5.2.4 Chapter aims
The aims and objectives o f  this chapter were
1. To investigate changes in gene expression with increasing cell division in a 
primary canine fibroblast culture (SFA) as the cells switched from actively 
replicating to senescent, and to identify potential genes that may be associated 
with cellular ageing and limiting cell proliferation.
2. To investigate changes in gene expression profiles in human ALT 
immortalised cells (GM847) following reactivation of telomerase activity, to 
identify genes that may be associated with an immortalised phenotype.
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5.3 Materials and Methods
5.3.1 Sample details
5.3.1.1 SFA
Cell pellets containing 2 x 1 0 ^  cells were harvested at passage from passages 2 , 4 
and 10 of the primary canine fibroblast cell culture SFA as described elsewhere 
(Section 3.3.1.4). Cells were washed in ice-cold PBS, repelleted and after 
removal of the supernatant were flash frozen in LNO2 and stored at -80“C until 
required. These passages were chosen to reflect a change in the culture from 
actively replicating, (at passage 2 < 5% SA-(3-GAL positive) to a majority of 
senescent cells (at passage 10 80% SA-p-GAL positive), as detailed in Section 
3.4.4.3. Too few cells were available from the two later passages of the SFA 
culture for analysis.
5.3.1.2 GM847 and GM847/hTERT
Pellets of 2 xlO^ cells were harvested at passage and stored as described above. 
Four time points were analysed in this experiment, the first corresponding to the 
passage of the GM847 cell line that was used for the hTERT transfection 
experiment (p i3). The remaining three time points utilised different passages of 
the hTERT expressing, telomerase positive cell line GM847/hTERT, including 
p i, p l9  and p26.
5.3.2 Isolation of total RNA from canine fibroblasts
Total RNA was isolated from primary canine fibroblast cultures using the 
RNeasy Total RNA Isolation Kit (QIAGEN, UK) following the manufacturer’s 
recommended protocol. Isolated RNA was eluted in 35 pi of RNAse free water 
and then precipitated by addition of 1/10 volume of 5 M NaOAc at pH 5.2 
(Sigma, UK), and 2.5 volumes of 100% ethanol. Samples were thoroughly 
mixed and incubated at -20°C for one hour before pelleting at 14000 g for 20
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minutes at 4°C. Glycogen (Ambion, UK) was added (1 pi o f a 5 mg/niL 
solution) as a co-precipitant to aid visualization of the RNA pellet. RNA quality 
and quantity were confirmed using the Nanodrop and Agilent 2100 Bioanalyzer 
(Agilent Technologies). A2 6 0 /A 2 8 0  ratios between 1.9 and 2.1 were considered 
acceptable.
5.3.3 Synthesis of double-stranded cDNA from total 
RNA
5.3.3.1 First strand cDNA synthesis
Synthesis reactions were carried out in 1.5 ml RNAse free tubes. A 5 pg amount 
o f total RNA was used for each sample. This protocol uses only high 
performance liquid chromatography (HPLC)-purified T7 01igo(dT)24 primer 
(100 pmol/pl, Affymetrix) as this is essential for efficient downstream 
applications. RNA and primer were made up to a total volume of 20 pi with 
DEPC treated H2 O. Primer hybridisation proceeded for 10 minutes at 70“C 
followed by a brief centrifugation step and quenching on ice. To each sample 4 
pi o f 5x First strand cDNA buffer (Invitrogen, UK), 2 pi of 0.1 M DTT and 1 pi 
o f 10 niM dNTP mix (Invitrogen) were added, samples were mixed well and 
then incubated at 42®C for 2  minutes. A volume containing 200 U of Superscript 
11 reverse transcriptase enzyme (Invitrogen) was then added to each sample, 
mixed thoroughly and incubated at 42“C for 1 hour.
5.3.3.2 Second strand cDNA synthesis
First strand reactions were placed on ice following a brief centrifugation step to 
bring down condensation on tube sides. To each sample was then added the 
components of the second strand reaction; 30 pi of 5x second strand reaction 
buffer (Invitrogen), 3 pi of a 10 mM dNTP mix, 10, 40 and 20 U each of the 
enzymes E.coli DNA Ligase, E.coli DNA polymerase 1 and E.coli RNAse H 
respectively (all sourced at Invitrogen), and 91 pi of DEPC treated water for a 
final total volume of 170 pi. Second strand reaction mixtures were gently mixed 
and then incubated at 16"C for 2 hours, after which 10 U of T4 DNA polymerase
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was added to each sample, samples were returned to 16“C for a 5 minute 
incubation before addition of 10 pi of 0.5 M EDTA to each sample. Samples 
were then ready for a cDNA clean-up procedure.
5.3.4 Clean-up of double-stranded cDNA
The cDNA clean-up procedure involves a standard phenol/chloroform/isoamyl 
alcohol extraction and the use of phase lock gel (PEG) (Eppendorf, UK) in 1.5 
ml eppendorf tubes. PEG forms an inert seal between the aqueous and organic 
phases and so allows complete recovery of the aqueous phase without 
contamination from the interphase. An equal volume o f (25:24:1) 
phenol'.chlorofonn;isoamyl alcohol saturated with 10 mM Tris-HCl pH 8.0, 1 
mM EDTA was added to the final cDNA synthesis preparation and vortexed 
before transfer to the 1.5 ml eppendorf tube containing pelleted PEG. Samples 
were then centrifuged at 14000 g for 2 minutes, and the resulting upper aqueous 
phase transferred to a fresh 1.5 ml tube.
5.3.5 Ethanol precipitation
Precipitation of purified cDNA was achieved by addition of 0.5 volumes of 7.5 
M NH4 OAC and 2.5 volumes of absolute ethanol (stored at -20°C) followed by 
vortexing. cDNA was immediately pelleted by centrifugation at room 
temperature for 2 0  minutes, followed by two wash steps in 80% ethanol (stored 
at -20°C). cDNA pellets were then air dried thoroughly before resuspension in 12 
pi of RNAse-free water.
5.3.6 Synthesis of biotin-labelled cRNA
In vitro transcription (IVT) and biotin labelling were carried out using the 
ENZO® Bioanay High Yield RNA transcript labelling kit (Affymetrix). Briefly, 
5 pi of each of the 12 pi cDNA samples were used per reaction, 7 pi being held 
in reserve. To each 5 pi sample was added 4 pi of lOx HY reaction buffer, 4 pi 
of biotin labelled ribonucleotides, 4 pi o f lOx DTT, 4 pi of lOx RNAse inhibitor
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mix, 2 pi of 20x T7 RNA polymerase and 17 pi of DEPC treated water for a 
total volume per reaction of 40 pi. Reactions were mixed by gentle pipetting, 
briefly spun to bring down mix from the sides of the reaction vessels and 
incubated at 37°C for 4 hours. This is the optimal time for producing good 
quality biotin labelled cRNA; overnight incubation has been found to produce 
relatively shorter products.
5.3.7 Clean-up and quantification of IVT products
5.3.7.1 Clean-up procedure
Clean up of IVT products are essential for 260 nm absorbency readings to truly 
reflect the quality of the cRNA product. Clean up facilitates this by removing all 
unincorporated NTPs from the reactions. Phenol/choloform extraction may not 
be used in this instance as the biotin label will cause some of the cRNA to 
partition into the organic phase and result in a low yield. Instead clean up was 
carried out using RNeasy spin columns (Qiagen) following the manufacturers’ 
standard protocol. A 20 pi volume of each 40 pi cRNA sample was used in the 
clean-up procedure, the other 20 pi being held in reserve to minimise the chance 
of the sample being lost completely.
5.3.7.2 Quantifying the cRNA
Spectrophotometric analysis was carried out on 1 pi of each sample using the 
Nanodrop® ND-IOOO system (Nanodrop technologies, Portland, DE). Yields of 
0.6 pg/ul or above and A2 6 0 /A2 S0 ratios between 1.9 and 2.1 were considered 
acceptable. Adjusted cRNA yields were calculated for each sample to reflect the 
carryover of unlabelled total RNA in each sample. Using an estimate of 100% 
carryover the true yield is determined by the formula:
adjusted cRNA yield = RNAm-(total RNAi)(y) 
where,
RNAm = amount of cRNA measured after IVT (pg) 
total RNAi = starting amount of total RNA (pg)
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y = fraction of cDNA used in IVT reaction
5.3.8 Fragmentation of cRNA for target preparation
A 20 pg amount of cRNA was used per sample for fragmentation, A minimum 
concentration of 0.6 pg/pl of cRNA allows each reaction to be carried out in a 
40 pi volume consisting o f 8 pi of 5x fragmentation buffer, cRNA and RNAse- 
free water. Fragmentation was carried out at 94”C for 35 minutes after which 
samples were quenched on ice. A 1 pi aliquot from each sample was used for 
confiiination of fragmentation using the Agilent 2100 Bioanalyzer. Fragmented 
RNA was then stored at -20°C until hybridisation.
5.3.9 Target hybridisation
Array chips used in these experiments were standard size human genome 
HGU133A, requiring 15 pg o f fragmented cRNA per hybridisation reaction. In 
addition the hybridisation cocktail contained 3 pi of 10 mg/ml Herring sperm 
DNA, 3 pi of 50 mg/ml acetylated BSA, 150 pi of 2x hybridisation buffer and 
20 pi of hybridisation controls. These comprised 15 pi o f a 20x Eukaryotic 
hybridisation control mix containing transcripts for the prokaryotic genes BioB, 
bioC, bioD and ere. BioB, bioC  and bioD are genes from the biotin synthesis 
pathway in E.coli, and ere is the recombinase gene from PI bacteriophage. The 
20x hybridisation control mix was heated to 65‘’C for 5 minutes to completely 
resuspend the cRNA before aliquotting. A 5 pi volume of B2 control oligo 
(Affymetrix) completed the control sets. The final volume o f the hybridisation 
cocktail was made up to 300 pi with RNase-free water.
Once complete the hybridisation cocktails for each sample were mixed by gentle 
pipetting and heated to 99*^ C for 5 minutes in a heat block. HU133A probe arrays 
were equilibrated to room temperature immediately before use and then filled 
with approximately 250 pi of Ix hybridisation buffer using a micropipette and 
appropriate tips. The probe array cartridge is filled using two pipette tips inserted 
through rubber sealed septa located on the back of the array cartridge. Solutions
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enter through one septum and the second allows venting of air from the array to 
ensure the cartridge remains at atmospheric pressure. Filled array chips were 
incubated at 45°C for 10 minutes with rotation in a GeneChip® Hybridisation 
oven (Affymetrix).
The hybridisation cocktail was transferred from 99^C to a heat block at 45“C for 
5 minutes, before centrifugation at 14000 g for 5 minutes to facilitate removal of 
any insoluble material from the hybridisation mixture. Buffer solution was then 
removed completely from the array cartridge and replaced with 200 pi of the 
clarified hybridisation cocktail. Array cartridges were then placed in the 
hybridisation oven at 45°C and rotated at 60 rpm for 16 hours.
5.3.10 Washing and staining of arrays
Washing and staining of the array cartridges was carried out using the 
GeneChip® Fluidics Station 400 (Affymetrix) following the manufacturer’s 
recommended protocol. The fluidics station was operated using MAS software 
set to the specific array cartridges used in all experiments (HGU133-A). The 
fluidics station was primed with appropriate non-stringent (6x standard saline 
phosphate with EDTA, 0.01% Tween 20, and 0.005% antifoam) and stringent 
wash buffer (100 mM Wmorpholinoethanesulfonic acid, 0.1 M NaCl, and 0.01% 
Tween 20), placed in reservoirs A and B respectively.
Following hybridisation, the hybridisation cocktail was removed completely 
from the array cartridges and filled completely with non-stringent wash buffer 
(approximately 250 pi required). Array cartridges were then ready for washing 
and staining procedures once they had equilibrated to room temperature.
5.3.11 Antibody amplification procedure for eukaryotic 
targets
This procedure is one of two protocols available for washing and staining the 
anay sets. This procedure was chosen in preference to the non-amplification
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protocol as this is recommended for HU133-A array cartridges due to the small 
size of the probe cells.
The staining solution comprised 600 pi of 2x 2-(N-Morpholino)ethanesulphonic 
acid (MES) stain buffer, 48 pi o f 50 mg/ml acetylated BSA, 12 pi of 1 mg/ml 
streptavidin-phycoerythrin (SAPE) and 540 pi of distilled H 2 O for a total volume 
of 1200 pi. Staining solution was mixed thoroughly and divided into two 600 pi 
aliquots per an*ay cartridge. Antibody solution mix consisted of 300 pi of 2x 
MES stain buffer, 24 pi of 50 mg/ml acetylated BSA, 6 pi of 0.1 mg/ml normal 
goat IgG antibody, 3.6 pi of 0.5 mg/ml goat anti-streptavidin antibody, and 
266.4 pi of distilled water for a total volume of 600 pi per array cartridge. The 
protocol used for washing and antibody amplification is outlined in Table 5-1.
The washing and staining protocol is semi-automated requiring only placement 
of required stains and antibody solutions when prompted by the LCD display on 
the fluidics station. When washing and staining is complete the probe arrays are 
ejected from the fluidics station and are stored at 4‘’C in the dark until scanning.
5.3.12 Probe array scan
Probe array cartridges were scanned using the Gene Array® Scanner. The scanner 
uses an argon-ion laser and is also controlled by the Affymetrix® MAS software. 
The laser performs a duplicate scan at a wavelength of 570 nm for each array 
cartridge, forming a final image that is an average of both scans. Cartridge 
windows may be carefully cleaned with a lint free tissue before scanning if this 
is required.
5.3.13. Data analysis
Data analysis was carried out using the standard data processing and analysis 
software detailed in Section 5.2.3.1. All user definable parameters remained at 
the Affymetrix default settings, and the search strategy used for the processed 
data is detailed in Section 5.4. The use o f replicates as controls in micro array
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experiments have been proposed at three different stages in experiment design, 
namely biological, or sample replicates, technical, or array replicates, and 
duplicate spots within individual arrays (Xiang, Yang et al 2003). These three 
levels of control are designed to reduce eiTor attributable to biological variation 
in the sample tissue or cells, technical error during extraction, labelling and 
hybridisation o f samples, and measurement error due to imperfections or 
blemishes such as dust on the array surface, respectively (Churchill 2002). It has 
been accepted that the cost of microarray experiments are such that the use of 
replicates are usually kept to the minimum required for meaningful interpretation 
of the data (Xiang, Yang et al 2003), and the design of the Affymetrix GeneChip 
array has reflected this concern with a number of inbuilt controls. First, the use 
of multiple probes interrogating non-overlapping areas of sequence o f each RNA 
target at physically different areas on the array reduces error when measuring the 
fluorescent signal. Second, the control hybridisation cocktail, detailed in Section 
5.3.9 allows quantification of technical error at the hybridisation stage of the 
experiment, and exclusion of GeneChips that do not meet an automatically 
defined standard required for inter-Chip comparison. Finally, the numbers of 
time points interrogated in both the SFA and GM847 experiments were 
increased beyond the 2 that were technically required in each experiment to 
investigate replicative senescence and telomerase reactivation respectively. In 
the SFA experiment, an additional time point at passage 4 was included, and in 
the GM847 experiment, three post-transfection time points corresponding to 
passages 1, 19 and 26 post-transfection were used. The Expressionist Analyst 
software was then used to isolate only those genes that displayed consistent 
patterns of expression, as detailed in Section 5.4.1. For the SFA experiment, this 
translated to those genes that displayed an increasing or decreasing level of 
expression in the cell population as the number of senescent cells increased. In 
the GM847 experiment, only those genes that were consistently up or down- 
regulated in all three of the post transfection time points were considered for 
further analysis.
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Table 5-1. Antibody amplification protocol for eukaryotic targets. Wash 
buffer A refers to non-stringent wash buffer (6x standard saline phosphate with 
EDTA, 0.01% Tween 20, and 0.005% antifoam), and wash buffer B refers to 
stringent wash buffer (100 mM W-morpholinoethanesulfonic acid, 0.1 M NaCl, 
and 0.01% Tween 20).
Stage- Comprises-
Post hybridisation wash 1 10 cycles of 2 mixes/cycle with wash buffer A at
25"C
Post hybridisation wash 2 4 cycles of 15 mixes/cycle with wash buffer B at
50°C
Stain the probe array for 10 minutes in SAPE 
solution at 25^C
10 cycles of 4 mixes/cycle with wash buffer A at 
25°C
Stain the probe array for 10 minutes in antibody 
solution at 25®C
Stain the probe array for 10 minutes in SAPE 
solution at 25"C
15 cycles of 4 mixes/cycle with wash buffer A at 
30“C, followed by the holding temperature of 25°C
Stain
Post stain wash
Second stain
Third stain
Final wash
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5.4 Results
Each HGU133-A probe array contained targets for 22,283 gene sequences. O f 
these, approximately 15% are called present for the typical cross species array 
using canine samples, and approximately 45% are present using human derived 
samples (Chismar, Mondala, et al 2002). The results obtained with the 7 
GeneChips used in this chapter followed this established pattern. For the canine 
primary fibroblasts, array experiments 1 (passage 2), 2 (passage 4), and 3 
(passage 10) called 14.7, 13.6, and 13.2% of the target mRNA sequences present 
respectively. For the human GM847 cell line, array experiments I 
(pretransfection), 2 (passage 1), 3 (passage 19), and 4 (passage 26) called 46.4, 
48.1, 49.7, and 47.7% present. In all cases, the arrays met the required standard 
for signal quality using the control sets detailed in Section 5.3.9, as 
automatically defined by the MAS software.
5.4.1 Initial data interrogation
Initial analysis of the microarray data was performed using a profile distance 
search. This method of viewing the data allowed identification of gene profiles 
that resembled a complex reference profile that could not be defined by any 
method other than drawing. Using this method, genes that were up regulated and 
down regulated as the SFA primary culture approached senescence were 
identified and isolated into appropriately labelled subgroups, as illustrated in 
Figure 5-3. The same process was applied to identify genes in the GM847 cell 
line that showed a consistent change in expression level after transfection. The 
reference profiles generated for genes identified as up regulated and down 
regulated in the SFA cell culture are shown respectively in Figure 5-4 and Figure 
5-5. The corresponding reference profiles for the GM847 cell line are shown in 
Figure 5-6 and Figure 5-7.
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5.4.2 Analysis of SFA subgroups
The SFA subgroups were defined by profile distance search as described above 
and could be divided into two categories; genes that were up regulated and genes 
that were down regulated as the cell line approached senescence. These groups 
included 627 and 689 genes respectively. The groups were then further filtered 
by an expression ratio analysis. This analysis selected genes from the two groups 
based upon highest ratio values. This value was calculated by dividing the 
highest expression value for an item by the lowest value for the same item, 
allowing genes with expression levels that had undergone the greatest change to 
be identified. The expression value is a measure of the relative abundance of 
each transcript. This tool was also used for identifying genes within the 
subgroups that had undergone small changes in expression levels (e.g. 2 fold 
change or less) allowing these possibly background variations to be removed 
from the analysis. Using this method, genes that underwent 4 fold and 8 fold or 
greater increase or decrease in mRNA expression over the time course o f the 
experiment were identified as shown for up regulation in Figures 5-8 and 5-9, 
and for down regulation in Figure 5-10 (no SFA genes underwent an 8 fold or 
greater decrease in expression level over the course of the experiment). In total, 
mRNAs from 12 genes underwent a four fold or greater increase as the SFA 
culture approached senescence. A group of 5 mRNAs underwent the same ratio 
change of down regulation as the culture approached senescence. Ontologies of 
these genes were then compiled by an accession number search using the Gene 
Finder search engine provided by the Cancer Genome Anatomy Project (CGAP) 
(http://cgap.nci.nih.gov/) . CGAP is a subsidiary o f the National Cancer Institute, 
which is the U.S. federal governmenf s principal agency concerned with cancer 
research. Details of the results of this search are provided in Table 5-2 and Table 
5-3.
5.4.3 Analysis of GM847 subgroups
The same analytic strategy was applied to the GM 847^GM 847/hTERT 
experiment. The initial profile distance search identified 887 genes that had a
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low expression value before transfection, switching to a consistently high 
expression value in the three post transfection time points. The converse profile; 
high expression before transfection switching to consistently low expression 
after transfection produced a group of 707 genes for analysis. Further selection 
was carried out by expression ratio analysis as detailed for the SFA experiment. 
The results of this analysis for 4-fold and 8-fold increase in mRNA expression 
are shown in Figures 5-11 and 5-12 respectively. Four-fold and 8-fold decrease 
in expression post transfection is shown in Figures 5-13 and 5-14 respectively. 
Descriptions of those genes undergoing 8 fold and greater decrease or increase in 
mRNA expression value post transfection (numbering 8 and 4 respectively) were 
accessed using the same search facility detailed for the SFA experiment, and are 
provided in Tables 5-4 and 5-5.
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Figure 5-3. Overview of the sampling strategy for the SFA culture. The three 
time points sampled correspond to passages 2, 4 and 10 o f the SFA primary 
culture, during which the culture went from containing less than 5% senescent 
cells (at passage 2) to 80% senescent cells (at passage 10), as defined by SA-p- 
GAL staining. These time points were chosen to allow comparison between an 
actively replicating cell population with most of its replicative potential intact 
and a cell population made up of a majority of senescent cells. The search 
strategy employed using Expressionist™ Analyst software was then to identify 
those genes with mRNA expression levels that had increased or decreased at 
least four fold over this time, thus highlighting those genes that experience the 
greatest change in expression level in association with the onset of replicative 
senescence in canine fibroblasts.
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1—  + 8 fold
—  + 4 fold
<5% 80%20%
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Figure 5-4. Profile distance search for the SFA cell culture highlighting up 
regulation. The linear display profile charts the expression level of mRNAs of 
each gene over the three time points corresponding to passages 2, 4 and 10 
respectively. The black line may be set by the user and indicates the preferred 
expression profile, in this case up regulation. The software then isolates each 
gene in the entire group that fits the specified profile (highlighted in red), 
allowing this group of genes (numbering 689) to be isolated in a subgroup for 
further analysis.
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Figure 5-5. Profile distance search for the SFA cell culture highlighting 
down regulation. The linear display profile charts the expression level of each 
gene over the three time points corresponding to passages 2, 4 and 10 
respectively. The black line may be set by the user and indicates the preferred 
expression profile, in this case down regulation. The software then isolates each 
gene in the entire group that fits the specified profile (highlighted in red), 
allowing this group of genes (numbering 627) to be isolated in a subgroup for 
further analysis.
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Figure 5-6. Profile distance search for the GM847 cell line highlighting up 
regulation. The linear display profile has been set to select for mRNAs that 
demonstrate sustained up regulation in post transfection cells compared with the 
original parent cell line. This pattern is reflected in the black line that represents 
the reference profile against which genes were selected. The group contained a 
total of 887 genes that are highlighted in red. This subgroup was then selected 
for further analysis by highest ratio profiling. Time points 2, 3 and 4 are all taken 
from passages o f the successfully transfected GM847 cell line (pi, p i 9, and p26 
respectively), whilst time point 1 is the passage of the parent GM847 cell line 
from which the transfected cell line was created.
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Figure 5-7. Profile distance search for the GM847 cell line highlighting 
down regulation. The linear display profile has been set to select for genes that 
demonstrate sustained down regulation in post transfection cells (time points 2, 3 
and 4) compared with the original parent cell line (time point 1 ). This pattern is 
reflected in the black line that represents the reference profile against which 
genes were selected. The selected group contained a total o f 707 genes that are 
highlighted in red. This subgroup was then selected for further analysis by 
highest ratio profiling.
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Figure 5-8. Gene group demonstrating four fold increase in expression 
value and above for mRNAs of the SFA cell culture. This figure illustrates a 
highest ratio analysis for increasing gene expression level in the SFA cell 
culture. The filter is set to select only those genes with mRNAs that have 
undergone a four-fold or greater increase in expression value over the course o f  
the experiment. This group is highlighted in blue and totals 12 genes. Horizontal 
blue bars indicate genes not detected at all three time points; for example a 
horizontal blue bar to the left o f time point 2 indicates expression o f that gene 
was not detected at time point 1.
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Figure 5-9. Gene group demonstrating eight-fold increase in mRNA 
expression and above for the SFA cell culture. The three genes in this group 
are highlighted in blue, whilst the grey background indicates genes below the 
highest ratio threshold of eight.
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Figure 5-10. Gene group demonstrating between four and eight fold 
decrease in mRNA expression for the SFA cell culture. Selected genes are 
highlighted in red, whilst unselected genes are shown in grey in the background.
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Figure 5-11. Gene group demonstrating four-fold or greater increase in 
mRNA expression value by highest ratio analysis in the GM847 cell line 
experiment. This group comprised 72 different genes.
10*-]
10^ 1
I>
102-
10-
1-*
2 3
262
Figure 5-12. Gene group demonstrating eight-fold or greater increase in 
mRNA expression value by highest ratio analysis in the GM847 cell line 
experiment. This group comprised 8 different genes, highlighted in blue. 
Unselected genes in this analysis group are shown in grey in the background.
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Figure 5-13. Gene group demonstrating four-fold or greater decrease in 
mRNA expression value for the GM847 cell line experiment. This group 
comprised 15 genes highlighted in red. Unselected genes are shown in grey in 
the background.
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Figure 5-14. Gene group demonstrating eight-fold or greater decrease in 
expression value for the GM847 cell line. This group comprised 3 different 
genes, highlighted in red. Unselected genes are shown in grey in the background.
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5.5 Discussion
The primary aims of this chapter were to cany out investigations of the changes 
in mRNA expression in cell cultures in experiments concerned with two 
different areas of telomere related biology; namely the changes during in vitro 
cellular ageing and the onset of replicative senescence in canine fibroblasts, and 
the changes following reactivation of telomerase in a human telomerase 
independent ALT cell line. The Affymetrix technology utilised for this purpose 
is currently the market leader in tenus of commercially available DNA arrays 
and allows a global picture of gene expression in human cells to be fonuulated. 
The HGU133-A and B Chip sets contain over 1 million oligonucleotides, 
representing more than 33,000 human genes (for product details refer to 
http://www.affymetrix.com/products/arrays/index.affx). The ‘A ’ chip was used 
in these experiments as it contained the greatest number o f oligonucleotides 
(22,283) targeted against well-characterised human genes. The lack of detailed 
information available on many o f the genes, and the smaller number of genes 
represented on the remaining ‘B’ chip precluded its use in the experiments in 
terms of cost/benefit. Even at the subsidised prices available for academic 
research, each ‘A’ GeneChip alone cost approximately £500 at the time of the 
experiments, and this despite the cost of purchase being reduced by at least half 
since the creation of the HGU133 Chip set in 2001 (Hasseman 2002).
5.5.1 Use of the Affymetrix HGU133-A GeneChip for 
cross-species hybridisation
Currently, no canine specific DNA microarrays with the complexity of the 
GeneChip platform are commercially available; at present canine specific arrays 
are much less complex and are designed with specific applications, such as 
toxicology in mind, as exemplified by the canine arrays o f Phase 1 Molecular 
Toxicology Inc., Santa Fe, NM (http://www.phaseltox.com/). Hence, 
investigation of large scale gene expression changes in canine samples is 
currently limited to using human specific arrays, and relies on cross species
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hybridisations. There are few reports o f the use of GeneChips for cross-species 
hybridisation experiments, and those that do exist tend to focus on non-human 
primates (Bigger, Brasky, et al 2001) (Kayo, Allison, et at 2001). The author is 
not aware of any published reports of the use of human genome array Chips for 
cross-species hybridisation with canine RNA samples and the present study 
therefore provides the first report o f such an investigation, and demonstrates that 
approximately 15% of the human mRNAs probed by the HGU133-A GeneChip 
can consistently be identified in canine samples.
The design of Affymetrix technology is such that a gene is called present only if 
multiple oligonucleotide targets, in the vast majority of cases interrogating 
unique, non-overlapping units of sequence make a present call. In addition, 
negative calls must be made by the corresponding MM probe sets, which differ 
in only one base from their PM counterparts (Section 5.2.3). With the use of 
such positive and negative controls it is therefore expected that cross-species 
genomic differences will be reflected in a lower percentage of genes being called 
'present' (as was identified in the SFA samples), rather than any degradation in 
the reliability of a positive call. This is corroborated by a study on the variability 
of results in cross-species GeneChip an ays using a non-human primate {Rhesus 
macaque) as the test species (Chismar, Mondala, et al 2002). In that study the 
percentage of genes called present in the non-human primate samples were 
29.4% +/- 3.5, (average +/- standard deviation) compared with 46.4% +/- 3.3 for 
the human derived samples. Whilst a comprehensive comparison between the 
complete canine and human genomic sequences has yet to be undertaken 
(Kirkness, Bafna, et al 2003), it is likely that the smaller percentages present in 
the SFA chips (13.8% +!- 0.78) compared with the human samples analysed in 
these experiments (48.0 +/- 1.4) reflect the greater diversity between the human 
and canine genomes than between the human Rhesus macaque genomes.
A second possibility is that the smaller percentages present in the canine samples 
reflect a genuine difference in canine and human biology in tenns of numbers of 
genes expressed in the cell at a given time. Whilst variations will occur, they are 
unlikely to be great enough to account for the 34.2% difference in the number of 
genes found present in the two species. Instead, it is likely that a proportion of
271
this subset o f genes that were typically called present in human samples yet 
typically called absent in canine samples are in fact active, but sequence 
differences between the two species results in a failure of Affymetrix to detect 
them. Some of the genes within this gioup will undoubtedly be o f experimental 
and biological significance, therefore the use of cross species arrays do not allow 
examination of global gene expression changes in the canine test cells. Despite 
this, Affymetrix is undoubtedly the most effective tool available at present for 
these types o f investigation.
5.5.2 Genes with significant changes in mRNA levels
In total, 28 genes that had undergone at least a four-fold change in mRNA levels 
during the course of both experiments were flagged by expression ratio analysis 
for further investigation. The biological function of each of these genes, to the 
extent of present knowledge, was then determined as described previously 
(Section 5.4.1). It was not possible, nor was it expected that each of these 28 
genes could be in some way directly related to the biological phenomena 
(senescence and telomerase activation) that were under investigation. However, 
a number of this group have interesting functions, and their possible relation to 
telomere biology is discussed below.
5.5.2.1 Genes up regulated between passages 2 and 10 in the SFA 
culture
A total o f 12 genes were identified from GeneChip analysis of the SFA culture 
with mRNA levels that increased at least 4 fold from passage 2 to passage 10. 
Included in this group was the gene that encodes phosphatidic acid phosphatase 
type 2A (PAP2), which is an integral membrane glycoprotein that hydrolyses a 
number o f structurally related lipid phosphate substrates and appears partly 
responsible for the uptake of lipids from the extra cellular space (Roberts & 
Morris 2000). Interestingly, this gene product has also been implicated in a 
tumour suppressor role, and is down regulated in both colonic tumours and 
prostatic cancer cell lines (Leung, Tompkins, et al 1998) (Porlcka & Visakorpi
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2001). Considering these previous studies, the finding that PAP2 was strongly 
up regulated in senescent canine primary fibroblasts may implicate it in a tumour 
suppressive role in this species, and it may provide a further molecular marker 
for senescence in canine cells, in the same manner that p i h a s  been found 
to accumulate in the senescent human and canine cells (Alcorta, Xiong, et al 
1996) (Koenig, Bianco et al 2002).
A second gene in this group, with mRNA expression levels that increased over 8 
fold between passages 2 and 10 is an inhibitor of angiogenesis, Thrombospondin 
1 (TSP-1). This antiangiogenic factor appears to act by binding with, and 
subsequently reducing the bioavailability of angiogenic factors such as fibroblast 
growth factor (Margosio, Marchetti, et al 2003). Oncogenes act as inducers of 
tumour neovascularization in part by suppression of factors such as TSP-1 
(Kalas, Gilpin, et al 2003), and so it is possible that a marked increase in TSP-1 
mRNA levels as the canine fibroblasts approached senescence reflects an 
attempt by the cells to counteract any such action. It has even been suggested 
that restoration of TSP1 levels might be a means with which to inhibit tumour 
angiogenesis (Kalas, Gilpin, et al 2003).
Levels of mRNA encoding insulin-like growth factor binding protein 2 (ÏGFBP- 
2) were also increased over 4 fold in the passage 10 SFA cells compared with 
passage 2. Elevated IGFBP-2 levels are associated with malignancy in many 
different types o f human tissue, particularly in the prostate (Richardsen, 
Ukkonen, et al 2003), and this molecule has even been proposed as a marker for 
malignant transformation in prostate epithelium (Richardsen, Ukkonen, et al 
2003). The increased expression of its mRNA in the SFA culture was initially 
unexpected, however studies have shown that IGFBP-2 appears to play a 
different role in cultures of primary cells, were it has been shown to act as a 
growth inhibitor in more than one type of tissue (Hoflich, Lahm, et al 1998) 
(Moore, Wetterau, et al 2003). The results would indicate that IGFBP-2 might 
have a similar growth inhibitory effect in primary canine fibroblasts.
Whilst breast cancer anti-oestrogen resistance gene 3 is described in the CGAP 
ontology as involved with regulation of the cell cycle, as the name suggests this
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has been primarily in association with breast cancer cells, rather than normal 
primary cultures (van Agthoven, van Agthoven, et al 1998), and so any 
significance of the increase in mRNA levels noted in this experiment is unclear.
Double homeobox 4 is linked with transcription factor activity (CGAP), 
however this particular gene transcript is not widespread, having been found in 
association with a type of muscular dystrophy (Gabriels, Beckers, et al 1999), so 
this gene cannot be readily linked to telomere biology. The remaining members 
o f this group, as detailed in Table 5-2 include genes such as synaptosomal 
associated protein, 91 kD homolog (mouse), Mannosyl (alpha-l,3-)-glycoprotein 
beta-1,4-N-acetylglucosaminyltransferase, isoenzyme B, and amyotrophic lateral 
sclerosis 2 chromosome region, candidate 2. These genes highlight the fact that 
technology as sensitive as Affymetrix will often highlight changes in the 
transcriptome that bear, with the extent of current knowledge, no relation to the 
area under investigation.
Another interesting finding in this group was the absence of the mRNAs of 
genes with products that have previously been associated with the onset of 
replicative senescence. Examples of this class have been described previously, 
such as p i6 and SA-P-GAL (Alcorta, Xiong, et al 1996) (Dimri, Lee, et al
1995); as these two are in common use as biomarkers o f senescence. However, 
over expression of a number of other genes have also been associated with the 
onset of replicative senescence in human cells. Examples include interferon beta, 
which was found up regulated in a primary human fibroblast culture at the end of 
its replicative lifespan, and was therefore implicated in replication suppression 
(Tahara, Kamada, et al, 1995). Satoh et al identified preferential expression of 
the gene encoding vimentin in senescent human fibroblasts (Satoh, Kashimura, 
et al 1994). Vimentin is a cytoskeletal protein, and its overproduction in 
senescent fibroblasts has been suggested as a possible explanation for the 
enlarged and flattened phenotype that is characteristic of senescence (Nishio, 
Inoue, et al 2001). Senescent human endothelial cells were found to contain high 
levels of the transcript for interleukin-1 alpha, a known inhibitor of endothelial 
cell proliferation in vitro, providing a further marker for senescence in that cell 
type (Maier, Voulalas, et al 1990), Up regulation of mRNA and protein levels
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for the glycoprotein Chisterin/apolipoprotein J have been detected in senescent 
human fibroblasts, and have been hypothesised to represent a secondary 
consequence of the senescent phenotype rather than a causal agent (Petropoulou, 
Trougakos, et al 2001). Gonos et al identified a number of genes that were up 
regulated in both senescent rat embryo fibroblasts and senescent human 
osteoblasts that included fibronectin, osteonectin, al-procollagen, 
apolipoprotein J, SM22, and G TP-a (Gonos, Derventzi, et al 1998). Fibronectin, 
osteonectin and a  1-procollagen are all extra cellular matrix genes, and the 
changes in expression levels of these are likely to be related to the cytoskeletal 
changes associated with the senescent phenotype. SM22 and GTP-a are both 
involved with negative regulation of calcium dependant signal transduction, and 
it has been suggested that the over expression of these genes may be responsible 
for the poor homeostasis of senescent cells (Gonos, Derventzi, et al 1998). In 
addition, Chang et al have described up regulation of a number of genes in 
association with growth arrested, SA-p-GAL positive cells produced by 
doxorubicin chemotherapy in the human colon carcinoma cell line HCT116. A 
number of these expression changes were found to correlate with changes in 
protein levels, and included maspin, keratin 18, and cyclin D1 (Chang, Swift, et 
al 2002). Maspin is a secreted growth inhibitor, whilst keratin 18 is known to 
have antiapoptotic activity, and cyclin D1 has been associated with ageing colon 
tissue (Chang, Swift, et al 2002).
Whilst activity of SA- P-GAL and the presence of p l6  have been identified 
in late passage SFA cells, as detailed in Section 3.4.4.3, none of the other genes 
outlined above were up regulated. This is not considered to be an unusual 
finding; for example it is important to note that only one of the additional nine 
gene products listed above (Apolipoprotein J), was detected in more than one of 
the referenced studies. This raises the point that all senescent cultures will not 
display up regulation of exactly the same genes. Even within the same cell type, 
minute variations in the culture environment may alter the expression profile of 
the study culture. Instead, it will be more useful to generate a list of genes that 
are associated with senescence, and use this infonuation to aid understanding of 
the phenotypic changes that are occurring in a culture as it ceases to be
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replicatively active. Furthermore, it is possible that the inability o f Affymetrix to 
detect the mRNAs of some of these gene products is an example of species 
differences in RNA sequence resulting in a failure of detection due to the 
stringent Affymetrix mismatch controls. The significantly lower percentage of 
genes called present in the SFA GeneChips compared with a typical human 
sample (approximately 15% compared with approximately 45%) implies that a 
large number of genes might fall into this category, and underlines the point that 
whilst the HGU133 Chipset has proved useful for cross species hybridisations, 
the results o f these investigations cannot be said to encompass changes in global 
gene expression in canine cells.
5.5.2.2 Genes down regulated between passages two and ten in 
the SFA culture
A total of 5 genes were identified from GeneChip analysis of the SFA culture 
with mRNA levels that decreased at least 4 fold from passage 2 to passage 10. 
Changes in the mRNA levels o f the ATPase, Na+/K+ transporting, beta 1 
polypeptide included it in this group. The significance of this is unclear, however 
the Na+/K+ ATPase is involved with the regulation of cell volume via 
maintenance of ionic gradients (Hernandez & Cristina 1998), and changes in 
Na+/K+ ATPase activity have been associated with ageing of skeletal muscle in 
rats (Sun, Nagarajan, et al 1999). Whether a change in activity o f the Na+/K+ 
ATPase system is in any way related to the increased volume of senescent cells 
in vitro (Mitsui & Schneider 1976), or whether this is purely a reflection of the 
lack of cell division is speculative. The control of cell volume is a complex field 
beyond the scope of this discussion, however it is recognised that the in situ 
mechanisms for governing cell volume will almost certainly extend beyond 
transcriptional regulation of a single gene product.
The finding that mRNA for the anti-proliferative B-cell translocation gene 1 was 
down regulated with the approach of senescence was surprising, as this gene is 
associated with negative regulation of proliferative activity (Maekawa, Nishida,
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et al 2002). However, the full range of functions of this gene in all tissues is not 
understood, and the gene has also been associated with cell proliferation, as 
listed in the CGAP ontology. The remaining three genes in this group, namely 
Methyl-CpG binding domain protein 2, discs, large (Drosophila) homolog 1, and 
adaptor-related protein complex 4, epsilon 1 subunit, are all widely expressed, 
and as detailed in Table 5-3, involved with general molecular processes within 
the cell that do not link readily with telomere biology.
Down regulation of a number of genes not included in the above group have 
previously been associated with senescence, including the c-fos component of 
the API transcription factor, the Idl and Id2 negative regulators of helix-loop- 
helix transcription factors, the E2F-1 component of the E2F transcription factor 
and MAD-2, which is involved in progression of mitosis (Dimri, Testori, et al
1996) (Chang, Swift, et al 2002). As described previously for gene up regulation 
(Section 5.5.2.1), genes with expression changes associated with senescence will 
not follow a characteristic pattern in all senescent cell populations that are 
investigated (for example, the additional genes noted above do not overlap 
between the two studies from which they were sourced). However, as none of 
the genes down regulated in the SFA study could be linlced directly to telomere 
biology, it is possible that all 5 of these genes are secondary to the senescent 
phenotype, rather than acting directly to trigger it.
S.5.2.3 Genes up regulated in association with reconstitution of 
telomerase activity
Microarray analysis of the human telomerase independent cell line GM847 
identified a greater than 8 fold up regulation of eight genes post telomerase 
reactivation. The most interesting result in this group was the finding that 
epiregulin mRNA levels were gi'eatly increased (> 8 fold) in GM847/hTERT 
cells assayed at three different time points compared with the parent GM847 cell 
line. Epiregulin is a potent growth factor belonging to the epidermal growth 
factor family and has been associated with the progression of certain carcinomas 
(Toyoda, Komurasaki, et al 1997). This result concurs with a previous cDNA
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study of hTERT immortalised human fibroblasts were epiregulin was found to 
be highly expressed in hTERT immortalised fibroblasts, but not in normal 
primary fibroblasts. This discovery was listed as the principal finding of the 
research and lead the authors to conclude that therapeutic use of telomerase 
should be approached with caution, due to the association between epiregulin 
and tumorigenesis (Lindvall, Hou, et al 2003). In addition it was concluded that 
epiregulin up-regulation is required for sustained cell proliferation. The fact that 
up-regulation of this gene has now been identified in association with the 
process of immortalisation in two separate studies adds credence to the idea that 
epiregulin has an important role to play in telomerase mediated cellular 
immortalisation. Whether the same applies to ALT immortalised cells is open to 
question, as the parent ALT dependent cell line had the ability to replicate with a 
very much lower epiregulin mRNA level than was detected post transfection. 
However, the detection of epiregulin mRNA at any level contrasts with the 
complete absence o f epiregulin activity detected in a previous study using 
human primary fibroblasts (Lindvall, Hou, et al 2003), and in this study using 
canine primary fibroblasts. It must be borne in mind that the hTERT mRNA 
copy number per cell o f the hTERT transfected cells in this study will be much 
higher than that encountered in vivo, due to their expression being driven by a 
strong constitutively active CMV promoter. This high hTERT mRNA expression 
translated to high telomerase activity and was reflected in the TRAP results of 
the GM847/hTERT cells, which were by far the highest of all the telomerase 
positive samples assayed in this project (Table 4-20). It may be that the lower 
epiregulin levels detected in the original GM847 cells were enough to permit 
continued proliferation, and that epiregulin mRNA activity is associated with 
both telomerase, and ALT activity.
The increase in mRNA levels of enolase 1 (alpha) were also of interest, as this 
gene product has been associated with transcription factor activity; however this 
ubiquitously expressed gene has also been associated with glycolysis (CGAP), 
and so the relevance o f the mRNA changes noted in this experiment were 
unclear, as they may simply reflect changes in cellular metabolism. A recent 
report found differential abundance of enolase 1 protein between human 
infiltrating ductal carcinoma of the breast and normal tissue (Somiari, Sullivan et
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al 2003) however the pattern of protein abundance was not consistent in all of 
the test samples, and so any possible association between enolase 1 and 
tumorigenesis remains unclear.
The remaining 6 members of this group contained two genes of unlmown 
biological function (Melanoma antigen family A, 6 and G protein-coupled 
receptor 61), whilst the remainder, as detailed in Table 5-4 are associated with 
very disparate ftinctions, as defined by CGAP. These include intracellular 
transport (Solute carrier family 16, member 3 and coated vesicle protein 
RNP24), protein manufacture (HIRA interacting protein 5), and lipid and protein 
metabolism (Ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky- 
Bielschowsky disease)). All these biological functions are concerned with 
general cellular metabolism, and are therefore likely to vary with time in a 
typical cell population.
5.S.2.4 Genes down regulated in association with reconstitution 
of telomerase activity
This group contained a total of three different genes with niRNA levels that 
decreased at least 8 fold in association with the reconstitution of telomerase 
activity. Two o f the three genes in this group, Mannosyl (alpha-1,3-)- 
glycoprotein beta-1,4-N-acetylglucosaminyltransferase isoenzyme B, and 
eukaryotic translation initiation factor 5A, are involved with metabolic processes 
such as carbohydrate metabolism and protein biosynthesis, processes that are 
associated with active, replicating cells, and so the down-regulation of these 
mRNAs post transfection is intriguing. However, these results were not reflected 
in any change in the population doubling time of the cell line, and likely 
represent background changes in cellular metabolism that are of little direct 
relevance to the transfection process. Similarly, the change in expression of the 
third member of the group, member G of the H4 histone family could not be 
linked directly to the experimental process.
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5.5.3 Biological significance of Affymetrix generated 
data
DNA microarray analyses have identified genes of interest related to both the 
onset of replicative senescence and the reconstitution of telomerase activity that 
waiTant further investigations. The primary concern of these investigations must 
be to ensure that the changes in the transcriptomes of the test cells that were 
identified in these studies were also reflected by changes in the proteomes. This 
is important as much modification and regulation occurs with mammalian gene 
products post transcription, and this raises the question of how related mRNA 
levels are to the biological activity of the proteins they encode. It may be 
misleading to inteipret great changes in mRNA levels as equalling changes of 
great biological significance. It is known that mRNA abundance in a cell often 
correlates poorly with the amount of protein synthesised, and furthermore 
proteins rather than mRNA transcripts are the major effector molecules in the 
cell (Gygi, Rochon, et al 1999). Whilst a protein equivalent of the Affymetrix 
DNA microarray is not technically feasible at present due to the structural 
diversity and complexity o f proteins compared with nucleic acids (Talapatra, 
Rouse, et al 2002) (Huber 2003), two-dimensional gel electrophoresis 
techniques have greatly improved identification and analysis o f changes at the 
protein level in cells (Ong & Pandey 2001). Such techniques could be adopted to 
aid confirmation of the significance of the results gained by the use of 
Affymetrix technology.
Potentially the most significant finding of the experiments was the consistent up 
regulation of epiregulin mRNA in association with telomerase reactivation. The 
association between epiregulin and cancer progression that has been identified 
previously in carcinomas (Toyoda, Komurasaki et al, 1997), and the finding that 
epiregulin up-regulation was necessary for sustained proliferation of hTERT 
immortalised fibroblasts (Lindvall, Hou et al 2003), and the failure to detect 
epiregulin mRNA in either normal human fibroblasts (Lindvall, Hou et al 2003) 
or canine fibroblasts in these experiments all suggest that the hTERT 
immortalised cells may in fact show changes associated with a transfonned
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phenotype. Although validation o f the results using the methods detailed above 
are an area for further investigation, the conclusion of the hTERT reactivation 
experiment detailed in this Chapter must be that any future therapeutic use of 
telomerase must be approached with caution.
Finally, the very large amount of data produced by these Affymetrix studies 
enforced a filtering of the results to facilitate interpretation. This was achieved 
by an expression ratio analysis, and excluded genes with mRNAs that had 
undergone a less than 4 fold change in expression. This is highly likely to 
exclude genes of biological significance, and again demonstrates that whilst the 
method detailed in this Chapter was usefiil for identifying genes o f interest in the 
two studies, it cannot be said to have identified all the genes that are associated 
with either senescence or telomerase reactivation that were active in the two cell 
cultures. An improved version of the primary canine fibroblast study, using a 
canine specific array of the complexity of the HGU133-A GeneChip would 
undoubtedly uncover more genes o f interest. At the time the experiments were 
carried out such technology was not available, however, the canine genome 
project and the interest it has generated within both the medical and veterinary 
medical research fields (Ostrander & Kruglyak 2000) will undoubtedly result in 
canine specific microainays of the complexity of the GeneChip in the near 
fliture.
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5.6 Summary
Affymetrix® GeneChip technology has proved very useful for the analysis o f
changes in mRNA expression in canine fibroblasts. The experiments detailed in 
this chapter have identified changes in mRNA expression of a number o f genes 
in association with replicative senescence that warrant further investigation. 
These include thrombospondin-1, phosphatidic acid phosphatase type 2A, and 
ATPase, Na+/K+ transporting, beta 1 polypeptide. Additionally, changes in 
mRNA levels in association with the reconstitution of telomerase activity in a 
human cell line have been identified that are o f relevance to the therapeutic use 
of telomerase reconstitution. Specifically, mRNA levels of the epiregulin gene 
were up regulated greater than 8 fold in the cell line in which telomerase had 
been reconstituted compared with the telomerase negative parent cell line. 
Epiregulin has been associated with the progression of human carcinomas, and is 
not detectable in normal human fibroblasts.
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Chapter VI
General Discussion
6.1 Work described in this thesis
The aims of this thesis were to carry out a study o f the biology of telomeres and 
telomerase in the dog and cat. The advances that have been made towards 
manipulating the biological functions of the telomere to provide novel treatments for 
cancer and age related disease in humans have spurred interest in this particular 
subject. In the veterinary field it is hoped that such a strategy could be used in a 
similar manner to provide new treatment regimes for the benefit of companion 
animals.
Given the relatively small amount of work in the literature concerning the telomeres 
o f companion animals, the thesis was concerned with the gathering of background 
data rather than focussing on research with a directly clinical bias; however this does 
not imply that clinical considerations were not taken into account. The key factor of 
interest in human telomere biology is evidence that the telomere is the ‘mitotic clock’ 
at the centre of a replication control mechanism in cells (Vaziri et al 1994), and that 
the growth arrest associated with this effect is a potent anti-cancer mechanism 
(Ishikawa 2000). Phenotypic ageing may even be a side-effect of the process 
(Campisi 2001). The main mechanism at work is telomere attrition; this cellular 
countdown is believed to be the trigger for cellular senescence. It was therefore 
fundamental in this thesis to establish that the phenomenon of telomere attrition 
occurs in both the dog and cat, both in vitro and in vivo, and a large proportion of the 
work undertaken focussed on this. The TRT methodology used for these experiments
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first identified a range of telomere lengths in the dog and cat that is comparable to that 
found in humans, and then comparison of samples taken from a wide age range of 
dogs and cats established that a significant decline in the telomere lengths of PBLs 
does occur as both dogs and cats get older. Blood samples were selected for this in 
vivo investigation primarily due to the twin considerations of ease of gathering the 
samples (within WCPN ethical policies) and a minimum of distress to the donor 
animals, allowing a much greater number of samples to be gathered than would 
otherwise have been possible. The only other route considered for sampling was 
cheek cell scraping, however this was abandoned due to the relatively small amount, 
and the generally poor quality of DNA harvested by this technique. Furthermore, it 
was subjectively felt that the animals sampled by cheek cell scrapings found this 
procedure more distressful than blood sampling.
In vitro investigations used primary fibroblast cell cultures. These are often used as 
the ‘typical’ cell for in vitro work, as is reflected in the human telomere literature 
(Allsopp et al 1992) (Hayflick 1965). Primary fibroblasts were also available within 
GUVS, which was a consideration given the relatively small number of commercially 
available primary cultures o f companion animal origin, in comparison with cultures of 
human origin.
Using these in vivo and in vitro approaches it was established that teloraeric attrition 
occurs in the dog and cat, and it was therefore plausible that an important link 
between telomeres, telomerase and cellular immortalisation exists in the companion 
animals, as has been found in humans (Artandi and DePinho 2000). The next logical 
step was to investigate the distribution of telomerase activity in the somatic tissues of 
the two species. Telomeric attrition will only occur to an effective degree in the 
absence o f telomerase activity, and so for a telomere based replicative arrest to be 
active in canine and feline somatic tissues the majority must be telomerase negative. 
To this end, the highly sensitive TRAP assay was employed to categorise a wide 
range o f normal somatic tissue in the dog and cat as either telomerase positive or 
negative. As is the established pattern in human tissues (Burger et al 1997), 
telomerase aetivity was found to be restricted to a handful o f sites, all of which 
contained tissues with high replicative burdens (Section 4.4.1). Furthermore, high 
telomerase aetivity was detected in the vast majority of canine and feline malignant
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tumours in a survey carried out on post-mortem and biopsy specimens, and in 
immortalised canine cell lines using the same protocol. Taken together these two 
findings demonstrate clearly that telomerase reactivation is central to continuing 
cellular proliferation in the dog and cat, and that telomerase activity is strongly down 
regulated in the vast majority of normal canine and feline somatic tissues.
All o f these findings link the telomere with the control of cellular proliferation in the 
dog and cat, and verified that telomerase may be a target for novel anti-cancer 
strategies in the companion animal species. Therefore a study was undertaken to 
investigate if a RTI could affect cell-doubling time in two immortalised canine cell 
lines shown previously to be telomerase positive. This particular category o f drug was 
chosen given previous findings that RTI inhibitors could demonstrably effect cell 
doubling times in human telomerase positive cell lines (Strahl and Blackburn 1996). 
Whilst the results of the study carried out in this project were disappointing in that 
exposure to AZT-TP did not have any discernable effect on the growth rate of the cell 
lines, this was in effect a pilot study, and lays the groundwork for possible future 
investigations into combinational therapy with a number of agents. A strategy that has 
received some recent attention is the use of agents to target both telomerase (e.g. 
AZT-TP) and its substrate, the telomere (e.g. G-quadmplex interacting compounds 
such as telomestatin, Tauchi et al 2003). The data recorded in the AZT-TP study may 
be combined with a fiiture larger study using a number of potentially therapeutic 
agents.
A major finding in human telomere research has been the discovery that ectopic 
expression of the catalytic subunit o f telomerase alone is sufficient to reconstitute 
activity in a number of different cell types (Bodnar et al 1998). Whilst the canine 
TERT gene and its promoter has now been cloned by this group, at the time of the 
experiments neither the canine or feline homologous sequences to hTERT were 
available. Instead, telomerase reactivation experiments in the dog and cat were carried 
out using a clone of the hTERT gene, and using a human ALT cell line and an equine 
fibroblast culture as controls. Whilst there were technical difficulties associated with 
transfecting feline primaiy fibroblasts, canine primary fibroblasts transfected with 
hTERT remained telomerase negative and entered senescence normally. The human 
cell line was successfully transfected using the same protocol employed for the canine
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and feline cells, and subsequently was shown to be telomerase positive, thus 
demonstrating that the experimental protocol was adequate. It is possible that the 
canine fibroblasts remained telomerase negative due to sequence differences between 
the human and canine TERTs, as the cTERT and hTERT sequences show only 77% 
similarity; (Nasir, L 2003, unpublished report). Given that the cTERT sequence is 
now Icnown, an interesting area for further investigation would be to repeat the 
experiment with the same protocol and substitute the cTERT sequence for the hTERT 
sequence in the canine fibroblasts. If species-specific sequence differences are to 
blame for the failure to reconstitute telomerase activity in the canine fibroblasts then 
the use of the homologous sequence should overcome this difficulty.
Targeting telomeres and telomerase for therapeutic intervention in a number of 
disease states may involve selection of co-factors and associated gene products in 
conjunction with targeting the telomere and the telomerase ribonucleoprotein directly. 
A good example of this is the recent finding of the association between epiregulin 
upregulation and continued cell proliferation in a cell population immortalised by 
ectopic expression of hTERT (Lindvall et al 2003). The upregulation of this gene 
product was identified by the use of a cDNA microarray, and this approach was also 
adopted in this project to investigate the changes associated with the approach of 
senescence in canine fibroblasts, and the reactivation of telomerase in an ALT cell 
line. Ideally, a canine fibroblast culture would have been used rather than the GM847 
ALT cell line for the telomerase reactivation experiment, however given the failure of 
ectopic expression of hTERT to reactivate telomerase activity in the canine primary 
fibroblast culture SFA, this option was not available. As described previously, a study 
of the changes in gene expression in association with telomerase reactivation in a 
human cell culture has been carried out previously, however that study used a human 
primary fibroblast culture. The use o f the immortal cell line GM847 in this thesis 
provided additional insight into the changes in mRNA levels found in association with 
telomerase reactivation beyond that already in place due to activation o f the ALT 
mechanism.
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6.2 Future studies
The work carried out in this project examined a number of different aspects of 
telomere biology, and within each area topics were identified that would benefit from 
further research. These are detailed below.
6.2.1 Telomere studies
It is felt that the most interesting finding of this work was the significant breed 
specific differences in telomere length in the dog. Although the sample numbers 
available were relatively small (;? = 112), a trend was identified that relatively low life 
expectancy in a canine breed is associated with shorter mean TRF in age matched 
individuals (Section 3.5.2). Whilst the differences in life expectancies of breeds such 
as the Miniature Schnauzer and Beagle are small, and with a possibly large degree of 
variation, it is noted that certain breeds, generally grouped as the ‘Giant breeds’ (e.g. 
the Great Dane) do have a significantly shorter life expectancy than other breeds and 
crossbreeds (Michell 1999). The small sample number of Great Danes examined in 
this thesis did prove to have the shortest telomeres of all the breeds examined, and it 
is felt that it would be interesting to extend this work to a much larger study 
comparing the TRFs o f Great Danes to those o f a physically smaller breed. The main 
hurdles to the gathering of this data will be harvesting an adequate number of blood 
samples from healthy individuals, due to the relative scarcity of Giant breeds in 
Britain, and the natural reluctance of owners to submit healthy animals to a procedure 
such as blood sampling. Involving breed associations in such a study would be 
productive; as owners affiliated with such societies may be more receptive to the idea 
of research with potential health benefits for the breed as a whole. Specifically, if an 
association between telomere length and life expectancy could be conclusively proven 
in dog breeds, then not only would this benefit human research into the potential 
association between the telomere and the ageing process, but it also might allow the 
development of a selective canine breeding program, based on telomere lengths in the 
hope of producing progeny with greater life expectancy.
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6.2.2 Telomerase studies
The specific association between telomerase reactivation and malignancy that has 
been identified in this thesis has verified that telomerase is a target for novel anti­
cancer di'ug development in the dog and cat. The pilot study carried out using the RTI 
AZT-TP may be used as the basis for a study on the efficacy of combining a number 
o f agents for a greater effect on telomerase activity, which should translate to a 
discernable effect on the growth rates o f immortal canine and feline cells. Although 
other agents rather than AZT-TP could be selected to act as one of these potential 
therapeutic agents, the work described in this thesis has shown that AZT-TP was 
capable of affecting telomerase activity in the MDCK cell line, and so it may be worth 
persisting with this dmg and combining it with other agents for a greater inhibitory 
effect. In addition, AZT-TP alone has been shown recently to have a significant effect 
on the growth rates of a human cancer cell line (Brown et al 2003), so this drug is not 
without promise. The nature o f this expanded study would be concerned with one or 
possibly two strategies combined. First, the addition of a second RTI inhibitor to 
effect an overall greater telomerase inhibition in the test cell lines, and / or combining 
this approach with one of the newer dmgs that target the availability of the telomere 
to the telomerase enzyme (e.g. Telomestatin, Tauchi et al 2003).
6.2.3 Gene expression studies
The Affymetrix work detailed in this thesis has identified a number of potential areas 
for fliither investigation. The most promising of these is the finding that epiregulin 
mRNA is upregulated in association with telomerase reactivation in the GM847 cell 
line. This corroborates with the findings o f a previous study, and inhibition of 
epiregulin activity has been shown to have an inhibitory effect on the growth rate of 
human immortalised cell lines (Lindvall et al 2003). This gene product shows 
considerable promise for targeting in human immortalised cells, and it would be 
interesting to determine, using canine and feline immortalised cell lines whether such 
an effect can be demonstrated in companion animal cells. This approach o f targeting 
potential telomerase co-factors could be combined with some of the therapies outlined 
above for the overall targeting o f telomerase in canine and feline cancers.
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GLOSSARY
293T Human renal cell line
3132T Canine lymphoma cell line
A 2 6 0 /A2 8 O Measure o f DNA/RNA quality
A72 Canine fibroblast cell line
AG07648 Primaiy canine fibroblasts
AG07906 Primary equine fibroblasts
AG08075 Primaiy canine fibroblasts
AG08157 Primary canine fibroblasts
ALT Alternative lengthening of telomeres
APB ALT associated PMLs
ATCC American Type Culture Collection
AZT-TP 3'-Azido-3'-deoxythymidine triphosphate
BCA Bicinchoninic acid
BMSSCs Bone marrow stromal stem cells
bp base pairs
BSA Bovine serum albumin
CCL-176 Primary feline fibroblasts
CCR Coriell Cell Repositories
cDNA Complementaiy DNA
CGAP Cancer Genome Anatomy Project
CHEF Contour clamped homogenous electric field
CMLIO Canine melanoma cell line
CMT3 Canine osteosarcoma cell line
CMT7 Canine mammary tumour cell line
CMT8 Canine osteosarcoma cell line
CMV Cytomegalovirus
D17 Canine osteosarcoma cell line
DAB 3,3 diaminobenzidine
DEPC Diethylpolycarbonate
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dHzO Distilled water
DIG Digoxigenin
(D)MEM (Diilbecco’s) Minimum Essential Medium
DNA-PK DNA dependant protein kinase
DOPE L-dioleoyl phosphatidyethanolamine
DSH Domestic Shorthaired (cat)
DTT DL-Dithiothreitol
ECTR Extra chiomosomal telomere repeats
EQl Primary equine cells
EREs Oestrogen response elements
PCS Foetal calf serum
FISH Fluorescent in situ hybridisation
GHK Canine renal cell line
GM847 Human fibroblast cell line
GSP Gene specific primers
GUVS Glasgow University Veterinary school
HGU133 Human genome Affymetrix GeneChip
HPA Hybridisation protection assay
HRPO Horseradish peroxidase
ICC Immunocytochemistiy
IGFBP-2 Insulin-like growth factor binding protein 2
lU International units
IVT In vitro transcription
Kb kilobase pairs
kDa Kilodaltons
LNO2 Liquid nitrogen
M l,M2 Mortality stages 1 and 2
MAS Affymetrix microarray suite software
MCF7 Human mammary tumour cell line
MDCK Madin Darby canine kidney cell line
MES 2-(N-Morpholino)ethanesulphonic acid
MM Mismatch
MMLV-RT Murine Moloney Virus reverse transcriptase
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mTR‘^‘ Murine telomerase RNA knockout
PAGE Polyacrylamide gel electrophoresis
PAP2 phosphatidic acid phosphatase type 2A
PARP Polyadenosine phosphate ribose polymerase
PBLs Peripheral blood leukocytes
PBS Phosphate buffered saline
PGR Polymerase chain reaction
PDs Population doublings
PLG Phase lock gel
PM Perfect match
PML Promyelocytic leukaemia nuclear bodies
RNAi RNA interference
RNAse Ribonuclease
RTA Relative telomerase activity
RTI Reverse transcriptase inhibitor
RT-PCR Reverse transcriptase PCR
S22 Primary feline fibroblasts
SA- p -G A L Senescence associated p-galactosidase
SAGE Serial analysis of gene expression
SAPE Streptavidin-phycoerythiin
SDS Sodium dodecyl sulphate
SFA Primaiy canine fibroblasts
siRNAs Short interfering RNAs
SV40 Simian virus 40
TEPi Telomerase associated protein 1
TERT Telomerase reverse transcriptase
Tm Annealing temperature
TMB 3,3% 5,5'-tetramethylbenzidine
TPE Telomere position effect
TR Telomerase RNA
TRAP Telomeric repeat amplification protocol
TRF Telomere restriction fragment
TSP-1 Thrombospondin 1
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WCPN Waltham Centre for Pet Nutrition
WTl W ilms’ tumour 1 tumour supressor
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